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 The overarching goal of this dissertation is the development of efficient 
methods for the generation of medium- and large-sized heterocycles, specifically 7- to 
11-membered sultams, for facilitating probe and drug discovery.  Chapter One 
summarizes the structural components that are prevalent in current marketed 
pharmaceutical agents, highlighting underrepresented rings, rings systems and 
frameworks, which have the potential to introduce chemical novelty into the existing 
limited list of chemical ring systems that describe the majority of the drugs.   
Chapter Two introduces the concept of pairing of a reaction triad, namely 
sulfonylation, SNAr addition and Mitsunobu alkylation, in varying order via the use of 
central o-fluorobenzene sulfonyl chloride building blocks that afford rapid access to 
both bridged- and fused-tricyclic, 7- to 10-membered benzofused sultams.  This 
simple approach obviates the need for the construction of elaborate multi-functional 
scaffolds and merely requires use of o-fluorobenzene sulfonyl chlorides, amines and 
alcohols as building blocks.  Simple changes in the reaction pair sequence (e.g., 
sulfonylation–SNAr vs sulfonylation–SNAr–Mitsunobu vs sulfonylation–Mitsunobu–
SNAr), or changes in the building blocks (1,2-amino alcohol vs 1,3-amino alcohol), 
allows access to skeletal and stereochemical diversity.   
Chapter Three presents the concept of complementary pairing of activated 
 iv 
sulfonyl aziridines (simple 6-atom bis-electrophilic synthon) via "chemo- and 
regioselective" aziridine ring-opening with an amino component of an amino alcohol 
(bis-nucleophiles).  Subsequent intramolecular SNAr cyclization with the alcohol 
component of the amino alcohol affords unprecedented, functionally rich medium-
sized benzofused sultams in overall, chemoselective “6+4” and “6+5” 
heterocyclization pathways.  Moreover, the use of primary amines for the sulfonyl 
aziridine ring-opening step, whereby the resulting secondary amines cyclize via a 
subsequent intramolecular SNAr reaction, enables the generation of 7-membered 
benzofused sultams via an overall “6+1” atom cyclization sequence  
Chapter Four describes efforts aimed at the use of one-pot, sequential 3- or 4-
component sulfonylation–aza-Michael–amide cyclization protocols to generate a 
library of skeletally and stereochemically diverse 7/4, 7/5 and 7/6-fused bicyclic acyl 
sultams.  In this library effort, sulfonylation of different amines with 2-chloroethane 
sulfonyl chloride, followed by Michael reaction with a variety of amino acids, and 
subsequent amide cyclization provides access to the titled bicyclic sultams, which are 
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The development of efficient methods1 for the generation of medium- and large-
sized heterocyclesI is an emerging area for use in probe advancement for chemical 
biology and drug discovery (Figure 1.1).2  In particular, 7- to 11-membered3 lactams have 
recently surfaced as both novel probes and drugs (Figure 1.1).2,4  Naturally occurring 
cyclic peptides have also been discovered to selectively bind proteins or small molecules, 
which has led many researchers to design and synthesize unique heterocycles as novel 
peptidomimetics.5  These strained rings are more easily adapted to biological targets than 
their more flexible linear peptide counterparts.  Due to their physicochemical properties, 
macrocycles are often more stable to hydrolysis, exhibit enhanced lipophilicity, cell 
permeability and bioavailability when compared to their linear counterparts.  These  
 
Figure 1.1. Biologically significant natural and synthetic medium- and large-sized 
heterocycles. 
 
[I] It should be noted that the definition of ring sizes are based on the number of 
atoms in the SN2 cyclization as defined in Reference 3 reported for instance, (a) 
small rings are 3- to 4-membered (b) common rings are 5- to 7-membered, (c) 












































































attributes have motivated several groups to develop methods aimed at the generation of a 
number of natural product-like medium-sized6 and macrocyclic ring systems,7 which has 
in turn, enabled efforts to address difficult drug targets such as those involving protein-
protein interactions,8 as well as, epigenetic targets.9   
In contrast, the production of medium-sized sultams (lactam surrogates), with 
diverse biological activities and medicinal value were relatively rare in the literature at 
the beginning of this dissertation.  Since 2010, more synthetic groups have developed 
methods for the construction of benzofused sultams, with the majority being 8-membered 
ring scaffolds,10 as well as a select number of 9- to 15-membered sultams.11  Two 
prominent examples of recently discovered bioactive sultams are the macrocyclic 
inhibitor of HIV-1 developed by Ghosh in 2009,11 and the recently developed inhibitor of 
lysosomal acidification reported by Schreiber in 201512 (Figure 1.2).  
  
Figure 1.2. Two prominent examples of bioactive sultams. 
 
It is the purpose of this thesis to report studies aimed at the development of 
several facile and modular strategies for the generation of 7- to 11-membered, polycyclic 
and bridged sp3-rich, benzofused sultams and non-aryl 7/4-, 7/5- and 7/6-fused bicyclic 
acyl sultams (Figure 1.3).  In particular, the syntheses to furnish 7- to 10-membered 
bridged benzofused sultams will be covered in Chapter 2, Chapter 3 will detail new 



































while Chapter 4 will finish with a detailed account of efforts to novel, non-aryl 7/4-, 7/5- 
and 7/6-fused bicyclic acyl sultams. 
  
Figure 1.3. Heterocyclic Rings in Drugs Analysis Models reviewed in Chapter 1 and 
their respective connectivity to Chapters 2–4. 
 The aim of this chapter is to highlight two recent analysis models developed by 
Njardarson and Taylor,13 which examine the prevalence of heterocyclic rings in currently 
marketed drugs. Their collective analyses highlight the variety of rings, ring sizes, 
structural diversity, and substitution patterns found in currently marketed drugs.  For the 
purpose of this chapter, emphasis is placed on the frequencies of common, medium and 
large-sized lactams, as well as on cyclic scaffolds containing amides or related motifs.   
Top 200 US Pharmaceutical 
Products of 2013
– Top 100 by Retail Sales
– Top 100 by Prescription
Rings in Drugs (2014)
Top 100 Most Frequently Used Ring
Systems from Small Molecule Drugs 
Listed in the FDA Orange Book
Top 25 Most Commonly Utilized




Definition of Ring Sizes:
1) Small: 3- to 4-membered
2) Common: 5- to 7-membered
3) Medium: 8- to 11-membered
4) Large: ≥ 12-membered
Njardarson Analysis Model
Chapter 2 
Reaction pairing strategies 
[sulfonylation–SNAr–Mitsunobu] to 
7- to 10-membered bridged benzofused sultams
Taylor Analysis Model
Chapter 3 
One-pot, aziridine-ring opening–SNAr 
























































 The two drug analysis models provided in this chapter (Njardarson and Taylor) 
are analyzed in a manner to aid in the identification of underrepresented chemical space 
that has the potential to be "drug- or probe-like" (Figure 1.3, page 4).  As summarized in 
Figure 1.3 (page 4), the heterocyclic rings in the drugs analysis models are covered in 
two reviews, which are derived mainly from the Orange Book of the US FDA,14 but 
compiled with different parameters by each respective investigator.  The first list is the 
Njardarson Analysis Model and is comprised of the recently tabulated top 200 US 
pharmaceuticals agents as of 2013.  The Njardarson Analysis Model is augmented with 
1,086 drugs in a mini-perspective that covers the frequency of nitrogen heterocycles.13a–c  
The second list of heterocyclic rings is the Taylor Analysis Model that contains 1,175 
drugs compiled by Taylor and co-workers in a 2014 report entitled “Rings in Drugs”.13d   
 The identification of scarcely represented structural components in both analyses 
has the potential to guide the design of new synthetic methods toward the generation of 
underrepresented, unique scaffolds.  In combination with chemical methods development, 
this data can be used to direct the design and synthesis of diverse scaffolds possessing 
inadequately represented ring systems, which in turn can provide tools for drug discovery 
and biological probe studies.  Understanding the various factors that make up a drug-like 
scaffold is highly significant, and will in turn enable the development of robust, scalable 
and efficient syntheses of new and unique nitrogen heterocycles.   
 Among the underrepresented heterocycles, we became interested in synthetic 
methods to generate 7- to 11-membered benzofused sultams and non-aryl 7/4-, 7/5- and 
7/6-fused bicyclic acyl sultams.  In this regard, sultams represent a class of non-natural 
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chemotypes that have gained interest in recent years due to their numerous biological 
activities including several with medicinal value.  However, they occupy a much smaller 
collective area of chemical space when compared with other heterocycles, yet possess 
innate properties that convey unique chemical characteristics, thus warranting their 
development, a detailed summary of which can be found in Chapters 2–4.II 
 In addition to the synthetic methods developed to generate these unique scaffolds, 
the sultams frameworks have been evaluated with several computational analyses, as 
outlined in Table 1.1.  As will be detailed in Chapters 2–4, cheminformatic studies reveal 
that the sultams detailed in this thesis lie within new chemical space when mapped using 
several analyses.  The focus of this thesis is to develop synthetic methods for the 
construction of distinct sultam scaffolds, mainly 8- to 11-membered benzofused sultams 
and non-aryl 7/4-, 7/5- and 7/6-fused bicyclic acyl sultams that are scarcely represented 
as evident from both the Njardarson and Taylor Analysis Models.  Although 7-membered 
heterocycles are more common, 7-membered heterocyclic scaffolds containing 
stereogenic centers and functional handles for diversification are still relatively deficient 
in both Analysis Models.  Hence, there is a demand for new chemical methods for the 
generation of unique and diverse 7-membered benzofused sultams as well as non-aryl 
7/4-, 7/5- and 7/6-fused bicyclic acyl sultams. 
 
 
[II] Several of the chemical properties and guidelines such as ADMET, Lipinski “rule 
of 5” and ring systems will be briefly described in section 1.1.1, providing the 
necessary parameters for a small-molecule new molecular entities (NMEs). 
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Table 1.1. Chemical Space Analysis.  
  
Chapter 2 
- Cartesian grid-based chemical 
diversity analysis  
- Overlay Analysis 
- Principal Moments of Inertia (PMI) 
- Conformational Analysis 




- Principal Moments of Inertia (PMI) 




- Principal Moments of Inertia (PMI) 
- Overlay Analysis 
 
1.1.1 Molecular Descriptors of Drug Molecules 
The philosophic view-point of scaffolds occupying drug-like space has been a 
pervasive issue in medicinal chemistry for a long period of time.15  The development of 
molecular descriptors of currently marketed drugs, which can aid in the design of new 
drugs, is a commonly accepted strategy adopted in order to improve the downstream 
success of small molecules in clinical trials.16  Indeed, the failure of new experimental 
drugs in the clinic can often be attributed to poor physicochemical characteristics, which 
resulted in poor efficacy, toxicology and safety.17  However, it is challenging to tabulate 

































Chapter 2 8-/9-membered Bridged Benzofused Sultams
Chapter 3 10-/11-membered Polycyclic Sultams











substructure occur during the early phase of discovery and involve issues like undesirable 
absorption, distribution, metabolism, excretion and toxicity (ADMET).   
A full understanding of a successful drug profile is essential to the development 
of future small-molecule new molecular entities (NMEs).18  Optimal drug-like parameters 
and characteristics are generally directed by the Lipinski “rule of 5”15a, which have 
become steadfast guidelines in medicinal chemistry.  The Lipinski “rule of 5” postulates a 
way of improving drug-like characteristics based on a set of molecular descriptors for 
small molecule marketed oral drugs.  These properties include molecular weight, cLogP, 
polar surface area, and the number of hydrogen bond donors and acceptors.   
In addition to the current drug-like parameters, there have been many extensions 
and improvements to categorize drug-like space of small molecules, including accounting 
for chemical composition, substructure scaffolds19 and ring systems within drugs.  Ring 
systems13d are the basic building blocks of most marketable drugs today as they play a 
pivotal role in molecular properties like electronic distribution, three dimensionality and 
scaffold rigidity; and these are key factors in the determination of lipophilicity, molecular 
reactivity, metabolism stability and toxicity.20  Hence, identifying ring systems that 
prevail in current marketed drugs will enable underrepresented structures to be 
highlighted as well, thus enhancing the probability of generating the unique scaffolds 
such as the aforementioned 7- to 11-membered benzofused sultams and non-aryl 7/4-, 
7/5- and 7/6-fused bicyclic sultams. 
Taken collectively, the aforementioned analyses can potentially assist in the 
development of screening collections of structurally diverse compounds that can aid in 
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the discovery of lead compounds in drug discovery.  Small-molecule probes continue to 
gain in importance as new biological targets emerge from the human genome project.  
These probes, which often initiate as hits from screening numerous compound collections 
via high-throughput screening (HTS), can be further developed into powerful tools in 
chemical biology that aid in the identification of fundamental processes in disease-
associated biological problems.21  As stated above, the quality and identity of the 
screening collections is intricately important to the success of the screening approach, 
which in turn emphasizes the significance that synthetic organic chemistry plays and the 
importance of generating quality collections of small-molecules to be screened.22  In the 
end, diversity and suitable physicochemical properties such as sp3-rich compounds will 
undoubtedly play a role in order for probe development to advance further.  
 
1.2 Background and Significance of Medium-sized and Macrocyclic Lactams 
During the past decade, an increasing interest has focused on the generation of 
medium-sized and macrocyclic lactams.  Due to their intriguing physico properties and a 
range of complex natural products being characterized by having lactam structures, their 
total synthesis is a broad field for organic chemists towards the development of new 
strategies and methods to access such ring systems.  In 2001, Nubbemeyer reported a 
relatively extensive review on the synthesis of medium-sized ring lactams covering 
several major methods toward the generation of medium-sized rings, including ring-
closure reactions, cycloadditions, ring-expansion reactions by N-insertion, ring expansion 
reactions by C-insertion, and fragmentation reactions.23   
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In 2009, Troin and coworkers reported the asymmetric synthesis of 7- and higher-
membered ring nitrogen heterocycles. 24   In 2010, Hassan described the recent 
applications of ring-closing metathesis in the synthesis of lactams and macrolactams.25  In 
2011, van der Eycken and co-workers reported a mini review, about microwave-assisted 
synthesis of medium-sized heterocycles, where a diverse range of N-, O- and S-
containing rings were obtained utilizing various reactions.1b  In 2011, Aubé and co-
workers reported an emerging area of medium-bridged lactams synthesized by the 
intramolecular Schmidt reaction, which they defined as a new class of non-planar 
amides.26  In 2014, Azev and coworkers disclosed a mini-review on employing aminoacyl 
incorporation reactions of peptides for the synthesis of medium-sized heterocycles, where 
rigid building blocks such as pyrrolizidines proceeded with a transamidation reaction, 
followed by nucleophilic substitution at a carbon atom of an activated imide group and 
ring expansion.27   
Taken collectively, the chemistry of medium and macrocyclic lactams has 
undergone a period of intense growth with numerous publications appearing throughout 
the years.  In contrast, only three reviews on the synthesis of sultams have been reported 
in the literature, this is surprising considering their broad biological profile (an extensive 
list of chemical and biological properties of sultams will be reviewed in Chapter 2, 
providing details to the structural uniqueness of sultams).  The first sultam review was 
reported by Mustafa in 1954, and covered the chemistry of sultones and sultams.28  Over 
five decades later in 2010, Majumdar and coworkers, reported recent developments in the 
synthesis of fused sultams, covering the period from 2000–2010.29  In 2012, Sokolov and 
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coworkers presented a second review on methods enabling the synthesis of mono- and 
polycyclic sultams.30  However, a full account of specified sultam ring sizes such as 8-, 9- 
10-, and 11-membered, as well as stereochemically-rich sultams, is noticeably absent in 
the literature, warranting the development of additional strategies to facilitate the 
synthesis of these unique structural scaffolds. 
 
1.2.1 Ring Enumeration and Study of Ring Properties 
In 2010, it was reported that the cost of drug discovery for a new molecular entity 
(NME) is estimated to be from $166 million for hit-to-lead and $414 million for lead 
optimization, stressing the significance of efficient and timely choices for both the 
adoption of the initial scaffold as well as subsequent development.31  These alarming 
figures have prompted a number of studies aimed at scaffold analysis.  The following is a 
short summary of contributions in this area.   
A significant report in 1996 by Bemis and co-workers,32 concluded that the shapes 
of half of the 5,120 drugs currently marketed, up till 1995, could be described by using 
32 most frequently occurring frameworks.  The structural data is organized by grouping 
the atoms of each drug molecule accordingly into ring, linker, framework and side chains 
atoms where it was suggested that the diversity of shapes in the set of known drugs is 
extremely low.  In 2003 and 2006, Lewell and co-workers33 and Ertl and co-workers,34 
constructed web-based databases of drug rings, where the second database of Ertl 
consists of five and six-membered rings showing bioactivity that was sparsely distributed 
among a small groups of compounds.  In addition, Vieth and co-workers reported that 
 
12 
30% of the 1,386 currently marketed drugs contain another drug as a scaffold building 
block.19  In 2010, Wang and co-workers35 applied a systematic and comprehensive 
approach to detail the scaffolds and rings in drugs and showed that there was important 
overlap between approved drugs and experimental drugs.  Several databases of rings and 
scaffolds were compared between various groups like Bemis, Lee and co-workers,36 and 
Vieth, noting substantial differences that were associated to the core databases, thus 
demonstrating the significance of a well-documented data set for this type of analysis. 
The aforementioned investigations have revolved around categorizing drug-like 
rings and several research groups have concluded that the number of ring systems in 
drugs, as well as bioactive space, is presently very small, and relegated to sparsely 
populated groups.  Other groups have focused on larger data sets,37 and have showed that 
the number of new molecular frameworks per year has increased since 1959, but these 
frameworks are comprised of a narrow distribution of building blocks derived by the 
assembly of the same small set of building blocks in novel ways, such as through the use 
of Pd-catalyzed cross-coupling chemistry.   
In 2008, Lipkus and co-workers38 analyzed the Chemical Abstracts Service (CAS) 
registry for structural diversity and concluded that a small percentage of frameworks 
occur in a large percentage of compounds.  In contrast, in 2009 Pitt and co-workers39 
compiled a list of possible ring systems that have not been synthesized.  In 2012, Ertl and 
co-workers extended their earlier work,40 and analyzed databases from ChEMBL,41 
DrugBank,42 and ZINC43 in order to generate a database of rings and scaffolds for 
scaffold hopping.   Taken collectively, all of these analyses suggest that synthetic cost is 
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a key factor, and that “chemical decision-making” must become a vital part of the drug 
discovery process. 
Various groups have investigated the properties of rings.  In 1996, Gibson44 and 
co-workers explored the 100 most common heterocyclic rings and derived a principal 
components model for in vitro biological activity.  More recently, two different groups 
explored the importance of aromatic ring count, concluding that more than three aromatic 
rings in a molecule corresponded with an increased risk of attrition in development.45  In 
addition, they defined a new molecular descriptor to assess the potential for a compound 
to be developed further, claiming it to be the second most important descriptor after 
hydrophobicity. 
 
1.3 Analysis of Ring Sizes and Structural Diversity from the Top 200 Drugs List and 
Orange Book of the FDA 
1.3.1 Introduction 
 As stated earlier, the Njardarson Analysis Model contains two parts, the first 
portion is the top 200 U.S. Pharmaceutical Products of 2013, recently published by 
Njardarson and co-workers,13a–b and the second portion includes 1,086 drugs covered in a 
recent mini-perspective by the same group about the structural diversity, substitution 
patterns and frequency of nitrogen heterocycles among the pharmaceuticals.13c  
Njardarson and co-workers have annually assembled a pharmaceutical product list since 
2006, with the ultimate goal of generating new research and teaching tools that exploit 
the pictorial language of organic chemistry in order to gain insight on topics such as 
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structural patterns, frequency of atoms and substructures while also acquiring information 
on the type of chemical structures that are deficient from approved pharmaceuticals.  The 
group has also reported investigations on sulfur, which is the fifth most prevalent 
element, as well as fluorine, a key element in about 20% of recently approved 
pharmaceuticals drugs.46   
The primary intent of the Njardarson Analysis Model is to critically analyze the 
top 200 drugs list by retail sales and prescription, where 47/100 drugs defined by retail 
sales are cyclic pharmaceutical agents excluding aromatic rings.  Furthermore, this list is 
comprised mainly of 4- to 7-membered rings, as well as two macrocycles.  Similarly, 
40/100 drugs defined by prescription were comprised of the same structural component; 
small and common-sized rings and one macrocycle.  Although the data set is relatively 
tiny, the top 200 pharmaceuticals list encompasses only a narrow window of rings, rings 
systems and frameworks, underlining the deficiency of numerous unique heterocycles 
such as 8- to 11-membered heterocycles.  
A second major point brought to light in the Njardarson Analysis Model is the 
validation that nitrogen heterocycles are among the most significant structural 
components of pharmaceuticals in the list of FDA-approved drugs.  Their analysis 
displays the top 25 most frequent nitrogen heterocycles, which highlights the majority of 
the rings as small and common-sized.  Evaluation of their database of FDA-approved 
drugs reveals that 59% (640/1086) of unique small-molecules drugs contain a nitrogen 
heterocycle.  However, within the 59%, only a few components contain 3- to 8-
membered ring sizes as well as > 12-membered ring sizes, with the majority being small 
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and common-sized cyclic scaffolds.  Likewise, to date, there are no 8- to 11-membered 
nitrogen heterocycles among the 1,086 small-molecules drugs reported by Njardarson 
and co-workers.  This is surprising when one considers the number of papers alluding to 
their activity,2,4 as well as potential to modulate protein-protein interactions8 and 
epigenetic targets.9  For the purpose of this discussion, we will be examining the limited 
list of 7- and 8-membered rings, as well as some examples of macrocyclic nitrogen 
heterocycles. 
Before analyzing ring sizes, several definitions as abbreviated by Taylor47 need to 
be explained.  The first is how to define a molecular series that is based on the core 
“rings”, “ring systems” and “frameworks”.  Therefore, by definition, a ring is defined as 
the smallest non-fused moiety with no acyclic (either hydrocarbon and/or heteroatom 
containing) linkers or terminal groups (Figure 1.4).  Next, a ring system is defined as a 
complete ring or rings formed by removing all terminal and acyclic linking groups 
without breaking any ring bonds.  Finally, a framework is defined as containing all the 
ring systems as well as ring systems that are linked by non-terminal acyclic groups 
(Figure 1.4). 
   














































1.3.2 Analysis of Top 200 US Pharmaceuticals and US FDA-Approved Drugs:  
Ring Sizes, Structural Diversity and Frequency of Nitrogen Heterocycles 
1.3.2.1 Analysis of Top 200 US Pharmaceuticals  
 The first part of the Top 200 US Pharmaceuticals list is comprised of two 
segments, which includes the top 100 pharmaceuticals by retail sales and the top 100 by 
prescription.  This is a relatively small list, but contains detailed analysis based on retail 
sales and prescriptions by medical doctors within the USA.  This data set highlights the 
top 200 out of almost 2000 pharmaceuticals established in the Orange Book of the FDA, 
and demonstrates the prevalence and importance of these 200 current drugs and their 
structural components.  One other significant factor of this list is that it categorizes non-
nitrogen heterocyclic small-molecule drugs, whereas other data sets are focused on the 
frequency of nitrogen heterocycles that are FDA-approved.  
Among the 100 drugs listed by retail sales, 33 drugs belong to oligopeptides, long 
chain polymers, proteins, and antibodies that were all removed from the data set.  In 
addition, for obvious reasons, three drugs that contain no rings such as lyrica 
(pregabalin–musculo-skeletal and nervous drug),48 lovaza (omega 3-acid ethyl esters–
cardiovascular drug)49 and Tecfidera (dimethyl fumarate– musculo-skeletal drug)50 were 
disregarded.  Similarly, drugs that contain only aromatic rings were not included as the 
molecular properties of aromatic rings are different than regular rings, namely in the 
absence of sp3 stereogenic centers.  This accounts for the elimination of 17 out of the 
remaining 64 drugs, which implies that only 47 are left to analyze.  Out of the remaining 
47, two drugs are macrocycles51 (cyclosporine–immunosuppressant and sensory organ 
drug and everolimus–anti-cancer and oncology drug), four are sulfonamide-containing 
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scaffolds (darunavir 52 –anti-infective drug and sildenafil 53 –genito-urinary and sex 
hormone drug) and 41 pharmaceuticals contain rings of different sizes (Figure 1.5).  
  
Figure 1.5. Two macrocycles and two sulfonamides from the top 100 list by retail sales. 
As shown in the top 100 drugs list, macrocyclic and sulfonamide-bearing drugs 
represent two unique sets of scaffolds that have attained prominence as pharmaceutical 
agents,  Although benzene-sulfonamide-containing compounds do not possess the 
“sulfonamide moiety within the ring”, and are comprised of mainly common-sized rings 
as substituents that are extending out from the central skeleton, they do play a pivotal 
role, suggesting the importance of ArSO2NR2 motifs.  These highlighted motifs and their 
respective flexible core structure might be assisting in the interaction between the binding 
sites and their respective targets as proven by several structure-activity-relationship 
(SAR) studies that were completed.54  
From these aforementioned 41 pharmaceutical agents, only one drug, Zetia 





































































combination with Simvastatin, have a four-membered lactam surrounded by several 
substituents (Figure 1.6), while 39 compounds are comprised of different types of ring 
sizes in distinctive combinations.  These 39 pharmaceutical agents consist of combination 
drugs, some which cannot be taken individually.  Since this analysis is focused on the  
  
Figure 1.6. 4-membered lactams within the list of the top 100 drugs by retail sales. 
frequency of rings, ring systems and frameworks, these combination drugs were included 
as part of the study.  Within these 39 pharmaceutical agentes, most of them consist of a 
combination of 5-, 6-membered and their respective benzofused systems as shown in 
Figure 1.7.  Different combinations of rings like 6/5-, 6/6-, 7/3- and 6/7/6-fused 
polycyclic systems are among the list.   
 
Many of the drugs are also comprised of rings such as pyrimidin-4-one, 
morpholin-3-one and oxazolidin-2-one as well as several bridged, N-heterocycles in the 
6/5- and 6/6-fused systems.  Only one example in the list is a dibenzothiazepine 
(Seroquel XR–quetiapine), which is a 7-membered nitrogen heterocycle fused with two 
aromatic rings (Figure 1.7).  This is the next largest ring size before macrocycles, contain 
more than 12 atoms in a ring.  There are also examples of polycyclic ring systems 























conformations that are associated with the binding cavity of their respective targets.   
  
Figure 1.7. Examples of different structural pattern in the list of the top 100 drugs by 
retail sales.  
The second segment within the Top 200 US Pharmaceuticals list is the top 100 list 
of drugs by prescription.  This list of pharmaceutical agents is quite similar to the top 100 
list of drugs by retail sales, differing by only four drugs, and signifying the importance of 
the utilization of these drugs by both doctors and patients.  Nearly similar numbers were 
derived from the top 100 list of drugs by prescription as compared to the top 100 by retail 
sales, where 40 out of 100 drugs are comprised of small and common ring sizes, 
highlighting the pivotal role that rings and ring systems play in drug development.  Of 
notable importance, is that there is only a single macrocycle within the current list, 
underscoring the importance of current efforts in the field, including this thesis, in 
developing new chemistry and the corresponding biological assays associated with 



































































An initial summary on the Top 200 US Pharmaceuticals list has described the 
prevailing rings, ring systems and frameworks among the current marketed drugs to be 4- 
to 7-membered heterocycles, two macrocyclic drugs and four sulfonamide-containing 
pharmaceuticals.  The medium-sized heterocyclic rings, in particular 8- to 11-membered 
lactams and sultams are deficient from the top 200 US Pharmaceutical compounds, 
justifying the demand for novel synthetic methods to generate underrepresented cyclic 
scaffolds, as well as generate opportunities for broad biological screening from the 
corresponding molecular libraries. 
 
1.3.2.2 Analysis of FDA Approved Drugs (Frequency of Nitrogen Heterocycles) 
The second portion of Njardarson Analysis Model includes 1,086 drugs compiled 
from the US FDA approved pharmaceutical compounds and the analysis reports on the 
frequency of nitrogen heterocycles amongst the approved drugs.13c  Overall, the database 
contains 1,994 pharmaceuticals and the focus of the investigation is small-molecule drugs 
that are structurally unique; hence, removing combination drugs (253), biologics (146), 
peptides (23) and drug duplications (537), which leaves 1,035 small-molecule remaining 
drugs in the analysis.  The number increased to 1,086 when combination drugs are 
accounted for, where there were 51 small-molecule drugs that were not approved on their 
own but only as part of a combination.  After the compilation, there are 640 small-
molecule drugs containing nitrogen heterocycles, with the list being categorized 
according to the most common structures.  Within the sub-list of 640 small-molecules, 
the top 25 most commonly utilized nitrogen heterocycles were sorted out.  The study was 
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then further divided into seven sections: (a) 3- and 4-membered rings, (b) 5-membered 
rings, (c) 6-membered rings, (d) fused rings, (e) 7- and 8-membered rings, (f) bicyclic 
rings, and (g) macro- and metallocycles (Figure 1.8).13c  For the purpose of the 
discussion, we will be examining the 7- and 8-membered nitrogen heterocycles as well as 
some examples of macrocyclic nitrogen heterocycles.   
 
Figure 1.8. Nitrogen heterocyclic drugs grouped into their relative distributions.13c  
As is evident from Figure 1.8, the prevalence of the rings varies significantly 
ranging from the most common sizes: 6-membered (59%) and 5-membered (39%) 
(common-sized) to the least: 7- and 8-membered, macrocycles and bicyclic compounds.  
Aromatic rings, are no exception, and are common structural features of many approved 
pharmaceuticals.  Based on the bar graph, the two sizes differ greatly with 62% of  
5-membered nitrogen heterocycles being aromatic, compared to only 28% of six-
membered rings (Figure 1.8, five- and six-membered rings).  The fused ring section 
focuses on ring systems that contain more than one nitrogen heterocycle fused together.  
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Ending the graph is the least prevalent ring sizes comprised of macrocyclic rings, 
followed by 7- and 8-membered heterocycles. 
 The analysis outlined in Figure 1.8 also provides data on the breakdown with 
respect to the number of nitrogen atoms within the top 25 most commonly utilized 
heterocycles; such as the fact that 56% contain a single nitrogen atom, 33% contain two, 
4% contains three nitrogens (1,2,4-triazole), and 7% contain four nitrogen atoms 
(tetrazole and purine).  In the list, 56% of the top 25 consist of a single ring, with even 
representation by 6- (7/15) and 5-membered (8/15) rings, and the remaining 44% of the 
top 25 that contain more than a single ring.  These analyses suggest that poorly 
represented ring systems include drugs with more than a single ring (≥ two rings), such as 
bicyclic or tricyclic frameworks, as well as drugs with more than two nitrogen atoms.  
Hence, there is demand for the development of new synthetic methods to facilitate the 
generation of distinct structural components, in particular, bicyclic and tricyclic sultams 
with two or more heteroatoms. 
7- and 8-membered nitrogen heterocycles are predominantly less common than 
their 5- and 6-membered ring counterparts, but as noted previously, they are gaining 
prominence in recent years with significant scaffolds addressing difficult targets.  These 
heterocycles are rapidly emerging as important pharmaceutical core fragments with 
selected scaffolds being considered privileged structures due to their desirable properties 
in tackle challenging targets, as well as more efficient synthetic methods being developed 
to generate these heterocycles.55  The top five most frequently utilized 7-membered 
heterocyclic scaffolds are shown in Figure 1.9, where the first structural class is the 
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benzodiazepine core, followed by similar but reduced analogues such as dibenzo-azepine, 
azepane, dibenzo-oxazepine and benzo-azepine.  All scaffolds assessed are benzofused 
except one, implying that the majority are unsaturated and flat.  
  
Figure 1.9. The top five most common 7-membered nitrogen heterocycles.  
As shown in Figure 1.10, the top four most commonly occurring structures 
contain bridged bicyclic cores.  The most frequent nature-derived or inspired structural 
component is the morphinan architecture, followed closely by the tropane family of 
alkaloids and quinuclidine core, representing the third most commonly used core.  As 
seen earlier in Figure 1.7 (page 19), oxycodone is one of the examples, which contains 
the morphinan core, as well as others such as buprenorphine, which is the most complex 
structure with an intriguing bridging carbon chain installed.  Included in this list is the 
tropane-containing drugs, including the most infamous member, cocaine, which contains 
the carboxylate group, whereas other examples lack it (Figure 1.10).  
  
Figure 1.10. The top four most common bridged bicyclic nitrogen heterocycles and 
examples of morphinan and tropane core drugs.  

















































limited list of structural components by which the majority of the small-molecule drugs 
are comprised of mainly small- to common-sized (4- to 7-membered) cyclic scaffolds, 
aromatic derivatives and approximately nine macrocycles.  Many of the small-molecules 
drugs are single ring, although statistics have shown that about 44% are more than a 
single ring.  The majority of the ring combinations are 6/5-, 6/5-, 7/6-, 6/7/6-, 6/6/6- as 
well as many others.  But to-date, there are numerous underrepresented ring sizes, ring 
systems and frameworks, namely 8- to 11-membered benzofused sultams, which if 
supplemented, would provide chemical novelty to the entire data set of FDA-approved 
drugs.  
 
1.3.3 Examples of Macrocyclic Nitrogen Heterocycles  
 Nitrogen-containing macrocycles have emerged as promising pharmaceuticals 
with cyclosporine and everolimus, a derivative of sirolimus (rapamycin), occurring 
within the top 200 drugs list (Figure 1.5, page 17).  Furthermore, almost all of the 
macrocycles are natural products or analogues of natural products (Figure 1.11).  
Tacrolimus,56 is a derivative of sirolimus, while rifaximin57 is derived from rifamycin,58 
an antibiotic.  Plerixafor is a bicyclam derivative, where all eight nitrogen atoms are 
strongly basic.59  In addition, the two macrocyclic rings chelate with metals like zinc, 
copper and nickel to form complexes, where the biologically active form occurs upon 




Figure 1.11. Representative examples of nitrogen macrocycles derived pharmaceuticals. 
 
1.3.4 Conclusion 
 In short, the critical information provided by both drug lists–top 200 drugs by 
retail sales and by prescription and nitrogen heterocycles in the FDA approved drugs–is 
the prevalence of small-molecules pharmaceuticals in the FDA approved drugs.  In this 
regard, the prevailing structural components are 4- to 7-membered cyclic scaffolds, of 
which 59% contain a nitrogen heterocycle and the remaining comprised of carbon and 
sulfur rings.  In addition, data was presented with nine macrocyclic drugs (> 12-
membered rings), as well as many aromatic-bearing pharmaceutical agents.  Most 
importantly, underrepresented structural components include a diverse collection of rings, 
ranging from 8-, 9-, 10-, 11- and 12-membered and their respective benzofused 
derivatives.  Fused and bicyclic systems containing nitrogen and sulfur atoms are less 
than 44% as well as the count of nitrogen in the ring(s), where more than 2 nitrogen 
atoms are contained in a ring(s) are less than 11%.  This inadequately represented space 















Tacrolimus: R1 = OH, R2 = HC=CH2
























development of efficient, adaptable, robust and scalable methods to provide more 
significant and unique scaffolds for biological assays.  
 
1.4 Analysis of Top 100 Most Frequently Used Ring Systems in FDA Orange Book: 
Ring Sizes and Structural Diversity 
1.4.1 Introduction 
 The second list analyzed is the Taylor Analysis Model, which contains 1,175 
drugs in a 2014 report entitled “Rings in Drugs”, adapted from Taylor and co-workers.13d 
The list is compiled from the FDA Orange Book14 for NMEs till the end of 2012 as the 
basic resource and then cross-referenced against ChEMBL,41 DrugBank,42 Wikipedia,61 
Nature Drug Reviews,62 the FDA Web site14 and the Annual Reports in Medicinal 
Chemistry.63  A well-combined list of drugs obtained from different resources will enable 
the various nitrogen heterocycles prevailing in the FDA-approved pharmaceuticals to be 
highlighted and helps in the identification of underrepresented ring sizes, ring systems 
and frameworks.  
  
A brief summary of the rings in current marketed drugs is the discovery of only 
351 ring systems and 1,197 frameworks in drugs, which came onto the market before 
2013 based on the existing list of 1,175 marketable drugs.  In addition, prior to 1983, the 
most frequently used ring systems were first used in drugs 83% of the time, and prior to 
this time, it was very seldom for a drug to contain more than one new ring system.  
Furthermore, on average, six new ring systems enter drug space on a yearly basis while 
only ~28% of new drugs contain a new ring system.  In light of this fact, the most 
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frequent non-aryl bicyclic lactams consist mainly of 6/4-, 5/4-, 7/6- and 6/5-fused 
systems.  In addition, there are more single lactams than bicyclic lactams.  Other 
heterocycles, that are less frequent, include benzofused sultams, bridged, bicyclic  
N-heterocycles and 7-membered cyclic scaffolds, that will be discussed further in the 
subsequent two sub-sections.  Syntheses of 6-membered benzofused sultams and bridged, 
bicyclic N-heterocycles will be briefly discussed, as they are relevant to Chapters 2–4.  
These observations provide insights into the chemical novelty of drugs in a 
molecular scaffold design process and highlight the potential demand for new ring 
systems or frameworks, with low synthetic cost to develop compound libraries 
efficiently–based on the core ring systems/molecular fragments derived–from hit 
identification to lead optimization and beyond.  In addition, this documentation of ring 
systems and frameworks provides an innate description of chemical space that is 





1.4.2 Analysis of Ring Systems with Amides or Amide-types Motifs 
The aforementioned Taylor Analysis Model of 1,175 drugs derived from FDA-
approved drugs, and cross-referenced with different resources, furnishes the ring sizes 
and structural diversity analysis of top 100 most frequently used ring systems.  The 
analysis discussed in this section involves an assessment of the Taylor database for ring 
systems with amides or amide-type motifs, and begins by removing other groups of 
drugs, such as oligopeptides, long chain polymers, proteins, antibodies, acyclic drugs and 
large macrocycles, as well as applying other filters from the data set, resulting in the basis 
set of 1,175 drugs.   
Based on this new basis set of drugs, the top 100 most frequently used ring 
systems were generated, and from this list, the ring systems that contain amides or amide-
type of functional motifs were compiled.  From this list, 20 out of the top 100 ring 
systems were small (4-membered fused and non-fused) and common (5-, 6- and 7-
membered fused and non-fused) in different possible combinations, with the exception of 
7/4- and 7/5-fused bicyclic scaffolds that were absent (Figure 1.12).  In regards to 
frequencies, these 20 motifs are only moderately common (122 out of 1,501 reported), 
and underscore the demand for developing facile, dynamic and highly adaptable methods 
to construct new and unique ring systems and frameworks such as non-aryl 7/4- and 7/5-
fused bicyclic sultams.   
Also, within the list, only a handful of ring systems have stereocenters.  
Moreover, those which possess stereogenic centers, have them located between fused 
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rings, substantiating the need for scaffolds possessing more broad ranging sp3 stereogenic 
centers.  Taken collectively, many of the scaffolds in this analysis are relatively flat and 




Figure 1.12. Representative examples of motifs within the top 100 most frequently used 
ring systems sorted by descending frequency (f). 
 
1.4.3 Analysis of Ring Systems: Sultams, Bridged and Azepine Scaffolds 
In addition to the first 20 out of 100 ring systems as previously described in 
section 1.4.2, there are certain unique ring systems added to the compilation, including: 
6-membered benzofused cyclic sulfonamides (benzo-thiadiazine 1,1-dioxides), bridged 
bicyclic heterocycles (quinuclidine and 8-azabicyclo[3.2.1]-octane), simple secondary 
amines (azepane), tricyclic benzofused rings (dibenzoazepine and benzotriazolo 





























































































































where 8 out of 100 ring systems are accounted in this section as denoted in Figure 1.13.  
Likewise, these systems are even less frequent (34 out of 1501 reported) than the 
aforementioned examples, and many understated ring sizes and ring systems are not 
found in the list (e.g. 7- to 11-membered benzofused bridged and non-bridged sultams 
and medium-sized heterocycles).  Also, these scaffolds lack 3-dimensionality as well as 
contain a small fraction of sp3 carbons, heightening the demand for more synthetic 
methods to produce novel rings, ring systems and frameworks comprising more drug-like 
physical properties, preferably with low synthetic cost.  
  
Figure 1.13. Unique examples of motifs within the top 100 most frequently used ring 
systems sorted by descending frequency (f). 
 
Two drug classes that are relevant to this thesis, namely, benzothiadiazine 1,1-
dioxides and quinuclidines will be presented.  Benzothiadiazine 1,1-dioxides, also known 
as sultams, have been utilized as non-steroidal anti-inflammatory drugs (NSAIDs), such 
as piroxicam64 which relieves symptoms of pain, inflammation, swelling, stiffness, and 









































analgesic, anti-inflammatory and anti-pyretic properties (Figure 1.14).  A slightly more 
extensive list of biologically active sultams can be found in Chapter 2.  
  
Figure 1.14. Examples of benzo-thiadiazine 1,1-dioxides-containing drugs. 
The second core component is quinuclidine, which is an interesting [2.2.2]-
bridged bicyclic nitrogen heterocycle found in some drugs for instance quinine, 
quinidine, aclidinium and palonosetron (Figure 1.15) and relevant to the 8-/9-membered, 
bridged bicyclic sultams developed in Chapter 2, vide infra.  Both quinine and quinidine, 
derived from natural products are stereoisomers of each other, and have different 
therapeutic effects.  Quinine is a fever-reducing, anti-malarial and anti-inflammatory 
drug, while quinidine is a class I anti-arrhythmic agent.67   Aclidinium is an inhaled 
muscarinic antagonist, and is used in the treatment of chronic obstructive pulmonary 
disease (COPD),68 whereas palonosetron is a 5-HT3 antagonist used in the prevention and 
treatment of chemotherapy-induced nausea and vomiting (Figure 1.15).69 
 


























































As concluded previously, the prevailing rings and ring systems in the current 
marketed pharmaceuticals are the common-sized (5- to 7-membered) heterocycles, as 
well as 6/5- and 6/6-fused bicyclic scaffolds, as seen by the number of reported syntheses 
and examples of drugs.  The data provided emphasizes the importance of investigating 
understudied ring systems and frameworks that are not on the radar of the current 
analysis., thus heightening the demand for new chemical methods that will be able to 
furnish the novel rings and ring systems.  
 
1.5 Summary and Outlook 
In conclusion, the analyses summarized within Chapter 1 provide insight into 
scaffold mining, by providing a number of important categories of analysis, such as  
(i) the limited size of chemical space70 being occupied by ring systems of all current 
drugs, and (ii) the insufficient number of new chemotypes introduced into drug space; 
The analyses also postulate insight to the design of hit-finding libraries, where libraries 
can be benchmarked to assist in the search of different combinations of drug ring systems 
and in the optimization of molecules.  Useful data for known novel ring systems can be 
retrieved from databases and evaluated during optimization for either the initial hit 
molecule or more developed lead if the ring systems are present in the candidates.  The 
plethora of valuable and extensive data that can be gleaned from the Njardarson and 
Taylor databases will be of assistance, with respect to scaffold and library design, 
intellectual property, and potential biological activity.   
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The ring system chemical space of all currently available drugs is a very small 
fraction, as indicated by the ring sizes and structural diversities analyses.  Ideally, novelty 
is often assessed by the nature of the scaffold and since only 30% of the drugs on the 
market contain novel ring systems, there is a demand for chemical novelty to be 
introduced into new scaffolds.  However, it was also suggested that chemical novelty is 
not as important as bringing together the correct ring systems from drug space.  If the 
arrangement of ring systems is new and can be uniquely introduced, it may provide an 
optimal solution.  In addition, it seems that medicinal chemists depend heavily on a 
subset of ring systems that has not changed since 1982, which is partially due to synthetic 
expediency and time-constraints of industrial projects.71   
Upon the evaluation of several databases, it is quite evident that there is a huge 
void of medium-sized heterocycles within all the lists described in this Chapter, hence 
warranting the development of facile and efficient methods for the synthesis of new 
cyclic scaffolds.  Preferentially, this will occur with economical cost in mind as there are 
many new chemical vendors providing unique and interesting building blocks.  With the 
new scaffolds in place, it will be possible to explore unknown or underrepresented 
chemical space, which will be guided by drug-like molecular properties, as well as a 
broad biological screening.  This is turn could enhance the number of hits, leads, probes 
and possibly drugs to treat diseases and syndromes that effect human health.  The 
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2.1 Introduction  
Medium-sized heterocycles ranging from 8- to 11-membered cyclic scaffolds 
comprise an underrepresented structural ring component as detailed in Chapter 1.  The 
various analyses of pharmaceutical agents crafted in the Njardarson and Taylor 
Heterocyclic Rings in Drugs Analysis Models summarized in Chapter 1 highlight the 
prevalence of rings and ring systems for 4- to 7-membered rings consisting of nitrogen 
and oxygen heterocycles, all-carbon core scaffolds and selected examples of 
fluorine/sulfur-bearing rings among more than 1,000 existing pharmaceuticals.1  The 
Njardarson and Taylor analysis models also provide insight into the chemical innovation 
of drug development and emphasize conceivable, low-cost strategies that are necessary to 
increase the likelihood of developing new frameworks from hit identification to lead 
optimization and beyond.  In Chapter 2, we report a facile strategy termed “Reaction 
Pairing” that is a method comprised of three simple reactions, namely sulfonylation, 
SNAr, and Mitsunobu alkylation reactions, which can be carried out in different pairing 
sequences using simple building blocks to facilitate the construction of unique, bridged- 
and fused-tricyclic, 7- to 10-membered benzofused sultams.2  These sultam scaffolds lie 
within new chemical space when mapped using the cartesian grid-based chemical 
diversity analysis, overlay analysis, principal moments of inertia (PMI) analysis, 
conformational analysis and quantitative estimate of drug-like (QED) values provided at 
the end of the Chapter 2, vida infra.2   
The development of new strategies to access diverse heterocyclic collections for 
high throughput screening (HTS) are an important aspect in modern drug discovery.  
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Advances in the fields of genomics and proteomics during the “post-genome era” have 
progressed rapidly, resulting in an increase in potential therapeutic targets for which there 
are no known small-molecule modulators.3  Thus, there is an ever growing demand for 
functionally diverse and complex libraries of small molecules.  Despite considerable 
efforts in this area, the lack of adequate screening technologies and diverse libraries of 
molecules has remained a hurdle within the scientific community.4  As early as 1997, 
Armstrong and coworkers utilized the concept of Scaffold-from-Scaffold5 to demonstrate 
the enhanced of skeletal diversity from a single scaffold.  This elegant concept has been 
utilized by others in the field and was an early example of what has become known as 
Diversity-Oriented Synthesis (DOS).  In this regard, DOS has emerged in recent years as 
an enabling strategy for the production of diverse collections of heterocycles. 6  
Representative examples of DOS strategies include numerous uses of build-couple-pair 
(BCP),7 functional group pairing,8 and split-pool synthesis.9  These methods as well as 
other innovative strategies have advanced the generation of chemical libraries that are 
rich in functional diversity, consisting of appendage, functional group, stereochemical 
and skeletal diversity.10  Taken collectively, these methods have emerged to address 
modern biological challenges and also offer new chemical opportunities.  In this regard, 
the continual identification of unique, underexplored subsets of chemical space that are 
sparsely populated, has the potential to continue to affect probe design and basic 
chemical biology.   
The Hanson group has been interested in the development of new motifs that are 
underrepresented subsets of chemical space.  In particular, as part of a program aimed at 
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developing new chemistry toward novel phosphorus- and sulfur-based heterocycles, 
efforts have been devoted toward the exploration of sulfonamides and their 
corresponding cyclic analogs (sultams).  The goal of this study is aimed at studying the 
unique properties of sulfonamides and sultams utilizing chemical methods and molecular 
library development, as well as biological screening, for ultimate use in drug discovery.11  
2.1.1 Biological Profiles of Sultams (Cyclic Sulfonamides) 
Sultams are cyclic sulfonamides that represent a class of non-natural chemotypes 
that have gained interest in recent years due to their activities against a broad spectrum of 
biological targets,12 including several with medicinal value.  In addition, their innate 
properties have enabled their widespread use as reagents, 13  chiral auxiliaries in 
asymmetric catalysis14 and ionic liquids as novel reaction medium.15  In particular, 
common- and large-sized benzofused sultams (benzannulated sultams), possessing a rich 
content of sp3 amine functionality, have shown a wide biological profile.  They include 
inhibitory properties against a variety of enzymes such as HIV integrase,16 Calpain I,17 
TNF α-converting,18 cyclin-dependent kinases (CDKs)/vascular endothelial growth factor 
receptor tyrosine kinase (VEGF-RTK)19 with anti-proliferative activities and trypsin-like 
serine protease Factor XIa involved in blood coagulation.20  Moreover, sultams have 
displayed activities such as anti-psychotic,21 anti-HIV,22 and anti-leukemic,23 as well as 
small-molecule inhibitor of lysosomal acidification,24 allosteric modulation of AMPA 
receptor,25 modulation of histamine H3-receptor,26 and glucokinase activation,27 to name a 
few (Figure 2.1).   
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Sultams have also been utilized as non-steroidal anti-inflammatory drugs 
(NSAIDs), such as tenoxicam,28 which relieve symptoms of inflammation, swelling, 
stiffness, and pain associated with rheumatoid arthritis; and lornoxicam29 that possess 
analgesic, anti-inflammatory and anti-pyretic properties (Figure 2.1).  There are also 
numerous reported syntheses of biologically active benzo-thiadiazine 1,1-dioxides and 
the related analogues,30 and some examples include inhibitors of the proliferation of non-
small cell lung cancer31 and HCV NS5B polymerase,32 as well as SUR1-selective KATP 
channel openers.33 
  
Figure 2.1. Representative examples of bioactive sultams and sultams as drugs. 
 
2.1.2 Chemical Profiles of Sulfonamides and Sultams 
 Sulfonamides and their cyclic analogs (sultams) have distinct and unique 







































































































that have the potential of effecting biological systems, and thus warrant continued 
investigations of these non-natural core motifs in drug discovery.  Sultams are often 
referred to as lactam surrogates with molecular properties that differ greatly.  While a 
number of heterocycles have been extensively studied in the field, the sultam class 
occupies a much smaller segment of chemical space as evident by the comparison to all 
heterocycles in the Pubchem database.34  The comparison parameters in the Pubchem 
database were setup using molecular properties such as CLogP, polar surface area and 
molecular weight].  In addition, chemical properties such as hydrolytic stability and 
crystallinity, further impart differences between sultams and other comparable 
heterocycles.  Most strikingly, the sp3 character of a sulfonamide/sultam is vastly 
different than their planar amide counterparts, relegating them to “non-flatland status” in 
molecular architecture as demonstrated by the X-ray structures of several benzofused 
sultams displayed in Figure 2.2.   
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In 2004, Hofmann and co-workers 35  reported a systematic study of the 
conformation of the sulfonamide bond and the respective amides at different levels of ab 
initio MO theory.  The distinct differences between the two motifs are as follows:  
(a) different values of the torsion angle ω (∠CαSNCα), which are about –100 and 60º in 
the two basic conformers of the sulfonamide bond, and 180 and 0º for the peptide bond, 
(b) the rotation barriers around the S–N bond, are distinctly lower than that for the 
peptide bond, hence imparting more flexibility in sulfonamido peptides, and (c) the 
nature of the sulfonamide nitrogen is pyramidal in comparison to a planar arrangement of 
the peptide amide bond.  Calculations also indicated that during the cis/trans 
isomerization of an amide peptide bond, the trans isomer is favored over the cis isomer 
due to the lower energetic values, and because of the structural conformation, this 
ultimately limits the reactivity of amides (Figure 2.3).   
In 2013, in collaboration with Lushington, Mulliken charges36 were calculated 
(Figure 2.4) for three different moieties–o-fluoro sulfonamide, phosphonamide and 
amide–where o-fluoro-N-methylbenzenesulfonamide was found to be more 
electropositive than o-fluoro-N-methylbenzamide, which are the least electropositive. 
These calculated values further substantiated the known lower pKa values of 
sulfonamides when compared with amides and phosphonamides.  This latter property  
 

















                         
Figure 2.4. Mulliken charges for an o-fluoro sulfonamide, phosphonamide and amide.  
(pKa), imparts unique chemistry with sulfonamides that can be exploited in sultam 
synthesis, such as mild alkylation conditions and the ability to undergo facile Mitsunobu 
reactions as well as intramolecular SNAr cyclization reactions, vide infra (Figure 2.5).  
  
Figure 2.5. Mild reaction conditions for sulfonamide and harsher conditions for others. 
A beneficial feature in the chemistry of sulfonamides is the ability to use high 
yielding click reactions in their formation, as well as in subsequent reactions, as shown in 
Figure 2.6.  In 2001, Sharpless and co-workers37 coined the term “click chemistry” to 
describe an approach that consists of a set of highly reliable and selective reactions for 
the rapid synthesis of valuable new compounds.  In this work, Sharpless further defined a 
set of stringent criteria that reactions must meet to be useful in this context.  The reaction 
must be modular, wide in scope, high yielding and must occur with simple reaction 





























































examples of carbon-heteroatom bond-forming reactions, including the following classes 
of chemical transformations are: (i) cycloaddition transformations, (ii) nucleophilic 
substitution chemistry particularly ring-opening reactions of strained heterocycles, (iii) 
carbonyl chemistry of the “non-aldol” types and (iv) additions to carbon-carbon multiple 
bonds.  In this seminal work, Sharpless also defined many reactions which are useful in 
sultam synthesis as “click reactions”, including: sulfonylation, sulfonamide alkylation, 
epoxide-opening, and sulfonyl aziridine-opening (Figure 2.6).  The importance of this 
latter point will become evident throughout this thesis. 
 
Figure 2.6. Representative examples of “Click” chemistry. 
In summary, the promising biological and chemical profiles of 
sultams/sulfonamides engender properties that promote them as attractive motifs for 
facile compound synthesis and drug discovery.  In this regard, it is the goal of this thesis 
to synthesize unique and underexplored sultam scaffolds and evaluate their properties by 
the several computational analyses in order to produce underrepresented ring systems 
with potential biological significance.  With this intention in mind, the remainder of this 
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sultams.  All compounds produced have been submitted for broad biological screening 
within the NIH Molecular Library Probe Center Network. 
 
2.1.3 Synthesis of Sultams: Intramolecular SNAr Methods  
Several classical methodologies have been developed for the synthesis of the 
sultam ring systems including use of Diels-Alder reaction,38 [2+2],39 [3+2],40 and [4+2]41 
cycloadditions, Michael–epoxide-opening cyclizations,42 base-, coupling reagents- and 
halogens-promoted cyclizations, 43  SN2 reactions, 44  and use of the Baylis-Hillman 
reaction.45  More recently, transition metal-catalyzed reactions for the construction of 
sultam skeletons have gained prominence, including: (a) Cu-catalyzed, 46  (b) Pd-
catalyzed,47 (c) Rh-catalyzed,48 (d) Ir-catalyzed49 cyclizations, as well as (e) ring-closing 
metathesis (RCM).50  In addition, radical cyclization procedures have also been utilized 
for the generation of sultam cores.51  Some of these methods have been covered in the 
recent two reviews reported in 2011 and 2013, respectively.52  Despite several innovative 
methods outlined in these recent reports, DOS strategies employing intramolecular SNAr 
reactions for the synthesis of sultams are much less prevalent than other reported 
approaches.  
Long standing interest in the facile generation of sultam scaffolds has prompted 
the exploration of a new approach we term reaction-pairing strategy described below.    
o-Haloaryl sulfonyl chlorides and their corresponding sulfonamides have emerged as 
highly versatile synthons for the generation of sultam scaffolds,53 which our group has 
developed, and which will be discussed more in Chapter 3.  For the remainder of Chapter 
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2, focus will be placed on the development and extension of the concept of reaction 
pairing and the corresponding pathways that have been investigated.  Before discussing 
our efforts, a summary of SNAr methods to generate sultams by other researchers will be 
reviewed.   
Reports of intramolecular heteroaryl cyclizations en route to sultams first surfaced 
in the 1990's, when Giannotti and co-workers54 reported ring closure on 2-amino-N-(2-
chloropyridin-3-yl)-N-methylbenzenesulfonamides in the presence of K2CO3 and DMF at 
reflux temperature to afford sultam 2.1.2 (Scheme 2.1).  In contrast, if an amide was 
employed, CuBr/Cu powder was required in the reaction to provide dihydro-dipyrido-
thiadiazepine 5,5-dioxide 2.1.4 in good yields.  
Scheme 2.1. Intramolecular heteroaryl cyclizations en route to sultams 
 
 In 2008, Penso and co-workers55 described the synthesis of polyfunctionalized 
benzo[d]sultams 2.2.2 and 2.2.3 that contain an α-amino ester unit, utilizing 
complementary solid-liquid phase transfer catalysis (SL-PTC) and homogeneous 
protocols (Scheme 2.2).  The investigations commenced with the optimization of 
cyclization reaction conditions using N-alkylated sulfonamides resulting from the 
alkylation of (pentafluorobenzene)sulfonamide with MeI, K2CO3 and 
triethylbenzylammonium chloride additive (TEBA) in MeCN using SL-PTC conditions 




























COMe2.1.1 2.1.2 2.1.3 2.1.4
 59 
solvent, indicated by the formation of an equimolar adduct (enolate:DMSO) as the 
plausible activated species to provide sultam 2.2.2.  Next, the homogeneous conditions 
with different bases, solvents and temperatures were studied, where the optimal 
conditions are DBU in MeCN at 25 ºC for 16 h, to afford the non-N-alkylated benzofused 
sultam 2.2.3 in excellent yield (Scheme 2.2).  The method was extended to a “one-pot” 
alkylation/cyclization employing SL-PTC reaction conditions, to generate a range of 
benzo-isothiazole-3-carboxylate 1,1-dioxides in modest to excellent yields depending on 
the alkylating reagents, with more sterically hindered alkylating reagents (BnBr and 
allylBr) furnishing lower yields. 
Scheme 2.2. Synthesis of polyfunctionalized benzo[d]sultams  
 
 In 2010, Cleator and co-workers56 reported a one-pot multi-component (MCR) for 
the synthesis of benzoxathiazepine-1,1-dioxides employing commercially available 
amines and epoxides (Scheme 2.3).  Concurrently, our group was investigating similar 
work57 and the results were published almost simultaneously in the literature.  The 
Cleator synthesis began in a stepwise fashion, with similar reaction conditions as the one-
pot protocol; benzylamine and K2CO3 in 1,4-dioxane at room temperature afforded the 
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dioxane at 100 ºC in the presence of tetra-n-butylammonium bromide (nBu4NBr), K2CO3 
and O-benzyl glycidyl ether to furnish the corresponding product 2.3.3 in 34% yield and 
the uncyclized, epoxide-ring opened sulfonamide 2.3.4 in 38% yield.  This initial 
observation lead the authors to proceed with the one-pot procedure where both amine and 
O-benzyl glycidyl ether were added to the mixture with nBu4NBr and K2CO3 in 1,4-
dioxane at 100 ºC for 72 h to afford the anticipated product in a higher yield of 75% 
(Scheme 2.3).  Different halogen substituents on the aryl ring were investigated, as well 
as an extension to Pd-catalyzed cross coupling, with the brominated scaffolds derived 
from the aforementioned method.  
Scheme 2.3. One-pot multi-component (MCR) for the synthesis of sultams 
 
In 2010, Schreiber and co-workers58 employed a build-couple-pair DOS strategy 
to effect an intramolecular cyclization pathway using an SNAr reaction for the ring 
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reaction conditions (NaH in THF) (Scheme 2.4).  Control of the temperature between -10 
and 0 °C was needed to obtain the endocyclic product 2.4.2 selectively in 75% yield.  In 
comparison, the anti-diastereomer (2R,3R)-2.4.3 only reacted at room temperature under 
the same conditions, generating (3R,4R) benzo-oxathiazepine 1,1-dioxide 2.4.4 in 
moderate yield due to lower selectivity of the ipso-substitution relative to the Smiles 
rearrangement. 
Scheme 2.4. SNAr cyclization pathway to sultams 
 
 In 2010, Juhl and co-workers59 reported a versatile conjugate addition–SNAr 
domino reaction for the synthesis of bicyclic benzo- and pyridyl-fused lactam and sultam 
derivatives.  The optimized reaction conditions are NaHMDS in DMF at 200 ºC for 1–4 h 
under mW irradiation to generate products 2.5.3 and 2.5.5 (Scheme 2.5).  These 
conditions were plagued with several problems, where oligomerization of the conjugate 
addition intermediates, decomposition of some substrates and incomplete conversion of 
starting material were observed.  In order to circumvent these issues, the authors 
modified the conditions, where slow addition of a dilute solution of the alkyne 2.5.2 to a 
pre-heated, deprotonated amide solution, was effective for certain substrates.  The authors 
found that use of 2 equivalents of alkyne allowed full conversion of starting material, and 
that controlling the temperature between 100 to 200 ºC prevented decomposition of the 

























substrate, a lower yield of 35% was observed, substantiating the fact that sulfonamides 
are better substrates than amides for this reaction pathway (Scheme 2.5).  This 
observation is most plausibly due to the higher electron-withdrawing ability of 
sulfonamides, which allows for a more facile ring-closing step with shorter reaction times.  
Moreover, very little oligomerization of the resulting intermediates was noted.59  
Scheme 2.5. Conjugate addition–SNAr domino reaction for the synthesis of sultams 
 
While these aforementioned strategies synthesized mostly common ring sizes (5- 
to 7-membered), to the best of our knowledge, there are only a handful of reports on the 
synthesis of medium sized (8- to 11-membered) sultams.  In 2011, Marcaurelle and co-
workers7e reported an aldol-based, “Build-Couple-Pair” (BCP) strategy for the synthesis 
of stereochemically diverse 8-membered sultam and lactam scaffolds via SNAr 
cycloetherification (Scheme 2.6).  In this method, each scaffold contained two handles, 
an amine and aryl bromide for solid-phase diversification via N-capping, and Pd-
mediated cross coupling.  For this section, only the Marcaurelle synthesis of sultams will 
be discussed.  In this regard, the build phase involved a series of asymmetric syn- and 
anti-aldol reactions, where four stereoisomers of a Boc-protected β-hydroxy-γ-amino 
acid were produced.  In the couple step, the chiral acid and resulting protected amines 
were coupled and reduced to generate elaborate building blocks comprised of all 8 
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stereoisomers with 4-bromo-2-fluorobenzenesulfonyl chloride 2.6.1 in order to furnish a 
series of benzofused sultams 2.6.4 in good yields (Scheme 2.6).   
In this BCP method, two sets of reaction conditions were employed for the 
cycloetherification step.  Thus, depending on the stereochemistry of the building blocks, 
sulfonamides bearing 2R,5S,6R and 2S,5S,6R stereochemistry derived from the syn-aldol 
were easily converted in a single step using method A (CsF, DMF at 85 ºC), whereas for 
sulfonamides bearing 2R,5S,6S and 2S,5S,6S stereochemistry and derived from an anti-
aldol, were converted in a two-step approach employing method B (CsF, DMF at 85 ºC, 
then NaH, THF, 0 ºC to rt) (Scheme 2.6).  Use of just CsF initially yielded a mixture of 
TBS-deprotected, uncyclized material along with some product.  However, treatment of 
the mixture with NaH in THF provided the complete conversion of starting material to 
the respective products 2.6.4 (Scheme 2.6).  With the scaffolds in hand, library 
diversification proceeded to generate 8000 compounds that were evaluated by various 
chemical informatics analysis, such as multifusion similarity (MFS) maps, Tanimoto 
coefficient and principal component analysis (PCA). 
Scheme 2.6. Aldol-based “build-couple-pair” strategy for the synthesis of 




























































In summary, while the SNAr reaction has been used for the construction of 
benzofused sultams, the methods outlined above, focused mainly on small ring sizes (5- 
to 7-membered),54–59 and more recently by Marcaurelle and co-workers in 2011,7e 
accessing 8-membered benzofused sultams.  In this regard, it was the aim of this thesis to 
extend the scope of the sultam methods using more unique building blocks.  In the 
following section (Section 2.2), we describe a strategy termed “reaction pairing”, which 
employs o-fluoroaryl sulfonamide SMs that undergo facile nucleophilic aromatic 
substitution (SNAr) for the rapid generation of 7- to 10-membered benzofused sultam 
scaffolds. 
 
2.2 Results and Discussion 
In the course of designing new methods for sultam synthesis, we have developed 
an orthogonal reaction pairing strategy we term “Reaction Pairing” that employs the use 
of three reactions, namely sulfonylation, Mitsunobu alkylation and SNAr for the facile, 
efficient and modular synthesis of sultams (Figure 2.7).2  The main concept in reaction 
pairing is the “pairing of reaction pathways” that are orthogonal (mutually exclusive) to 
each other.  The utility of this related strategy lies in its potential to generate diverse 
skeletons from a single central bi-functional core without the need for the construction of 
an elaborate multi-functional scaffold (Figure 2.7).  The reaction probability of bi-
functional scaffolds can be exploited to obtain skeletally diverse motifs by simply pairing 
the core scaffold with compatible synthons via suitable orthogonal reaction pathways, 




Figure 2.7. Three different reaction pathways to diverse benzofused sultams. 
 While sulfonylation and Mitsunobu alkylation are well precedented for 
sulfonamides,60 the ability of these synthons to undergo facile SNAr is far less prevalent, 
as previously noted in the section above.  Collectively, it was therefore envisioned that 
pairing of the reaction triad (sulfonylation, SNAr addition and Mitsunobu alkylation) in 
varying order alongside the central o-fluorobenzene sulfonyl chloride building blocks 
could afford rapid access to both bridged- and fused-tricyclic sultams (Figure 2.8).  This 
simple approach obviates the need for construction of elaborate multifunctional scaffolds 
and merely requires o-fluorobenzene sulfonyl chlorides, amines and alcohols as building 
blocks.  Simple changes in the reaction pair sequence (e.g., sulfonylation–SNAr vs 
sulfonylation–SNAr–Mitsunobu vs sulfonylation–Mitsunobu–SNAr) or changes in 
building blocks (1,2-amino alcohol vs 1,3-amino alcohol) allows access to skeletal and 

















































Figure 2.8. Reaction pairing strategies to diverse benzofused sultams. 
 
2.2.1 Optimization Studies 
Investigations commenced with the exploration of pairing (S)-prolinol with 4-
bromo-2-fluorobenzenesulfonyl chloride 2.7.1 via a combination of sulfonylation, SNAr 
and Mitsunobu methods (Scheme 2.7).  Thus, (S)-prolinol was sulfonylated with 4-
bromo-2-fluorobenzenesulfonyl chloride in CH2Cl2/H2O, in the presence of NaHCO3, to 
provide β-hydroxy o-fluorobenzene sulfonamide 2.7.2 in 97% yield.  Subjection of the 
sulfonamide to microwave (mW) irradiation at 150 ºC for 30 min in DMF in the presence 
of Cs2CO3 gratifyingly produced the benzofused tricyclic sultam 2.7.3 in 88% yield.  In 
contrast, SNAr addition of (S)-prolinol to n-butyl-derived o-fluorobenzene sulfonamide 
2.7.4 under mW irradiation in DMSO at 140 ºC for 30 min afforded the desired SNAr 
adducts 2.7.5 in 97% yield (Scheme 2.7).  Addition of PPh3 to a stirring solution of the 
prolinol-derived SNAr adduct in THF (0.05 M), followed by slow addition of DIAD, was 
found to proceed quickly (10 min) to furnish the desired tricyclic benzothiadiazepine-1,1- 












































Scheme 2.7. Two distinct reaction pairing pathways with amino alcohols 
 
a See reference 61 for full characterization data.  
skeletons by implementing a single sulfonyl chloride in conjunction with an amino 
alcohol by merely changing the order of reaction pairing.   
 
2.2.2 Scope of Reactions 
With these results in hand, the generation of diverse benzofused sultams was 
explored by utilizing the reaction pairing strategy.  Thus, use of (S)-prolinol alongside 
propargylamine derived o-fluorobenzene sulfonamides in the established SNAr–
Mitsunobu pairing afforded the desired tricyclic sultam 2.8.1 in good yield (Scheme 2.8).  
A simple switch in the amino alcohol component to (R)-(+)-3-hydroxypyrrolidine 
gratifyingly afforded the corresponding bridged, tricyclic benzofused sultams 2.8.2 and 
2.8.3 in moderate to good yield.  Of notable importance is the facile production of the 
unique bridged tricyclic sultam 2.8.2 containing a bridge-head nitrogen connected to an 


















































i. NaHCO3, rt 
   CH2Cl2/H2O
ii. Cs2CO3, DMF
    140 ºC , mW
i. NaHCO3, nBuNH2 
   CH2Cl2/H2O, rt
ii. Cs2CO3, DMF
    140 ºC , mW
iii. PPh3, DIAD
    THF, rt
2.7.1
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could cause a deviation in the geometry of the sulfonamide group leading to potential 
hybridization and geometry changes at nitrogen, ultimately affecting physical 
properties.62,63  It has been reported that twisted amides (anti-Bredt) possess a distorted 
amide bond, which dramatically affect stability and reactivity in comparison to their 
standard planar amides while increasing the basicity of the N atom (or bridgehead N).64   
Scheme 2.8. Reaction pairing strategy to access skeletally diverse sultams with an array 
of amino alcoholsa 
 
a Sulfonylation: R1NH2 (Compounds 2.8.1 and 2.8.3: R1 = Propargyl; 2.8.5 and 2.8.7: R1 
= nBu). SNAr: Cs2CO3, DMF, 140 ºC, mW. Mitsunobu: PPh3, DIAD, THF, rt. b See 
reference 61 for full characterization data. 
In considering potential physical property changes within constrained 
sulfonamides one must start with the preferred conformation of a sulfonamide as outlined 




























































































maximize the σ* orbital delocalization.62f  This conformation effectively allows the 
orientation of the lone pair to bisect the O=S=O internuclear angle.65  As seen in the X-
ray of bridged sultam (±)-2.8.6, the preferred conformation of the Ar-SO2NR1R2 moiety 
is conserved.  Despite this conservation of geometry––between normal and bridged 
sultams, bridged sultams are structurally different than their twisted amide counterparts 
and thus represent interesting probe molecules that we will continue to pursue [Note also: 
a twisted amide is structurally different from a typical amide for reasons outlined above]. 
       
Figure 2.9. Preferred conformation of sultam 2.8.6. 
While (R)-(+)-3-hydroxypyrrolidine was first used in the reaction sequence, the  
S-isomer was also exploited to provide desired benzo-oxathiazocine 1,1-dioxides 2.9.7–
2.9.10, with both stereoisomers having 4- and 6-fluoro substituents on benzenesulfonyl 
chlorides (Scheme 2.9).  With the four scaffolds on hand, a peripherally diverse 80-
member library of bridged and benzofused sultams were generated, as described in 
Section 2.3. 
Building on these results, utilization of 2-piperidinemethanol in the established 
reaction pairing protocol generated the corresponding benzofused tricyclic sultams 2.8.4 
and 2.8.5 in good yields (Scheme 2.8).  In contrast, use of 3-hydroxypiperidine and 4-













Scheme 2.9. Sulfonylation–SNAr reaction pathway to bridged, benzofused sultams 
 
2.8.6 and 2.8.7 in satisfactory yields (Scheme 2.8), with 2.8.6 [see X-ray crystallographic 
analysis in the experimental section, Chapter 5] possessing similar bridged sultam 
structural characteristics as 2.8.2.  Similarly, 3-hydroxypiperidine and 4- and 6-fluoro-
benzenesulfonyl chlorides were employed to generate fluoro-substituted 9-membered 
bridged benzofused sultams 2.9.13–2.9.14 in satisfactory yields (Scheme 2.9). 
Overall, this reaction pairing sequence allowed for the rapid construction of a 
skeletally and stereochemically diverse collection of benzofused sultams by simple 
variation of the amine component.   
 
2.2.3 Sulfonylation–Mitsunobu–Intramolecular SNAr Strategy 
Alternatively, it was envisioned that utilization of mono protected 1,3-, 1,4- and 1, 
5-diols, alongside o-fluorobenzene sulfonamides in a Mitsunobu alkylation-
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sultams 2.10.10–2.10.20 (Scheme 2.10).  This method began with use of a simple mono-
protected 3-silyloxy-1-propanol, whereby subjection to Mitsunobu alkylation with n-
butyl-derived o-fluorobenzene sulfonamide, furnished the 3º sulfonamides 2.10.1–
2.10.10 in good yields. 
It was envisioned that deprotection of the TBS group under basic conditions 
would allowed for an intramolecular SNAr cyclization to take place.  Hence, a THF 
solution of sulfonamide 2.10.1 was stirred in the presence of TBAF for 30 min under mW 
irradiation at 150 ºC to our delight, yielded the desired sultam 2.10.11 in 88% yield 
(Scheme 2.10 and Table 2.1, entry 1).  Application of the enantiomers (R)- and (S)-3-
((tert-butyldimethylsilyl)oxy)-butan-1-ol in the above Mitsunobu–SNAr pairing sequence 
was again found to cleanly furnished the corresponding benzothiazocine- 1,1-dioxides 
2.10.14 and 2.10.17 in good yields, albeit longer reaction times for deprotection of 
secondary alcohols before the cyclization process (Table 2.1, entries 4 and 7).  The 
substrate scope was investigated with commercially available benzenesulfonyl chlorides, 
where 4-bromo, 4-fluoro and 6-fluoro substituents work satisfactory in the reaction 
sequence, as well as simple alkyl amines including cyclopropylamine for the synthesis of 
2º sulfonamides.   
Scheme 2.10. Mitsunobu–intramolecular SNAr strategy to 8- to 10-membered sultams 
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Table 2.1. Substrate scope of Mitsunobu–intramolecular SNAr strategy 
entry R1 R2 R3 n/ring size yield (%) product 
1 4-Br nBu H 1/8 88% 2.10.11 
2 4-F cyclopropyl H 1/8 90% 2.10.12 
3 6-F cyclopropyl H 1/8 72% 2.10.13 
4 4-Br nBu (R)-Me 1/8 90% 2.10.14a 
5 4-F cyclopropyl (R)-Me 1/8 90% 2.10.15a 
6 6-F cyclopropyl (R)-Me 1/8 98% 2.10.16a 
7 4-Br nBu (S)-Me 1/8 87% 2.10.17a 
8 4-F cyclopropyl H 2/9 31% 2.10.18 
9 6-F cyclopropyl H 2/9 66% 2.10.19 
10 4-F cyclopropyl H 3/10 59% 2.10.20 
aIM-SNAr: TBAF, rt, 12 h, then Cs2CO3, 150 ºC, mW, 30 mins. 
Next, mono-protected 1,4-diols were examined where benzo-oxathiazonine 1,1-
dioxides 2.10.18 and 2.10.19 (9-membered) were synthesized in satisfactory yields 
(Table 2.1, entries 8 and 9).  Lastly, an ether-containing 1,5 mono-protected diol (2-(2-
((tert-butyldimethylsilyl)-oxy)ethoxy)-ethanol) was utilized in the Mitsunobu-SNAr 
pathway to generate the 10-membered sultam 2.10.20 in 59% yield (Table 2.1, entry 10). 
The scope was further expanded to unique 1,2 amino alcohols and 1,3 diols where 
skeletally diverse 7- and 8-membered sultams were synthesized in a facile Mitsunobu–
intramolecular SNAr sequence.  In a similar approach, a range of 2º sulfonamides were 
obtained via a sulfonylation reaction with benzenesulfonyl chlorides and alkyl amines, 
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followed by intermolecular Mitsunobu alkylation with the respective mono-protected 1,2 
amino alcohols and 1,3 diols.  These substrates include protected amino alcohols – (S)-
tert-butyl (1-hydroxy-4-methylpentan-2-yl)carbamate, olefin-containing diols – 2-(((tert-
butyl-dimethylsilyl)oxy)methyl)pent-4-en-1-ol and spiro-cycloalkyl diols – (1-(((tert-
butyldimethyl-silyl)oxy)methyl)cyclobutyl)methanol (Scheme 2.11).  Upon the synthesis 
of these 3º sulfonamides, an intramolecular SNAr cyclization was executed to provide 
diverse benzofused sultams 2.11.3–2.11.7 in decent yields (Scheme 2.11).  The structure 
of sultam 2.11.3 was confirmed by X-ray crystallography analysis (Scheme 2.11).   
A nice caveat to this method occurred when mono-protected 1,3-diols were 
employed, the removal of the TBS-protecting group with TBAF at rt for 12 h preceded 
the cyclization with Cs2CO3 under mW irradiation for 30 mins at 150 ºC (Scheme 2.11).  
Scheme 2.11. Expanded substrate scope of 1,2 amino alcohols and 1,3 diols in a 
Mitsunobu–SNAr pathway 
 
a For mono protected 1,3 diols, reaction conditions for step ii, TBAF, rt, 12 h, then 
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This resulted in an overall, one-pot, TBS-deprotection–cyclization to afford benzofused 
sultams, as well as the spiro-cycloalkyl substituents scaffolds.  In cases when protected 
amino alcohols were used in the reaction sequence, a one-pot TBS-deprotection–
cyclization–Boc-deprotection was accomplished as the Boc group was removed after ring 
closure, under mW irradiation at high temperatures. 
Overall, simply changing of the order of pairing for the sulfonylation–
intermolecular SNAr–Mitsunobu sequence to sulfonylation–Mitsunobu–intramolecular 
SNAr allows for facile access to skeletally, as well as stereochemically, diverse 
benzofused sultams. 
 
2.2.4 Mitsunobu–SNAr–[3+2] Cycloaddition Reaction Pairing 
Utilization of a [3+2] Huisgen cycloaddition reaction for the production of 
triazole-containing sultams was next explored.  Hemming and co-workers reported the 
elegant use of a one pot, tandem alkynylation–[3+2] cycloaddition approach to 
triazolosultams,66 while a recent report by Yao and co-workers outline the utilization of a 
Cu-catalyzed tandem [3+2] dipolar cycloaddition–N-arylation approach to these motifs 
utilizing o-bromo and o-iodobenzenesulfonamides.67  However, there are no reports of the 
use of non-metal catalyzed, SNAr–[3+2] Huisgen cycloaddition for the generation of 
benzofused sultams.  Thus, a sulfonylation–Mitsunobu protocol using propargyl alcohol 
and o-fluorobenzene sulfonamide as the Mitsunobu partners produced the desired 
propargylated o-fluorobenzene sulfonamides 2.12.1–2.12.4 in excellent overall yield 
(Scheme 2.12).  Azidation of sulfonamides 2.12.1–2.12.4 was carried out using NaN3 in 
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DMF at 90 ºC in the presence of 18-crown-6 (1 eq.) for 12 h to afford the tricyclic 
triazole-containing sultams 2.12.5–2.12.861 which had participated in an intramolecular 
[3+2] Huisgen cycloaddition ring closure following intermolecular SNAr azidation.  To 
the best of our knowledge, in 2011, this represented the first report of a one-pot tandem 
SNAr-intramolecular [3+2] Huisgen cycloaddition for the synthesis of benzofused 
sultams. 68   The reported method was reviewed in a dissertation (Thiwanka 
Samarakoon).61  Overall, the sulfonylation–Mitsunobu–SNAr protocol is augmented by 
pairing with an intramolecular [3+2] cycloaddition protocol for the synthesis of triazol-
bearing benzofused sultams in 3 steps. 




2.2.5 Chemical Informatic Analysis 
From chemical informatics analysis, utilizing a multi-fusion similarity (MFS) analysis,69 
it is apparent that sultams synthesized in Chapter 2 (red) are fairly unique relative to the 
manifold of currently available analogs,2 (April 2012) and that there is a reasonable 
amount of structural diversity present (Figure 2.10).70  Selected sultams are a distance 


































unpopulated chemical space. Analysis was conducted against all 1198 compounds (blue) 
in the NIH Molecular Libraries Probe Production Center Network (MLPCN) as of 2010 
that contained the maximum common substructure (4-bromo-N-propylbenzene 
sulfonamide) evident within our own (Figure 2.10).  The graph is guided by the chemical 
space defined by BCUT polarizability metrics where the x-axis reports values of an AM1 
polarizability metric scaled by molecular bond-order profile and the y-axis reports an 
AM1 polarizability metric scaled by an inverse topological distance profile.  
 
Figure 2.10. Diversity distribution of sultams (red spheres) relative to analogous 
MLPCN compounds (blue) currently present in the NIH Molecular Libraries Probe 
Production Center Network (MLPCN) as of 2010. 
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2.2.6 Conclusion 
In conclusion, we have developed a reaction pairing strategy employing the 
reaction triad–sulfonylation, Mitsunobu, SNAr for the rapid synthesis of a diverse 
collection of benzofused sultams.  Simple changes to the order of the pairing sequence 
and/or building blocks, allows for access to skeletal and stereochemical diversity.  
Overall, this strategy affords a diverse set of heterocycles in 2–3 steps from commercially 
available building blocks.  These results are highly amenable for library production to 
generate collections of skeletally diverse sultams for high throughput screening. 
 
2.3 Exploring Chemical Diversity via a Modular Reaction Pairing Strategy 
2.3.1 Introduction 
While there are numerous methods reported in the literature for the synthesis of  
5-, 6- and 7-membered benzofused sultams, reports on the generation of 8-membered 
benzofused sultams have been sparse.7e,71  In this regard, our group has focused on the 
development of several protocols for the generation of diverse sultam collections.72  
Recent highlights towards these goals include, “click-click-cyclize”, 73  and 
complementary ambiphile pairing (CAP).57,71a.  In 2011 and in the preceding part of this 
Chapter 2, we reported the development and application of an efficient reaction pairing 
strategy utilizing three simple reactions, namely sulfonylation, Mitsunobu alkylation and 
SNAr, which when combined in different sequences or with different coupling reagents, 
provided access to skeletally diverse 7- and 8-membered sultams (vide supra).2  Building 
on this strategy, we report the design and synthesis of an 80-member library of 
 78 
benzofused sultams by a microwave-assisted, intermolecular SNAr diversification of core 
benzo-oxathiazocine 1,1-dioxide scaffolds (Scheme 2.13).74  




2.3.2 Results and Discussion 
Initial efforts focused on the synthesis of eight core scaffolds 2.9.3–2.9.6, 
2.10.12–2.10.13, 2.10.15–2.10.16 on multi-gram scale through the use of three efficient 
steps, namely sulfonylation, Mitsunobu alkylation and SNAr (Scheme 2.14).75  The 
bridged benzofused sultam scaffolds were prepared by a sulfonylation–intramolecular 
SNAr protocol, reported previously,2 utilizing 3-hydroxypyrrolidine in combination with 
2,4-difluoro- and 2,6-difluoro-benzenesulfonyl chloride.  Both R and S isomers of 3-
hydroxypyrrolidine were employed for the synthesis.  Likewise, the non-bridged 
scaffolds were also prepared as reported by a sulfonylation–intermolecular Mitsunobu 
alkylation–intramolecular SNAr protocol.2  Cyclopropyl amine was sulfonylated with 2,4-
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with 3-silyloxybutan-1-ol and subsequent one-pot desilylation–intramolecular SNAr 
alkoxylation (Scheme 2.14).  Each of the scaffolds 2.9.3–2.9.6, 2.10.12–2.10.13, 
2.10.15–2.10.16 was prepared on a 2.5 gram scale. 
Scheme 2.14. Utilization of a reaction pairing strategy for the synthesis of benzo-oxa-
thiazocine 1,1-dioxides core scaffolds 2.9.3–2.9.6, 2.10.12–2.10.13, 2.10.15–2.10.16 
 
 
2.3.2.1 Optimization of Conditions 
With scaffolds 2.9.3–2.9.6, 2.10.12–2.10.13, 2.10.15–2.10.16 in hand, efforts 
were focused on the diversification of these core scaffolds with a variety of chiral, non-
racemic amines/amino alcohols, using intermolecular SNAr with benzo-oxathiazocine 
1,1-dioxide 2.9.6 as the test substrate (Table 2.2).  A variety of reaction conditions (eq. of 
amine, presence of base, concentration of solvent, time and temperature) were examined 
to identify the optimal conditions.  Our initial attempt gave an excellent yield of 94% 
when 4.4 equivalents of amine were employed, in the absence of base, at a concentration 


































































Table 2.2. Optimization studies for the SNAr reaction utilizing sultam 2.9.6 
 







1c (R)-3-Pyrrolidinol 1.3 0.1 30 150 NA 
2 (R)-3-Pyrrolidinol 4.4 0.1 20 150 94 
3 (S)-2-Pyrrolidine methanol 4.4 0.1 30 150 29 
4 (S)-2-Methoxymethyl pyrrolidine 4.3 0.1 50 180 NA 
5 (S)-3- Dimethylamino pyrrolidine 5.0 0.1 50 180 88 
5 (R)-2-Methylpyrrolidine 5.0 0.1 30 150 42 
6 (R)-2-Methylpyrrolidine 5.0 0.1 40 180 62b 
7 (R)-2-Methylpyrrolidine 5.0 0.1 50 180 70 
8 (R)-2-Methylpyrrolidine 5.0 0.1 60 180 35 
9 (R)-2-Methylpyrrolidine 5.0 0.5 50 180 95b 
10 (R)-2-Methylpyrrolidine 5.0 1.0 50 180 83b 
aYields are reported after flash column chromatography on silica gel. bCrude yield as 
judged by 1H NMR. cCs2CO3 was added to the reaction.  
However, when a hindered amine was utilized, it resulted in low (29%) or no 
yield, even when the reaction time was extended (Table 2.2, entry 3) or when slightly 
harsher conditions were used (Table 2.2, entry 4).  The equivalents of amine were 
increased and the choice of substrate was changed to examine further, with the substrates 
listed on the series of building blocks proposed in the Library Design section.  Hence, 
more experiments were executed to investigate other factors, in which the nature and 
equivalents of amine remained the same while the concentration of solvent, temperature 
and reaction time were increased.  Finally, the optimal results were obtained in the 





















under 50 min of mW irradiation at 180 °C (Table 2.2, entry 9).  All reactions were 
performed under identical conditions, thus attempts were not made to optimize the 
conditions further for individual substrates.  
 
2.3.2.2 Library Design  
 An 80-member, full matrix library was designed by using in silico analysis.76  
Eight benzo-oxathiazocine 1,1-dioxide scaffolds 2.9.3–2.9.6, 2.10.12–2.10.13, 2.10.15–
2.10.16 were designed, of which library I (2.9.3–2.9.6) was composed of the entire 
spectrum of possible stereoisomers, and library II (2.10.12–2.10.13, 2.10.15–2.10.16) 
was composed of two sets of benzofused sultams having an H or Me group at the R1 
position (Figure 2.11).  The use of all possible stereoisomers provides the opportunity to 
generate stereochemical SAR (SSAR) for each building block combination.7a  With the 
core sultams in hand, a virtual library incorporating all possible combinations of the 
building blocks of the secondary amines {1–10} was constructed for each scaffold.  
Physico-chemical property filters were applied, guiding the elimination of undesirable 
building blocks that led to products with undesirable in silico properties (see Chapter 5 
for the Supporting Information for full in silico data and detailed information on the 
calculations).  These metric filters included standard Lipinski’s rule of five parameters 
(molecular weight <500, ClogP <5.0, number of H-acceptors <10, and number of H-
donors <5), in addition to consideration of the number of rotatable bonds (<5) and polar 
surface area.  Absorption, distribution, metabolism and excretion (ADME) properties 
were calculated by using the Volsurf program.77  Cartesian grid based chemical diversity 
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analysis was performed according to the method described previously, 78  by using 
standard H-aware 3D BCUT descriptors comparing against the MLSMR screening set 
(ca. 7/2010; ~330,000 unique chemical structures).  Guided by this library design 
analysis, benzoxathiazocine 1,1-dioxides scaffolds 2.9.3–2.9.6, 2.10.12–2.10.13, 
2.10.15–2.10.16 and amines {1–10} were chosen to generate the aforementioned 80-
member library. 
 
Figure 2.11. Benzo-oxathiazocine 1,1-dioxides 2.9.3–2.9.6, 2.10.12–2.10.13, 2.10.15–




















Benzo-oxathiazocine 1,1-dioxides core scaffolds















































2.10.12 2.10.13 2.10.15 2.10.16
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2.3.2.3 Validation and Library Generation 
With the optimized conditions in hand, a 20-member validation library was 
prepared by using scaffolds selected from 2.9.3–2.9.6, 2.10.12 and amines {1–10} in 
DMSO (0.5 M) at 180 °C for 50 min, in 1 dram vials, using the Anton Parr Synthos 
3000® platform (Table 2.3).79  Upon completion, the crude reaction mixtures were 
diluted, filtered through silica SPE, and purified by automated mass-directed HPLC.  
Library validation was essential to assess both substrate and reaction scope, along with 
evaluating the application of automated mass-directed HPLC as the final analysis and 
purification method.  Key goals for this compound collection were the synthesis of 
compounds in >90% purity in 40–50 mg quantities, which would be sufficient for HTS 
screening in the Molecular Library Probe Center Network (MLPCN) (20 mg), for 
external biological outreach screening partners (20 mg), and to retain a sample (10 mg) 
for follow-up evaluation or to resupply the NIH MLPCN.  Evaluation of this validation 
library demonstrated that all 20 members were successfully prepared (average purity = 
99.7%, yield = 70%, quantity = 73.0 mg) in the desired sultam final masses, with all 20 
possessing a final purity >98%. 
With the validation completed, the remaining 60 compounds of both libraries I 
and II were synthesized by the diversification of core benzo-oxathiazocine 1,1-dioxides 
scaffolds 2.9.3–2.9.6, 2.10.12–2.10.13, 2.10.15–2.10.16 and amines {1–10}.  Under the 
optimal SNAr reaction conditions, libraries I and II were generated and purified by 
automated mass-directed HPLC.  A total of 80 compounds were prepared and isolated in 
good yields (average yield 65%), and all compounds had purities greater than 95% after 
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automated purification (see Supporting Information for all compounds with full numeric 
data).  Final assessment of both libraries I and II demonstrated that the primary 
objectives set out in the library design were achieved; final masses ranged between 18–
127 mg and the average final mass was 68 mg (original target being 50 mg). 
Table 2.3. Use of a 20-member validation library to probe the reaction scope 
 
Sultam a Purity (%) b 
Yield 




 (%) b 
Yield 
 (%) b 
Quantity 
(mg) 
2.9.3{3} 99.8 78 79.5 2.10.12{1} 100 80 79.8 
2.9.4{3} 99.4 69 70.0 2.10.12{2} 100 80 79.4 
2.9.5{3} 100 48 49.3 2.10.12{3} 100 76 75.8 
2.9.6{3} 99.7 53 54.1 2.10.12{4} 100 79 79.1 
2.9.3{1} 100 71 71.7 2.10.12{5} 100 83 85.7 
2.9.3{2} 100 72 73.4 2.10.12{6} 100 80 83.1 
2.9.3{4} 99.8 75 76.7 2.10.12{7} 98.2 17 18.7c 
2.9.3{5} 99.7 69 73.6 2.10.12{8} 99.9 46 49.2 
2.9.3{6} 99.6 85 90.2 2.10.12{9} 99.1 79 85.3 
2.9.3{8} 100 86 94.9 2.10.12{10} 99.1 78 83.7 
aReaction conditions: Benzo-oxathiazocine-1,1-dioxides 2.9.3–2.9.6, 2.10.12–2.10.13, 
2.10.15–2.10.16 (1 eq., 80 mg), dry DMSO (0.5 M) and amine (5 equiv.).  bPurified by 
automated preparative reverse phase HPLC (detected by mass spectroscopy); purity was 
assessed by HPLC (214nm).  cThe low yield obtained was due to instrumental error (see 
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2.3.3 In Silico Analysis of Chemical Diversity and Drug-likeness 
In silico analysis of the molecular library was performed to achieve enhanced 
drug-like and lead-like properties, as well as to assess the molecular diversity.  In order to 
assess diversity, five computational analyses were performed, including 
1. Cartesian grid-based chemical diversity analysis78 [Section 2.3.3.1] 
2. Overlay analysis80 [Section 2.3.3.2] 
3. Principal moments of inertia (PMI) analysis81 [Section 2.3.3.3] 
4. Conformational analysis [Section 2.3.3.4] 
5. Quantitative estimate of drug-like (QED) values82 [Section 2.3.3.5] 
 
2.3.3.1 Cartesian Grid-based Chemical Diversity Analysis 
 The grid-based diversity analysis protocol, described previously in the Library 
Design section 2.3.2.2, provides a simple measure of the relative novelty of a compound.  
By computing the position of a compound within the molecular property space defined 
by a large reference set of other interesting compounds, chemical novelty can be 
estimated from the density of reference compounds in close proximity to the compound 
of interest.  This analysis suggests that our compounds consistently occupy regions of 
chemical space that are under-represented within the MLSMR reference set as of April-
2010.  Specifically, all 80 compounds were located in regions with local compound 
densities of less than the mean value, with compounds 2.9.5{3}, 2.9.6{3}, 2.9.6{4}, 
2.10.12{3} and 2.10.12{4} occupying a particularly sparse region of space (all co-
locating within a cell whose density was 3.5% of the mean density experienced by the 
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reference compounds), while the least unique eight compounds (2.10.12{5}, 2.10.12{6}, 
2.10.15{3}, 2.10.15{4}, 2.10.15{5}, 2.10.15{6}, 2.10.16{3} and 2.10.16{4}) all co-
located in a cell with density equal to 78.9% of the mean density experienced by the 
reference compounds.  The mean local density experienced by the 80 compounds 
reported herein, was only 31.7% of the mean density experienced by the reference 
compounds.  All related information can be found in Chapter 5 (Experimental Data). 
 
2.3.3.2 Overlay Analysis 
The overlay produced for the 80 compounds reported herein is depicted in Figure 
2.12 and provides a rudimentary indication of the shape distribution and diversity evident 
in this library.  Orientations 2.12iv and 2.12v collectively suggest that the library  
 
 
Figure 2.12. (i) Simple cartoon of the library compounds, with a core of MW ~ 80, based 
on Lipinski’s rules (MW < 500), and comprising three substituents, each having MW < 
140, to establish different functional groups. (ii) This cartoon demonstrates that the 
substituents extend out of the core in a circular motion. (iii) Overlay images exhibiting 
the common core in these 80 compounds. (iv) and (v) both overlay images revealing that 





iii iv v 
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generally tends toward elongated (rod-like) structures, while the apparent distribution of 
functional substituents across angles spanning the better part of the whole sphere 
surrounding the conserved core, suggests that the library as a whole achieves a reasonable 
level of shape-based diversity. 
 
2.3.3.3 Principal Moments of Inertia (PMI) Analysis 
 The rudimentary information gleaned from overlay analysis can be quantified 
more rigorously via principal moments of inertia (PMI) analysis, which is also employed 
herein to assess the molecular diversity (Figure 2.13).81  PMI analysis utilizes shape-
based descriptors: The minimum energy conformation of each library member is 
determined, PMI ratios are calculated and normalized, and a subsequent triangular plot  
 
Figure 2.13. Distribution of 80 compounds (colored spheres) relative to the set of 771 
















depicts the shape diversity of the library.  The analysis reveals that the 80 compounds 
generally mirror the shape distribution of the set of 771 known drugs (Figure 2.13), thus 
demonstrating the potential drug-likeness of our scaffold.  In contrast, some of the 
compounds are located in the unpopulated region of chemical space, illustrating the novel 
nature of some of our compounds from the perspective of molecular shape. 
 
2.3.3.4 Conformational Analysis 
 While overlay and PMI analysis tend to focus on the shape diversity of libraries as 
a function of the combined structure of the core scaffold and all known substituents, it is 
useful to quantify the conformational diversity of the core alone, since this provides 
additional insight into the prospects for sampling new diversity space as a function of 
hitherto untested substituents.  To quantify this, computations were generated for the 
mean pairwise atomic root-mean-squared distance (RMSD) using a small set of 
representative products from the library that was synthesized and compared this value 
with similar pairwise RMSD calculations for other analogous libraries (Figure 2.14).  In 
all cases, the structures have been sketched and optimized in SYBYL,83 according to 
default molecular mechanics settings, and the resulting optimized structures were then all 
mutually aligned in order to minimize the total pairwise RMSD among conserved 
scaffold core atoms.  The pairwise RMSD values reported in Figure 2.14 also only 
correspond to conserved core atoms.  The fact that the highlighted core scaffold achieves 
a 0.33 value, a much higher RMSD than the other libraries suggests that the scaffold 
conformation is more sensitive to the choice of substituents, whereas the other libraries 
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exhibit little variation as a function of different substituents.  This greater sensitivity on 
the part of the highlighted library should correspond to greater conformational diversity, 
which implies sampling of a broader range of property and pharmacophore space than 
those libraries with lesser conformational diversity. 
 
Figure 2.14. Comparison using RMSD calculations of a small set of our representative 
compounds versus two sultams synthesized by our group as well as a biologically active 
compound.12d 
 
2.3.3.5 Quantitative Estimate of Drug-like (QED) Values and Z–scores 
 While molecular diversity is in itself a topic of intellectual value, in applied 
sciences it is important to balance this intellectual aspect with suitability toward the 
intended application.  In other words, if one intends to synthesize novel compounds for 
potential pharmacological applications it is critical that the compounds not only be 
unique but also be drug-like.  Quantifying drug-likeness is one of the numerous methods 
that are regularly utilized as useful guidelines for early stage drug discovery.  A measure 
of drug-likeness based on the concept of desirability called the quantitative estimate of 
drug-likeness (QED) has been proposed.82  The QED concept is a simple approach to 
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R2 = H or methyl
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eight molecular properties, i.e., molecular weight, ALogP, polar surface area, H-bond 
donor, acceptor, rotatable bond and aryl ring counts, and the presence of structural alerts.  
The weighted QED values were calculated based on the equation provided by Hopkins et 
al., mapping compounds to a range from 0 to 1, in which a value of 1 indicates that all 
properties are within a favorable range.  Based on this measure, the 80 compounds 
reported herein may have elevated prospects for interesting chemical biology: the lowest 
QED values among these 80 compounds (QED = 0.819 for 2.9.3{3} and 2.9.3{4}) are 
actually significantly above the mean value (QED = 0.615) for the 771 known drugs 
analyzed by Hopkins et al., while several distinct scaffolds within our library produced 
QED values of greater than 0.90 (Figure 2.15). 
 
Figure 2.15. Three representative compounds with high QED values. 
 To characterize the QED scores of our scaffolds relative to the reference set of 
771 known drugs, we computed mean Z-scores for each scaffold and plotted them in 
Figure 2.16.  Since Z-scores of 1.64 and 1.0 correspond to percentile rankings of 95 and 
84.1, respectively, it is apparent that all of the reported scaffolds contain compounds with 
QED values in the upper 80th to lower 90th percentile.  The 80 compounds exhibited an 





























Figure 2.16. Representation of Z-scores for the 80 compounds. 
2.3.4 Conclusion  
 In conclusion, an efficient microwave-assisted intermolecular-SNAr method for 
the synthesis of amino benzoxa-thiazocine 1,1-dioxides has been developed.  Employing 
a variety of commercially available chiral, nonracemic amines, the 80-member library of 
bridged, benzofused, bicyclic sultams was generated by the microwave assisted-SNAr 
diversification at 4-F and 6-F positions.  A series of computational analyses was 




































































reaction pairing strategy, which will be reported in due course.  Further computational 
analysis revealed that the compounds reported herein generally occupy underrepresented 
chemical space relative to the MLSMR screening set, and are drug-like both in terms of 
their distribution in shape space (as compared to a collection of 771 known orally 
available drugs depicted according to molecular PMI profiles) and according to the QED 
measure (by which all of this library of compounds are predicted to be significantly more 
drug-like than the average real drug).  Structural overlays and PMI analysis suggest that 
the highlighted compounds tend to sample a reasonable array of shape space within the 
range between rod-like and disk-like compounds.  RMSD comparisons of a selection of 
representative structures from this library suggest that the core scaffold has a greater 
inherent flexibility than comparable products from other related libraries.  This flexibility 
can produce libraries with greater molecular diversity as a function of a fixed number of 
substituents than is observed for comparably sized libraries arising from more rigid 
scaffolds.  It is our hope that the combination of drug-likeness and inherent molecular 
diversity evident in this library will produce products that demonstrate interesting 
behavior in biological screening.  To gauge these prospects rigorously, these compounds 
have been submitted for evaluation of their biological activity in high-throughput 
screening assays at the NIH MLPCN and the results will be reported in due course. 
 
2.4 Summary and Outlook 
 In summary, facile, efficient and modular methods to synthesize skeletally diverse 
and unique medium-sized  (8- to 10-membered) polycyclic sultams have been developed.  
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The scope of sultams synthesized, includes: (i) bridged benzofused sultams with both 
possible stereoisomers of different ring sizes, as well as (ii) non-bridged benzofused 
sultams consisting of all possible stereochemistries.  The reported strategy was extended 
to library development that comprised a library of 80 compounds, demonstrating the 
reliability of the method.  In addition, the cheminformatics derived from the several 
computational analyses suggested that these sultams are populating the gap of 
underrepresented chemical space and ring systems.  
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A Modular, One-pot, Sequential  
Aziridine Ring-Opening–SNAr Strategy  





The development of efficient methods for the generation of medium- and large-
sized heterocycles1 is an important facet of screening campaigns for facilitating drug 
discovery.2  In particular, medium and macrocyclic lactams1,3 constitute an important 
group of molecules in compound collections derived from target-oriented- and diversity-
oriented4 synthetic approaches.  Furthermore, macrocycles are also known to be a 
pharmacological and physicochemical relevant molecular class for which numerous 
methods have been developed to synthesize the collections of molecules in a facile and 
effective manner.1  Their distinct properties that were also detailed in Chapter 1 include 
conformational constraint, lower rotatable bond count, reduced polarity, increased 
proteolytic stability and potential for higher target binding and selectivity.5 Macrocycles 
are also manifested in improved pharmacokinetics and pharmacodynamics, rendering 
them as attractive lead molecules for drug development.2  Taken collectively, these 
attributes have inspired limited production of natural product-like6 medium-sized and 
macrocyclic ring systems, enabling efforts to address emerging difficult drug targets such 
as those involving protein-protein interactions7 and epigenetic targets.8  However, the 
strategy for the development of novel macrocycle-based drugs or probes is still an 
emerging field as the synthetic challenges of assembling macrocycles that are 
stereochemically-rich, and enhanced in terms of their fraction of sp3 carbons,9 have began 
surfacing in this area.  
Accordingly, the innate properties of medium and large-sized strained rings (10- 
to 13-membered)10 can conceivably produce uncommon molecular shapes, alternative 
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bond geometries and spatial orientations of functional groups that are different from 
unstrained or acyclic motifs.  While the chemical space of these unique systems represent 
an intriguing target in synthesis, i  they also exemplify difficult scaffolds to access 
chemically.   
Macrocycles, both macrolactones and macrolactams, in general have exhibited 
broad biological activity11 in a variety of areas ranging from antibiotics,12 inhibitors of 
CDK2/cyclin A,13 Hsp90 inhibitors,14 protein kinase C (PKC) inhibitors,15 anti-fungal 
activity,16 anthelmintic activity,17 hepatitis C virus (HCV) NS3/4A serine protease18 in 
drug discovery19 to insecticidal agents in agriculture.20  As previously mentioned in 
Chapter 1, while medium and macrocyclic lactams are well documented in the literature, 
their sulfonamide-based counterparts, medium and macrocyclic sultams, are unnatural 
and less prevalent synthetically but have been found to exhibit a variety of biological 
activities ranging from anti-proliferative, 21  anti-HIV activity, 22  treatment of feline 
immunodeficiency virus,23 inhibitory activity of trypsin-like serine protease Factor XIa 
involved in blood coagulation,24 inhibitors of phosphoinositide 3’OH kinase (PI3K class I 
sub-type)25 and inhibitors of hepatitis C virus (HCV)26 where in fact, several examples of 
macrocyclic sultams are treatments of HCV (Figure 3.1).  
Based on the studies of Heterocyclic Rings in Drugs Analysis Models in Chapter 
1, the underrepresented ring systems were highlighted and in particular, medium-sized 
 
[i] Note: A short section towards the end of this chapter, is used to describe the 




sultams such as 10-/11-membered rings will be discussed in the remaining of this chapter.  
In Chapter 3, a one-pot, sequential aziridine-ring opening and intramolecular SNAr 
cyclization employing heretofore unknown o-fluoroaryl-sulfonyl aziridines and amino 
alcohols in a “6+4” and “6+5” heterocyclization pathways to generate 10-/11-membered 
polycyclic benzofused sultams.  The method was extended for the construction of 7-
membered benzofused sultams with functional handles for diversification by exploiting 
amines in a “6+1” cyclization sequence.  These sultam scaffolds lie within new chemical 
space when mapped using the principal moments of inertia (PMI) analysis and overlay 
analysis presented at the end of Chapter 3, vida infra. 
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3.1.1 Basics of Macrocyclization 
 In 1981 and 1984, respectively, Illuminati and Mandolini carried out 
investigations that illustrated the physical aspects of cyclization reactions that imply the 
use of bi-functional substrates undertaking a ring closure by an intramolecular reaction.27  
Studies by Mandolini and co-workers on the macrolactonization of ω-bromo alkanoic 
acids, Br-(CH2)n−2CO2H via intramolecular nucleophilic substitution (SN2) have shown 
that medium ring (8- to 11-membered) cyclizations have the most strain energy due to the 
medium-ring effects based on the data provided, 28  whereas for other ring sizes––
including small rings (3- to 4-membered), common rings (5- to 7-membered) and large 
rings (>12-membered)––are less obvious (Figure 3.2).27  Since SNAr reactions belong to 
the realm of substitution chemistry, cyclization studies carried out using SN2 reactions are 
quite relevant when discussing SNAr reactions based on certain similarities that they 
collectively share.  
The SN2 macrocyclization studies revealed that the formation of medium size 
rings (8- to 11-membered) is in many instances the most difficult to effect, even under 
high dilution conditions.  These results were relatively similar to other profiles that were 
investigated, for instance, the formation of catechol polymethylene ethers29 from o-–
OC6H4O(CH2)n–4Br and lactones 30  from Br(CH2)n–2CO2– and even earlier work by 
Ruzicka31 and Ziegler.32   
In 2013, Campagne and coworkers assembled an elegant review entitled 
“Macrolactonizations in the Total Synthesis of Natural Products”33 that substantiated the 
aforementioned Illuminati and Mandolini studies, and again detailed the various factors 
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one needs to consider when designing a macrocyclization event.  For the purpose of 
convenience, these are summarized as follows: the difficulties seen in medium ring 
cyclizations are primarily due to the high strain energy (enthalpic factor) in the ring being 
formed that outweighs the entropic factor (Figure 3.2).  In contrast, intramolecular 
reaction in large ring sizes, the entropic factor is increased further, but the enthalpic 
factor has decreased significantly since the rings formed are almost strain free.  Hence, 
medium ring formation are the most difficult cases due to entropic and enthalpic factors.  
Several reasons cited in these investigations are ring strain (enthalpic factor) that consist 
mainly of (a) angle strain; (b) conformational strain and (c) transannular strain, as well as 
the relative rates of ring formation (entropic factor), which is inversely proportional to the 
length of the acyclic chain.   
         











Since larger chains can assume a greater total number of conformations, the 
likelihood of the chain assuming “the one reactive conformation,” is reduced.  Moreover, 
a portion of the entropic cost of forming a ring comes from the fact that the 
conformational degrees of freedom are being lost in a ring-like transition state that is 
considerably more ordered than the flexible acyclic starting material.  Thus, entropic 
costs start to increase sharply at medium ring sizes, as the transition states remain fairly 
rigid, while the number of degrees of freedom that are being lost, increases greatly.  For 
macrocycles, the ability to bend and twist in space increases as the size increases thus 
reducing ring strain, which is thought to partially compensate for the freezing of rotors.  
 
3.1.2 Synthesis of Macrocycles for Drug Discovery 
Due to the aforementioned difficulties in macrocycle synthesis, and Lipinki’s 
‘rule of 5’ physicochemical properties, applications in medicinal chemistry have been 
limited until recently, as more methods have been developed to address the issues.  The 
focus of the present section will be on synthetic approaches to macrocyclic compounds, 
as well as libraries related to the parent molecules.  Several of these strategies possess 
some general advantages: (a) well-developed chemistry and procedures; (b) broad 
selection of readily available reagents; (c) suitability for a wide range of ring sizes and 
(d) efficient formation of acyclic precursors with high diversity.  In contrast, the 
challenges common to all macrocyclizations include: (a) high dilution conditions to 
prevent formation of oligomeric side-products; (b) the efficiency of the cyclization 
 
125 
guided by kinetics which play a major role and (c) linear precursors to adopt an 
appropriate conformation suitable for cyclization. 
These macrocyclization approaches include a collection of methods that range 
from standard processes like macrolactamization/macrolactonization and substitution 
chemistry (SN2 and SNAr), to more intricate ring-closing metathesis (RCM), 
organometallic methods (Pd, Ru and Ni), multi-component reactions (MCR) and 
cycloadditions, and reactions that are significant in the synthetic realm; Wittig chemistry, 
Mitsunobu reactions,ring expansion/opening and finally some miscellaneous reactions 
(Cope rearrangement and Staudinger-type ring closure).34  However, for brevity, only a 
short list of reactions will be discussed in this chapter.  
 
3.1.2.1 Macrolactamization and Macrolactonization 
 Historically, the two most established reactions for the formation of macrocycles 
are macrolactamization and macrolactonization, both of which are still in regular use.  
This is due partially to the peptidomimetic nature of many of those structures, whose 
targets are typically protease enzyme inhibitors.  Thus, amide bond formation via 
macrolactamization or macrolactonization is traditionally a viable option for the synthesis 
of cyclodepsipeptide-like compounds. 35   Classical examples of the two general 
transformations are shown in Scheme 3.1, where 3.1.2 is a thrombin inhibitor and 3.1.4 is 
an inhibitor of bacterial DNA primase (Sch 642305).  
For both macrolactamization and macrolactonization, there is an extensive 
selection of coupling reagents available, including carbodiimides, phosphonium salts,  
 
126 
Scheme 3.1. Examples of macrolactamization and macrolactonization  
 
other phosphorus derivatives, pyridinium salts, triazines, acylazoles and halogenating 
reagents, and for the latter, comprised of thioesters activation of acids in the absence or 
presence of metal salts, Mukaiyama’s salt, mixed anhydrides [2,4,6-trichlorobenzoyl 
chloride (Yamaguchi’s reagent) and 2-methyl-6-nitrobenzoic anhydride (Shiina’s 
reagent)], mixed anhydrides under Lewis acid activation and phosphorus-based reagents 
with more, constantly adding to the lists.36  Several of these reagents are now available on 
polymer support, which provide ease of use in parallel synthesis and library production.   
More often, macrolactamization has been the strategy for peptidomimetic 
macrocycles and has successfully synthesized a broad range of structures from small ring 
inhibitors, such as neutral endopeptidase 24.11 (NEP),37 to large macrocycles, such as 
protein epitope mimics (PEM) (Figure 3.3). 38   This list also includes macrocyclic 
peptidomimetic and non-peptide compounds, comprising human immunodeficiency 
(HIV) protease inhibitors,39 renin inhibitors,40 thrombin inhibitors,41 β-secretase (BACE-
1) inhibitors,42 and TNF-α converting enzyme (TACE) inhibitors,43 among many other 












































series of finger loop inhibitors of hepatitis C virus (HCV) nonstructural protein 5B 
(NS5b) polymerase, leading to the discovery of the clinical candidate TMC647055 
currently in phase II trials (Figure 3.3).45   
While there are many efficient macrolactamization methods for the preparations 
of peptidomimetic and non-peptide compounds, the use of macrolactonization for the 
generation of de novo macrocyclic molecules are still limited.  The majority of synthetic 
efforts for macrolactonization have been to synthesize the myriad of macrolide natural 
products, their derivatives and analogues.  This could be due to the fact that the ester of 
the lactone has a greater hydrolytic lability than its counterpart-lactam, thus the slight 
bias.  Nonetheless, a 14-membered macrolactone that is a naturally occurring kinase 
inhibitor against MEK (mitogen-activated protein kinase enzyme) was accessed by 
Yamaguchi’s conditions for the pivotal ring closure (Figure 3.3).46  
 
Figure 3.3. Examples of macrolactamization and macrolactonization products. 
The two strategies, macrolactamization and macrolactonization, together with 
innovative technologies have been used for generating macrocyclic libraries up to 44,000 
analogues, with wide level of diversity initiating from commercially available building 










































3.1.2.2 Substitution Chemistry: SN2 and SNAr Reactions 
A chemical reaction during which one functional group in a chemical compound 
is directly displaced by another functional group is known as substitution chemistry, also 
one of the common strategies used to build macrocyclic motifs.  Other than the 
aforementioned considerations, additional advantages to utilization of substitution 
chemistry are that more possibilities are available to investigate different sites of ring 
closure.  In contrast, however, a drawback of substitution chemistry is potential 
incompatibilities of functional groups or reactive motifs that will require tedious 
protection/deprotection protocols. 
The classic intramolecular SN2 displacement reaction has various applications in 
certain macrocyclic structures, usually the simpler, less complex molecules with limited 
functionality.  For example, the intramolecular SN2 reaction under the conditions of 
Cs2CO3 in DMF was used to synthesize 14-membered macrocycle 3.2.2, inhibitors of 
matrix metalloproteinases (MMP-1, -3 and -9) (Scheme 3.2).47  Likewise, inhibitors of  
Scheme 3.2. SN2 reaction towards macrocycles and AMD3465 
 
CXCR4-targeted immunostimulating cyclams AMD3100 (plerixafor)48 and AMD346549 
were also constructed under similar conditions.  Their therapeutic effects are primarily 
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In addition to the intramolecular SN2 displacement approach, sequential or 
pseudo-simultaneous substitution reactions have been used to produce ring systems, 
whereby reactants are used, that are equipped with two electrophilic sites in the same 
acyclic precursor together with two nucleophilic groups.  Furthermore, these latter 
transformations have successfully provided both complex structures as well as some 
bioactive macrocyclic compounds.  These examples include macroheterocyclic 
peptidomimetic BACE inhibitors,50 macrocyclic peptidomimetics designed to mimic β-
turns, 51  thiazole-containing RGD analogues, 52  cyclin-dependent kinase (CDK) 
inhibitors,53 hydroxamic acid MMP and TACE inhibitors (Figure 3.4).47,54  The synthesis 
of β-turns mimics using solid support was extended to library assembly and more than 
3,600 derivatives were prepared.55  With a similar strategy, using the SN2 process, 
produced up to 4,000 derivatives and analogues.56 
 
Figure 3.4. Selected macrocycles from SN2 chemistry. 
Equally important is the use of substitution reactions with aromatic rings also 
known as a nucleophilic aromatic substitution (SNAr) reaction that has been applied to the 
generation of macrocyclic compounds.  For example, the key cyclization for the synthesis 
of RP-66453 3.3.2 was accomplished under defined conditions (K2CO3, 0.002 M in 
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introduced to the reaction mixture to promote the methylation of the remaining free 
hydroxyl function to afford the desired cyclized compound (Scheme 3.3). 57 
Intramolecular SNAr cyclizations have been utilized to access unique structures 
comprising (1) 5-membered indoles and indolines, 58  (2) “privileged structure” in 
bioactive natural products such as complestatin,59 vancomycin60 and many others61 that 
contain the biaryl ether moiety, as well as (3) cyclopeptide alkaloids like sanjoinine G1 
that are peptidomimetics-like and its related motifs.  Despite these successful applications 
of SNAr cyclizations, there are still many other reactions being employed for the 
generation of more complex macrocyclic compounds.57,62   
Scheme 3.3. SNAr reaction towards macrocyclic natural products 
 
Although this effective transformation has been applied to mainly bioactive 
natural products, there are increasing examples of de novo macrocyclic compounds being 
synthesized via SNAr cyclization.  To name a few, aminopyrimidine macrocycles that 
possessed inhibitory activity against both CDK and vascular endothelial growth factor 
receptor-2 (VEGF-R2) and exhibited in vivo oral activity in a tumor xenograft model,63 
agonists of the TrkC neurotrophin-3 receptor and the TrkA nerve growth factor 
receptor,64 as well as TrkC antagonists,65 and lastly, a series of macrocyclic piperazinone 



































use of intramolecular SNAr cyclization, the ease and speed of executions for this 
transformation have been greatly enhanced with technologies available like solid phase 
synthesis and microwave irradiation.  Several different libraries capitalized on this 
existing assistance, whereby almost 14,000 derivatives were synthesized for biological 
screening, resulting in various lead compounds being identified.67  
 
Figure 3.5. Selected macrocycles from SNAr chemistry. 
 
3.1.2.3 Miscellaneous Methods: Mitsunobu reaction, Ring Expansion/Opening and 
MCR-Ugi-type Macrocyclization 
 Several other reaction methods, which have limited applications to macrocyclic 
structures but have been exploited in the synthetic arena, are the Mitsunobu reaction, ring 
expansion/opening and Ugi-type macrocyclizations.  Examples of utilization of the 
Mitsunobu reaction are in the production of key intermediates en route to MMP68 and 
HCV NS3-4A protease inhibitors69 3.4.2, as well as a TACE inhibitor (Scheme 3.4). 70  
 In contrast to the previous list, ring expansion/opening chemistry has more 
applications in methods development space and is less obvious for the synthesis of 
macrocycles.  However, macrocyclic structures can be generated by cleavage of 
appropriate bonds in multi-ring systems, although only certain reactions can withstand 


































Scheme 3.4. Mitsunobu reaction to key intermediates of inhibitors 
 
macrocycles obtained via ring expansion/opening chemistry are phosphatase cdc25B 
inhibitors and their 500 analogues,71 cyclic dopamine antagonists azecine LE30072 (10-
membered ring) 3.5.2 and also neutral endopeptidase 24.11 inhibitor CGS 25155 and 
related analogues (Scheme 3.5).73  Furthermore, a similar process is utilization of nitrogen 
insertion/ring expansion of cyclic ketones that have yielded either macrolactones or 
macrolactams, with the relative proportions dependent on the ring size of the precursor 
and the pH of the reaction medium.74  The limitations of the ring expansion/opening 
approaches become more apparent, when taking into account the relative simplicity of the 
molecules produced.   
Scheme 3.5. Ring expansion/opening chemistry towards macrocyclic products 
 
In addition to the previously mentioned methods, a number of newer strategies 
have been developed to access more complex and diversified structures.  In this regard, in 
2012, Tan and coworkers developed an oxidative ring expansion using polycyclic 














































macrolactams 3.6.3.75  In 2011, Suh and coworkers utilized readily prepared, smaller 
exocyclic lactam-containing precursors to generate functionalized macrolactams 3.6.6 
and 3.6.7 via aza-Claisen rearrangement.76  In 2011, Dudley and coworkers used a 
reductive cyclization, followed by a ring-expanding fragmentation, en route to cyclic 
alkynyl ketones 3.6.9 (Scheme 3.6).77   
Scheme 3.6. Macrocyclic compounds from different ring expansion/opening chemistries. 
 
Finally, in 2010, Yudin and co-workers reported a high yielding macrocyclization 
process to generate challenging medium and large-sized cyclic peptide products with 
high diastereoselectivity and no dimerization or oligomerization products.78  In this 
approach (Scheme 3.7), a multi-component Ugi-type reaction was utilized in a 
macrocyclization of linear peptides enabled by amphoteric aziridine aldehydes, which 
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with nucleophilic aziridine aldehydes 3.7.1 as core building blocks together with a range 
of amino acids 3.7.2 and tert-butyl isocyanide in trifluoroethanol to provide the desired 
cyclic peptide products 3.7.3 in good yields with varying peptide chain lengths, as it 
affects the reaction outcome in terms of selectivity.  Gratifyingly for the authors, the 
medium and large-sized rings were readily synthesized.  In addition, the authors found 
that the resulting cyclic products which incorporated an activated aziridine ring, provided 
a valuable point for conjugation to different side chains via nucleophilic ring-opening, for 
example, the commonly used fluorescent tag 7-mercapto-4-methyl-coumarin (7-mmc) 
was attached in a site-specific manner to the cyclic peptides at a late stage of the 
synthesis, as shown in Scheme 3.7. 
Scheme 3.7. Macrocyclic compounds from MCR Ugi-type reaction 
 
 
3.1.3 Importance of Stereochemically (sp3)-Rich Molecules 
Since the introduction of the Lipinski “rule of 5” guidelines,79 the medicinal 
chemistry community has become more aware of the value of these physical properties of 
potential drug candidates.  These properties include molecular weight (MW), topological 
polar surface area (pTSA), rotatable bonds and hydrogen bond donors and acceptors.  
These properties are not only incorporated to the medicinal chemistry dictionary but are 

























































shift to high-throughput synthesis of compounds over the past years that may have given 
an inclination for molecules to fail by directing discovery efforts toward achiral, aromatic 
compounds.  As such, two simple and interpretable measures of the complexity of 
molecules prepared were hypothesized in relation to the potential of drug candidates.  
The first is carbon bond saturation as described by fraction sp3 (Fsp3) where Fsp3 = 
(number of sp3 hybridized carbons/total carbon count) (Figure 3.6).  The second is 
whether or not a chiral carbon exists in the molecule.  Considering both aspects [e.g. 
carbon bond saturation (as measured by Fsp3) and the presence of chiral centers], is now 
deemed important when associated with potential success, as compounds transition from 
discovery, through clinical testing to drugs.9  Judicial use of these parameters may permit 
the generation of architecturally more complex molecules, as well as more chemically 
diverse space, without increasing the molecular weight considerably.  This point is 
brought to light by looking at two simple examples outlined in Figure 3.6, whereby 
dimethyl pyridine has only five possible isomers, in contrast to the saturated structure of 
dimethylpiperidine, possessing two stereogenic centers, which is able to accommodate up 
to 34 isomers (Figure 3.6).   
 
Figure 3.6. Comparison between isomers of dimethyl pyridine and dimethylpiperidine. 
In addition to an increase in diversity, increasing sp3 character may also improve 






















substantiate this claim, as well as the medicinal chemistry belief82 that reducing the 
aromatic character of a molecule might improve physical characteristics, namely 
solubility.  Using the formula provided, investigations were executed to interpret that 
highly complex molecules, as measured by saturation, increased the likelihood of higher 
solubility and lower melting points.  As such, if the compounds have appropriate values 
for these properties, they will be more likely to succeed as drugs.  The presence of 
stereocenters, another descriptor for complexity, also increases the likelihood.   
In addition to higher solubility and lower melting points, saturation and presence 
of stereocenters also allow more complex molecules to access larger chemical space, 
which leads to a greater probability to identify compounds that better complement the 
spatial intricacies of target proteins (Figure 3.7).  Other properties that influence the 
shape complementarity between ligands and its binding site are as follow: (a) size, a 
molecule needs to have an appropriate size to enter the binding pocket, (b) shape, a 
molecule needs to be able to exhibit a comparable shape to prevent clashes with the 
protein, and (c) electrostatics, whereby a molecule needs to ensure ideal positioning of its 
functional groups in the molecular setting to finally establish the essential electrostatic 
complementarity with the target protein (Figure 3.7).83 
The molecular properties of drug molecules were first introduced in Chapter 1, 
and further illustrated in the current section, suggesting that the molecular descriptors 
portray a pivotal role when small-molecule is en route to a potential druggable 
compound.  With the desired molecular properties in hand, there is a higher probability of 
achieving high impact small-molecule hits through a high-throughout screening platform 
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and thus reaching a hit identification to lead optimization and beyond process.  Hence, 
there is the growing need to incorporate all the relevant properties when designing the 
synthetic methods to generate unique small-molecules.     
 
Figure 3.7. Shape complementarity of ligands and 3D binding pocket of target protein. 
 
3.2 Complementary Ambiphile Pairing (CAP) and Complementary Pairing (CP)  
Strategies to Benzofused Sultams 
As described in Chapter 2 and Section 3.1, sulfonamides84 and sultams are 
unnatural and less prevalent in the literature, but have been found to exhibit some 
biological activities.  Despite advances in the field,85 methods to generate medium- to 
large-sized lactams and sultams remain a challenge.  
Previously, our group has reported two strategies termed complementary pairing 
(CP) and complementary ambiphile pairing (CAP) 86 for the synthesis of skeletally 
diverse common ring sultams (5–7 membered rings) in a modular and efficient fashion. 
As shown in Figure 3.8A, CP involves simple coupling of bis-electrophile components 
reacting with complementary bis-nucleophiles, namely amino alcohols or amines.  In 
contrast, CAP strategies unite a pair of ambiphilic compounds––possessing both 
electrophilic and nucleophilic components––in a synergistic complementary manner.  On 





such as aziridine aldehydes that contain a nucleophile and electrophile on the same 
molecule (Figure 3.8B).78  A high yielding macrocyclization of linear peptides using 
aziridine aldehydes as core building block under mild conditions were reported, which 
afforded medium and large-sized rings with high diastereoselectivity and no dimerization 
or oligomerization byproducts.  The nucleophilic aziridine functionality is retained in 
their synthesis, whereas our current work of activated electrophilic sulfonyl aziridine 




Figure 3.8. CP, CAP and amphoteric molecules. 
We have previously investigated and reported the use of o-haloaryl sulfonyl 
chlorides in a number of CP/CAP strategies, including: CP ‘4+1’,87 CP ‘3+4’,88 CAP 
‘4+3’,86a CAP ‘4+4’86b and lastly CP/CAP reaction pairing89 to generate a variety of 
bridged and benzofused sultams (Figure 3.9).  Based on these studies, we sought to 
expand the scope to another unique class of bis-electrophiles, namely, heretofore 
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counterparts, such as amino alcohols, as well as consecutive coupling with primary 
amines.90  We envisioned complementary pairing of activated sulfonyl aziridines (simple 
6-atom bis-electrophilic synthon) via "chemo- and regioselective" ring-opening by the 
amino component of the amino alcohol (bis-nucleophiles) and subsequent SNAr 
cyclization with the alcohol component to furnish unprecedented, functionally rich 
medium-sized benzofused sultams in a chemoselective “6+4” and “6+5” 
heterocyclization pathways.  Moreover, we envisioned the use of o-fluoroaryl-sulfonyl 
aziridines to generate complex 7-membered benzofused sultams via “6+1” atom 
cyclization sequence, when primary amines are utilized for sulfonyl aziridine ring-
opening and the resulting secondary amines cyclize via a subsequent SNAr reaction 
(Figure 3.9).   
 





















































































3.3 Results and Discussion 
3.3.1 Optimization Studies 
The titled investigation commenced with the preparation of chiral aziridines 3.8.3 
via a mild Wenker synthesis91 from the respective amino alcohols, with all preparations 
occurring in excellent yields.  Sulfonylation of aziridines with o-fluorobenzene sulfonyl 
chlorides furnished a variety of 1-((2-fluorophenyl)sulfonyl)aziridines 3.8.4a–l in good 
yields ranging from 70–80% (Scheme 3.8).  The variety of sulfonyl aziridines can be 
observed from the sultams constructed via the reported methodology.   
Scheme 3.8. Generation of various aziridines via Wenker synthesis and sulfonylation of 
the derived aziridines 
 
Studies on the one-pot, sequential process began with (S)-1-((4-bromo-2-
fluorophenyl)sulfonyl)-2-isobutylaziridine 3.8.4a (aziridine ring-opening), which was 
reacted with N-methylethanolamine 3.1.1 (1.2 eq.) in DMF at 130 ºC, using microwave 
(mW) irradiation for 30 mins (Table 3.1, entry 1).  The reaction was monitored by TLC 
and upon disappearance of starting material–Cs2CO3 (2.5 eq.) was added to the crude 
mixture.  The mixture was next subjected to 30 additional min. of mW irradiation at 150 
ºC in order to facilitate the SNAr reaction, and ultimately afford the desired benzo-
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With this result in hand, optimization of reaction conditions was carried out.  
Notably, it was found that solvent concentrations, reaction time and temperature were key 
factors since the aziridine ring-opening and SNAr reactions are inter- and intramolecular 
pathways, respectively.  In particular, increased reaction time and temperature were 
found to effect reaction decomposition.  It should also be noted that the first reaction 
(aziridine ring-opening) was carried out under relatively high concentrations, while the 
subsequent intramolecular SNAr reactions required dilute concentrations  (Table 3.1, 
entries 3–5).  Furthermore, it should also be noted that while aziridine ring-opening 
proceeds at rt, the reaction took 5 days to go to completion; while utilization of mW 
irradiation allowed for completion of reaction in 30 mins.  Efforts to improve this 
reaction by screening other bases for instance CsF, K2CO3, K3PO4, DBU and NaH 
revealed that use of Cs2CO3 was optimal. After thorough investigation, the optimized 
conditions for this one-pot, sequential aziridine ring-opening–SNAr protocol were 
achieved, whereby, arylsulfonyl aziridine 3.8.4a and amino alcohol 3.1.1 were subjected 
to mW irradiation in DMF at 130 ºC for 30 mins and 150 ºC for 40 mins, respectively.  
This led to 10-membered sultam 3.1.2a in good yield (66% over 2 rxns; 81% avg/rxn) 
(Table 3.1, entry 5).  The structure of sultam 3.1.2a was confirmed by X-ray 
crystallographic analysis (Figure 3.10).  This set of optimized conditions was also utilized 
for the synthesis of 7-membered benzofused sultams, with some substrates having a 







Table 3.1. Optimization of reaction conditions 
 
entryc conc (i to ii M) time (i, ii mins) yield (%)a 
1 0.3 30, 30 43b 
2 0.3 30, 40 50b 
3 0.3 to 0.1 30, 40 58b 
4 0.3 to 0.08 30, 40 66b 
5 0.3 to 0.05 30, 40 34b 
aFinal isolated yield over 2 reactions after flash chromatography. bAziridine-
opening: 3.8.4a (1.0 equiv) and 3.1.1 (1.05–1.3 equiv) in DMF at 130 ºC. SNAr: 
Cs2CO3 (2.5 equiv) in DMF at 150 ºC. cReactions were monitored by TLC. 
As seen in the X-ray crystallographic analysis of the cyclic products shown in 
Figure 3.10, the preferred conformation92 as noted in Chapter 2 of the Ar-SO2NR1R2 
moiety is also conserved, however in this case, it renders the core macrocycle in a unique 
conformation, whereby the N–H bond points inward. 
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3.3.2 Synthesis of 10- and 11-membered Benzofused Sultams 
With the optimization conditions in hand, substrate scope studies commenced 
with the synthesis of medium-sized, fused polycyclic and spirocyclic benzofuzed sultams 
using various secondary acyclic and cyclic amino alcohols 3.9.1a–e, which proceeded to 
occur in average to good overall yields (Scheme 3.9).  Notable applications include both 
R and S-prolinol, racemic 2-piperidinemethanol and 2-piperidine- ethanol to afford the 
6,10,5-fused, 6,10,6- fused and 6,11,6-fused tricyclic systems, respectively.  The 
synthesized structures have stereocenters on the core medium-sized rings, which 
consequently imparts “non-flatland” architecture.  During the investigation, it was 
determined that by increasing the reaction time for some substrates, slightly higher yields 
were obtained thus, sultam 3.9.2b was generated in 70% yield over 2 reactions (84% 
avg/rxn) when the reaction time for SNAr reaction was extended to 50 mins, while 
maintaining all other reaction conditions (Scheme 3.9).  Also, the 10-membered 
benzofused sultams 3.9.2g and 3.9.2m were synthesized from sulfonamides derived from 
spiro-cyclohexyl aziridine in good yields.  Another interesting reaction occurred in the 
production of the 6,11,6-fused tricyclic sultam, 3.9.2p, that was furnished as a single 
diastereomer as confirmed by X-ray crystallographic analysis (Figure 3.10, page 25), 
albeit it in lower yield, when racemic 2-piperidine-ethanol was utilized in the opening of 
non-racemic aziridine.  Presumably only one of the diastereomeric intermediates 





Scheme 3.9. “6+4” and “6+5” cyclization to bi-and tricyclic, 10- and 11-membered 
sultams 
 
The proposed plausible mechanism for all substrates is that the secondary amino 
group proceeded with the aziridine-ring opening, vide infra, and the resulting tertiary 
amine which is incapable of executing a subsequent intramolecular SNAr cyclization 
reaction, allowed the unprotected primary or secondary hydroxyl group to cyclize under 











































































































































































3.3.3 Synthesis of Stereochemically-rich Benzofused Sultams 
Next, we further investigated the scope of this one-pot, sequential procedure by 
using chiral, non-racemic, substituted secondary amino alcohols (Scheme 3.10).  
Derivatives of ephedrine 3.10.1a–e were subjected to the "Click" aziridine ring-opening–
SNAr reaction conditions and to our delight, the secondary alcohols proceeded smoothly 
to afford medium-sized sultams (3.10.2a–f) in average to good yields over 2 reactions, 
albeit lower yield for (1S,2S)-(+)-pseudoephedrine derived 3.10.2c.  Sultam 3.10.2b was 
confirmed by X-ray crystallography where the respective stereocenters (6R,7R) 
correspond to the structure as shown in Figure 3.10 (page 25).  In addition, regardless of 
the substrate, both primary and branched secondary hydroxyl groups were able to 
undergo the aziridine-ring opening–SNAr protocol to furnish the respective sultams.  
Also, use of the N-(methylamino) cyclohexyl methanol in the aforementioned method, 
















































































3.10.2c, R1 = Br, R2 = iPr; 13%




provided the spiro-benzo-oxathiadiazecine-cyclohexane 1,1-dioxide 3.10.2f in 46% yield 
over 2 reactions (68% avg/rxn) (Scheme 3.10).  On a similar note, secondary amino 
alcohols that react with the sulfonyl-aziridines generated tertiary amine-containing 
intermediates (incapable of intramolecular SNAr cyclization), whereby the adjacent free 
secondary hydroxyl groups underwent facile cyclization to provide sultams bearing three 
stereogenic centers.   
 
3.3.4 Synthesis of 7-membered Benzofused Sultams 
This one-pot, sequential strategy was extended to several amines 3.11.1 whereby 
their dual reactivity facilitates access to 7-membered (common-sized) benzofused 
sultams in an overall “6+1” atom cyclization sequence involving consecutive aziridine 
ring-opening and intramolecular SNAr reaction (Scheme 3.11).  The use of simple alkyl 
and aromatic amines containing different substituents furnished benzo-thiadiazepine 1,1-
dioxides 3.11.2a–3.11.2e in satisfactory yields (44–53% over 2 rxns, 67–73% avg/rxn).  
Amines with both cyclic and linear ether moieties were also employed successfully to 
provide 7-membered benzofused sultams 3.11.2f–3.11.2i in moderate yields (46–56% 
over 2 rxns, 68–75% avg/rxns).  The primary amines proceeded with aziridine-ring 
opening and the secondary amines derived after the first reaction, were then cyclized to 
form cyclic sulfonamides.  Similarly, common-sized benzofused sultams 3.11.2j–3.11.2p 
consisting of amines having hydroxyl moieties were resulted from different aziridinyl 
sulfonamides  (cyclohexyl, iPr and iBu) in albeit slightly lower yields (12–56% over 2 
rxns, 35–75% avg/rxn).  Likewise, a plausible mechanism was proposed; when the 
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nucleophiles are primary amines with free hydroxyl groups, the secondary amines 
generated after aziridine-ring opening proceeded with the SNAr cyclization instead of free 
hydroxyl groups for the formation of benzo-thiadiazepine 1,1-dioxides.  A high degree of 
chemoselective was observed in all the cases, except formation of side-product during the 
SNAr reaction and possibly decomposition of the final product. 



























































































































3.3.5 Mitsunobu Reaction to Bridge Benzofused Sultams 
An added feature of the 7-membered sultams is their ability to undergo facile and 
unprecedented intramolecular Mitsunobu alkylation reactions to synthesize the strained 
[3.2.2] bridge bicyclic sultams (Scheme 3.12).  Thus, sultam 3.11.2l was treated with 
Ph3P and DIAD in THF at room temperature, stirred overnight and upon completion, 
provided ethanobenzo-thiadiazepine 1,1-dioxide 3.12.1a in 87% yield.  The structure of 
sultam 3.11.2m was confirmed by X-ray crystallography and shown to display an optimal 
positioning of the hydroxyl group on order to participate in facile Mitsunobu alkylation to 
afford sultam 3.12.1b bearing a two-carbon bridgehead.  Further demonstration of this 
notable intramolecular Mitsunobu reaction was realized in the production of the spiro-
cyclohexyl-containing [3.2.2] bridged benzofused sultam 3.12.1c, albeit in a lower yield 
of 40%.  The structure was confirmed by X-ray crystallographic analysis (Scheme 3.12).  
Scheme 3.12. Utilization of the Mitsunobo reaction to access bridged, 7-membered 
sultams 
  
In contrast, the more sterically hindered sultam 3.11.2o was unsuccessful in 
yielding the two-carbon bridged sultam after several attempts using similar reaction 

























3.12.1a: R1 = H; 87% 
3.12.1b: R1 = Me; 46%3.11.2l: R1 = H;





in the various Mitsunobu reaction attempts, as well as excess reagents that were used in 
the reaction, were isolated.  While sultam 3.11.2o was unsuccessful, a unique [4.3.2] 
bridged, 9-membered benzofused sultam 3.13.1a was observed when hydroxyl-
containing sultam 3.11.2p underwent the intramolecular Mitsunobu reaction with the 
same reaction conditions, albeit a much lower yield of 5% was obtained (Scheme 3.13).   
Scheme 3.13. Utilization of the Mitsunobo reaction to access [4.3.2] bridged 9-
membered benzofused sultam 
  
 
3.3.6 19F NMR of Benzenesulfonamides Intermediates 
A key finding during these studies was the isolation of the intermediate, aziridine-
ring-opened product, which was observable using 19F NMR as detailed in Figure 3.11.  In 
this experiment, aziridinyl-sulfonamide A was chosen and shown to contain a single 
resonance (triplet) in the 19F NMR spectrum (Figure 3.11.A).  Reaction with racemic 2-
piperidinemethanol furnished the ring-opened intermediate B, which was detected as a 
single resonance (triplet) in the 19F NMR spectrum (Figure 3.11.B) but shifted upfield 
marginally due to the electronic changes within the molecule.  After SNAr reaction, the 
19F NMR of the desired product C was obtained and shown to have complete absence of 
any fluorine resonances (Figure 3.11.C).  As this particular bis-nucleophile is racemic, 














































































3.3.7 “Click, Click, Click, Cyclize” to Stereochemically-rich, 10-membered 
Benzofused sultams 
Encouraged by these results, efforts were focused toward the extension of the 
method using distinct building blocks that were obtained in one step (Scheme 3.14).  
Hence, both R- and S-benzyl glycidyl ethers were subjected to "Click" epoxide ring-
opening90 with TBS-protected D-alaninol, to furnish elaborate amino alcohols 3.14.5 and 
3.14.6.  These chiral, non-racemic building blocks were then utilized in the established 
aziridine ring-opening–SNAr procedure to afford 10-membered sultams 3.14.7 and 3.14.8 
bearing three stereogenic centers, along with pendant free hydroxy group, in moderate 
yields.  In addition, it should be noted that the displaced fluoride anion in the 
intramolecular SNAr reaction served an additional role by deprotecting the TBS-ether, 
thus representing an overall atom economical one-pot, sequential aziridine ring-opening–
SNAr–desilylation protocol. 



















































3.14.5 R = 40%






3.14.7 R = 42%






















3.3.8 Principal Moments of Inertia (PMI) Analysis 
 The small strained macrocycles denoted an intriguing region of chemical space 
that can be difficult to access chemically.  As so, principal moments of inertia (PMI) 
analyses as developed by Sauer and Schwarz 93  were computed to quantify more 
rigorously the chemical space that the common and medium-sized sultams might occupy, 
which was employed herein to assess the molecular diversity.  PMI analysis utilizes 
shape-based descriptors: the minimum energy conformation of each compound is 
determined, PMI ratios are calculated and normalized, and a subsequent triangular plot 
depicts the shape diversity of the library.  The analysis reveals that the 7-membered and 
10/11-membered benzofused sultams generally mirror the shape distribution of the set of 
FDA approved drugs (Figure 3.12), thus demonstrating the potential drug-likeness of the 
scaffolds.  The most populated region has the majority of sultams as well as the hybrid 
region, which is the center of the triangular plot, and contains some of the 10/11-
membered sultams.  In addition, the area also has lesser unpopulated regions of chemical  
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space, illustrating the novel nature of some FDA-approved drugs, as well as sultams 
generated in this method, from the perspective of molecular shape. 
In addition, a second analysis was tabulated, plotted against medium to large-
sized rings (10- to 14-membered rings) extracted from the ZINC database (Figure 3.13).94  
Although these compounds are not necessarily drugs, they could be utilized as probes or 
leads in different screens.  The presence of these molecules in the ZINC database is an 
indication that there is also demand for such analyses, which further substantiates that 
macrocyclic-based drug discovery/development, is a recently evolving field.  With 
similar calculations in Figure 3.12, the plot demonstrates that 10- to 14-membered rings 
in the database are relatively widespread in terms of chemical space, suggesting they are 
not necessarily a specified shape.  Upon comparison, both the 7- and 10-/11-membered 
benzofused sultams are also outspread, parallel to the rings extracted from the database.  
The compounds are located in both the populated and underrepresented regions, 
signifying their diverse molecular shape distribution.  
 
Figure 3.13. Distribution of 7-membered and 10/11-membered sultams versus 10- to 14-
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3.3.9 Overlay Analysis95 
The overlay produced for the sultam scaffolds reported herein is depicted in 
Figure 3.14 and provides a simple indication of the diversity and shape distribution 
evident in this library.  The peripheral spatial variation seems to be portraying a non-
trivial role in the shape-diversity although the critical source of diversity comes from the 
core.  Both sources of diversity are interrelated as the cores have sufficient torsional 
flexibility that varying the side chains can influence the core backbone orientation.  
Hence, the orientations in Figure 3.14iii and 3.14v collectively suggest that the 7-
membered sultams (benzo[f][1,2,5]-thiadiazepine 1,1-dioxides) have a good combination 
of elongated (rod-like) and flat (disc-like) structures, depending on the substituents 
extending out from the conserved core, benzofused rings.  Also, the orientations in 
Figures 3.14iv and 3.14vi together, propose a likewise scenario, although the 10-
membered sultams (benzo[b][1,4,5,8]oxathia-diazecine 1,1-dioxides, benzo[b]pyrrolo-
[1,2-h][1,4,5,8]oxathiadiazecine 8,8-dioxides and benzo[b]-pyrido[1,2-h][1,4,5,8]oxathia-
diazecine 5,5-dioxide and benzo[b]-pyrido[1,2-h][1,4,5,8]-oxathiadiazacycloundecine 
5,5-dioxides) are more hybrid, where it is a good mixture of elongated, flat and sphere-
like characteristics than the 7-membered scaffolds.  By varying the substituents or ring 
sizes, it can influence the shape as seen in Figure 3.14vi where some motifs are covering 
different space than others.  The distribution of functional substituents across angles 
spanning some parts of the whole sphere surrounding the conserved core, suggests that 







Figure 3.14. (i) Simple cartoon of the library compounds, with a core of MW ~ 150–193, 
based on Lipinski’s rules (MW < 500), and comprising three substituents, each having 
MW < 180, to establish different functional groups. (ii) This cartoon demonstrates that 
the substituents extend out of the core in a circular motion. (iii) and (iv) both overlay 
images exhibiting the conserved core of 7-membered and 10-membered sultams 
respectively. (v): 7-membered and (vi): 10-membered, both overlay images revealing that 
the substituents are extending outwards in a semi-circular or circular motion as 











3.4 Summary and Outlook 
In summary, we have developed a one-pot, CP strategy introducing the 1-((2-
fluoroaryl)sulfonyl)aziridine building block as a versatile bis-electrophilic species for 
reaction with amino alcohols/amines for the preparation of common and medium-sized 
benzofused sultams containing up to three stereogenic centers.  This approach was 
extended to the utilization of elaborate chiral, non-racemic building blocks as well as 
cyclic and spirocyclic amino alcohols to afford a diverse array of polycyclic scaffolds.  
Furthermore, the method is highly modular and adaptable for the preparation of sultam 
libraries in an atom economical, one-pot, sequential manner.  Work in this regard is 
underway and will be reported in due course. 
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Modular One-pot, Sequential Protocols  





4.1 Introduction  
As analyzed in Chapter 1, there are only 351 ring systemsi and 1,197 frameworks 
among more than 1,000 current marketed small-molecule drugs, which came onto the 
market before 2013.1  Moreover, the most frequently used ring systems (83%) were first 
used in drugs developed prior to 1983, and it is also very unusual for a drug to contain 
more than one new ring system.  Furthermore, on average, six new ring systems enter 
drug space on a yearly basis and only ~28% of new drugs contain a new ring system.  In 
light of these facts, the most frequent non-aryl, bicyclic lactams consist mainly of 6/4-, 
5/4-, 7/6-, 6/5-fused systems.  These observations provide insights into the chemical 
novelty of drugs and highlight the potential demand for new ring systems or frameworks, 
with low synthetic cost to develop compound libraries efficiently from hit identification 
to lead optimization and beyond.  Herein, is reported a facile one-pot, sequential  
3-component approach employing sulfonylation–aza-Michael addition–intramolecular 
amidation to generate 79/90-member library of 7/4-, 7/5-, 7/6-fused bicyclic sultams with 
attenuated electronic, steric and stereochemical properties, depending on the selected 
building blocks for each scaffold.  These sultam scaffolds lie within new chemical space 
when mapped using the principal moments of inertia (PMI) analysis and overlay analysis 
presented at the end of Chapter 4, vida infra.  
Based on the ring systems within the top 100 most frequently used, and sorted by 
descending frequency in Chapter 1, the top two most frequent frameworks are thia-
                                                
[i] A ring system is a complete ring or rings formed by removing all terminal and 
acyclic linking groups without breaking any ring bonds.  
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azabicyclo octenone and thia-azabicyclo heptanone, which contain the 6/4- and 5/4-fused 
bicyclic lactam motifs, respectively.  There are numerous pharmaceutical compounds that 
contain the highlighted motifs and the two examples are penicillins and cephalosporins, 
which are both acylating agents.  They are capable of acylating nucleophilic residues in a 
diverse range of viral, bacterial and mammalian enzymes.  More recently, fine-tuning of 
the β-lactam scaffold has enabled the development of not only serine-based enzyme 
inhibitors but also inhibitors of cysteine-based and metalloenzymes.2  However, due to 
the rapidly eroding effectiveness of this class of compounds as a result of the ever-
evolving microbial development of β-lactamases, there is an exponentially growing need 
for new compounds to facilitate or replace the current class of drugs.  In this regard, the 
targets in Chapter 4, namely non-aryl 7/4-, 7/5- and 7/6-fused bicyclic acyl sultams, could 
be regarded in this light.  One potential application of the acyl sultams is the development 
of probes as acylating agents, by acylating the nucleophilic residues in biological 
systems.  A brief summary of the current landscape of electrophiles for covalent 
modification with the numerous nucleophiles (amino acids-selectivity) on the chemical-
proteomic platforms will be discussed in Section 4.1.2. 
 
4.1.1 Acyl sulfonamides/sultams  
Acyl sultams, which are a subset of sultams, represent an interesting and 
unnatural motif for the development of probes in biological systems due to their distinct 
physical and chemical properties.  Several of the physico-chemical properties include 
hydrolytic stability, crystallinity and unique sp3 characteristic, where an extensive list can 
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be found in Chapter 2.  These properties make them an attractive target where they 
exhibit a variety of biological activities, including anti-inflammatory, anti-bacterial, and 
anti-cancer, as well as unique biological profiles in different cell assays.3  Shown in 
Figure 4.1 are a few important examples of bioactive acyl sulfonamides and sultams, 
however an extensive list of biological activities can be found in a recent dissertation 
from our laboratory.4   
 
Figure 4.1. Bioactive acyl sultams and sulfonamides. 
The prevalence of acyl sulfonamides/sultams as biologically active molecules3 has 
inspired the present study aimed at the development of a facile and efficient synthesis of 
non-aryl, 7/4-, 7/5- and 7/6-fused bicyclic acyl sultams, bearing stereogenic centers with 
different substituents.5  In this regard, the growing need to develop streamlined synthetic 
strategies to access diverse libraries of acyl sulfonamides/sultams has led to this present 
study; we herein report a complementary ambiphilic pairing (CAP) strategy, vide infra, 
employing 2-chloroethane sulfonyl chloride with different amines and unprotected amino 





































































intramolecular amidation–click or carbamoylation) procedures for the generation of sp3-
rich, 7/4, 7/5 and 7/6-fused bicyclic acyl sultams.   
Upon the generation of approximately 203-member library of bicyclic acyl 
sultams, there are several interesting electrophilic motifs on these acyl sultams, which 
will be useful in future, applications that include reactivity studies with various 
nucleophiles (Figure 4.2).  Some of the electrophilic motifs are the acyl functional group 
within the sultam, the carbamate motifs and aryl-halogens, as well as sulfonamides 
containing aziridines and epoxides, and vinylsulfonamides.  The existing landscape of 
electrophiles for covalent modifications with their respective nucleophiles will be briefly 
reviewed in the following Section (4.1.2). 
 
Figure 4.2. Different electrophilic motifs on acyl sultams. 
 
4.1.2 Application: Covalent Protein Modification via Residue-specific Electrophiles 
 One possible application for acyl sultams is the investigation of electrophilic 
reactivity toward amino acids within the complex proteome.  This is based on the 
numerous functional amino acids that portray vital roles in catalysis and regulation, and 






























selectively targeted for covalent modification by reactive electrophiles.6  The concepts of 
electrophilicity and nucleophilicity establish the basic principles of organic chemistry are 
of utmost importance to understanding the fundamentals of chemical reactivity.  The 
formation of covalent bond occurs when a nucleophile attacks an electrophilic center, 
where the affinity is facilitated primarily by the relative hardness/softness of the two 
entities.  Also, most frequently, nucleophiles are present in proteins provided by the 
functional side chains of several amino acids, including, serine,7 threonine,8 cysteine,9 
lysine,10 as well as biological molecules like DNA11 and other compounds such as 
gluthathione.12  Within each class, nucleophilicity depends on the protein 
microenvironment, where side chains such as lysine exist in the predominantly 
protonated form at physiological pH.  Nucleophiles often react or bind with their 
counterparts such as electrophilic natural products, covalently acting drugs13 and small-
molecules probes allowing nature to affect a wide range of biological functions.14  
Chemical-proteomic platforms like activity-based protein profiling (ABPP),15 exploit this 
covalently modified reactivity with a chemical probe to selectively target a single enzyme 
or a functionally related family of proteins.  There are different examples of ABPP 
including the use of fluorophosphonate (FP)-based probes for targeting serine hydrolases 
(SHs), and vinyl sulfone and epoxide-based probes for lysosomal cysteine proteases and 
also non-directed strategies by utilizing electrophiles such as sulfonate esters and 





4.1.2.1 Covalent Modification of Serine  
 An activated serine can be found within a catalytic dyad or triad in the SH 
enzyme family and this covers approximately 1% of the human proteome.17  However, 
the serine residue will have a low reactivity if it is found outside of a typical catalytic site, 
thus limiting certain electrophiles.  The sensitivity of SHs to inhibition by fluoro-
phosphonates and FPs was well investigated and the use of probes has enabled the 
functional explanation of novel SHs, the discovery of selective inhibitors and 
characterization of dis-regulated SH activities in diseases such as cancer.18  Furthermore, 
the high affinity of FPs toward hydroxyl nucleophiles over other reactive groups, like 
thiols and amines, has rendered the serine-FPs reaction highly effective for proteomic 
applications (Figure 4.3i).   
 
Figure 4.3. Serine-mediated electrophiles for covalent protein modification.6 
Another important class of serine-reactive electrophiles are β-lactams as they are 
well characterized by the covalent modification of the serine nucleophile in penicillin 
binding proteins (PBPs) (Figure 4.3ii).  β-lactams activity-based probes libraries were 
synthesized and evaluated in bacterial proteomes as well as probes originating from 
several known antibiotics like ampicillin and related analogues, have revealed various 












































preferences of these privileged scaffolds.19  The labeling work disclosed that some of 
these β-lactam-bearing electrophiles are not selective for serine nucleophiles but a similar 
electrophile β-sultam reacted with an activated threonine-residue in azoreductases.20   
 Sulfonyl-fluoride derivatives such as 4-(2-aminoethyl) benzenesulfonyl fluoride 
(pan-serine protease inhibitor) were shown to covalently label multiple serine protease 
sub-classes, indicating utility as a serine-reactive electrophile (Figure 4.3iii).21  Although 
it is widely utilized in protease cocktails, the reactivity of the sulfonyl-fluoride 
electrophile was poorly characterized.   
Other common serine-reactive electrophiles include carbamates where several 
carbamate-based inhibitors happen for various SHs and recently, investigations on the 
balance between affinity and reactivity of this electrophile were completed (Figure 
4.3iv).22  A group of carbamates with various leaving groups for instance O-aryl, O-hexa-
fluoroisopropyl (HFIP), and N-hydroxysuccinimidyl (NHS) was shown to be highly 
selective for SHs; where an HFIP-containing carbamate showed excellent selectivity for 
two SHs, α-β hydrolase-6 (ABHD6) and monoacylglycerol lipase (MAGL), and was 
further developed into a fluorescent activity-based imaging probe (JW912).23  
 
4.1.2.2 Covalent Modification of Cysteine 
 The cysteine thiol is very reactive due to the electron-rich nature and 
polarizability of sulfur, facilitating a range of functions, including nucleophilic and redox 
catalysis, allosteric regulation and metal binding.24  Diverse proteins such as proteases, 
oxidoreductases and kinases contain functional cysteines, which enables cysteine-
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targeted electrophiles to expand the protein families amenable to ABPP.  Epoxides are 
found in many electrophilic natural products like fosfomycin25 and also cysteine protease 
inhibitor E-64,26 which target cysteine proteases (Figure 4.4i).  In addition, studies27 have 
shown that epoxides are relatively promiscuous to different amino acids.  The properties 
(steric, electronics and stereoelectronics) of the peptide backbone which the mild-
electrophile epoxide is connected to, can be attenuated to enable selectivity specific for 
an amino acid. 
 Two widely utilized electrophiles in various ABPP applications are 
chloroacetamides (CA) and iodoacetamides (IA) (Figure 4.4ii).  The more reactive IA 
covalently modifies ~1000 cysteines in the proteome,28 sanctioning the global description 
of changes in cysteine reactivity.  Several instrumental results were identified including 
bacterial redox modulators,29 cellular targets of electrophilic lipids,30 and zinc-binding 
cysteines within complex proteomes.31  These studies emphasize the benefits of a highly-
reactive, yet residue-selective electrophile to gain understanding into modulators of 
amino-acid nucleophilicity.  IA has been shown to react with other nucleophiles, such as 
the amine group of lysine,32 albeit at high millimolar concentrations.28  In constrast, CA is 
less reactive than IA but has been also integrated into libraries based on peptide16d,33 and 
piperidine34 scaffolds, leading to the identification of covalent modifiers for nitrilases and 
glutathione S-transferase omega 1 (GSTO1), respectively.  
 Other chemotypes that covalently modify cysteine include Michael accepting 
motifs; acrylamides and vinylsulfonamides (Figure 4.4iii and iv).  Two groups were first 
examined for preferential reactivity toward cysteine over lysine35 as well as evaluated for 
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fragment-screening applications related to thiol reactivity.36  Among these, reactivity can 
be attenuated based on the substituents/substituent effect on the electrophiles and this was 
highlighted by the acrylamide reactivity with different substituents where >2000-fold 
deviation was observed.36  Finally, the reversibility of Michael adducts with cysteine has 
been analyzed and can be tuned in a predictable manner where concerns related to off-
target protein modification can be obviated.37  Likewise for vinyl sulfonamides can be 
modulated accordingly to suit the appropriate nucleophiles.  
 
Figure 4.4. Cysteine-mediated electrophiles for covalent protein modification.6 
 
4.1.2.3 Covalent Modification of Lysine  
 A significant challenge of selective modification of functional lysine residues is 
the abundance of non-functional lysines and N-terminal protein amines.  However, recent 
work on aryl halides as protein-reactive electrophiles revealed that the lysine-reactive 
dichlorotriazine function through a SNAr mechanism (Figure 4.5i).  Advantages including 
identification of sites of acetylation, active-sites residues and ATP-binding sites by 
labeling the lysine residues.38  The general reactivity of N-phenyl-sulfonamides is poorly 
studied, although there is an example where the N-phenylsulfonamide-containing Toll-







































albumin (HSA) (Figure 4.5ii).39  Additional investigation is required to demonstrate more 
fittingly the potential utility as a lysine-reactive electrophile. 
 
Figure 4.5. Lysine-mediated electrophiles for covalent protein modification.6 
While the current prospect of reactive electrophiles and their respective 
nucleophiles is promising, electrophiles typically react with more than a single residue 
(nucleophile).  In this regard, continued expansion and development of novel 
electrophilic species is highly warranted, as is the need for more investigations on their 
respective reactivity patterns and chemoselectivity.  Several properties that can be 
attenuated include electronic, steric, stereo-electronic and ring-strain of selected 
electrophiles.  Hence, the demand for new small-molecules bearing electrophilic groups 
with the potential of modulation has motivate efforts to develop efficient syntheses of 
unique scaffolds.  In this regard, this Chapter details efforts to 7/4, 7/5 and 7/6-fused 
bicyclic acyl sultams that are sp3-rich.  In the final section of Chapter 4, these sultam 
scaffolds are evaluated by several computational analyses to demonstrate their 
































4.1.3 One-pot, Sequential Multi-component Protocols  
One-pot, sequential multi-component protocols are versatile strategies to rapidly 
generate structurally distinct and complex moieties in an efficient manner.40  These 
methods have important ramifications in economical, environmental and synthetic 
aspects and as a result, these procedures have gained prominence in modern organic 
synthesis.40b  One-pot, sequential strategies are utilized to effect multiple transformations 
in the same flask thus, negating several purification steps and minimizing hazardous 
chemical waste making this process green and eco-friendly.  In contrast, the one-pot/one-
pot, sequential transformations have several obstacles that need to be circumvented.  
Some of these hurdles include, (i) compatibility of multiple reactions: (ii) side products 
from earlier reactions that may interfere with the one-pot protocols, and (iii) minimal 
usage of solvents and reagents.  Nevertheless, these one-pot protocols are highly 
desirable with regards to time, energy, efficiency and purification.  
Application of one-pot, sequential protocols to diversity-oriented synthesis (DOS) 
has emerged as a facilitating platform for the synthesis of new heterocyclic small 
molecules for high throughput screening (HTS) toward unveiling their biological activity 
profiles.  Within the realms of DOS, accessing diversity elements including skeletal, 
stereochemical, functional and appendage on small multiple scaffold libraries are highly 
coveted.41  Incorporating these essential elements–with high emphasis given to molecular 
skeletal diversity–into library synthesis generally affords considerable ‘molecular shape 
space’ coverage, which correlates to broad biological space and also potentially higher 
biological hit rates.42  In contrast, traditional libraries having similar core skeletons 
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possess only peripheral diversity occupy narrow chemical space, which typically leads to 
lower biological hit rates.  In view of that, the construction of libraries with enhanced 
structural diversity has the potential to address these challenges.  Introduced in the 
following section, is an efficient strategy that allows for rapid access to structural diverse 
libraries encompassing molecular complexity, as well as stereochemical and functional 
diversity. 
 
4.2 Results and Discussion 
We previously demonstrated a highly scalable, one-pot complementary ambiphile 
pairing (CAP) method employing vinyl sulfonamides and amino acids for the preparation 
of skeletally, stereochemically and peripherally diverse sp3-rich acyl sultam scaffolds 
(Figure 4.6).5  The method employs an aza-Michael and amide coupling reactions in a 
one-pot, sequential protecting group-free protocol utilizing both linear and cyclic amino  
 























































































acids building blocks.  Use of cyclic amino acids in this protocol, generated an array of 
sp3-rich 7/4-, 7/5- and 7/6-fused bicyclic acyl sultams.  The CAP method employed 
utilizes the ambiphilic nature of both vinyl sulfonamides and amino acids, whereby 
sulfonamides, can readily undergo hetero-Michael additions as well as facile amidation.  
The one-pot, sequential aza-Michael–amidation method was also extended to include an 
initial sulfonylation reaction in a protecting-group free protocol. 
With the core strategy in place, we next extended the method to include one-pot, 
sequential 3- or 4-component protocols in a library platform.  In this approach, 
sulfonylation of different amines with 2-chloroethane sulfonyl chloride, followed by 
Michael reaction with variety of amino acids and subsequent amide cyclization, enables 
access to skeletally and stereochemically diverse acyl sultam scaffolds (Figure 4.7).  The 
next objective was to further extrapolate the one-pot, sequential process to a 4-component 
protocol.  Two pathways were envisioned – (i) sulfonylation with propargylamine, 
followed by a click reaction as the fourth step would provide triazolated products and  
 



























































(ii) aza-Michael reaction with hydroxyproline to afford a hydroxyl functional handle for 
carbamoylation with isocyanates (Figure 4.7).  However, for this chapter, only the 
generation of 90-member library employing the one-pot, sequential 3-component 
approach will be discussed in detail.  The 4-component pathways were reviewed in a 
recent dissertation (Naeem Asad).4 
 
4.2.1 Optimization Studies 
The one-pot, sequential 3-component method was first investigated in 2014 and 
based on the reported protocol, the first experiment was setup and optimized utilizing the 
initial reaction conditions provided.  The preliminary reaction conditions were employed 
for the synthesis of vinyl sulfonamide via a sulfonylation of allylamine 4.1.2{10} with  
2-chloroethane sulfonyl chloride 4.1.1 in the presence of Et3N and CH2Cl2 (Table 4.1, 
entry 1a), followed by a one-pot aza-Michael addition and an intramolecular amide 
coupling provided the desired acyl sultam in good yield (86% over 2 rxns; 93% avg/rxn) 
(Table 4.1, entry 1b).  With the result, efforts were made for the one-pot, sequential, 3-
component reaction protocol, by examining equivalents of reagents, as this is vital for 
one-pot, multicomponent reactions-to prevent excess reagents/by-products from 
advancing to the next reaction.  Hence, the equivalents of amino acid 4.1.3{7} were 
increased to ensure full conversion of the starting material to the Michael adduct 
intermediate, and also the equivalents of Et3N was decreased to prevent excess of reagent.  
Lastly, for the intramolecular amidation, the amount of hydroxybenzotriazole (HOBt) and 
solvent were investigated to facilitate the full conversion of starting material (Table 4.1, 
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entry 2).  Finally, the optimal reaction conditions were achieved with sulfonylation [1.5 
eq. of 4.1.2{10}, 2.0 eq. of Et3N, and CH2Cl2 (0.5 M)] at room temperature, followed by 
aza-Michael addition [1.2 eq. of 4.1.3{7}, 2.0 eq. of Et3N and MeOH/H2O (0.5 M)] at 60 
ºC for 12 h and lastly, intramolecular amidation [2.0 eq. of EDC, 1.5 eq. of HOBt, 2.0 eq. 
of Et3N, DMF (0.08 M)] at room temperature afforded acyl sultam 4.1.4{10,7} in 
satisfactory yield (30% over 3 rxns; 67% avg/rxn) (Table 4.1, entry 3). 
Table 4.1. Optimization of one-pot, sequential 3-component reaction protocol 
 
entry reactions reagents (eq.) T/time yield 
1a sulfonylation 4.1.2{10} (1.5), Et3N (2.0), CH2Cl2 (0.5 M) rt/12 h 88% 
1b Michael 4.1.3{7} (1.0), Et3N (3.0), MeOH/H2O (0.5 M) 60 ºC 
/12 h 
- 
amidation EDC (2.0), HOBt (0.2), Et3N (2.0),  
DMF (0.05 M) 
rt/12 h 86% 
2 sulfonylation 4.1.2{10} (1.5), Et3N (2.0), CH2Cl2 (0.5 M) rt/12 h - 
Michael 4.1.3{7} (1.2), Et3N (2.0), MeOH/H2O (0.5 M) 60 ºC 
/12 h 
- 
amidation EDC (2.0), HOBt (1.0), Et3N (2.0),  
DMF (0.08 M) 
rt/12 h 29%a 
3 sulfonylation 4.1.2{10} (1.5), Et3N (2.0), CH2Cl2 (0.5 M) rt/12 h - 
Michael 4.1.3{7} (1.2), Et3N (2.0), MeOH/H2O (0.5 M) 60 ºC 
/12 h - 
amidation EDC (2.0), HOBt (1.5), Et3N (2.0),  
DMF (0.08 M) 
rt/12 h 30%a 








































4.2.2 Library Design and Scope of Reagents 
 A 90-member, full matrix library was designed by using in silico analysis.43  Nine 
amines were selected based on the physico-chemical property filters that were applied, to 
guide the elimination of undesirable building blocks that led to products with undesirable 
in silico properties (see Supporting Information in Chapter 5 for full in silico data and 
detailed information on the calculations).  Simple aliphatic and aromatic with different 
substituents amines were introduced as well as others with functional motifs like olefins 
to modulate the physico-chemical properties of the substrates.   Furthermore, the amino 
acids were carefully chosen and investigated with the one-pot protocol.   
Simple alkyl amino acids with both stereochemistry (R and S) and ring sizes were 
studied and selected as the resulting core bicyclic acyl sultams will be skeletally diverse 
within the group of scaffolds.  In addition, inclusion of heteroatoms in the core introduces 
diversity and moderates the properties, however, selected examples proved to be 
problematic, thus the elimination of some building block, but retainment of the non-
challenging substrates 4.1.3{8–9}.   
Hydroxyl-containing amino acids 4.1.3{6–7} were favored as they are able to 
enhance the physico-chemical properties like solubility and CLogP values.  Hence, the 
desired diversity reagents were selected and a virtual library incorporating all possible 
combinations of the building blocks amines 4.1.2{1–10} and amino acids 4.1.3{1–9} was 
constructed (Figure 4.8).  Physico-chemical property filters were applied and these metric 
filters included standard Lipinski’s rule of five parameters (molecular weight <500, 
ClogP <5.0, number of H-acceptors <10, and number of H-donors <5), in addition to 
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consideration of the number of rotatable bonds (<5) and polar surface area.  Absorption, 
distribution, metabolism and excretion (ADME) properties were calculated by using the 
Volsurf program.44  Cartesian grid based chemical diversity analysis was performed 
according to the method described previously,45 by using standard H-aware 3D BCUT 
descriptors comparing against the MLPCN screening set (ca. 7/2010; ~330,000 unique 
chemical structures).  Guided by this library design analysis, amines 4.1.2{1–10} and 
amino acids 4.1.3{1–9} were chosen to generate the aforementioned 90-member library. 
 
Figure 4.8. Diversity reagents of 12 amines 4.1.2{1–12} and ten amino acids 4.1.3{1–
10}.  
Efforts next extended the one-pot, sequential protocol via the inclusion of a fourth 
component, namely a click reaction with the corresponding azides 4.1.5{1–13} and a 
propargylic amine to provide a number of triazolated scaffolds (Scheme 4.1).  
Alternatively, carbamoylation with the addition of isocyanates 4.2.5’{1–16} afforded the 
carbamates containing acyl sultams (Scheme 4.2).  More detailed description of this 
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Scheme 4.1. Reaction pathway with Huisgen [3+2] or ‘Click’ reaction as the 4-
component 
 
Scheme 4.2. Reaction pathway with carbamoylation as the 4-component 
 
 
4.2.3 Validation and Library Generation 
With the optimal reaction conditions in hand, a 20-member validation library was 
prepared by using ten amines 4.1.2{1–10} and two different amino acids–4.1.3{3} and 
4.1.3{7}–in pressure tubes and carousel for stirring and heating purposes (Table 4.2).  
Upon completion of the three reactions, all 20 crude reaction mixtures were diluted with 
water, extracted with EtOAc (2x), and the layers were separated.  The resulting organic 
layers were filtered through a silica SPE, and purified by automated mass-directed HPLC.  
Library validation was vital to assess both substrate and reaction scope, along with 
evaluating the application of automated mass-directed HPLC as the final analysis and 
purification method.  Evaluation of the validation library demonstrated that all 20 
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nearly all of the desired acyl sultam final masses (20–40 mg), with all 20 possessing a 
final purity >90%.  These sultams were purified several times due to the properties of the 
substrates/structures, resulting in yields that are relatively lower than average.  The 
protocol is very dependent on the polarity of the substrates as well as the extraction 
method, which led to the isolated yields being relatively different. 
 
Table 4.2. Optimization of one-pot, sequential 3-component reaction protocol 
 
entry sultam yield (%)a entry sultam yield (%)a 
1 4.1.4{1,3} 56 1 4.1.4{1,7} 4b 
2 4.1.4{2,3} 49 2 4.1.4{2,7} 4b 
3 4.1.4{3,3} 29 3 4.1.4{3,7} 16 
4 4.1.4{4,3} 50 4 4.1.4{4,7} 14 
5 4.1.4{5,3} 41 5 4.1.4{5,7} 8 
6 4.1.4{6,3} 64 6 4.1.4{6,7} 25 
7 4.1.4{7,3} 32 7 4.1.4{7,7} 48 
8 4.1.4{8,3} 7b 8 4.1.4{8,7} 11 
9 4.1.4{9,3} 16 9 4.1.4{9,7} 33 
10 4.1.4{10,3} 54 10 4.1.4{10,7} 30 
aIsolated yield after three reactions. bRe-purified thrice. 
With the validation completed, the remaining 70 compounds were synthesized via 














































amidation with ten amines 4.1.2{1–10} and seven other amino acids 4.1.3{1–2}, 
4.1.3{4–6} and 4.1.3{8–9}.  Under the optimized reaction conditions, the 70-member 
library were constructed and purified by automated mass-directed HPLC, although some 
scaffolds had to be purified thrice.  A total of 90 compounds were prepared, isolated in 
satisfactory yields (average yield: 30% over 3 rxns; 67% avg/rxn) and 79/90 compounds 
had purity greater than 90% after automated purification (see Supporting Information for 
all compounds with full numeric data).  Final assessment of the library established that 
the diverse compounds could be generated in a facile manner via a one-pot, sequential 
protocol.   
 
4.2.4 Computer Analysis of Molecular Properties and Shape Diversity  
4.2.4.1 Molecular Properties 
 Molecular properties for the library were calculated (Figure 4.9) and average 
property values for the respective core acyl sultams are displayed in Table 4.3.  Analysis 
of molecular properties suggests some compounds may have desirable qualities for 
biological or reactivity probes, while others could have a more appropriate role as drug 
lead discovery (Table 4.3).46  The average molecular weights of all acyl sultams fall 
within the acceptable range (molecular weight less than 500 Da) for drug-like 
compounds,46a as well as the lack of hydrogen bond donors may alternatively allowed 





Figure 4.9. Molecular properties of the 90-member library. HBD: hydrogen bond donor, 
HBA: hydrogen bond acceptor, TopoPSA: topological polar surface area, XLogP: 
partition coefficient. 
 











MW 279 293 307 309 358 
HBD 0 0 0 1 0 
HBA 5.3 5.3 5.3 6.3 7.3 





4.2.4.2 Principal Moments of Inertia (PMI) Analysis  
 As described in previous chapters, the basic information can be quantified more 
thoroughly via principal moments of inertia (PMI) analysis,47 which was used herein to 
assess the molecular shape diversity.  PMI analysis utilizes shape-based descriptors: The 
minimum energy conformation of each library member is determined, PMI ratios are 
calculated and normalized, and a subsequent triangular plot depicts the shape diversity of 
the library.  From it, the greater shape diversity of a library associates with increased 
probability of the library containing bioactive molecules.   
The analysis reveals three sets of acyl sultams (green, red and cayenne spheres) 
largely emulate the shape distribution of the set of FDA approved drugs (Figure 4.10), 
thus demonstrating the potential drug-likeness of the scaffolds and populating the 
chemical space with more unique scaffolds.  The synthesis of 90 compounds represented 
by the green spheres was described in the earlier sections and is the highlight of this 
chapter.  However, for the purpose of the discussion here, based on the graphics provided 
in Figure 4.10, four sets of bicyclic acyl sultams are briefly mentioned.  The most 
populated region contains the majority of the acyl sultams as well as the hybrid region, 
situated in the center of the triangle, which contains a mixture of acyl sultams with 
different peripheral substituents.  The hybrid region has a smaller amount of the FDA-
approved drugs where the majority of the blue spheres representing the carbamate-
containing acyl sultams, occupy an underrepresented region of chemical space, thus 
illustrating the novel nature of some compounds from the perspective of molecular shape.  
Overall, the shape diversity of the library implies a potential influence in compound 
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binding to a biological target.   
    
 
 
Figure 4.10. Distribution of four acyl sultam libraries. 
 
4.2.4.3 Overlay Analysis48 
The overlay produced for the 90 compounds reported herein is depicted in Figure 
4.11 and provides a fundamental indication of the shape distribution and diversity evident 
in this library.  The peripheral spatial distinction is the main source of diversity, however, 
the conserved core has several distinct differences derived from the building blocks, 
which consists of 7/4, 7/5 or 7/6-fused bicyclic system, where some have substituents 
extending outwards.  Hence, orientations 4.11iii and 4.11iv collectively suggest that the 
library generally tends to lie between elongated (rod-like) and flat (disc-like) structures, 
while the distribution of functional substituents across angles covering most part of the 
whole sphere adjoining the conserved core, suggests that the library as a whole attains a 
Rod Sphere 
Disc 











































realistic level of shape-based diversity. 
 
 
Figure 4.11. (i) Simple cartoon of the library compounds, with a core of MW~189–217, 
based on Lipinski’s rules (MW<500), and comprising one substituent having MW~50–
180, to establish different functional groups and the second substituent that influence the 
core structure with MW~10–100. (ii) This cartoon reveals that the substituents extend out 
of the core in a circular motion. (iii) Overlay image exhibiting the common core in these 
90 compounds. (iv) Overlay image revealing that the substituents are extending outwards 
in a semi-circular motion as mentioned in overlay image (ii).  
 
4.2.5 Conclusion  
 Overall, a one-pot, sequential 3-component reaction protocol employing 
sulfonylation–aza-Michael addition–Intramolecular amidation has been developed.  
Utilizing various commercially available amines and amino acids, a 79/90-member 
library of 7/4, 7/5 and 7/6-fused bicyclic acyl sultams was generated.  A series of 
computational analyses was performed, and revealed that the compounds reported herein 









FDA-approved drugs.  The compounds also sample a reasonable array of shape space 
within all three rod-like, disc-like and sphere-like structures.  The products have been 
submitted for evaluation of their biological activity in high-throughput screening assays 
at the NIH MLPCN and the results will be reported in due course. 
 
4.2.6 Reactivity Profiling of Potential Electrophilic Modifiers 
4.2.6.1 Initial Reactivity Profiling of Acyl Sultams 
Recent interest in drugs that covalently modify their protein targets or other bio-
macromolecules has motivated the search for small molecules with enhanced efficacy 
and selectivity towards the suppression of enzymatic activity by targeting uniquely 
positioned nucleophilic amino acid residues.49  As described in Section 4.1.2, one of the 
potential applications for the non-aryl 7/4-, 7/5- and 7/6-fused bicyclic acyl sultams is the 
ability to serve as unique electrophilic modifiers by reacting in the presence of 
biologically relevant nucleophiles such as cysteine, serine and lysine, among other 
examples.6  In this regard, preliminary investigations have begun to study the reactivity of 
the cyclic and bicyclic acyl sultams detailed in this Chapter.  This is with respect to their 
ability to serve as novel electrophilic modifiers with ultimate potential as probes in 
chemical biology and/or targeted small-molecule covalent inhibitors.   
Initial studies on electrophilic reactivity describe reactions of acyl sultams with 
the nucleophiles glutathione (GSH), cysteine (Cys) and serine (Ser).  Before these studies 
began, we aimed to investigate the stability of various acyl sultams in 100 mM phosphate 
buffered saline (PBS) solution at pH 7.4 as traditionally, experiments with GSH often 
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occur in this buffered media.  The exposure time of acyl sultam 4.3.1 in PBS was 
extended up to 69 h to determine its stability over a long period of time at room 
temperature (Scheme 4.3).  Subsequently, GSH and 4.3.1 were stirred in PBS at a 
concentration of 0.03 M and at room temperature, and the reaction mixture was 
monitored by TLC, for up to 69 h.  When 4.3.1 did not show reactivity as evidenced by 
TLC, the reaction mixture was then heated to 37 ºC and monitoring by TLC was 
continued over another 69 h.  Mass spectral data analyses for acyl sultam 4.3.1 supported 
the TLC findings, which indicated that the starting material was still present in the 
reaction mixture.  These results suggest that the acyl sultam is relatively stable in PBS 
buffer with both absence and presence of GSH, as described in Scheme 4.3.  
 
Scheme 4.3. Initial reactivity studies in phosphate buffer and with glutathione (GSH) 
  
Reactivity with N-acetyl-L-cysteine was next investigated, whereby acyl sultam 
4.3.1 was reacted with this nucleophilic residue at different solvent concentrations.  The 
initial experiment reacted within a shorter reaction time of 20 h for complete SM 
consumption when the concentration was at 0.5 M in H2O, and a longer reaction time 
with heating up to 37 ºC when the condition was more diluted (0.08 M) (Scheme 4.4).   















i. rt, 69 h
ii. 37 ºC, 69 h


















preliminary results revealed that the thiol of cysteine reacts with the electrophilic acyl 
sultam to a certain extent as shown by the initial TLC findings, implying the 
disappearance of the SM with new products being formed.  This is supported by mass 
spectrometry data for both reactions.   
 
Scheme 4.4. Initial reactivity studies with cysteine. 
   
 The primary goal of this project that is currently at the infancy stage is to 
determine if there is chemoselectivity for the reactions between the electrophilic acyl 
sultams and nucleophilic residues such as cysteine, serine and lysine under various 
conditions.  With the initial data highlighted in Scheme 4.4, investigations were extended 
to acyl sultams containing different ring systems, and thus varying the ring strain, with a 
preliminary array of nucleophiles.  
Hence, the investigations began with the 7/6-fused acyl sultam 4.4.1 where 
reaction with N-acetyl-L-cysteine only occurred after prolonged heating for several hours 
at both 37 ºC and 60 ºC (Table 4.4, entry 1), as supported by both TLC and mass spectral 
analyses.  As a second nucleophile, N-Boc-D-alaninol was employed for preliminary 
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starting material within 63.5 h of heating at 37 ºC, with mass spectral data supporting the 
TLC analysis (Table 4.4, entry 3).  In addition, the 7/6-fused acyl sultam 4.4.1 reacted 
with K2CO3 in MeOH at room temperature and within 15 h of stirring afforded the 
corresponding sulfonamide methyl ester, which was also supported by 1H NMR data 
(Table 4.4, entry 4). 
The substrate for this preliminary investigation was the novel, 7/4-fused bicyclic 
acyl sultam 4.4.2, which was presumed to be an interesting electrophilic modifier due to 
enhanced ring strain, and thus could potentially react faster with a range of nucleophiles 
under milder reaction conditions.  These assumptions were substantiated via reaction with 
N-acetyl-L-cysteine when performed in H2O at room temperature to yield the ring-opened 
product sulfonamide as verified again by mass spectral data, together with the initial TLC 
analysis, although this initial reaction was conducted at a higher concentration of 1.3 M 
(Table 4.4, entry 2).  However, the reaction with N-acetyl-L-cysteine at a lower  
 















rt, 37 ºC, 60 ºC 
D-Alaninol 
 in PBS Buffer
Reactive @ rt, 7 ha
(0.066 M)
Reactive @37 ºC, 63.5 ha
(0.022 M)
rt, 37 ºC, 60 ºC 
K2CO3 in MeOH
Reactive @ rt, 15 h
0.2 M, 1H NMR
Reactive @ rt, 10 ha
(0.2 M)
rt, 37 ºC, 60 ºC 
N-Acetyl-L-Cys 
 in PBS Buffer
Stable @ 37 ºC, 63.5 h
Reactive @ 60 ºC, 73 ha
(0.022 M)
rt, 37 ºC, 60 ºC 
N-Acetyl-L-Cys
in H2O
Reactive @ rt, 7 ha 
(1.3 M)
No SM by TLC
@ rt, 7 h
–
1 2 3 4
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concentration [0.066 M] in PBS buffer solution was inconclusive, as the mass spectral 
data did not confirm the formation of the expected product although the starting material 
was consumed as attributed by TLC (Table 4.4, entry 1).  Likewise, the 7/4-fused ring 
system 4.4.2 reacted with N-Boc-D-alaninol and provided the sulfamoyl-carboxylate 
derivative, as supported by both TLC and mass spectral data (Table 4.4, entry 3).  
Furthermore, this electrophilic motif reacted with K2CO3 in MeOH at room temperature 
within 10 h of stirring to furnish a similar methyl ester-analogue with mass spectral data 
substantiating the TLC analysis (Table 4.4, entry 4).  
As described in Table 4.5 is the overall summary of four different acyl sultams 
and their respective results with the different nucleophilic residues.  The final substrate 
for this study is the un-substituted 7/5-fused bicyclic acyl sultam 4.5.1 where harsher 
reaction conditions were employed for the three nucleophiles (GSH, N-acetyl-L-cysteine 
and N-Boc-D-alaninol) that were not reacting with the aforementioned electrophile at 
room temperature (Table 4.5, entries 2–4).  Heating up to 60 ºC and prolonged reaction 
times were required and the complete disappearance of SM 4.5.1 was seen only after the 
extended period of time.  This is based on the TLC findings although the mass spectral 
data supporting this observation was inconclusive.  Thus, more experiments are required  
to further analyze this substrate.  A final, but notable result that was carried out involving 
the comparison between the reactions of 7/6-, 7/5- and 7/4-fused acyl sultams (4.4.1, 
4.5.1 and 4.4.2) with GSH, whereby both larger systems remained unreactive, and 
whereas the more strained 7/4-fused ring system 4.4.2 reacted with GSH with complete 
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SM disappearance in under 72 h heated at 60 ºC (Table 4.5, entry 2).  This is based on the 
TLC findings together with the mass spectral data supporting this observation.   
 
Table 4.5. Summary of electrophilic reactivity of bicyclic acyl sultams. 
 
awith LC/MS data provided. 
 In summary, the aforementioned promising preliminary results demonstrate that 
the titled novel, fused bicyclic acyl sultams are acting as electrophilic modifiers and thus 
have potential as electrophilic probes.  Current and future efforts are aimed at further 
developing routes to additional acyl sultams that are attenuated electronically, sterically 
and stereochemically for subsequent reactivity profiling with a range of nucleophiles with 

















rt, 37 ºC, 60 ºC in 
GSH (0.03 M)
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Reactive @ rt, 20 ha
0.5 M
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0.08 M
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@ 60 ºC, 93 h
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4.3 Summary and Outlook 
 In summary, with a number of interesting applications readily available for these 
newly synthesized bicyclic acyl sultams, efforts will be focused on new strategies to 
modulate the properties of these unique systems.  In addition, submission of the 7/4, 7/5 
and 7/6-fused bicyclic acyl sultams to biological collaborators will allow for additional 
screening to potentially reveal interesting biological activity.  Efforts along these courses 
of action are currently in order and will be reported in due course.  
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5.1 Experimental for Chapter 2 
General Experimental Methods 
All air and moisture sensitive reactions were carried out in flame- or oven-dried 
glassware under argon atmosphere using standard gas tight syringes, cannula, and septa.  
Stirring was achieved with oven-dried, magnetic stir bars.  CH2Cl2 was purified by 
passage through the Solv-Tek purification system employing activated Al2O3 [1].  Et3N 
was purified by passage through basic alumina and was stored over KOH.  Flash column 
chromatography was performed with SiO2 from Mallinckrodt Chemicals (V120-25, Silica 
gel, 60 A, 40–63 µm).  Thin layer chromatography was performed on silica gel 60F254 
plates (EMD-5715-7, Merck).  Deuterated solvents were purchased from Cambridge 
Isotope Laboratories.  1H and 13C NMR spectra were recorded on a Bruker Avance 
spectrometer operating at 400, 500 MHz and 126 MHz, respectively.  High-resolution 
mass spectrometry (HRMS) and FAB spectra were obtained either on a VG Instrument 
ZAB double-focusing mass spectrometer boron a LCT Premier Spectrometer (Micromass 
UK Ltd) operating in the ESI mode (MeOH).  GC/mass spectrometry was performed 
using a Quattro micro GC (Micromass UK Limited).  Chapter 2 library syntheses were 
carried out in 1 dram vials utilizing a reaction heating block in an Anton Paar ® Synthos 
3000 synthesizer.  Microwave-assisted reactions were carried out in 1 dram vials utilizing 
a reaction heating block in an Anton Paar® Synthos 3000 synthesizer and also Biotage® 
Initiator.  Parallel evaporations were performed using a GeneVac EZ-2 Plus evaporator.  
Automated preparative reverse-phase HPLC purification was performed using a Waters 
Mass-Directed Fractionation system (Prep Pump 2525, Make-up pump 515, Sample 
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Manager 2767, UV-DAD detection 2996, and Micromass ZD quadrapole mass 
spectrometer).  Purification via preparative chromatography was achieved utilizing a 
Waters X-Bridge C18 column (19 x 150 mm, 5 µm, w/ 19 x 10 mm guard column) at a 
flow rate of 20 mL/min.  Samples were diluted in DMSO and purified using a elution 
mixture of water (modified to pH 9.8 by the addition of NH4OH) and CH3CN, running a 
concentration gradient which increased to 20% CH3CN over a 4 min period.  The 
corresponding preparative gradient, triggering thresholds, and UV wavelength were 
selected based on the HPLC analysis of each crude sample.  Analytical analysis of each 
sample after preparative chromatography utilized a Waters Acquity system with UV-
detection and mass-detection (Waters LCT Premier).  The analytical method conditions 
included a Waters Aquity BEH C18 column (2.1 x 50 mm, 1.7µm) and elution with a 
linear gradient of 5% water (modified to pH 9.8 through addition of NH4OH) to 100% 
CH3CN at 0.6 mL/min flow rate.  Purity of each sample was determined using UV peak 
area detected at 214 nm wavelength.   
Note:  
1. All reactions involving the use and heating of azides were carried out behind a 
safety shield taking extra precautions due to the explosive nature of these 
materials. 
2. 20 of the 80 compounds in Chapter 2 were fully characterized with mp, FTIR, 1H, 
13C NMR and HRMS. 
3. 20 of the 90 compounds in Chapter 4 were fully characterized with mp, FTIR, 1H, 
13C NMR and HRMS. 




General Procedure A: preparation of o-fluorobenzene sulfonamide via 
sulfonylation.  To a round bottom flask containing a solution of amine (8.77 mmol, 1.2 
equiv.) in dry CH2Cl2 (0.3 M), was added Et3N (14.6 mmol, 2.0 equiv.) and DMAP 
(0.089 g, 0.73 mmol, 0.1 equiv.).  The reaction mixture was cooled to 0 ºC, stirred for 
10–20 min, after which benzenesulfonyl chloride (7.31 mmol, 1.0 equiv.) was added to 
the reaction mixture, warmed to rt and left to stir overnight.  Alternatively, to a vigorously 
stirred solution of amine (7.34 mmol, 2.0 equiv.) in CH2Cl2 (12.2 mL, 0.4 M) in a round 
bottom flask was added NaHCO3 (3 equiv.) and H2O (6.1 mL, 0.8 M).  A solution of 
benzenesulfonyl chloride (1.0 g, 3.67 mmol) in CH2Cl2 (3.6 mL, 1 M) was added 
dropwise, and the reaction was stirred for 4–8 hours.  Upon disappearance of sulfonyl 
chloride, the reaction was quenched with 10% aq. HCl (2 mL), organic layer was 
separated and the aqueous layer was extracted with CH2Cl2 (3 x 5 mL).  The combined 
organic layers were washed with brine (10 mL), dried (Na2SO4), and concentrated under 
reduced pressure to afford the desired o-fluorobenzene sulfonamide.  
 
General Procedure B: intermolecular SNAr of amino alcohols with o-fluorobenzene 
sulfonamides.  To a flame dried microwave vial under Ar was added o-fluorobenzene 
sulfonamide (0.69 mmol), amino alcohol (2.07 mmol) and DMSO (0.35 mL) and the 
reaction was heated at 140 ºC for 30 min in the microwave.  The reaction mixture was 
transferred to a separatory funnel along with Et2O (3 mL), EtOAc (1 mL) and H2O (2 
mL) and extracted.  The aqueous layer was extracted with Et2O (4 x 1 mL), and the 
combined organic layers were dried (Na2SO4).  The extract was concentrated under 
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reduced pressure and subject to column chromatography (6:1 hexane:EtOAc) to afford 
the desired product. 
 
General procedure C: intramolecular SNAr cyclization for the synthesis of benzo-
oxathiazepine-dioxides (7-membered sultams).  To a microwave vial charged with 
fluorobenzene sulfonamide (1.52 mmol, 1.0 equiv.) in dry DMF (0.1 M), was added 
Cs2CO3 (4.56 mmol, 3.0 equiv.).  Alternatively, to a microwave vial charged with 
fluorobenzene sulfonamide (1.52 mmol, 1.0 equiv.) in dry DMSO (0.1 M), was added 
Cs2CO3 (4.56 mmol, 3.0 equiv.).  The reaction was heated at 150 ºC under mW irradiation 
for 30–40 min, which upon completion, the crude reaction was quenched with aq., HCl, 
diluted EtOAc and stirred for an additional 5 min at rt.  After such time, the organic layer 
was separated and the aqueous layer extracted with EtOAc (3x).  The combined organic 
layers were washed with brine, dried over Na2SO4, concentrated under reduced pressure 
and subject to column chromatography (3:1 hexane:EtOAc) to afford the desired product. 
 
General procedure D: intramolecular Mitsunobu ring closure for the synthesis of 
sultams.  To a flame dried round bottom flask under argon, was added hydroxy-
benzenesulfonamide (0.25 mmol, 1.0 equiv.), PPh3 (0.49 mmol, 2.0 equiv.) and dry THF 
(5 mL, 0.05 M).  After stirring to completely dissolve PPh3, DIAD (0.37 mmol, 1.5 
equiv.) was added via slow dropwise to the stirring reaction mixture.  The reaction was 
stirred for 10–30 min (TLC monitoring of SM) up to 12 h, concentrated under reduced 




General procedure E: intermolecular Mitsunobu alkylation for the preparation of 3º 
sulfonamides.  To a flame-dried round bottom flask under charged with a solution of 
sulfonamide (0.81 mmol, 1.0 equiv.) in dry THF (0.05 M), was added PPh3 (2.42 mmol, 
3.0 equiv.) and alcohol (1.38–1.62 mmol, 1.7–2.0 equiv.).  The reaction mixture was 
stirred for 10 min, after which DIAD (2.01 mmol, 2.5 equiv.) was added via slow drop-
wise addition to the reaction mixture.  Alternatively, to a flame-dried round bottom flask 
under charged with a solution of sulfonamide (0.64 mmol, 1.0 equiv.) in dry THF or 
CH2Cl2 (0.05 M), was added PPh3 (1.35 mmol, 2.1 equiv.) and alcohol (0.97 mmol, 1.5 
equiv.).  The reaction mixture was stirred for 10 min, after which DIAD (1.16 mmol, 1.8 
equiv.) was added via slow drop-wise addition to the reaction mixture.  The reaction was 
stirred at rt for 12 h, after which it was concentrated under reduced pressure and 
subjected to chromatography (15:1 hexane:EtOAc) to afford the desired product. 
 
General procedure F: intramolecular SNAr cyclization to yield 8- to 10-membered 
sultams.  To a microwave vial with protected hydroxyl-fluorobenzenesulfonamide (0.21 
mmol, 1.0 equiv.) in dry DMF (0.1 M), was added TBAF (0.403 mmol, 2.0 equiv.) and 
stirred overnight at rt.  The reaction was monitored by TLC and upon absence of starting 
material, was added Cs2CO3 (0.503 mmol, 2.5 equiv.).  The reaction was heated at 150 ºC 
under mW irradiation for 30 min; upon completion the crude mixture was concentrated 
and subjected to column chromatography (7:1 hexane:EtOAc) to yield the desired 
sultams 14b and 14c. 
227 
 
General procedure G: intramolecular SNAr ring closure to yield benzo-
thiadiazepine 1,1-dioxides (7-membered sultams).  To a microwave vial with 
alkylated-fluorobenzenesulfonamide (0.23 mmol, 1.0 equiv.) in dry DMSO (0.1 M), was 
added Cs2CO3 (0.46 mmol, 2.0–2.5 equiv.).  The reaction mixture was heated at 150 ºC 
under mW irradiation for 30 min.  The crude mixture was transferred to a separatory 
funnel along with EtOAc (3 mL) and H2O (3 mL).  The aqueous layer was extracted with 
EtOAc (3 x 3 mL).  The combined organic layers were washed with brine and dried over 
Na2SO4.  The extract was concentrated under reduced pressure and subjected to column 
chromatography (10:1 hexane:EtOAc) to yield the desired sultams 
 
General procedure H: intramolecular SNAr ring closure to yield benzo-
oxathiazocine 1,1-dioxides (8-membered sultams).  To a microwave vial with 
protected-fluorobenzenesulfonamide (0.036 mmol, 1.0 equiv.) in dry DMSO (0.1 M), 
was added TBAF (0.073 mmol, 2.0 equiv.).  The reaction was stirred at rt for 4–12 h until 
the starting material was consumed based on TLC analysis.  Cs2CO3 (0.090 mmol, 2.5 
equiv.) was then added and the reaction mixture was heated at 150 ºC under mW 
irradiation for 30–40 min.  The crude mixture was transferred to a separatory funnel 
along with EtOAc (3 mL) and H2O (3 mL). The aqueous layer was extracted with EtOAc 
(3 x 3 mL), the combined organic layers were washed with brine and dried over Na2SO4.  
The extract was concentrated under reduced pressure and subjected to column 






According to general procedure A, 2.7.2 (1.23 g, 97%) was isolated as dark yellow oil. 
FTIR (neat) 3531, 3377, 2953, 1587, 1470, 1346, 1161, 1063, 830 cm-1; 
[𝜶]𝑫𝟐𝟎 = -43.3 (c = 0.84, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.79 (t, J = 7.8 Hz, 1H, aromatic), 7.46–7.40 (m, 
2H, aromatic), 3.82 (dq, J = 7.3, 5.0 Hz, 1H, NCHCH2), 3.68 (qd, J = 11.5, 4.9 Hz, 2H, 
CH2OH), 3.51–3.35 (m, 2H, NCH2CH2), 2.41 (bs, 1H, OH), 1.95–1.78 (m, 3H, 
NCH2CHaHbCH2), 1.71–1.62 (m, 1H, NCH2CHaHbCH2); 
13C NMR (126 MHz, CDCl3) δ ppm 158.5 (d, 1JC-F = 260.0 Hz), 132.8 (d, 4JC-F = 1.8 Hz), 
128.6 (d, 3JC-F = 9.3 Hz), 128.0 (d, 3JC-F = 3.8 Hz), 125.2 (2JC-F = 15.8 Hz), 121.0 (2JC-F = 
25.7 Hz), 65.5, 61.8, 49.5, 28.9, 24.5; 






According to general procedure C, 2.7.3 was isolated (165 mg, 88%) as a white solid. 












FTIR (neat) 3088, 2970, 2957, 2874, 1580, 1460, 1335, 1161, 1068, 820, 763, 733 cm-1; 
[𝜶]𝑫𝟐𝟎 = +19.5 (c = 0.2, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.68 (d, J = 8.4 Hz, 1H, aromatic), 7.31 (dd, J = 8.4, 
1.9 Hz, 1H, aromatic), 7.27 (d, J = 1.9 Hz, 1H, aromatic), 4.80 (dd, J = 13.1, 2.8 Hz, 1H, 
OCHaHbCHN), 4.18–4.12 (m, 1H, OCH2CHN), 3.97 (dd, J = 13.1, 4.4 Hz, 1H, 
OCHaHbCHN), 3.61–3.57 (m, 1H, NCHaHb), 3.09–3.03 (m, 1H, NCHaHb), 2.25 (ddd, J = 
10.6, 8.7, 5.1 Hz, 1H, NCHCHaHb), 2.02–1.93 (m, 3H, NCHCHaHbCH2); 
13C NMR (126 MHz, CDCl3) δ ppm 155.8, 130.9, 130.2, 127.2, 126.9, 125.2, 73.8, 59.6, 
48.6, 28.5, 23.9; 






According to general procedure C, 2.8.2 (50 mg, 56%) was isolated as a white solid. 
mp 164–166 °C; 
FTIR (neat) 2957, 2924, 1578, 1460, 1340, 1161 cm-1; 
[𝜶]𝑫𝟐𝟎 = -43.6 (c = 0.11, CHCl3); 
1H NMR (400 MHz, CD2Cl2) δ ppm 7.74 (d, J = 8.5 Hz, 1H), 7.37 (dd, J = 8.5, 1.9 Hz, 








(dddd, J = 14.0, 9.2, 4.8, 1.9 Hz, 1H), 3.27–3.20 (m, 1H), 3.18 (dd, J = 2.8, 14.1 Hz, 1H), 
2.06 (ddd, J = 15.7, 10.9, 5.5 Hz, 1H), 1.98–1.89 (m, 1H); 
13C NMR (126 MHz, CD2Cl2) δ ppm 152.1, 132.0, 131.7, 128.6, 128.5, 127.6, 81.6, 
57.5, 47.7, 29.7; 





According to general procedure A, SI-1 (453 mg, 35%) was isolated as a dark yellow 
solid. 
mp 85 °C; 
FTIR (neat) 3529, 2941, 2872, 1587, 1398, 1159, 1064, 820 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.79 (dd, J = 8.6, 7.7 Hz, 1H, aromatic), 7.44–7.36 
(m, 2H, aromatic), 4.07 (dt, J = 5.8, 4.9 Hz, 1H, NCHCH2), 3.91–3.81 (m, 2H, 
NCHaHbCH2, CHaHbOH), 3.60 (ddd, J = 11.4, 6.5, 5.9 Hz, 1H, CHaHbOH), 3.18–3.09 (m, 
1H, NCHaHbCH2), 1.81 (dd, J = 6.6, 5.3 Hz, 1H, OH), 1.70–1.67 (m, 1H, NCH2CHaHb), 
1.59 (dd, J = 12.4, 4.2 Hz, 2H, NCHCHaHb, NCH2CH2CHaHb), 1.53–1.43 (m, 2H, 








13C NMR (126 MHz, CDCl3) δ ppm 158.3 (d, 1JC-F = 260.8 Hz), 131.7, 128.4 (d, 2JC-F = 
13.9 Hz), 128.0 (d, 3JC-F = 8.8 Hz), 127.8 (d, 4JC-F = 3.8 Hz), 120.8 (d, 2JC-F = 25.2 Hz), 
60.6, 54.7, 41.4, 25.3, 24.8, 18.9; 






According to general procedure C, 2.8.4 (63.1 mg, 67%) was isolated as a white solid. 
mp 163–168 °C; 
FTIR (neat) 2941, 1578, 1477, 1381, 1340, 1167, 835 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.66 (d, J = 8.3 Hz, 1H, aromatic), 7.42–7.33 (m, 
2H, aromatic), 4.58–4.49 (m, 1H, NCHCH2O), 4.23–4.12 (m, 2H, NCHCH2O), 3.57–3.47 
(m, 1H, NCHaHbCH2), 2.57 (td, J = 11.8, 3.6 Hz, 1H, NCHaHbCH2), 1.97–1.84 (m, 1H, 
NCHCHaHb), 1.80–1.59 (m, 4H, NCHCHaHbCHaHbCH2), 1.20 (dddd, J = 17.7, 13.7, 7.6, 
3.5 Hz, 1H, NCHCH2CHaHbCH2); 
13C NMR (126 MHz, CDCl3) δ ppm 156.2, 132.2, 130.9, 127.9, 127.8, 127.0, 69.6, 55.0, 
41.3, 26.5, 24.8, 19.4; 











According to general procedure B, SI-2 (100 mg, 15%) was isolated as clear oil.  
FTIR (neat) 3495, 3246, 2934, 1574, 1555, 1448, 1321, 1165, 1061, 827 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.88 (d, J = 8.5 Hz, 1H, aromatic), 7.55 (s, 1H, 
aromatic), 7.49 (d, J = 8.4 Hz, 1H, aromatic), 5.71 (s, 1H, NH), 3.51 (dd, J = 12.3, 2.2 
Hz, 1H, CHaHbOH), 3.38 (d, J = 11.7 Hz, 1H, CHaHbOH), 3.16 (d, J = 11.2 Hz, 1H, 
NCHaHb), 3.01 (s, 1H, NCHCH2OH), 2.96–2.78 (m, 3H, NHCH2, OH), 2.61 (t, J = 10.1 
Hz, 1H, NCHaHb), 1.95 (dd, J = 12.0, 5.4 Hz, 2H, NCHCHaHbCHaHb), 1.83 (d, J = 11.1 
Hz, 1H, NCHCHaHbCH2), 1.76 (d, J = 12.9 Hz, 1H, NCH2CHaHb), 1.64 (dd, J = 24.7, 
12.3 Hz, 1H, NCH2CHaHb), 1.54–1.48 (m, 3H, NHCH2CH2CH2CH3, NCHCH2CHaHb), 
1.40–1.31 (m, 2H, NHCH2CH2CH2CH3), 0.91 (t, J = 7.4 Hz, 3H, NHCH2CH2CH2CH3); 
13C NMR (126 MHz, CDCl3) δ ppm 151.8, 136.8, 131.2, 129.3, 129.1, 127.8, 62.9, 62.4, 
43.7, 32.0, 29.7, 28.1, 26.3, 24.0, 19.9, 13.7; 













pine 5,5-dioxide (2.8.5) 
 
According to general procedure D, 2.8.5 (54 mg, 47%) was isolated as colorless oil. 
FTIR (neat) 2934, 1576, 1452, 1333, 1153, 812, 770, 731 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.62 (d, J = 8.5 Hz, 1H, aromatic), 7.21 (s, 1H, 
aromatic), 7.11 (d, J = 8.3 Hz, 1H, aromatic), 3.91 (s, 1H, NCHCH2N), 3.61 (s, 1H, 
NCHCHaHbN), 3.40 (t, J = 5.8 Hz, 2H, NCH2), 3.18 (d, J = 13.2 Hz, 1H, NCHCHaHbN), 
3.14–3.02 (m, 2H, NCH2CH2CH2CH3), 1.80 (dddd, J = 14.8, 13.3, 10.6, 5.9 Hz, 3H, 
NCH2CH2CHaHb), 1.68 (dt, J = 14.6, 5.4 Hz, 1H, NCH2CH2CHaHb), 1.64–1.55 (m, 4H, 
NCH2CH2CH2CH3, NCHCH2), 1.39–1.30 (m, 2H, NCH2CH2CH2CH3), 0.92 (t, J = 7.4 Hz, 
3H, NCH2CH2CH2CH3); 
13C NMR (126 MHz, CDCl3) δ ppm 149.9, 130.2 (2C), 126.8, 124.4 (2C), 54.6, 50.5, 
49.5, 47.3, 30.9, 27.1, 25.0, 19.7, 18.9, 13.7; 

















According to general procedure B, SI-3 (1.05 g, 71%) was isolated as a white solid. 
mp 93–95 ºC; 
FTIR (neat) 3501, 3204, 2955, 1574, 1555, 1456, 1319, 1161, 1084, 822, 777, 731 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.86 (dd, J = 8.2, 3.0 Hz, 1H, aromatic), 7.42 (dd, J 
= 7.4, 1.9 Hz, 2H, aromatic), 6.84 (s, 1H, NH), 4.14 (s, 1H, NCH2CHOH), 3.38 (s, 1H, 
NCHaHbCH2), 3.12 (s, 1H, NCHaHbCHOH), 2.93–2.81 (m, 2H, NCHaHbCH2, 
NCHaHbCHOH), 2.76 (s, 1H, NHCHaHb), 2.66 (s, 1H, NHCHaHb), 2.33 (bs, 1H, OH), 
2.13 (d, J = 11.1 Hz, 1H, NCH2CHaHb), 1.90 (s, 1H, NCH2CH2CHaHb), 1.66 (d, J = 12.0 
Hz, 2H, NCH2CHaHbCHaHb), 1.43 (dd, J = 13.2, 6.2 Hz, 2H, NHCH2CH2), 1.31 (dd, J = 
14.4, 7.2 Hz, 2H, NHCH2CH2CH2), 0.89–0.82 (m, 3H, NHCH2CH2CH2CH3); 
13C NMR (126 MHz, CDCl3) δ ppm 152.3, 134.7, 131.7, 128.4, 127.7, 127.2, 65.7, 59.8, 
54.1, 43.3, 31.8, 30.1, 21.1, 19.9, 13.6; 






According to general procedure D, 2.8.7 (95 mg, 50%) was isolated as a white solid. 
mp 83–84 ºC; 








1H NMR (500 MHz, CDCl3) δ ppm 7.62 (d, J = 8.7 Hz, 1H, aromatic), 7.06 (d, J = 1.9 
Hz, 1H, aromatic), 6.94 (dd, J = 8.6, 1.9 Hz, 1H, aromatic), 4.79 (ddd, J = 16.0, 5.0, 2.4 
Hz, 1H, NCHaHbCH), 3.72 (dd, J = 13.7, 1.7 Hz, 1H, NCHaHb), 3.59–3.51 (m, 2H, 
NCH2CH, SNCHaHb), 3.37–3.30 (m, 1H, NCHaHb), 3.25 (dd, J = 16.0, 1.3 Hz, 1H, 
NCHaHbCH), 3.17–3.10 (m, 1H, SNCHaHb), 2.20–2.15 (m, 1H, NCH2CH2CHaHb), 1.74–
1.64 (m, 2H, NCH2CHaHbCHaHb), 1.59–1.45 (m, 2H, NCH2CH2CH2CH3), 1.39–1.22 (m, 
3H, NCH2CH2CH2CH3, NCH2CHaHb), 0.87 (t, J = 7.3 Hz, 3H, NCH2CH2CH2CH3); 
13C NMR (126 MHz, CDCl3) δ ppm 149.3, 134.6, 128.0, 126.1, 125.8, 123.2, 55.4, 53.8, 
51.6, 45.7, 30.4, 29.7, 28.5, 20.0, 13.8; 





According to general procedure A, 2.9.3 (3.65 g, 98%) was isolated as yellow oil. 
FTIR (neat) 3508, 3101, 2949, 1601, 1481, 1344, 1161, 1082, 856, 797, 712 cm-1; 
[𝜶]𝑫𝟐𝟎 = -6.7 (c = 0.36, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.94 (ddd, J = 8.8, 7.9, 6.2 Hz, 1H, aromatic), 7.03–
6.93 (m, 2H, aromatic), 4.53–4.46 (m, 1H, CHOH), 3.56–3.51 (m, 2H, NCH2CH), 3.51–
3.46 (m, 1H, NCHaHbCH2), 3.44–3.40 (m, 1H, NCHaHbCH2), 2.08–2.00 (m, 1H, 









13C NMR (126 MHz, CDCl3) δ ppm 165.6 (dd, JC-F = 257.2, 11.4 Hz), 159.8 (dd, JC-F = 
257.6, 12.6 Hz), 133.0 (dd, JC-F = 10.4, 2.5 Hz), 122.5 (dd, JC-F = 15.5, 3.9 Hz), 111.7 (dd, 
JC-F = 21.7, 3.8 Hz), 105.7 (dd, JC-F = 26.0, 25.9 Hz), 70.8, 55.8, 45.6, 34.4; 





According to general procedure A, 2.9.4 (3.07 g, 99%) was isolated as yellow oil. 
FTIR (neat) 3512, 3027, 2953, 1601, 1481, 1344, 1161, 1082, 856, 797, 712 cm-1; 
[𝜶]𝑫𝟐𝟎 = +6.1 (c = 1.575, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.94 (ddd, J = 8.8, 7.9, 6.2 Hz, 1H, aromatic), 7.12–
6.76 (m, 2H, aromatic), 4.49 (tt, J = 4.5, 2.2 Hz, 1H, CHOH), 3.57–3.52 (m, 2H, 
NCH2CH), 3.48 (ddd, J = 9.7, 9.6, 6.8 Hz, 1H, NCHaHbCH2), 3.42 (ddd, J = 11.3, 1.8, 1.6 
Hz, 1H, NCHaHbCH2), 2.13–1.98 (m, 1H, NCH2CHaHb), 1.99–1.84 (m, 1H, 
NCH2CHaHb), 1.53 (d, J = 3.5 Hz, 1H, OH); 
13C NMR (126 MHz, CDCl3) δ ppm 165.6 (dd, JC-F = 257.1, 11.5 Hz), 159.9 (dd, JC-F = 
257.5, 12.7 Hz), 133.0 (dd, JC-F = 10.4, 2.3 Hz), 122.5 (dd, J = 15.6, 4.0 Hz), 111.7 (dd, 
JC-F = 21.8, 3.7 Hz), 105.7 (dd, JC-F = 25.9 Hz), 70.8, 55.8, 45.6, 34.4; 












According to general procedure A, 2.9.5 (1.24 g, 99%) was isolated as a brown solid. 
mp 122–125 ºC; 
FTIR (neat) 3489, 3298, 2993, 1612, 1583, 1464, 1346, 1163, 1103, 787, 770, 704 cm-1; 
[𝜶]𝑫𝟐𝟎 = -9.7 (c = 0.248, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.68–7.31 (m, 1H, aromatic), 7.16–6.89 (m, 2H, 
aromatic), 4.51 (dddd, J = 4.4, 4.2, 2.1, 2.1 Hz, 1H, CHOH), 3.68–3.53 (m, 3H, 
NCH2CH, NCHaHbCH2), 3.49 (ddd, J = 11.4, 1.8, 1.7 Hz, 1H, NCHaHbCH2), 2.07 (dddd, 
J = 13.3, 9.6, 8.6, 4.6 Hz, 1H, NCH2CHaHb), 2.00–1.92 (m, 1H, NCH2CHaHb), 1.60 (d, J 
= 3.8 Hz, 1H, OH); 
13C NMR (126 MHz, CDCl3) δ ppm 159.8 (dd, JC-F = 258.1, 4.4 Hz, 2C), 134.2 (t, JC-F = 
11.0 Hz), 116.5 (dd, JC-F = 17.2, 17.0 Hz), 113.1 (dd, JC-F = 24.2, 3.8 Hz, 2C), 70.7, 55.8, 
45.6, 34.4; 

















According to general procedure A, 2.9.6 (2.46 g, 99%) was isolated as a yellow solid. 
mp 124–127 ºC; 
FTIR (neat) 3487, 2993, 1612, 1583, 1464, 1346, 1163, 1103, 787, 770, 704 cm-1; 
[𝜶]𝑫𝟐𝟎 = +4.4 (c = 0.29, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.58–7.42 (m, 1H, aromatic), 7.11–6.94 (m, 2H, 
aromatic), 4.51 (s, 1H, CHOH), 3.67–3.52 (m, 3H, NCH2CH, NCHaHbCH2), 3.49 (d, J = 
11.2 Hz, 1H, NCHaHbCH2), 2.14–2.01 (m, 1H, NCH2CHaHb), 2.01–1.88 (m, 1H, 
NCH2CHaHb), 1.56 (s, 1H, OH); 
13C NMR (126 MHz, CDCl3) δ ppm 159.8 (dd, JC-F = 257.9, 4.5 Hz, 2C), 134.2 (t, JC-F = 
11.0 Hz), 116.5, 113.1 (dd, JC-F = 24.2, 3.8 Hz, 2C), 70.8, 55.8, 45.6, 34.4; 






According to general procedure C, 2.9.7 (57.3 mg, 62%) was isolated as a white solid. 
mp 124–127 °C; 
FTIR (thin film) 3105, 2964, 1599, 1583, 1474, 1335, 1153, 1117, 824, 746 cm-1; 








1H NMR (500 MHz, CDCl3) δ ppm 7.93 (dd, J = 8.8, 6.3 Hz, 1H, aromatic), 6.93 (ddd, J 
= 8.9, 7.5, 2.5 Hz, 1H, aromatic), 6.79 (dd, J = 9.6, 2.5 Hz, 1H, aromatic), 5.16 (dd, J = 
6.3, 2.7 Hz, 1H, OCH), 4.38 (ddd, J = 14.2, 2.3, 2.2 Hz, 1H, NCHaHbCHO), 3.57 (dddd, J 
= 14.0, 9.3, 4.8, 2.0 Hz, 1H, NCHaHbCH2), 3.30–3.23 (m, 1H, NCHaHbCH2), 3.21 (dd, J = 
14.3, 2.8 Hz, 1H, NCHaHbCHO), 2.08 (dddd, J = 15.5, 10.9, 6.4, 4.9 Hz, 1H, 
NCH2CHaHb), 1.98 (dddd, J = 15.7, 9.0, 6.5, 2.4 Hz, 1H, NCH2CHaHb); 
13C NMR (126 MHz, CDCl3) δ ppm 165.8 (d, 1JC-F = 255.8 Hz), 152.8 (d, 3JC-F = 12.7 
Hz), 132.5 (d, 3JC-F = 10.6 Hz), 128.0 (d, 4JC-F = 3.2 Hz), 112.0 (d, 2JC-F = 23.6 Hz), 111.4 
(d, 2JC-F = 22.2 Hz), 80.7, 56.9, 47.2, 29.3; 





According to general procedure C, 2.9.8 (51.0 mg, 55%) was isolated as a white solid. 
mp 122–125 °C; 
FTIR (thin film) 3099, 2972, 1601, 1581, 1474, 1339, 1159, 1117, 820, 741, 706 cm-1; 
[𝜶]𝑫𝟐𝟎 = +24.4 (c = 0.39, CHCl3); 
1H NMR (400 MHz, CDCl3) δ ppm 7.93 (dd, J = 8.9, 6.3 Hz, 1H, aromatic), 6.93 (ddd, J 
= 8.9, 7.4, 2.5 Hz, 1H, aromatic), 6.79 (dd, J = 9.6, 2.5 Hz, 1H, aromatic), 5.16 (dd, J = 








= 14.0, 9.3, 4.9, 2.0 Hz, 1H, NCHaHbCH2), 3.34–3.07 (m, 2H, NCHaHbCHO, 
NCHaHbCH2), 2.23–1.87 (m, 2H, NCH2CH2); 
13C NMR (126 MHz, CDCl3) δ ppm 165.8 (d, 1JC-F = 255.7 Hz), 152.8 (d, 3JC-F = 12.7 
Hz), 132.5 (d, 3JC-F = 10.6 Hz), 128.0 (d, 4JC-F = 3.3 Hz), 112.0 (d, 2JC-F = 23.6 Hz), 111.4 
(d, 2JC-F = 22.2 Hz), 80.7, 56.9, 47.2, 29.3; 





According to general procedure C, 2.9.9 (90.6 mg, 98%) was isolated as a yellow solid. 
mp 130–134 °C; 
FTIR (thin film) 3078, 2959, 1601, 1564, 1456, 1348, 1159, 1112, 793, 718 cm-1; 
[𝜶]𝑫𝟐𝟎 = -8.0 (c = 0.785, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.39 (ddd, J = 8.3, 5.9 Hz, 1H, aromatic), 6.94 (ddd, 
J = 10.1, 8.3, 1.2 Hz, 1H, aromatic), 6.85 (ddd, J = 8.3, 1.3 Hz, 1H, aromatic), 5.11 (ddd, 
J = 5.4, 2.4, 1.4 Hz, 1H, OCH), 4.34 (dd, J = 14.2, 2.0, 1.9 Hz, 1H, NCHaHbCHO), 3.92–
3.72 (m, 1H, NCHaHbCH2), 3.43–3.30 (m, 1H, NCHaHbCH2), 3.21 (dd, J = 14.2, 2.5 Hz, 
1H, NCHaHbCHO), 2.24–2.02 (m, 2H, NCH2CH2); 
13C NMR (126 MHz, CDCl3) δ ppm 161.5 (d, 1JC-F = 259.3 Hz), 151.8, 133.9 (d, 3JC-F = 













According to general procedure C, 2.9.10 (1.38 g, 66%) was isolated as a white solid. 
mp 133–135 °C; 
FTIR (thin film) 3018, 2959, 1601, 1564, 1456, 1350, 1159, 1112, 793, 717 cm-1; 
[𝜶]𝑫𝟐𝟎 = +5.0 (c = 0.285, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.39 (ddd, J = 8.3, 5.9 Hz, 1H, aromatic), 6.94 (ddd, 
J = 9.8, 8.3, 1.2 Hz, 1H, aromatic), 6.85 (ddd, J = 8.2, 1.3 Hz, 1H, aromatic), 5.11 (ddd, J 
= 4.3, 2.3, 2.0 Hz, 1H, OCH), 4.34 (ddd, J = 14.2, 2.0, 1.9 Hz, 1H, NCHaHbCHO), 3.82 
(dddd, J = 14.3, 8.0, 5.9, 1.9 Hz, 1H, NCHaHbCH2), 3.36 (ddd, J = 13.8, 10.0, 6.9 Hz, 1H, 
NCHaHbCH2), 3.21 (dd, J = 14.2, 2.5 Hz, 1H, NCHaHbCHO), 2.28–2.01 (m, 2H, 
NCH2CH2); 
13C NMR (126 MHz, CDCl3) δ ppm 161.5 (d, 1JC-F = 258.9 Hz), 151.8 (d, 4JC-F = 1.9 Hz), 
133.9 (d, 3JC-F = 11.3 Hz), 122.2 (d, 3JC-F = 14.3 Hz), 120.4 (d, 3JC-F = 3.5 Hz), 112.4 (d, 
2JC-F = 23.9 Hz), 80.5, 55.9, 47.3, 29.8; 












According to general procedure A, 2.9.11 (1.28 g, 98%) was isolated as a white solid. 
mp 96–99 ºC; 
FTIR (neat) 3502, 3101, 2943, 1603, 1481, 1344, 1169, 1074, 856, 752, 708 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.89 (ddd, J = 8.9, 7.9, 6.1 Hz, 1H, aromatic), 7.15–
6.61 (m, 2H, aromatic), 4.00–3.80 (m, 1H, CHOH), 3.49 (ddd, J = 12.0, 3.6, 1.3 Hz, 1H, 
NCHaHbCH), 3.37–3.26 (m, 1H, NCHaHbCH2), 3.03 (ddd, J = 12.0, 8.2, 3.1 Hz, 1H, 
NCHaHbCH), 2.92 (dd, J = 12.0, 7.3 Hz, 1H, NCHaHbCH2), 2.00–1.74 (m, 3H, 
NCH2CH2CHaHb), 1.69–1.59 (m, 1H, NCH2CH2CHaHb), 1.55–1.44 (m, 1H, OH); 
13C NMR (126 MHz, CDCl3) δ ppm 165.7 (dd, JC-F = 257.6, 11.4 Hz), 159.7 (dd, JC-F = 
258.4, 12.7 Hz), 132.9 (dd, JC-F = 10.4, 2.1 Hz), 122.3 (dd, JC-F = 14.9, 3.9 Hz), 112.0 (dd, 
JC-F = 21.8, 3.7 Hz), 105.8 (dd, JC-F = 25.8, 25.6 Hz), 65.7, 52.1, 45.9, 31.7, 22.1; 




According to general procedure A, 2.9.12 (942 mg, 72%) was isolated as a white solid. 














FTIR (neat) 3419, 3092, 2943, 1610, 1585, 1466, 1356, 1173, 1103, 773, 734 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.52 (tt, J = 8.4, 5.9 Hz, 1H, aromatic), 7.16–6.86 
(m, 2H, aromatic), 4.00–3.83 (m, 1H, CHOH), 3.58 (dd, J = 12.2, 3.6 Hz, 1H, 
NCHaHbCH), 3.40 (ddd, J = 11.3, 6.3, 3.8 Hz, 1H, NCHaHbCH2), 3.10 (ddd, J = 12.0, 8.3, 
3.0 Hz, 1H, NCHaHbCH), 2.99 (dd, J = 12.1, 7.3 Hz, 1H, NCHaHbCH2), 2.05–1.76 (m, 
3H, NCH2CH2CH2), 1.73–1.60 (m, 1H, NCH2CH2CHaHb), 1.57–1.44 (m, 1H, 
NCH2CH2CHaHb); 
13C NMR (126 MHz, CDCl3) δ ppm 159.7 (dd, JC-F = 258.9, 4.2 Hz, 2C), 134.5 (t, JC-F = 
11.0 Hz), 115.9 (dd, J = 17.5, 15.9 Hz), 113.2 (dd, JC-F = 24.0, 3.8 Hz, 2C), 65.6, 51.9, 
45.8, 31.7, 22.1; 






According to general procedure C, 2.9.13 (53.1 mg, 57%) was isolated as a white solid. 
mp 132–135 °C; 
FTIR (neat) 3097, 2961, 1599, 1583, 1472, 1339, 1163, 1111, 818, 731 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.90–7.79 (m, 1H, aromatic), 7.01–6.83 (m, 2H, 
aromatic), 4.56 (dddd, J = 4.3, 2.2, 2.1, 2.0 Hz, 1H, OCHCH2N), 4.42 (dddd, J = 15.3, 








Hz, 1H, OCHCHaHbN), 3.33–3.18 (m, 1H, NCHaHb), 2.25–2.13 (m, 1H, 
NCH2CHCHaHb), 2.04–1.82 (m, 1H, NCH2CHCHaHb), 1.28–1.09 (m, 2H, NCH2CH2); 
13C NMR (126 MHz, CDCl3) δ ppm 165.5 (d, 1JC-F = 255.4 Hz), 155.1 (d, 3JC-F = 12.3 
Hz), 133.4 (d, 4JC-F = 3.6 Hz), 130.6 (d, 3JC-F = 10.5 Hz), 112.4 (d, 2JC-F = 23.2 Hz), 111.3 
(d, 2JC-F = 22.1 Hz), 72.2, 51.9, 46.2, 27.4, 16.8; 





According to general procedure C, 2.9.14 (290 mg, 62%) was isolated as a white solid. 
mp 118–120 °C; 
FTIR (neat) 3084, 2957, 1599, 1568, 1458, 1346, 1163, 1105, 798, 754, 721 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.40 (ddd, J = 8.3, 8.0, 5.8 Hz, 1H, aromatic), 7.01–
6.93 (m, 2H, aromatic), 4.55 (dddd, J = 4.0, 2.9, 2.7, 1.1 Hz, 1H, OCHCH2N), 4.38 
(dddd, J = 15.1, 2.4, 2.2, 2.2 Hz, 1H, OCHCHaHbN), 4.14–4.04 (m, 1H, NCHaHb), 3.38 
(dd, J = 15.1, 1.3 Hz, 1H, OCHCHaHbN), 3.30 (ddd, J = 14.8, 13.4, 4.5 Hz, 1H, 
NCHaHb), 2.26–2.17 (m, 1H, NCH2CHCHaHb), 1.93 (dddd, J = 15.4, 12.9, 6.9, 4.1 Hz, 







13C NMR (126 MHz, CDCl3) δ ppm 159.8 (d, 1JC-F = 259.2 Hz), 154.3 (d, 4JC-F = 1.9 Hz), 
133.7 (d, 3JC-F = 11.0 Hz), 126.7 (d, 2JC-F = 13.4 Hz), 120.7 (d, 3JC-F = 3.3 Hz), 113.0 (d, 
2JC-F = 23.9 Hz), 73.0, 51.2, 46.5, 27.5, 16.9; 






According to general procedure E, 2.10.1 (265 mg, 68%) was isolated as yellow oil. 
FTIR (neat) 2955, 1589, 1470, 1398, 1348, 1161, 1059, 835, 775 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.78–7.75 (m, 1H, aromatic), 7.41–7.36 (m, 2H, 
aromatic), 3.58 (t, J = 5.8 Hz, 2H, CH2OTBS), 3.33–3.30 (m, 2H, NCH2CH2CH2O), 
3.26–3.23 (m, 2H, NCH2CH2CH2CH3), 1.74–1.71 (m, 2H, NCH2CH2CH2O), 1.53–1.50 
(m, 2H, NCH2CH2CH2CH3), 1.32–1.25 (m, 2H, NCH2CH2CH2CH3), 0.89 (t, J = 7.3 Hz, 
3H, NCH2CH2CH2CH3), 0.87 (s, 9H, (CH3)3), 0.02 (s, 6H, (CH3)2);  
13C NMR (126 MHz, CDCl3) δ ppm 158.4 (d, 1JC-F = 259.3 Hz), 131.9 (d, 4JC-F = 1.6 Hz), 
127.8 (d, 3JC-F = 15.1 Hz), 127.7 (d, 3JC-F = 9.0 Hz), 127.6, 120.7 (d, 2JC-F = 25.0 Hz), 60.1, 
47.8 (2C), 44.8 (2C), 31.8, 30.4, 25.8, 21.6, 19.8, 18.2, 13.7, -5.5;  












According to general procedure E, 2.10.2 (1.98 g, 88%) was isolated as colorless oil. 
FTIR (thin film) 3098, 2955, 1603, 1487, 1362, 1165, 1096, 835, 775, 715 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.95 (ddd, J = 8.9, 8.0, 6.2 Hz, 1H, aromatic), 7.00 
(dddd, J = 8.7, 7.6, 2.4, 1.0 Hz, 1H, aromatic), 6.94 (ddd, J = 10.0, 8.5, 2.4 Hz, 1H, 
aromatic), 3.65 (t, J = 6.0 Hz, 2H, CH2OTBS), 3.45–3.33 (m, 2H, NCH2CH2CH2O), 
2.40–2.24 (m, 1H, NCH), 1.95–1.76 (m, 2H, NCH2CH2CH2O), 0.90 (s, 9H, (CH3)3), 
0.81–0.73 (m, 2H, NCHCH2CH2), 0.73–0.65 (m, 2H, NCHCH2CH2), 0.05 (s, 6H, (CH3)2); 
13C NMR (126 MHz, CDCl3) δ ppm 165.6 (dd, JC-F = 257.1, 11.3 Hz), 159.7 (dd, JC-F = 
258.6, 12.6 Hz), 133.0 (dd, JC-F = 10.3, 1.9 Hz), 124.3 (dd, JC-F = 14.9, 3.9 Hz), 111.7 (dd, 
JC-F = 21.8, 3.9 Hz), 105.6 (dd, JC-F = 25.8, 25.6 Hz), 60.4, 47.9, 32.0, 29.9, 25.9 (3C), 
18.2, 7.2 (2C), -5.4 (2C); 


















According to general procedure E, 2.10.4 (192 mg, 60%) was isolated as colorless oil. 
FTIR (neat) 2957, 1589, 1470, 1398, 1348, 1161, 1136, 1090, 1059, 835 cm-1; 
[𝜶]𝑫𝟐𝟎 = -31.5 (c = 0.2, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.78–7.74 (m, 1H, aromatic), 7.41–7.36 (m, 2H, 
aromatic), 3.80–3.79 (m, 1H, CH3CHOTBS), 3.30–3.19 (m, 4H, NCH2CH2CH, 
NCH2CH2CH2CH3), 1.66–1.62 (m, 2H, NCH2CH2CH), 1.52–1.47 (m, 2H, 
NCH2CH2CH2CH3), 1.32–1.24 (m, 2H, NCH2CH2CH2CH3), 1.11 (d, J = 6.0 Hz, 3H, 
CH3CHOTBS), 0.89 (t, J = 7.3 Hz, 3H, NCH2CH2CH2CH3), 0.86 (s, 9H, (CH3)3), 0.03 (d, 
J = 8.0 Hz, 6H, (CH3)2);  
13C NMR (126 MHz, CDCl3) δ ppm 158.4 (d, 1JC-F = 259.3 Hz), 131.9 (d, 4JC-F = 1.3 Hz), 
127.9 (d, 3JC-F = 15.1 Hz), 127.7 (d, 3JC-F = 3.6 Hz), 127.6, 120.7 (d, 2JC-F = 25.0 Hz), 66.4, 
47.6 (2C), 44.7 (2C), 38.2, 30.5, 25.8, 23.7, 19.8, 18.0, 13.7, -4.3, -5.0;  






According to general procedure E, 2.10.5 (1.92 g, 89%) was isolated as colorless oil. 
FTIR (thin film) 3099, 2955, 1603, 1486, 1358, 1167, 1072, 835, 773, 714 cm-1; 








1H NMR (500 MHz, CDCl3) δ ppm 7.95 (ddd, J = 8.8, 8.0, 6.2 Hz, 1H, aromatic), 7.00 
(dddd, J = 8.8, 7.7, 2.5, 1.0 Hz, 1H, aromatic), 6.94 (ddd, J = 10.0, 8.5, 2.4 Hz, 1H, 
aromatic), 3.84 (ddddd, J = 6.2, 6.2, 6.1, 6.1, 6.1 Hz, 1H, CH3CHOTBS), 3.52–3.26 (m, 
2H, NCH2CH2CH), 2.34 (dddd, J = 8.8, 6.1, 3.9, 1.2 Hz, 1H, NCH), 1.78 (ddd, J = 9.0, 
7.8, 5.8 Hz, 2H, NCH2CH2CH), 1.15 (d, J = 6.1 Hz, 3H, CH3CHOTBS), 0.89 (s, 9H, 
(CH3)3), 0.82–0.63 (m, 4H, NCHCH2CH2), 0.05 (d, J = 4.6 Hz, 6H, (CH3)2); 
13C NMR (126 MHz, CDCl3) δ ppm 165.6 (dd, JC-F = 257.3, 11.3 Hz), 159.6 (dd, JC-F = 
258.7, 12.8 Hz), 133.0 (d, JC-F = 8.7 Hz), 124.4 (d, JC-F = 10.8 Hz), 111.7 (dd, JC-F = 21.6, 
3.8 Hz), 105.6 (dd, JC-F = 25.7, 25.3 Hz), 66.6, 47.7, 38.3, 29.6, 25.8 (3C), 23.8, 18.0, 7.2, 
7.0, -4.3, -4.9; 






According to general procedure E, 2.10.7 (288 mg, 90%) was isolated as colorless oil. 
FTIR (neat) 2957, 1589, 1470, 1398, 1348, 1161, 1136, 1090, 835 cm-1; 
[𝜶]𝑫𝟐𝟎 = +9.9 (c = 0.242, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.76 (t, J = 7.8 Hz, 1H, aromatic), 7.41–7.36 (m, 








NCH2CH2CH2CH3), 1.63–1.61 (m, 2H, NCH2CH2CH), 1.54–1.47 (m, 2H, 
NCH2CH2CH2CH3), 1.32–1.24 (m, 2H, NCH2CH2CH2CH3), 1.11 (d, J = 6.0 Hz, 3H, 
CH3CHOTBS), 0.89 (t, J = 7.5 Hz, 3H, NCH2CH2CH2CH3), 0.86 (s, 9H, (CH3)3), 0.02 (d, 
J = 8.5 Hz, 6H, (CH3)2);  
13C NMR (126 MHz, CDCl3) δ ppm 158.4 (d, 1JC-F = 259.3 Hz), 131.9 (d, 4JC-F = 1.5 Hz), 
127.9 (d, 3JC-F = 15.2 Hz), 127.7 (d, 3JC-F = 3.6 Hz), 127.6, 120.7 (d, 2JC-F = 25.1 Hz), 66.4, 
47.6 (2C) 44.7 (2C), 38.2, 30.5, 25.8, 23.7, 19.8, 18.0, 13.7, -4.3, -5.0; 






According to general procedure E, 2.10.8 (284 mg, 85%) was isolated as colorless oil. 
FTIR (thin film) 3099, 2953, 2930, 1603, 1487, 1348, 1165, 1072, 835, 775, 715 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.95 (ddd, J = 8.9, 7.9, 6.2 Hz, 1H, aromatic), 7.00 
(dddd, J = 8.8, 7.8, 2.5, 0.9 Hz, 1H, aromatic), 6.94 (ddd, J = 10.1, 8.5, 2.4 Hz, 1H, 
aromatic), 3.63 (t, J = 6.2 Hz, 2H, CH2OTBS), 3.42–3.28 (m, 2H, NCH2CH2CH2CH2O), 
2.39–2.25 (m, 1H, NCH), 1.77–1.66 (m, 2H, NCH2CH2CH2CH2O), 1.59–1.47 (m, 2H, 
NCH2CH2CH2CH2O), 0.89 (s, 9H, (CH3)3), 0.76–0.71 (m, 2H, NCHCH2CH2), 0.70–0.65 







13C NMR (126 MHz, CDCl3) δ ppm 165.6 (dd, JC-F = 257.1, 11.5 Hz), 159.6 (dd, JC-F = 
258.4, 12.7 Hz), 132.9 (d, JC-F = 2.0 Hz), 124.5 (d, JC-F = 11.0 Hz), 111.7 (dd, JC-F = 21.7, 
3.7 Hz), 105.6 (dd, JC-F = 25.9, 25.7 Hz), 62.6, 50.5, 30.0, 29.4, 25.9 (3C), 25.1, 18.3, 7.0 
(2C), -5.3 (2C); 






According to general procedure E, 2.10.9 (340 mg, 97%) was isolated as colorless oil. 
FTIR (thin film) 2928, 1610, 1585, 1466, 1362, 1167, 1055, 835, 775, 698 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.55–7.43 (m, 1H, aromatic), 7.06–6.97 (m, 2H, 
aromatic), 3.64 (t, J = 6.2 Hz, 2H, CH2OTBS), 3.45–3.34 (m, 2H, NCH2CH2CH2CH2O), 
2.49–2.35 (m, 1H, NCH), 1.82–1.69 (m, 2H, NCH2CH2CH2CH2O), 1.61–1.48 (m, 2H, 
NCH2CH2CH2CH2O), 0.89 (s, 9H, (CH3)3), 0.84–0.78 (m, 2H, NCHCH2CH2), 0.78–0.64 
(m, 2H, NCHCH2CH2), 0.05 (s, 6H, (CH3)2); 
13C NMR (126 MHz, CDCl3) δ ppm 159.8 (dd, JC-F = 258.9, 4.2 Hz, 2C), 134.1 (t, JC-F = 
10.8 Hz), 118.3, 113.1 (dd, JC-F = 24.0, 3.7 Hz, 2C), 62.6, 50.4, 30.0, 29.4, 25.9 (3C), 














According to general procedure E, SI-4 (576 mg, 90%) was isolated as colorless oil. 
FTIR (thin film) 3092, 2928, 1610, 1585, 1468, 1364, 1146, 1103, 833, 777, 680 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.61–7.40 (m, 1H, aromatic), 7.10–6.94 (m, 2H, 
aromatic), 3.76–3.62 (m, 4H, CH2OCH2), 3.55 (t, J = 6.1 Hz, 2H, OCH2CH2OTBS), 3.50 
(dd, J = 5.6, 4.9 Hz, 2H, NCH2CH2O), 2.54–2.42 (m, 1H, NCH), 0.90 (s, 9H, (CH3)3), 
0.89–0.86 (m, 2H, NCHCH2CH2), 0.78–0.69 (m, 2H, NCHCH2CH2), 0.07 (s, 6H, (CH3)2); 
13C NMR (126 MHz, CDCl3) δ ppm 159.8 (dd, JC-F = 259.0, 4.3 Hz, 2C), 134.2 (t, JC-F = 
11.0 Hz), 118.0 (dd, JC-F = 16.7, 16.6 Hz), 113.1 (dd, JC-F = 24.0, 3.8 Hz, 2C), 72.5, 69.7, 
62.6, 50.1, 30.5, 25.9 (3C), 18.4, 7.4 (2C), -5.3 (2C); 















According to general procedure F, 2.10.11 (64 mg, 88%) was isolated as a white solid. 
mp 115–118 ºC; 
FTIR (neat) 2957, 1574, 1468, 1454, 1371, 1337, 1161, 1061, 831 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.75 (d, J = 8.3 Hz, 1H, aromatic), 7.36 (dt, J = 8.3, 
1.8 Hz, 2H, aromatic), 4.25 (t, J = 6.1 Hz, 2H, OCH2CH2CH2N), 3.83–3.65 (m, 2H, 
NCH2CH2CH2O), 2.99–2.77 (m, 2H, NCH2CH2CH2CH3), 1.83 (dt, J = 10.6, 6.1 Hz, 2H, 
NCH2CH2CH2O), 1.63–1.56 (m, 2H, NCH2CH2CH2CH3), 1.33 (dd, J = 15.2, 7.5 Hz, 2H, 
NCH2CH2CH2CH3), 0.92 (t, J = 7.4 Hz, 3H, NCH2CH2CH2CH3); 
13C NMR (126 MHz, CDCl3) δ ppm 156.8, 134.1, 130.7, 127.3 (2C), 126.8, 75.0, 45.6, 
43.2, 30.4, 24.9, 19.8, 13.7; 






According to general procedure F, 2.10.12 (60.9 mg, 90%) was isolated as a white solid. 











FTIR (thin film) 3103, 2920, 1587, 1474, 1346, 1167, 1070, 851 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.97 (ddd, J = 8.3, 6.4, 0.7 Hz, 1H, aromatic), 7.06–
6.85 (m, 2H, aromatic), 4.35 (dd, J = 6.2, 6.1 Hz, 2H, OCH2CH2CH2N), 3.88–3.61 (m, 
2H, NCH2CH2CH2O), 1.96 (tt, J = 6.9, 3.6 Hz, 1H, NCH), 1.91–1.81 (m, 2H, 
NCH2CH2CH2O), 1.01–0.84 (m, 2H, NCHCH2CH2), 0.73 (ddd, J = 6.7, 4.2, 2.9 Hz, 2H, 
NCHCH2CH2); 
13C NMR (126 MHz, CDCl3) δ ppm 165.8 (d, 1JC-F = 255.8 Hz), 157.9 (d, 3JC-F = 11.2 
Hz), 132.4 (d, 3JC-F = 10.5 Hz), 129.9 (d, 4JC-F = 3.6 Hz), 111.3 (d, 2JC-F = 21.9 Hz), 111.0 
(d, 2JC-F = 22.7 Hz), 75.2, 46.9, 28.0, 24.2, 8.1 (2C); 





According to general procedure F, 2.10.13 (483 mg, 72%) was isolated as a white solid. 
mp 86–88 ºC; 
FTIR (thin film) 3084, 2945, 1599, 1568, 1458, 1352, 1177, 1063, 800, 756 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.43 (ddd, J = 8.3, 6.0 Hz, 1H, aromatic), 7.07–6.89 
(m, 2H, aromatic), 4.30 (dd, J = 5.5, 5.4 Hz, 2H, OCH2CH2CH2N), 3.91–3.67 (m, 2H, 






NCH2CH2CH2O), 1.11–0.87 (m, 2H, NCHCH2CH2), 0.80 (dd, J = 6.9, 1.8 Hz, 2H, 
NCHCH2CH2); 
13C NMR (126 MHz, CDCl3) δ ppm 160.6 (d, 1JC-F = 258.4 Hz), 156.1 (d, 3JC-F = 2.6 Hz), 
133.5 (d, 3JC-F = 10.9 Hz), 124.7 (d, 2JC-F = 13.5 Hz), 119.3 (d, 4JC-F = 3.6 Hz), 113.2 (d, 
2JC-F = 23.6 Hz), 75.5, 48.6, 28.7, 24.6, 8.1 (2C); 





According to general procedure F, 2.10.14 (66 mg, 90%) was isolated as colorless oil. 
FTIR (neat) 2957, 2932, 1574, 1456, 1379, 1333, 1161, 1136, 1090, 1063 cm-1; 
[𝜶]𝑫𝟐𝟎 = +41.1 (c = 0.496, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.76 (d, J = 8.5 Hz, 1H, aromatic), 7.36–7.32 (m, 
2H, aromatic), 4.13–4.10 (m, 2H, OCHCH2CHaHbN), 3.45–3.42  (m, 1H, 
OCHCH2CHaHbN), 3.23–3.20 (m, 1H, NCHaHbCH2CH2CH3), 2.75–2.72 (m, 1H, 
NCHaHbCH2CH2CH3), 1.91–1.89 (m, 1H, OCHCHaHbCH2N), 1.77–1.75 (m, 1H, 
OCHCHaHbCH2N), 1.63–1.59 (m, 2H, NCH2CH2CH2CH3), 1.47, (d, J = 6.5 Hz, 3H, 









13C NMR (126 MHz, CDCl3) δ ppm 156.8, 134.2, 130.9, 127.5, 127.4, 127.1, 82.2, 45.2, 
41.6, 31.6, 30.4, 21.2, 19.8, 13.7;  






According to general procedure F, 2.10.15 (548 mg, 90%) was isolated as a white solid. 
mp 93–95 ºC; 
FTIR (thin film) 3085, 2955, 1585, 1472, 1344, 1167, 1068, 834, 756 cm-1; 
[𝜶]𝑫𝟐𝟎 = -28.8 (c = 1.99, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.97 (dd, J = 8.8, 6.4 Hz, 1H, aromatic), 7.02–6.80 
(m, 2H, aromatic), 4.50–4.23 (m, 1H, OCHCH3), 4.08 (ddd, J = 15.3, 8.4, 3.0 Hz, 1H, 
NCHaHbCH2CHO), 3.46 (ddd, J = 15.3, 7.1, 3.0 Hz, 1H, NCHaHbCH2CHO), 2.13–1.93 
(m, 2H, NCH, OCHCHaHbCH2N), 1.70 (dddd, J = 15.8, 7.1, 5.9, 3.1 Hz, 1H, 
OCHCHaHbCH2N), 1.50 (d, J = 6.4 Hz, 3H, OCHCH3), 1.08 (dddd, J = 10.4, 7.0, 5.3, 3.6 
Hz, 1H, NCHCHaHbCH2), 0.82 (dddd, J = 9.6, 7.1, 6.8, 5.3 Hz, 1H, NCHCHaHbCH2), 
0.75 (dddd, J = 10.6, 7.0, 5.1, 3.7 Hz, 1H, NCHCH2CHaHb), 0.64 (dddd, J = 9.7, 7.2, 7.0, 









13C NMR (126 MHz, CDCl3) δ ppm 165.6 (d, 1JC-F = 255.5 Hz), 157.7 (d, 3JC-F = 11.4 
Hz), 132.3 (d, 3JC-F = 10.7 Hz), 130.1 (d, 4JC-F = 3.6 Hz), 111.5 (d, 2JC-F = 21.1 Hz), 111.4 
(d, 2JC-F = 20.5 Hz), 82.2, 44.9, 31.0, 27.8, 21.3, 9.6, 6.3; 





According to general procedure F, 2.10.16 (67.0 mg, 98%) was isolated as colorless oil. 
FTIR (thin film) 3084, 2976, 1599, 1568, 1462, 1340, 1148, 1103, 797, 758, 725 cm-1; 
[𝜶]𝑫𝟐𝟎 = -51.3 (c = 2.235, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.40 (ddd, J = 8.3, 8.2, 6.0 Hz, 1H, aromatic), 7.00 
(ddd, J = 9.6, 8.4, 1.2 Hz, 1H, aromatic), 6.90 (ddd, J = 8.2, 1.2, 1.1 Hz, 1H, aromatic), 
4.23–4.14 (m, 1H, OCHCH3), 4.04–3.91 (m, 1H, NCHaHbCH2CHO), 3.61 (ddd, J = 15.2, 
4.5, 4.3 Hz, 1H, NCHaHbCH2CHO), 2.79–2.70 (m, 1H, NCH), 2.10 (dddd, J = 14.7, 10.6, 
8.8, 3.9 Hz, 1H, NCH2CHaHbCHO), 1.83–1.67 (m, 1H, NCH2CHaHbCHO), 1.44 (d, J = 
6.3 Hz, 3H, OCHCH3), 1.20 (s, 1H, NCHCHaHbCH2), 0.94–0.68 (m, 3H, 
NCHCHaHbCH2); 
13C NMR (126 MHz, CDCl3) δ ppm 160.9 (d, 1JC-F = 257.7 Hz), 133.1 (d, 3JC-F = 10.9 
Hz, 2C), 119.9, 113.3 (d, 2JC-F = 23.5 Hz, 2C), 83.1, 47.4, 31.6, 28.3, 21.5, 9.5, 6.5; 












According to general procedure F, 2.10.17 (64 mg, 87%) was isolated as colorless oil. 
FTIR (neat) 2957, 2932, 1574, 1456, 1379, 1333, 1161, 1136, 1061, 833 cm-1; 
[𝜶]𝑫𝟐𝟎 = -55.0 (c = 0.2, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.76 (d, J = 8.5 Hz, 1H, aromatic), 7.36–7.32 (m, 
2H, aromatic), 4.16–4.12 (m, 2H, OCHCH2CHaHbN), 3.46–3.42  (m, 1H, 
OCHCH2CHaHbN), 3.23–3.20 (m, 1H, NCHaHbCH2CH2CH3), 2.76–2.71 (m, 1H, 
NCHaHbCH2CH2CH3), 1.91–1.89 (m, 1H, OCHCHaHbCH2N), 1.77–1.75 (m, 1H, 
OCHCHaHbCH2N), 1.63–1.58 (m, 2H, NCH2CH2CH2CH3), 1.47, (d, J = 6.0 Hz, 3H, 
OCHCH3), 1.36–1.30 (m, 2H, NCH2CH2CH2CH3), 0.92 (t, J = 7.3 Hz, 3H, 
NCH2CH2CH2CH3);  
13C NMR (126 MHz, CDCl3) δ ppm 156.8, 134.1, 130.9, 127.5, 127.4, 127.1, 82.2, 45.2, 
41.6, 31.6, 30.4, 21.2, 19.8, 13.7;  














According to general procedure F, 2.10.18 (21.4 mg, 31%) was isolated as a white solid. 
mp 140–144 ºC; 
FTIR (thin film) 2920, 1585, 1473, 1334, 1165, 1151, 1068 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 8.02–7.81 (m, 1H, aromatic), 6.92–6.75 (m, 2H, 
aromatic), 4.45–4.30 (m, 2H, OCH2CH2CH2CH2N), 3.87 (s, 2H, NCH2CH2CH2CH2O), 
2.09–1.83 (m, 3H, NCH, NCH2CH2CH2CH2O), 1.73–1.58 (m, 2H, NCH2CH2CH2CH2O), 
0.91 (s, 2H, NCHCH2CH2), 0.80–0.56 (m, 2H, NCHCH2CH2); 
13C NMR (126 MHz, CDCl3) δ ppm 165.9 (d, 1JC-F = 254.4 Hz), 157.6 (d, 3JC-F = 10.6 
Hz), 132.0 (d, 3JC-F = 10.7 Hz), 129.6 (d, 4JC-F = 3.4 Hz), 109.8 (d, 2JC-F = 22.0 Hz), 106.7 
(d, 2JC-F = 24.0 Hz), 74.2, 47.9, 26.6, 26.4, 26.0, 7.8 (2C); 





According to general procedure F, 2.10.19 (44.9 mg, 66%) was isolated as a white solid. 











FTIR (thin film) 3018, 2930, 1599, 1570, 1464, 1340, 1165, 1040, 829, 788, 669 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.44 (ddd, J = 8.4, 8.2, 5.7 Hz, 1H, aromatic), 6.97–
6.77 (m, 2H, aromatic), 4.35 (dd, J = 6.0, 3.8 Hz, 2H, OCH2CH2CH2CH2N), 3.85 (bs, 2H, 
NCH2CH2CH2CH2O), 2.08 (tt, J = 7.0, 3.7 Hz, 1H, NCH), 1.98–1.86 (m, 2H, 
NCH2CH2CH2CH2O), 1.79–1.67 (m, 2H, NCH2CH2CH2CH2O), 0.94 (s, 2H, 
NCHCH2CH2), 0.76 (dt, J = 6.9, 2.1 Hz, 2H, NCHCH2CH2); 
13C NMR (126 MHz, CDCl3) δ ppm 160.3 (d, 1JC-F = 260.8 Hz), 157.9 (d, 3JC-F = 2.7 Hz), 
133.8 (d, 3JC-F = 11.1 Hz), 121.1 (d, 2JC-F = 11.9 Hz), 113.3 (d, 4JC-F = 3.7 Hz), 111.2 (d, 
2JC-F = 24.1 Hz), 73.7, 49.0, 27.0 (2C), 26.1, 7.6 (2C); 





According to general procedure F, 2.10.20 (41.2 mg, 59%) was isolated as a white solid. 
mp 142–144 ºC; 
FTIR (thin film) 2922, 1599, 1572, 1470, 1337, 1151, 1111, 1078 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.45 (ddd, J = 8.4, 8.2, 5.7 Hz, 1H, aromatic), 6.83 
(ddd, J = 10.4, 8.5, 1.1 Hz, 1H, aromatic), 6.77 (ddd, J = 8.3, 1.2, 1.1 Hz, 1H, aromatic), 








3.90 (dd, J = 4.9, 3.7 Hz, 2H, COCH2CH2O), 3.81–3.67 (m, 2H, NCH2CH2O), 2.52–2.31 
(m, 1H, NCH), 0.74–0.53 (m, 4H, NCHCH2CH2); 
13C NMR (126 MHz, CDCl3) δ ppm 160.7 (d, 1JC-F = 260.9 Hz), 158.9 (d, 4JC-F = 2.8 Hz), 
134.3 (d, 2JC-F = 11.5 Hz), 119.0 (d, 3JC-F = 11.4 Hz), 111.3 (d, 3JC-F = 3.6 Hz), 110.5 (d, 
2JC-F = 24.8 Hz), 72.8, 68.6, 67.9, 49.4, 28.8, 6.9 (2C); 





According to general procedure E, 2.11.2 (210 mg, 75%) was isolated as a white solid. 
mp 131–134 ºC; 
FTIR (thin film) 3404, 2957, 1697, 1612, 1514, 1468, 1366, 1167, 777, 719 cm-1; 
[𝜶]𝑫𝟐𝟎 = -10.7 (c = 0.55, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.54–7.44 (m, 1H, aromatic), 7.01 (dd, J = 8.9, 8.6 
Hz, 2H, aromatic), 4.53 (d, J = 9.5 Hz, 1H, NH), 4.13–3.98 (m, 1H, NHCH), 3.51 (dd, J 
= 14.2, 9.8 Hz, 1H, NCHaHbCHNH), 3.17 (dd, J = 14.4, 5.1 Hz, 1H, NCHaHbCHNH), 
2.58–2.46 (m, 1H, NCH), 1.79–1.68 (m, 1H, CH3CHCH3), 1.46 (s, 9H, (CH3)3), 1.41 (s, 
1H, CHCHaHbCHCH3), 1.34–1.26 (m, 2H CHCHaHbCHCH3, NCHCHaHbCH2), 0.95 (dd, 








13C NMR (126 MHz, CDCl3) δ ppm 159.7 (dd, JC-F = 258.4, 4.1 Hz, 2C), 155.8, 134.1 (t, 
JC-F = 11.0 Hz), 118.8, 113.1 (dd, JC-F = 23.7, 3.7 Hz, 2C), 79.3, 54.0, 46.8, 42.4, 29.4, 
28.4 (3C), 24.9, 23.2, 22.1 (2C), 6.5, 6.3; 






According to general procedure G, 2.11.3 (28 mg, 39%) was isolated as a white solid. 
mp 131–135 ºC; 
FTIR (thin film) 3373, 2957, 2922, 1609, 1578, 1504, 1470, 1344, 1155 cm-1; 
[𝜶]𝑫𝟐𝟎 = -29.6 (c = 0.805, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ ppm 7.18 (ddd, J = 8.3, 8.2, 5.8 Hz, 1H, aromatic), 6.67–
6.62 (m, 1H, aromatic), 6.51 (d, J = 8.2 Hz, 1H, aromatic), 4.12–4.04 (m, 1H, NHCH), 
4.01 (s, 1H, NH), 3.72 (dd, J = 13.2, 4.4 Hz, 1H, NCHaHbCHNH), 3.05 (dd, J = 12.9, 
12.1 Hz, 1H, NCHaHbCHNH), 2.81–2.71 (m, 1H, NCH), 1.74–1.65 (m, 1H, CH3CHCH3), 
1.48–1.37 (m, 2H, CHCH2CHCH3), 1.24–1.16 (m, 1H, NCHCHaHbCH2), 0.97 (d, J = 6.6 
Hz, 3H, CH3CHCH3), 0.91 (d, J = 6.6 Hz, 3H, CH3CHCH3), 0.84–0.74 (m, 1H, 







13C NMR (126 MHz, CDCl3) δ ppm 161.9 (d, 1JC-F = 254.3 Hz), 148.4 (d, 3JC-F = 3.6 Hz), 
132.6 (d, 3JC-F = 11.0 Hz), 116.5 (d, 2JC-F = 16.5 Hz), 114.3 (d, 4JC-F = 3.3 Hz), 107.8 (d, 
2JC-F = 22.7 Hz), 59.4, 56.0, 42.7, 33.7, 25.3, 22.7, 22.4, 11.1, 6.4; 






According to general procedure E, SI-5 (26.9 mg, 35%) was isolated as colorless oil. 
FTIR (thin film) 3599, 3354, 2959, 1714, 1576, 1456, 1387, 1339, 1159, 1061, 852 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.77 (d, J = 8.3 Hz, 1H, aromatic), 7.43–7.33 (m, 
2H, aromatic), 4.74 (d, J = 8.6 Hz, 1H, NH), 4.28 (dd, J = 11.2, 5.3 Hz, 1H, CHaHbOH), 
4.21–4.05 (m, 2H, NCHaHbCHNH), 3.97 (dd, J = 11.3, 4.2 Hz, 1H, CHaHbOH), 3.43 (d, J 
= 11.3 Hz, 1H, NCHaHbCHNH), 3.28 (dt, J = 15.1, 7.9 Hz, 1H, NCHaHbCH2CH2CH3), 
2.90 (dt, J = 14.0, 7.1 Hz, 1H, NCHaHbCH2CH2CH3), 1.76–1.58 (m, 2H, 
NCH2CH2CH2CH3), 1.46 (s, 9H, (CH3)3), 1.40–1.28 (m, 2H, NCH2CH2CH2CH3), 1.27 (s, 
1H, OH), 1.03–0.85 (m, 3H, NCH2CH2CH2CH3); 
13C NMR (126 MHz, CDCl3) δ ppm 156.1 (d, 1JC-F = 261.2 Hz), 154.9, 133.7, 130.7, 















According to general procedure G, 2.11.4 (11 mg, 29%) was isolated as colorless oil. 
FTIR (thin film) 3501, 3354, 2957, 1582, 1504, 1462, 1325, 1155, 1090, 862, 763 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.69 (d, J = 8.4 Hz, 1H, aromatic), 7.13 (dd, J = 8.4, 
1.8 Hz, 1H, aromatic), 7.10 (d, J = 1.7 Hz, 1H, aromatic), 4.65 (s, 1H, NH), 3.83 (dt, J = 
10.4, 3.4 Hz, 1H, CHaHbOH), 3.79–3.71 (m, 1H, NHCH), 3.63 (ddd, J = 10.3, 8.5, 5.9 
Hz, 1H, CHaHbOH), 3.46 (dd, J = 14.1, 10.9 Hz, 1H, NCHaHbCH), 3.30 (dd, J = 14.1, 2.2 
Hz, 1H, NCHaHbCH), 3.22 (dt, J = 14.3, 7.3 Hz, 1H, NCHaHbCH2), 2.94 (dt, J = 14.0, 7.1 
Hz, 1H, NCHaHbCH2), 1.79 (dd, J = 5.7, 3.4 Hz, 1H, OH), 1.62–1.55 (m, 2H, 
NCH2CH2CH2CH3), 1.41–1.31 (m, 2H, NCH2CH2CH2CH3), 0.94 (t, J = 7.4 Hz, 3H, 
NCH2CH2CH2CH3); 
13C NMR (126 MHz, CDCl3) δ ppm 146.3, 130.9, 127.9, 127.1, 123.8, 123.5, 62.6, 55.2, 
50.7, 48.6, 30.7, 19.7, 13.7; 














According to general procedure E, SI-6 (260 mg, 69%) was isolated as colorless oil. 
FTIR (thin film) 3150, 2928, 1612, 1585, 1468, 1361, 1174, 1105, 914, 777, 723 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.54–7.47 (m, 1H, aromatic), 7.02 (t, J = 8.7 Hz, 
2H, aromatic), 5.80 (ddt, J = 17.1, 10.1, 6.9 Hz, 1H, CH2HC=CH2), 5.06 (m, 2H, 
CH2HC=CH2), 3.60 (ddd, J = 23.3, 10.2, 4.6 Hz, 2H, CH2OTBS), 3.33 (d, J = 2H, 
NCH2CH), 2.40–2.34 (m, 1H, NCH), 2.18–2.09 (m, 3H, NCH2CHCH2), 0.92–0.82 (m, 
10H, (CH3)3, NCHCHaHbCH2), 0.73 (m, 3H, NCHCHaHbCH2), 0.05 (d, J = 2.1 Hz, 6H, 
(CH3)2); 
13C NMR (126 MHz, CDCl3) δ ppm 159.9 (dd, JC-F = 258.9, 4.4 Hz, 2C), 136.4, 134.2 (t, 
JC-F = 11.0 Hz), 117.7, 116.5, 113.1 (dd, JC-F = 23.7, 3.7 Hz, 2C), 62.8, 52.0, 51.9, 39.4, 
33.3, 30.5, 25.9 (3C), 18.2, 6.8, 6.6, -5.5 (2C); 















According to general procedure H, 2.11.5 (41 mg, 74%) was isolated as colorless oil. 
FTIR (thin film) 3078, 2935, 1599, 1568, 1470, 1458, 1348, 1145, 991, 924, 833 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.43 (td, J = 8.3, 6.0 Hz, 1H, aromatic), 7.02–6.97 
(m, 1H, aromatic), 6.96 (d, J = 8.2 Hz, 1H, aromatic), 5.79–5.65 (m, 1H, HC=CH2), 5.11 
(s, 1H, HC=CHaHb), 5.09–5.07 (m, 1H, HC=CHaHb), 4.32–4.23 (m, 1H, OCHaHb), 3.95 
(dd, J = 11.0, 10.5 Hz, 1H, OCHaHb), 3.86–3.78 (m, 1H, NCHaHb), 3.42 (d, J = 14.6 Hz, 
1H, NCHaHb), 2.62 (s, 1H, NCH), 2.48–2.37 (m, 1H, NCH2CH), 1.98 (dd, J = 7.1, 6.6 
Hz, 2H, CH2HC=CHaHb), 1.22 (s, 1H, NCHCHaHbCH2), 0.90–0.83 (m, 1H, 
NCHCHaHbCH2), 0.79–0.66 (m, 2H, NCHCH2CH2); 
13C NMR (126 MHz, CDCl3) δ ppm 160.9 (d, 1JC-F = 258.8 Hz), 156.4, 134.4, 133.5 (d, 
3JC-F = 10.9 Hz), 119.1 (d, 4JC-F = 3.5 Hz), 117.9, 113.2 (d, 2JC-F = 23.1 Hz, 2C), 79.5, 
53.5, 34.0, 33.8, 29.1, 10.0, 6.5; 






According to general procedure E, SI-7 (265 mg, 81%) was isolated as colorless oil. 








1H NMR (500 MHz, CDCl3) δ ppm 7.78 (dd, J = 8.4, 7.5 Hz, 1H, aromatic), 7.40 (ddd, J 
= 8.4, 1.8, 0.6 Hz, 1H, aromatic), 7.37 (dd, J = 9.5, 1.8 Hz, 1H, aromatic), 3.41 (s, 2H, 
CH2OTBS), 3.38–3.33 (m, 2H, NCH2CH2), 3.31 (s, 2H, NCH2), 1.54–1.47 (m, 2H, 
NCH2CH2CH2), 1.31–1.18 (m, 2H, NCH2CH2CH2), 0.93–0.84 (m, 12H, (CH3)3, 
NCH2CH2CH2CH3), 0.49–0.45 (m, 2H, CCH2CH2), 0.41–0.36 (m, 2H, CCH2CH2), 0.01 
(s, 6H, (CH3)2); 
13C NMR (126 MHz, CDCl3) δ ppm 158.4 (d, 1JC-F = 258.9 Hz), 131.9 (d, 4JC-F = 1.8 Hz), 
128.5 (d, 2JC-F = 15.0 Hz), 127.6 (d, 3JC-F = 3.7 Hz), 127.5 (d, 3JC-F = 9.1 Hz), 120.6 (d, 2JC-
F = 25.0 Hz), 65.0, 51.8, 48.3, 30.1, 25.9 (3C), 21.0, 20.0, 18.3, 13.7, 8.7 (2C), -5.4 (2C); 






According to general procedure H, 2.11.6 (11 mg, 32%) was isolated as colorless oil. 
FTIR (thin film) 2957, 1574, 1454, 1335, 1203, 1155, 1061, 818, 760 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.82 (d, J = 8.4 Hz, 1H, aromatic), 7.38 (dd, J = 8.4, 
1.9 Hz, 1H, aromatic), 7.28 (d, J = 1.9 Hz, 1H, aromatic), 3.88 (s, 2H, OCH2), 3.65 (s, 







(m, 2H, NCH2CH2CH2CH3), 0.93 (t, J = 7.4 Hz, 3H, NCH2CH2CH2CH3), 0.55 (d, J = 4.0 
Hz, 4H, CCH2CH2); 
13C NMR (126 MHz, CDCl3) δ ppm 157.7, 134.1, 131.2, 127.8, 127.2, 127.1, 82.7, 51.0, 
46.0, 30.3, 19.9, 17.8, 13.8, 9.2 (2C); 






According to general procedure E, SI-8 (16.2 mg, 36%) was isolated as colorless oil. 
FTIR (thin film) 2928, 1585, 1468, 1364, 1167, 1089, 835, 777, 706 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.63–7.37 (m, 1H, aromatic), 7.15–6.89 (m, 2H, 
aromatic), 3.67 (s, 2H, CH2OTBS), 3.44 (s, 2H, NCH2), 2.52 (tt, J = 7.2, 4.0 Hz, 1H, 
NCH), 2.14–1.95 (m, 2H, CCH2CH2CH2), 1.96–1.71 (m, 4H, CCH2CH2CH2), 0.92 (s, 9H, 
(CH3)3), 0.75–0.70 (m, 2H, NCHCH2CH2), 0.69–0.64 (m, 2H, NCHCH2CH2), 0.09 (s, 6H, 
(CH3)2); 
13C NMR (126 MHz, CDCl3) δ ppm 159.7 (d, JC-F = 258.1 Hz, 2C), 133.9 (t, JC-F = 11.0 
Hz), 113.1 (d, JC-F = 3.7 Hz), 112.9 (d, JC-F = 3.7 Hz, 2C), 66.9, 54.9, 44.0, 30.9, 29.7, 











-butane] 1,1-dioxide (2.11.7) 
 
According to general procedure H, 2.11.7 (5 mg, 44%) was isolated as colorless oil. 
FTIR (thin film) 2930, 1601, 1572, 1456, 1339, 1150, 810, 742 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.40 (ddd, J = 8.3, 8.2, 6.0 Hz, 1H, aromatic), 7.02–
6.96 (m, 1H, aromatic), 6.94 (ddd, J = 8.2, 1.1, 1.0 Hz, 1H, aromatic), 4.24 (s, 2H, 
OCH2), 3.75 (s, 2H, NCH2), 2.69–2.60 (m, 1H, NCH), 2.12–1.89 (m, 6H, C(CH2)3), 1.06 
(s, 2H, NCHCH2CH2), 0.78 (dd, J = 6.8, 1.5 Hz, 2H, NCHCH2CH2); 
13C NMR (126 MHz, CDCl3) δ ppm 161.0 (d, 1JC-F = 257.9 Hz), 156.8 (d, 4JC-F = 2.6 Hz), 
133.2 (d, 3JC-F = 10.9 Hz), 124.3 (d, 2JC-F = 13.8 Hz), 119.3 (d, 3JC-F = 3.6 Hz), 113.3 (d, 
2JC-F = 23.1 Hz), 81.8, 58.1, 41.3, 28.8 (2C), 28.7, 15.9, 9.0 (2C); 








General procedure I: Microwave-assisted SNAr diversification of Benzoxa-
thiazocine-1,1-dioxides 2.9.3–2.9.6, 2.10.12–2.10.13, 2.10.15–2.10.16 cores. Into a 1-
dram vial was added benzoxathiazocine-1,1-dioxide 2.9.3–2.9.6, 2.10.12–2.10.13, 
2.10.15–2.10.16 (1 equiv., 80 mg), dry DMSO (0.5 M) and the corresponding amine (5 
equiv.).  The reaction vessel was capped, placed in Anton Paar Synthos 3000 ® 
microwave and heated at 180 ºC for 50 min [Power = 1200 W, 8 min ramp then 50 min 
hold].  After such time, the reaction was diluted with 10% MeOH on CH2Cl2, filtered 
through a SiO2 SPE and concentrated.  The crude reaction was concentrated and 




thiazocine 1,1-dioxide (2.10.12{1}) 
 
According to general procedure I, 2.10.12{1} was isolated (79.8 mg, 80%) as a yellow 
solid; 
mp 92.5 ºC; 
[𝜶]𝑫𝟐𝟎 = -66.0 (c = 0.106, CH2Cl2); 
FTIR (thin film) 2964, 2930, 1595, 1497, 1464, 1383, 1335, 1202, 1150, 1049 cm-1; 
1H NMR (500 MHz, DMSO) δ ppm 7.51 (d, J = 8.8 Hz, 1H), 6.47–6.34 (m, 2H), 4.27–








1H), 3.15 (dd, J = 17.7, 8.2 Hz, 1H), 2.10–1.92 (m, 3H), 1.85 (tt, J = 6.9, 3.6 Hz, 1H), 
1.74–1.66 (m, 3H), 1.10 (d, J = 6.2 Hz, 3H), 0.74–0.66 (m, 2H), 0.64–0.56 (m, 2H); 
13C NMR (126 MHz, DMSO) δ ppm 157.5, 151.1, 131.1, 117.3, 106.5, 105.4, 74.6, 
53.3, 47.6, 46.6, 32.3, 27.6, 22.9, 22.5, 18.4, 7.7, 7.4; 
HRMS calculated for C17H25N2O3S (M+H)+ 337.1586; found 337.1580 (TOF MS ES+). 
 
(R)-2-cyclopropyl-8-(3-hydroxypyrrolidin-1-yl)-2,3,4,5-tetrahydrobenzo[b][1,4,5]-
oxathiazocine 1,1-dioxide (2.10.12{3}) 
 
According to general procedure I, 2.10.12{3} was isolated (75.8 mg, 76%) as yellow oil; 
[𝜶]𝑫𝟐𝟎 = +9.88 (c = 0.162, CH2Cl2); 
FTIR (neat) 3404, 3394, 2937, 2918, 1597, 1502, 1331, 1254, 1148, 1026 cm-1; 
1H NMR (500 MHz, DMSO) δ ppm 7.52 (d, J = 8.8 Hz, 1H), 6.43 (d, J = 2.3 Hz, 1H), 
6.35 (dd, J = 8.8, 2.3 Hz, 1H), 5.03 (d, J = 3.7 Hz, 1H), 4.40 (s, 1H), 4.24 (t, J = 6.1 Hz, 
2H), 3.57–3.51 (m, 2H), 3.43 (dd, J = 10.7, 4.6 Hz, 1H), 3.37 (dd, J = 9.6, 2.7 Hz, 2H), 
3.14 (d, J = 10.7 Hz, 1H), 2.03 (dtd, J = 13.2, 8.8, 4.6 Hz, 1H), 1.94–1.87 (m, 1H), 1.82 
(dt, J = 10.4, 3.5 Hz, 1H), 1.73–1.67 (m, 2H), 0.72–0.68 (m, 2H), 0.61 (dd, J = 6.7, 2.0 
Hz, 2H);  
13C NMR (126 MHz, DMSO) δ ppm 157.4, 151.9, 131.1, 117.5, 106.2, 105.2, 74.5, 
69.0, 55.9, 46.7, 45.5, 33.5, 27.6, 22.8, 7.6, 7.5;  










According to general procedure I, 2.10.12{5} was isolated (85.7 mg, 83%) as dark 
yellow oil; 
[𝜶]𝑫𝟐𝟎  = -66.4 (c = 0.128, CH2Cl2); 
FTIR (neat) 3381, 2918, 1595, 1498, 1331, 1153, 1045, 1026 cm-1; 
1H NMR (500 MHz, DMSO) δ ppm 7.51 (d, J = 8.8 Hz, 1H), 6.51 (d, J = 2.2 Hz, 1H), 
6.44 (dd, J = 8.9, 2.3 Hz, 1H), 4.83 (dd, J = 6.4, 5.3 Hz, 1H), 4.23 (t, J = 6.1 Hz, 2H), 
3.77 (td, J = 7.8, 3.6 Hz, 1H), 3.54 (qt, J = 11.7, 5.9 Hz, 2H), 3.48–3.42 (m, 1H), 3.39 (t, 
J = 7.7 Hz, 1H), 3.22 (ddd, J = 10.9, 8.1, 6.7 Hz, 1H), 3.11 (td, J = 9.7, 7.3 Hz, 1H), 
2.02–1.83 (m, 5H), 1.75–1.67 (m, 2H), 0.74–0.66 (m, 2H), 0.65–0.57 (m, 2H); 
13C NMR (126 MHz, DMSO) δ ppm 157.4, 151.8, 131.0, 117.8, 106.6, 105.7, 74.6, 
60.6, 60.1, 48.1, 46.6, 27.8, 27.6, 22.9, 22.5, 7.7, 7.4; 
HRMS calculated for C17H25N2O4S (M+H)+ 353.1535; found 353.1510 (TOF MS ES+). 
 
(S)-2-cyclopropyl-8-(3-(dimethylamino)pyrrolidin-1-yl)-2,3,4,5-tetrahydrobenzo[b]-














According to general procedure I, 2.10.12{8} was isolated (49.2 mg, 46%) as a light 
brown solid; 
mp 170.5 ºC; 
[𝜶]𝑫𝟐𝟎  = -32.9 (c = 0.140, CH2Cl2); 
FTIR (thin film) 2947, 2866, 1597, 1501, 1437, 1387, 1333, 1194, 1150, 1074 cm-1; 
1H NMR (500 MHz, DMSO) δ ppm 7.52 (d, J = 8.8 Hz, 1H), 6.47 (d, J = 2.3 Hz, 1H), 
6.37 (dd, J = 8.9, 2.3 Hz, 1H), 4.24 (td, J = 6.1, 1.6 Hz, 2H), 3.56–3.48 (m, 3H), 3.46–
3.41 (m, 1H), 3.27 (td, J = 10.0, 6.9 Hz, 1H), 3.08–3.03 (m, 1H), 2.77 (dt, J = 15.1, 7.5 
Hz, 1H), 2.20 (s, 6H), 2.16 (dd, J = 11.9, 6.4 Hz, 1H), 1.81 (ddd, J = 18.6, 9.2, 6.2 Hz, 
2H), 1.71 (ddd, J = 9.8, 6.0, 4.0 Hz, 2H), 0.74–0.66 (m, 2H), 0.61 (d, J = 6.5 Hz, 2H); 
13C NMR (126 MHz, DMSO) δ ppm 157.4, 151.7, 131.0, 117.7, 106.1, 105.3, 74.5, 
64.8, 51.9, 46.7, 46.7, 43.9, 40.4, 29.5, 27.6, 22.8, 7.7, 7.4; 
HRMS calculated for C18H28N3O3S (M+H)+ 366.1851; found 366.1826 (TOF MS ES+). 
 
(R)-2-cyclopropyl-8-(2-(methoxymethyl)pyrrolidin-1-yl)-2,3,4,5-tetrahydrobenzo[b]-
[1,4,5]oxathiazocine 1,1-dioxide (2.10.12{10}) 
 
According to general procedure I, 2.10.12{10} was isolated (83.7 mg, 78%) as dark 
yellow oil;   
[𝜶]𝑫𝟐𝟎= +91.9 (c = 0.124, CH2Cl2); 








1H NMR (500 MHz, DMSO) δ ppm 7.52 (d, J = 8.8 Hz, 1H), 6.50 (d, J = 2.3 Hz, 1H), 
6.45 (dd, J = 8.9, 2.3 Hz, 1H), 4.23 (td, J = 6.2, 2.7 Hz, 2H), 3.98–3.92 (m, 1H), 3.55 (td, 
J = 7.9, 2.8 Hz, 2H), 3.38 (ddd, J = 13.7, 13.1, 6.3 Hz, 2H), 3.28–3.24 (m, 4H), 3.13 (dt, 
J = 13.0, 4.8 Hz, 1H), 2.08–1.98 (m, 1H), 1.97–1.90 (m, 3H), 1.88–1.84 (m, 1H), 1.72 
(dd, J = 9.4, 4.4 Hz, 2H), 0.71 (dd, J = 5.8, 2.7 Hz, 2H), 0.62 (dd, J = 6.8, 2.4 Hz, 2H); 
13C NMR (126 MHz, DMSO) δ ppm 157.4, 151.7, 131.0, 118.1, 106.7, 105.9, 74.6, 
72.0, 58.5, 57.5, 48.1, 46.6, 28.3, 27.6, 22.9, 22.6, 7.8, 7.4; 
HRMS calculated for C18H27N2O4S (M+H)+ 367.1692; found 367.1680 (TOF MS ES+). 
 
(S)-2-cyclopropyl-10-(3-hydroxypyrrolidin-1-yl)-2,3,4,5-tetrahydrobenzo[b][1,4,5]-
oxathiazocine 1,1-dioxide (2.10.13{4}) 
 
According to general procedure I, 2.10.13{4} was isolated (61.0 mg, 61%) as dark brown 
oil;   
[𝜶]𝑫𝟐𝟎  = +266.8 (c = 0.196, CH2Cl2); 
FTIR (neat) 3385, 2943, 2918, 1589, 1549, 1323, 1236, 1151, 1028 cm-1; 
1H NMR (400 MHz, DMSO) δ ppm 7.22 (dd, J = 8.5, 8.0 Hz, 1H), 6.58 (dd, J = 10.2, 
8.3 Hz, 2H), 4.86 (s, 1H), 4.36 (t, J = 6.8 Hz, 2H), 4.25 (d, J = 2.7 Hz, 1H), 3.72 (s, 2H), 
3.49 (d, J = 7.0 Hz, 1H), 3.35 (s, 1H), 3.29 (d, J = 4.3 Hz, 1H), 3.05 (d, J = 10.9 Hz, 1H), 
1.95 (ddd, J = 12.5, 11.4, 6.9 Hz, 2H), 1.81 (d, J = 2.8 Hz, 2H), 1.55 (d, J = 3.5 Hz, 1H), 







13C NMR (126 MHz, DMSO) δ ppm 159.6, 151.6, 132.0, 115.5, 109.2, 105.2, 70.1, 
68.9, 62.0, 54.9, 49.2, 45.8, 33.2, 27.2, 23.1, 5.8; 
HRMS calculated for C16H23N2O4S (M+H)+ 339.1379; found 339.1356 (TOF MS ES+). 
 
(R)-2-cyclopropyl-10-(2-(hydroxymethyl)pyrrolidin-1-yl)-2,3,4,5-tetrahydrobenzo-
[b][1,4,5]oxathiazocine 1,1-dioxide (2.10.13{6}) 
 
According to general procedure I, 2.10.13{6} was isolated (67.7 mg, 65%) as brown oil;   
[𝜶]𝑫𝟐𝟎  = +76.0 (c = 0.550, CH2Cl2); 
FTIR (neat) 3474, 2945, 2872, 1585, 1474, 1458, 1327, 1237, 1151, 1059 cm-1;  
1H NMR (500 MHz, DMSO) δ ppm 7.32 (t, J = 8.2 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 
6.77 (d, J = 7.8 Hz, 1H), 4.42–4.34 (m, 1H), 4.33–4.24 (m, 1H), 4.14 (dd, J = 6.9, 4.8 Hz, 
1H), 3.91 (d, J = 3.5 Hz, 1H), 3.87–3.76 (m, 2H), 3.43 (ddd, J = 10.3, 7.0, 3.1 Hz, 1H), 
3.32–3.25 (m, 2H), 2.92–2.87 (m, 1H), 2.13–1.98 (m, 2H), 1.84–1.63 (m, 5H), 0.86–0.78 
(m, 1H), 0.58–0.48 (m, 3H); 
13C NMR (126 MHz, DMSO) δ ppm 158.4, 151.0, 132.5, 113.7, 110.1, 71.3, 62.4, 60.7, 
56.9, 46.7, 28.7, 27.6, 24.6, 23.0, 9.7, 5.1; 










hydrobenzo[b][1,4,5]oxathiazocine 1,1-dioxide (2.10.15{9}) 
 
According to general procedure I, 2.10.15{9} was isolated (67.4 mg, 63%) as dark 
yellow oil;   
[𝜶]𝑫𝟐𝟎  = -33.0 (c = 0.224, CH2Cl2); 
FTIR (neat) 2974, 2930, 2878, 1595, 1489, 1435, 1375, 1329, 1209, 1155, 1074 cm-1; 
1H NMR (400 MHz, DMSO) δ ppm 7.52 (d, J = 9.0 Hz, 1H), 6.49–6.42 (m, 2H), 4.28 
(m, 1H), 3.98–3.86 (m, 2H), 3.43–3.31 (m, 4H), 3.31–3.27 (m, 1H), 3.27–3.19 (m, 2H), 
3.18–3.10 (m, 1H), 2.06–1.89 (m, 6H), 1.55–1.46 (m, 1H), 1.37 (d, J = 6.4 Hz, 3H), 
0.91–0.82 (m, 1H), 0.75–0.66 (m, 1H), 0.64–0.49 (m, 2H); 
13C NMR (126 MHz, DMSO) δ ppm 157.5, 151.5, 130.9, 118.3, 106.8, 106.3, 81.1, 
72.2, 58.5, 57.6, 48.1, 43.9, 29.6, 28.3, 27.3, 22.7, 20.9, 9.8, 5.0; 
HRMS calculated for C19H29N2O4S (M+H)+ 381.1848; found 381.1831 (TOF MS ES+). 
 
(R)-2-cyclopropyl-5-methyl-10-((S)-2-methylpyrrolidin-1-yl)-2,3,4,5-tetrahydro-















According to general procedure I, 2.10.16{2} was isolated (33.9 mg, 35%) as a dark 
yellow solid; 
mp 111.5 ºC; 
[𝜶]𝑫𝟐𝟎  = -29.4 (c = 0.330, CH2Cl2); 
FTIR (thin film) 2968, 2918, 1572, 1454, 1441, 1377, 1319, 1236, 1140, 1055 cm-1; 
1H NMR (500 MHz, DMSO) δ ppm 7.34 (t, J = 8.1 Hz, 1H), 7.03 (d, J = 8.2 Hz, 1H), 
6.68 (d, J = 7.7 Hz, 1H), 4.07 (s, 1H), 3.75 (dd, J = 16.0, 7.2 Hz, 3H), 3.50 (d, J = 14.8 
Hz, 1H), 2.89 (td, J = 8.5, 4.9 Hz, 1H), 2.61–2.55 (m, 1H), 2.11–2.04 (m, 1H), 1.93 (dtd, 
J = 14.3, 9.6, 4.6 Hz, 1H), 1.85–1.72 (m, 2H), 1.68 (ddd, J = 16.5, 8.2, 3.9 Hz, 1H), 1.47 
(dq, J = 11.8, 8.7 Hz, 1H), 1.31 (d, J = 6.2 Hz, 3H), 0.99 (d, J = 6.0 Hz, 3H), 0.92 (d, J = 
9.2 Hz, 1H), 0.72–0.61 (m, 3H); 
13C NMR (126 MHz, DMSO) δ ppm 151.1, 132.6, 117.7, 116.3, 82.4, 56.2, 55.7, 54.9, 
46.6, 33.1, 31.6, 27.7, 23.5, 21.2, 18.7, 9.1, 6.2; 
HRMS calculated for C18H27N2O3S (M+H)+ 351.1742; found 351.1700 (TOF MS ES+). 
 
(R)-2-cyclopropyl-10-((R)-3-(dimethylamino)pyrrolidin-1-yl)-5-methyl-2,3,4,5-tetra-
hydrobenzo[b][1,4,5]oxathiazocine 1,1-dioxide (2.10.16{7}) 
 










mp 91.5 ºC; 
[𝜶]𝑫𝟐𝟎  = -158.6 (c = 0.140, CH2Cl2); 
FTIR (thin film) 2972, 2932, 2824, 1583, 1460, 1377, 1323, 1221, 1155, 1103 cm-1; 
1H NMR (400 MHz, DMSO) δ ppm 7.27–7.21 (m, 1H), 6.71 (d, J = 8.1 Hz, 1H), 6.54 
(d, J = 7.2 Hz, 1H), 4.44–4.35 (m, 1H), 3.71 (s, 1H), 3.56 (dd, J = 10.4, 6.3 Hz, 2H), 3.42 
(dd, J = 10.8, 4.7 Hz, 1H), 3.30 (dd, J = 9.7, 7.1 Hz, 1H), 3.21 (dd, J = 10.4, 5.7 Hz, 1H), 
2.70 (m, 1H), 2.12 (s, 6H), 1.97 (td, J = 12.6, 6.5 Hz, 3H), 1.83 (td, J = 13.7, 7.0 Hz, 1H), 
1.71 (d, J = 6.9 Hz, 1H), 1.35 (d, J = 6.2 Hz, 3H), 0.72 (s, 2H), 0.56 (td, J = 6.7, 2.0 Hz, 
2H); 
13C NMR (126 MHz, DMSO) δ ppm 158.3, 150.9, 132.4, 119.2, 111.7, 109.4, 79.4, 
64.7, 57.2, 54.9, 50.8, 45.4, 43.4, 31.1, 28.9, 27.2, 22.1, 8.2, 6.6; 
HRMS calculated for C19H30N3O3S (M+H)+ 380.2008; found 380.1976 (TOF MS ES+). 
 
(5S)-8-((S)-2-methylpyrrolidin-1-yl)-4,5-dihydro-3H-2,5-methanobenzo[b][1,4,5]oxa-
thiazocine 1,1-dioxide (2.9.3{2}) 
 
According to general procedure I, 2.9.3{2} was isolated (73.4 mg, 72%) as a pale yellow 
solid; 
mp 143.0 ºC; 
[𝜶]𝑫𝟐𝟎  = +72.3 (c = 0.260, CH2Cl2); 










1H NMR (400 MHz, DMSO) δ ppm 7.46 (d, J = 8.9 Hz, 1H), 6.40 (dd, J = 8.9, 2.4 Hz, 
1H), 6.12 (d, J = 2.4 Hz, 1H), 5.05 (dd, J = 6.4, 2.7 Hz, 1H), 4.01–3.89 (m, 2H), 3.38 (t, J 
= 8.8 Hz, 1H), 3.27 (dd, J = 8.3, 3.5 Hz, 1H), 3.20–3.08 (m, 3H), 2.05–1.92 (m, 4H), 1.76 
(dt, J = 15.4, 7.8 Hz, 1H), 1.70–1.62 (m, 1H), 1.08 (d, J = 6.2 Hz, 3H); 
13C NMR (126 MHz, DMSO) δ ppm 152.1, 150.9, 130.8, 116.1, 107.1, 105.4, 80.0, 
56.7, 53.3, 47.6, 47.0, 32.3, 28.2, 22.5, 18.4; 
HRMS calculated for C15H21N2O3S (M+H)+ 309.1273; found 309.1243 (TOF MS ES+). 
 
(5S)-8-((S)-3-hydroxypyrrolidin-1-yl)-4,5-dihydro-3H-2,5-methanobenzo[b][1,4,5]-
oxathiazocine 1,1-dioxide (2.9.3{4}) 
 
According to general procedure I, 2.9.3{4} was isolated (76.7 mg, 75%) as a pale yellow 
solid; 
mp 208.0 ºC; 
[𝜶]𝑫𝟐𝟎  = +63.1 (c = 0.160, CH2Cl2); 
FTIR (thin film) 3406, 3009, 2945, 2920, 1601, 1504, 1437, 1321, 1140, 1107 cm-1; 
1H NMR (400 MHz, DMSO) δ ppm 7.47 (d, J = 8.9 Hz, 1H), 6.37 (dd, J = 8.9, 2.4 Hz, 
1H), 6.09 (d, J = 2.3 Hz, 1H), 5.05 (dd, J = 6.4, 2.7 Hz, 1H), 5.01 (d, J = 3.6 Hz, 1H), 
4.39 (s, 1H), 3.99 (d, J = 13.9 Hz, 1H), 3.41 (dd, J = 10.8, 4.6 Hz, 1H), 3.36 (d, J = 6.9 
Hz, 1H), 3.32–3.22 (m, 2H), 3.20–3.06 (m, 3H), 2.06–1.94 (m, 2H), 1.93–1.85 (m, 1H), 









13C NMR (126 MHz, DMSO) δ ppm 152.1, 151.7, 130.8, 116.3, 106.8, 105.2, 80.0, 
69.0, 56.7, 55.9, 47.0, 45.5, 33.4, 28.1; 
HRMS calculated for C14H19N2O4S (M+H)+ 311.1066; found 311.1032 (TOF MS ES+). 
 
(5S)-8-((R)-2-(hydroxymethyl)pyrrolidin-1-yl)-4,5-dihydro-3H-2,5-methanobenzo-
[b][1,4,5]oxathiazocine 1,1-dioxide (2.9.3{6}) 
 
According to general procedure I, 2.9.3{6} was isolated (90.2 mg, 85%) as brown oil; 
[𝜶]𝑫𝟐𝟎  = +105.5 (c = 0.254, CH2Cl2); 
FTIR (neat) 3420, 2972, 2878, 1599, 1497, 1437, 1323, 1140, 1107 cm-1; 
1H NMR (400 MHz, DMSO) δ ppm 7.46 (d, J = 8.9 Hz, 1H), 6.45 (dd, J = 8.9, 2.3 Hz, 
1H), 6.20 (d, J = 2.2 Hz, 1H), 5.05 (dd, J = 6.4, 2.6 Hz, 1H), 4.83 (t, J = 5.8 Hz, 1H), 
3.99 (d, J = 13.9 Hz, 1H), 3.74 (td, J = 7.8, 3.6 Hz, 1H), 3.41 (ddd, J = 11.7, 9.4, 4.6 Hz, 
2H), 3.29–3.05 (m, 5H), 2.05–1.95 (m, 3H), 1.94–1.82 (m, 2H), 1.77 (dt, J = 13.4, 6.8 
Hz, 1H); 
13C NMR (126 MHz, DMSO) δ ppm 152.1, 151.6, 130.7, 116.5, 107.3, 105.6, 80.0, 
60.5, 60.1, 56.7, 48.1, 47.0, 28.2, 27.7, 22.5; 













[b][1,4,5]oxathiazocine 1,1-dioxide (2.9.3{9}) 
 
According to general procedure I, 2.9.3{9} was isolated (84.7 mg, 76%) as a light brown 
solid; 
mp 152.0 ºC; 
[𝜶]𝑫𝟐𝟎  = -36.1 (c = 0.180, CH2Cl2); 
FTIR (thin film) 2972, 2953, 2928, 1597, 1495, 1435, 1381, 1327, 1142, 1107 cm-1; 
1H NMR (500 MHz, DMSO) δ ppm 7.47 (d, J = 8.9 Hz, 1H), 6.48 (dd, J = 8.9, 2.3 Hz, 
1H), 6.17 (d, J = 2.3 Hz, 1H), 5.06 (dd, J = 6.4, 2.6 Hz, 1H), 4.07–3.95 (m, 1H), 3.93 (d, 
J = 10.3 Hz, 1H), 3.44–3.34 (m, 3H), 3.30–3.22 (m, 5H), 3.22–3.06 (m, 3H), 2.05–1.88 
(m, 4H), 1.78 (dd, J = 14.3, 7.6 Hz, 1H); 
13C NMR (126 MHz, DMSO) δ ppm 152.6, 152.0, 131.2, 117.3, 107.9, 106.2, 80.5, 
72.4, 59.0, 58.1, 57.2, 48.5, 47.5, 28.8, 28.7, 23.1; 
HRMS calculated for C16H23N2O4S (M+H)+ 339.1379; found 339.1345 (TOF MS ES+). 
 
(5R)-8-((R)-3-hydroxypyrrolidin-1-yl)-4,5-dihydro-3H-2,5-methanobenzo[b][1,4,5]-

















According to general procedure I, 2.9.4{3} was isolated (70.0 mg, 69%) as a light yellow 
solid; 
mp 202.0 ºC; 
[𝜶]𝑫𝟐𝟎  = -49.2 (c = 0.240, CH2Cl2); 
FTIR (thin film) 3394, 2949, 2920, 2858, 1601, 1504, 1437, 1321, 1140, 1107 cm-1; 
1H NMR (400 MHz, DMSO) δ ppm 7.47 (d, J = 8.8 Hz, 1H), 6.37 (dd, J = 8.9, 2.4 Hz, 
1H), 6.09 (d, J = 2.3 Hz, 1H), 5.05 (dd, J = 6.3, 2.6 Hz, 1H), 5.01 (d, J = 3.6 Hz, 1H), 
4.39 (s, 1H), 3.99 (d, J = 13.9 Hz, 1H), 3.41 (dd, J = 10.8, 4.6 Hz, 1H), 3.36 (d, J = 7.0 
Hz, 1H), 3.27 (ddd, J = 11.9, 9.8, 4.0 Hz, 2H), 3.18 (dd, J = 13.9, 2.7 Hz, 1H), 3.14–3.06 
(m, 2H), 2.06–1.95 (m, 2H), 1.90 (dd, J = 9.7, 6.2 Hz, 1H), 1.81–1.71 (m, 1H); 
13C NMR (126 MHz, DMSO) δ ppm 152.1, 151.7, 130.8, 116.3, 106.8, 105.2, 80.0, 
69.0, 56.7, 55.9, 47.0, 45.5, 33.4, 28.1; 
HRMS calculated for C14H19N2O4S (M+H)+ 311.1066; found 311.1014 (TOF MS ES+). 
 
(5R)-10-((R)-3-hydroxypyrrolidin-1-yl)-4,5-dihydro-3H-2,5-methanobenzo[b][1,4,5]-
oxathiazocine 1,1-dioxide (2.9.5{3}) 
 
According to general procedure I, 2.9.5{3} was isolated (49.3 mg, 48%) as dark yellow 
oil; 










FTIR (neat) 3404, 3394, 2962, 2897, 1585, 1464, 1375, 1327, 1140, 1113 cm-1; 
1H NMR (500 MHz, DMSO) δ ppm 7.24 (t, J = 8.2 Hz, 1H), 6.72 (d, J = 8.6 Hz, 1H), 
6.37 (d, J = 7.7 Hz, 1H), 5.10 (d, J = 4.7 Hz, 1H), 4.86 (d, J = 4.1 Hz, 1H), 4.22 (dq, J = 
12.4, 6.4 Hz, 1H), 3.93 (d, J = 13.2 Hz, 1H), 3.51 (td, J = 9.5, 6.7 Hz, 1H), 3.42–3.35 (m, 
2H), 3.31–3.25 (m, 1H), 3.15 (ddd, J = 15.0, 10.6, 4.5 Hz, 1H), 3.06 (t, J = 12.1 Hz, 2H), 
2.10–2.01 (m, 2H), 1.90 (ddd, J = 14.7, 10.5, 5.9 Hz, 1H), 1.73 (dq, J = 11.5, 8.1 Hz, 
1H); 
13C NMR (126 MHz, DMSO) δ ppm 153.8, 151.0, 132.0, 119.9, 113.3, 112.2, 79.8, 
68.9, 59.8, 56.4, 49.7, 46.4, 33.5, 28.5; 
HRMS calculated for C14H19N2O4S (M+H)+ 311.1066; found 311.1028 (TOF MS ES+). 
 
(5S)-10-((R)-3-hydroxypyrrolidin-1-yl)-4,5-dihydro-3H-2,5-methanobenzo[b][1,4,5]-
oxathiazocine 1,1-dioxide (2.9.6{3}) 
 
According to general procedure I, 2.9.6{3} was isolated (54.1 mg, 53%) as light brown 
oil; 
[𝜶]𝑫𝟐𝟎  = -378.0 (c = 2.60, CH2Cl2); 
FTIR (neat) 3439, 3418, 1643, 1634, 1589, 1327, 1227, 1138 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.17 (dd, J = 8.4, 7.9 Hz, 1H), 6.71 (dd, J = 8.6, 1.0 










13.2 Hz, 1H), 3.87 (ddd, J = 14.2, 8.4, 5.4 Hz, 2H), 3.28–3.13 (m, 4H), 3.05 (dd, J = 
13.2, 1.2 Hz, 1H), 2.37 (s, 1H), 2.29–2.21 (m, 1H), 2.10–2.00 (m, 2H), 1.93–1.84 (m, 
1H); 
13C NMR (126 MHz, CDCl3) δ ppm 154.2, 152.0, 132.0, 121.3, 115.3, 113.3, 80.2, 71.1, 
61.7, 58.1, 49.6, 46.6, 33.9, 28.8; 
HRMS calculated for C14H19N2O4S (M+H)+ 311.1066; found 311.1051 (TOF MS ES+). 
 
(5S)-10-((R)-2-methylpyrrolidin-1-yl)-4,5-dihydro-3H-2,5-methanobenzo[b][1,4,5]-
oxathiazocine 1,1-dioxide (2.9.6{1}) 
 
According to general procedure I, 2.9.6{1} was isolated (70.8 mg, 70%) as a pale yellow 
solid; 
mp 139.0 ºC; 
[𝜶]𝑫𝟐𝟎  = -359.0 (c = 0.286, CH2Cl2); 
FTIR (thin film) 2964, 2928, 2889, 1583, 1460, 1373, 1333, 1227, 1142, 1115 cm-1; 
1H NMR (400 MHz, CDCl3) δ ppm 7.14 (dd, J = 8.5, 7.8 Hz, 1H), 6.72 (d, J = 8.1 Hz, 
1H), 6.36 (dd, J = 7.7, 1.0 Hz, 1H), 4.92 (d, J = 4.7 Hz, 1H), 4.42 (dd, J = 13.2, 2.3 Hz, 
1H), 4.03–3.91 (m, 2H), 3.32–3.24 (m, 1H), 3.20–3.11 (m, 2H), 3.04 (dd, J = 13.2, 1.2 











13C NMR (126 MHz, CDCl3) δ ppm 154.5, 151.6, 131.4, 121.8, 114.6, 113.5, 80.1, 58.4, 
55.7, 55.3, 46.4, 34.3, 28.7, 25.3, 19.1; 
HRMS calculated for C15H21N2O3S (M+H)+ 309.1273; found 309.1259 (TOF MS ES+). 
 
(5S)-10-((S)-2-(hydroxymethyl)pyrrolidin-1-yl)-4,5-dihydro-3H-2,5-methanobenzo-
[b][1,4,5]oxathiazocine 1,1-dioxide (2.9.6{5}) 
 
According to general procedure I, 2.9.6{5} was isolated (72.9 mg, 68%) as a white solid; 
mp 149.0 ºC; 
[𝜶]𝑫𝟐𝟎  = -128.0 (c = 0.530, CH2Cl2); 
FTIR (thin film) 3472, 2968, 2874, 1582, 1456, 1331, 1142, 1115, 1067 cm-1; 
1H NMR (400 MHz, CDCl3) δ ppm 7.21 (t, J = 8.1 Hz, 1H), 6.95 (d, J = 8.1 Hz, 1H), 
6.53 (dd, J = 7.9, 1.0 Hz, 1H), 4.97 (dd, J = 5.1, 1.3 Hz, 1H), 4.37 (d, J = 13.5 Hz, 1H), 
4.07 (t, J = 7.7 Hz, 1H), 3.98 (td, J = 9.5, 6.0 Hz, 1H), 3.77 (dd, J = 11.3, 2.9 Hz, 1H), 
3.42 (t, J = 10.0 Hz, 1H), 3.28–3.14 (m, 4H), 3.10 (dd, J = 13.5, 1.6 Hz, 1H), 2.26–2.17 
(m, 1H), 2.16–2.07 (m, 1H), 2.03 (ddd, J = 7.2, 5.6, 2.6 Hz, 1H), 2.00–1.88 (m, 2H), 
1.82–1.70 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ ppm 153.9, 151.6, 132.1, 125.6, 117.7, 115.9, 80.1, 61.3, 
60.7, 57.7, 57.3, 46.7, 29.0, 27.4, 25.7; 











[b][1,4,5]oxathiazocine 1,1-dioxide 2.9.6{8} 
 
According to general procedure I, 2.9.6{8} was isolated (86.3 mg, 78%) as dark brown 
oil; 
[𝜶]𝑫𝟐𝟎  = -449.0 (c = 0.152, CH2Cl2); 
FTIR (neat) 2955, 1637, 1585, 1464, 1375, 1331, 1223, 1142, 1115 cm-1; 
1H NMR (400 MHz, CDCl3) δ ppm 7.19–7.09 (m, 1H), 6.66 (d, J = 8.6 Hz, 1H), 6.40–
6.31 (m, 1H), 4.93 (d, J = 4.5 Hz, 1H), 4.41 (d, J = 13.2 Hz, 1H), 3.88 (td, J = 10.8, 6.2 
Hz, 1H), 3.58–3.46 (m, 2H), 3.40 (t, J = 9.0 Hz, 1H), 3.16 (dd, J = 8.8, 6.5 Hz, 2H), 3.04 
(d, J = 13.1 Hz, 1H), 2.74 (tt, J = 10.1, 6.1 Hz, 1H), 2.31 (s, 6H), 2.28–2.21 (m, 1H), 
2.20–2.11 (m, 1H), 1.91–1.72 (m, 2H); 
13C NMR (126 MHz, CDCl3) δ ppm 154.5, 151.9, 131.6, 120.0, 114.4, 112.1, 80.2, 65.5, 
58.4, 57.2, 52.3, 46.5, 44.6, 31.0, 29.7, 28.7; 






























































































































































































































































































































































































































































































































































































































































































































































































































Table of Mass Spectroscopy Data, Final Mass and Purity for all Library Compounds 




(mg) a Purity (%) 
2.9.3{1} 308.1195 309.1271 71.7 100 
2.9.3{2} 308.1195 309.1243 73.4 100 
2.9.3{3} 310.0987 311.1057 79.5 99.8 
2.9.3{4} 310.0987 311.1032 76.7 99.8 
2.9.3{5} 324.1144 325.1189 73.6 99.7 
2.9.3{6} 324.1144 325.1183 90.2 99.6 
2.9.3{7} 337.1460 338.1500 21.2 99.1 
2.9.3{8} 337.1460 338.1493 94.9 100 
2.9.3{9} 338.1300 339.1345 84.7 100 
2.9.3{10} 338.1300 339.1363 93.9 100 
2.9.4{1} 308.1195 309.1249 80.5 99.6 
2.9.4{2} 308.1195 309.1248 69.8 99.5 
2.9.4{3} 310.0987 311.1014 70.0 99.4 
2.9.4{4} 310.0987 311.1046 46.1 98.7 
2.9.4{5} 324.1144 325.1216 83.8 99.1 
2.9.4{6} 324.1144 325.1199 82.9 99 
2.9.4{7} 337.1460 338.1511 78.5 99.2 
2.9.4{8} 337.1460 338.1511 18.2 98.5 
2.9.4{9} 338.1300 339.1357 39.6 99.9 
2.9.4{10} 338.1300 339.1364 78.8 100 
2.9.5{1} 308.1195 309.1248 70.1 99.5 
2.9.5{2} 308.1195 309.1262 64.5 99.6 
2.9.5{3} 310.0987 311.1028 49.3 100 
2.9.5{4} 310.0987 311.1028 63.9 99.3 
2.9.5{5} 324.1144 325.1205 72.1 99.6 
2.9.5{6} 324.1144 325.1203 65.3 100 
2.9.5{7} 337.1460 338.1520 69.4 99.1 
2.9.5{8} 337.1460 338.1519 69.7 98.6 
2.9.5{9} 338.1300 339.1353 80.6 99.7 
2.9.5{10} 338.1300 339.1356 69.4 100 
2.9.6{1} 308.1195 309.1259 70.8 99.1 
2.9.6{2} 308.1195 309.1260 70.4 99 
2.9.6{3} 310.0987 311.1051 54.1 99.7 
2.9.6{4} 310.0987 311.1035 41.3 99.5 
2.9.6{5} 324.1144 325.1194 72.9 100 
2.9.6{6} 324.1144 325.1208 82.2 99.5 
2.9.6{7} 337.1460 338.1516 83.7 98.6 
2.9.6{8} 337.1460 338.1517 86.3 99.1 
356 
 
2.9.6{9} 338.1300 339.1367 88.5 99.1 
2.9.6{10} 338.1300 339.1368 83.5 99.7 
2.10.12{1} 336.1508 337.1580 79.8 100 
2.10.12{2} 336.1508 337.1584 79.4 100 
2.10.12{3} 338.1300 339.1339 75.8 100 
2.10.12{4} 338.1300 339.1344 79.1 100 
2.10.12{5} 352.1457 353.1510 85.7 100 
2.10.12{6} 352.1457 353.1508 83.1 100 
2.10.12{7} 365.1773 366.1813 18.7 98.2 
2.10.12{8} 365.1773 366.1826 49.2 99.9 
2.10.12{9} 366.1613 367.1661 85.3 99.1 
2.10.12{10} 366.1613 367.1680 83.7 99.1 
2.10.13{1} 336.1508 337.1581 66.1 98.8 
2.10.13{2} 336.1508 337.1578 69.5 98 
2.10.13{3} 338.1300 339.1376 77.2 97.6 
2.10.13{4} 338.1300 339.1356 61.0 97.7 
2.10.13{5} 352.1457 353.1501 68.6 99.7 
2.10.13{6} 352.1457 353.1519 67.7 99.6 
2.10.13{7} 365.1773 366.1834 76.2 96.9 
2.10.13{8} 365.1773 366.1840 75.2 98.1 
2.10.13{9} 366.1613 367.1668 76.1 100 
2.10.13{10} 366.1613 367.1677 81.5 99.9 
2.10.15{1} 350.1664 351.1730 72.7 99 
2.10.15{2} 350.1664 351.1709 44.2 99.5 
2.10.15{3} 352.1457 353.1500 74.0 97.7 
2.10.15{4} 352.1457 353.1539 61.8 97.7 
2.10.15{5} 366.1613 367.1680 76.9 98.7 
2.10.15{6} 366.1613 367.1686 76.7 98.6 
2.10.15{7} 379.1930 380.1978 46.5 99.5 
2.10.15{8} 379.1930 380.1995 77.9 99.3 
2.10.15{9} 380.1770 381.1831 67.4 99.9 
2.10.15{10} 380.1770 381.1830 92.6 100 
2.10.16{1} 350.1664 351.1712 50.8 98.6 
2.10.16{2} 350.1664 351.1700 33.9 98.6 
2.10.16{3} 352.1457 353.1500 49.9 99.6 
2.10.16{4} 352.1457 353.1517 42.7 99.6 
2.10.16{5} 366.1613 367.1684 70.1 99.6 
2.10.16{6} 366.1613 367.1682 46.1 99.4 
2.10.16{7} 379.1930 380.1976 37.9 95.5 
2.10.16{8} 379.1930 380.1981 127.4 97.3 
2.10.16{9} 380.1770 381.1844 34.6 99.6 
2.10.16{10} 380.1770 381.1821 22.3 98.9 
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 aLow yields obtained are due to several reasons including: 
1. Peaks having bad shouldering problems  
2. Only a small amount of the peak that could satisfies the 90% purity 
threshold 
3. Mechanical/instrumental error: over-pressured. 
 
In-Silico Analysis 
Sketched electronic versions of the library compounds were imported into the Tripos 
Molecular Spreadsheet [2] wherein standard Lipinski’s Rule of 5 parameters (molecular 
weight, ClogP, number of H-acceptors, and number of H-donors [3]) plus the number of 
rotatable bonds and polar surface area were computed.  Lipinski violations were specified 
according to molecular weight > 500, ClogP > 5.0, number of acceptors > 10, number of 
donors > 5, and number of rotatable bonds > 5.  The structures were then exported into 
SDF format and coverted into three-dimensional protonated structures via Concord [4].  
Absorption, distribution, metabolism and excretion (ADME) profiles of these compounds 
was then generated via Volsurf [5].  Descriptors were generated using three probes 
(water, hydrophobic and carbonyl oxygen) with a grid space distribution of 1.0 Å.  
Predictions were then projected onto internal ADME models at the 5-component level.  
Finally diversity analysis was carried out using DiverseSolutions [6] using standard H-
aware 3D BCUT descriptors.  The library was then projected onto a chemical space 
defined by the following descriptors:  gastchrg_invdist2_000.550_K_L, 
gastchrg_invdist6_000.500_K_H, haccept_invdist2_001.000_K_H, tabpolar_invdist_ 
000.250_K_H, tabpolar_invdist_000.500_K_L and populated (for comparison) by a 
recent version of the MLSMR screening set (ca. 7/2010; ~330,000 unique chemical 
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structures).  Diversity scores (div(A)) for our library were then generated for each of our 









where Nocc is the number of cells occupied by PubChem compounds in an evenly 
distributed 10×10×10×10×10 grid decomposition of the chemistry space, and pop(i) is the 
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0.46 0.44 1.10 -0.06 
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5.2 Experimental for Chapter 3 
General Procedure A: preparation of o-fluorobenzyl aziridinyl sulfonamides.  To a 
round bottom flask containing a solution of aziridine (2.2 mmol, 2.0 eq.) in dry CH2Cl2 
(0.5 M), was added Et3N (2.2 mmol, 2.0 eq.).  The reaction mixture was cooled to -40 ºC, 
stirred for 10 min and sulfonyl chloride (1.1 mmol, 1.0 eq.) was added to the reaction 
mixture in a drop-wise fashion. The reaction was then stirred for 0.5–2 h at -40 ºC after, 
which conversion of starting material was monitored by TLC.  Upon completion of 
reaction, the mixture was warmed to rt, quenched with cold water (2.2 mL) and the layers 
were separated.  The organic portion was washed with cold 10% aq. HCl and resulting 
layers were separated.  This partitioning was then repeated with cold water, cold sat. 
NaHCO3, cold water again and finally brine.  The final organic layer was dried (Na2SO4), 
and concentrated under reduced pressure to afford the desired aziridinyl sulfonamide. 
 
General Procedure B: one-pot, sequential (aziridine ring-opening and SNAr).  To a 
microwave vial containing a solution of aziridinyl sulfonamide (1.0 eq.) in DMF (0.3 M), 
was added amine/amino alcohol (1.05–1.2 eq.).  The reaction vessel was capped and 
heated in the Biotage® Initiator microwave at 130 ºC for 30–40 mins, after which, 
conversion of starting material was monitored by TLC.  To the crude mixture, DMF (0.08 
M) and Cs2CO3 (2.5 eq) were added and the mixture underwent microwave irradiation 
again at 150 ºC for 30–50 mins.  Water was added to the crude mixture, which was 
extracted with EtOAc (4x).  The organic layer was separated and the combined organic 
layers were washed with water, brine, dried (Na2SO4) and concentrated under reduced 
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pressure to afford the crude product, which was purified by automated flash column 
chromatography system. 
 
General Procedure C: one-pot, sequential (aziridine ring-opening and SNAr).  To a 
microwave vial containing a solution of sulfonamide (1.0 eq.) in DMF (0.3 M), was 
added amine/amino alcohol (1.05–1.2 eq.).  The reaction vessel was capped and heated in 
the Biotage® Initiator microwave at 130 ºC for 30–40 mins, after which, conversion of 
starting material was monitored by TLC.  To the crude mixture, Cs2CO3 (2.5 eq) was 
added and the mixture underwent microwave irradiation again at 150 ºC for 30–50 mins.  
Water was added to the crude mixture, which was extracted with EtOAc (4x).  The 
organic layer was separated and the combined organic layers were washed with water, 
brine, dried (Na2SO4) and concentrated under reduced pressure to afford the crude 
product, which was purified by automated flash column chromatography system. 
 
General Procedure D: Mitsunobu reaction.  To a flame-dried round bottom flask 
containing a solution of sultam (0.0466 mmol, 1.0 eq.) in dry THF (0.05 M), was added 
triphenylphosphine (0.140 mmol, 3.0 eq.).  The reaction mixture was stirred for 10 min 
and diisopropyl azodicarboxylate (0.117 mmol, 2.5 eq.) was added to the mixture in a 
drop-wise fashion.  The reaction was then stirred overnight at rt, which conversion of 
starting material was monitored by TLC.  The solvent was removed in vacuo to yield 







According to general procedure A, 3.8.4b (854.4 mg, 72%) was isolated as yellow oil.  
[𝜶]𝑫𝟐𝟎 = -47.6 (c = 0.675, CHCl3);  
FTIR (thin film) 3094, 2962, 1589, 1472, 1398, 1333, 1167,  879, 735 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.88–7.76 (m, 1H, aromatic), 7.53–7.41 (m, 2H, 
aromatic), 2.80 (dd, J = 7.1, 1.1 Hz, 1H, NCHaHbCH), 2.72 (ddd, J = 7.3, 7.2, 4.8 Hz, 1H, 
NCHCH), 2.24 (d, J = 4.8 Hz, 1H, NCHaHbCH), 1.59–1.39 (m, 1H, CH3CHCH3), 0.96 (d, 
J = 6.8 Hz, 3H, CH3CHCH3), 0.91 (d, J = 6.7 Hz, 3H, CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 159.1 (d, 1JC–F = 262.2 Hz), 131.4, 129.4 (d, 3JC–F = 
9.0 Hz), 127.9 (d, 3JC–F = 3.8 Hz), 121.0 (d, 2JC–F = 24.5 Hz), 120.5 (d, 2JC–F = 24.2 Hz), 
46.6, 33.8, 30.1, 19.5, 18.9;  





According to general procedure A, 3.8.4d (889.4 mg, 72%) was isolated as yellow oil.  
[𝜶]𝑫𝟐𝟎 = -5.0 (c = 1.43, CHCl3);  











1H NMR (500 MHz, CDCl3) δ ppm 8.10–7.85 (m, 1H, aromatic), 7.12–6.88 (m, 2H, 
aromatic), 2.80 (dd, J = 7.1, 1.1 Hz, 1H, NCHaHbCH), 2.70 (ddd, J = 7.3, 7.2, 4.6 Hz, 1H, 
NCHCH), 2.24 (d, J = 3.8 Hz, 1H, NCHaHbCH), 1.61–1.43 (m, 1H, CH3CHCH3), 0.96 (d, 
J = 6.8 Hz, 3H, CH3CHCH3), 0.90 (d, J = 6.7 Hz, 3H, CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 166.3 (dd, J = 258.5, 11.4 Hz), 160.4 (dd, J = 
260.8, 12.8 Hz), 132.4 (dd, J = 10.6, 1.6 Hz), 111.9 (dd, J = 22.0, 3.8 Hz), 105.8 (dd, J = 
25.5, 25.4 Hz), 105.4 (dd, J = 26.0, 25.9 Hz), 46.5, 33.7, 30.1, 19.4, 18.9;  




diazecine 1,1-dioxide (3.1.2a) 
 
According to general procedure B, 3.1.2a (38.7 mg, 66%) was isolated as a white solid.  
mp 192–195 ºC;  
[𝜶]𝑫𝟐𝟎 = +167.5 (c = 1.02, CHCl3);  
FTIR (thin film) 3267, 3090, 2966, 1576, 1558, 1462, 1400, 1323, 1165, 1059, 824, 
781, 748, 725 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.85 (d, J = 8.3 Hz, 1H, aromatic), 7.34–7.28 (m, 
2H, aromatic), 7.09 (s, 1H, NH), 4.41–4.31 (m, 2H, OCH2CH2), 2.73 (dddd, J = 9.2, 9.0, 
4.7, 4.6 Hz, 1H, NHCHCH2N), 2.66 (dd, J = 12.6, 4.9 Hz, 1H, NHCHCHaHbN), 2.58 









1.7, 1.6 Hz, 1H, NCHaHbCH2O), 2.24 (dd, J = 12.6, 10.5 Hz, 1H, NHCHCHaHbN), 1.85 
(ddd, J = 13.7, 9.4, 4.2 Hz, 1H, NHCHCHaHb), 1.62–1.49 (m, 1H, CH3CHCH3), 1.33 
(ddd, J = 13.8, 8.8, 5.0 Hz, 1H, NHCHCHaHb), 0.86 (d, J = 6.6 Hz, 3H, CH3CHCH3), 
0.73 (d, J = 6.6 Hz, 3H, CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 155.1, 132.8, 129.3, 128.4, 125.7, 120.6, 69.7, 60.0, 
53.2, 49.8, 44.3, 43.1, 24.4, 23.6, 21.9;  






According to general procedure B, 3.9.2b (41.0 mg, 70%) was isolated as a white solid.  
mp 175–180 ºC;  
[𝜶]𝑫𝟐𝟎 = +170.4 (c = 0.545, CHCl3);  
FTIR (thin film) 3263, 2968, 1578, 1560, 1452, 1371, 1323, 1163 1057, 820, 737 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.84 (d, J = 8.4 Hz, 1H, aromatic), 7.36–7.29 (m, 
2H, aromatic), 7.05 (s, 1H, NH), 4.43–4.27 (m, 2H, OCH2CH2), 2.68 (ddd, J = 11.2, 4.6, 
4.5 Hz, 1H, NHCHCH2N), 2.60 (ddd, J = 14.5, 10.6, 3.5 Hz, 1H, NHCHCHaHbN), 2.49 









NHCHCHaHbN, NCHaHbCH2O, CH3CHCH3), 0.98 (d, J = 6.9 Hz, 3H, CH3CHCH3), 0.79 
(d, J = 7.3 Hz, 3H, CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 155.2, 132.9, 129.2, 128.3, 125.7, 120.7, 69.7, 55.6, 
53.7, 53.1, 44.3, 28.9, 18.3, 15.6;  




diazecine 1,1-dioxide (3.9.2c) 
 
According to general procedure C, 3.9.2c (26.8 mg, 43%) was isolated as a white solid.  
mp 145–148 ºC;  
[𝜶]𝑫𝟐𝟎 = +148.7 (c = 0.87, CHCl3);  
FTIR (thin film) 3265, 2962, 1603, 1587, 1458, 1350, 1323, 1163, 1057, 818, 785, 733, 
704 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 7.99 (dd, J = 8.6, 6.4 Hz, 1H, aromatic), 7.07 (s, 1H, 
NH), 6.92–6.78 (m, 2H, aromatic), 4.46–4.19 (m, 2H, OCH2CH2), 2.70 (dddd, J = 9.0, 
8.8, 4.6, 4.4 Hz, 1H, NHCHCH2N), 2.65 (dd, J = 12.4, 4.9 Hz, 1H, NHCHCHaHbN), 2.58 
(ddd, J = 14.9, 8.9, 5.5 Hz, 1H, NCHaHbCH2O), 2.46 (s, 3H, NCH3), 2.34 (ddd, J = 15.1, 
1.8, 1.7 Hz, 1H, NCHaHbCH2O), 2.23 (dd, J = 12.4, 10.5 Hz, 1H, NHCHCHaHbN), 1.85 









(ddd, J = 13.8, 8.6, 5.0 Hz, 1H, NHCHCHaHb), 0.86 (d, J = 6.6 Hz, 3H, CH3CHCH3), 
0.72 (d, J = 6.6 Hz, 3H, CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 166.3 (d, 1JC–F = 254.8 Hz), 156.3 (d, 3JC–F = 10.5 
Hz), 133.7 (d, 3JC–F = 10.8 Hz), 126.2 (d, 4JC–F = 3.2 Hz), 109.7 (d, 2JC–F = 22.1 Hz), 104.9 
(d, 2JC–F = 25.0 Hz), 69.7, 60.0, 53.2, 49.9, 44.4, 43.1, 24.4, 23.6, 21.8;  






According to general procedure C, 3.9.2d (44.6 mg, 40%) was isolated as a white solid.  
mp 183–188 ºC;  
[𝜶]𝑫𝟐𝟎 = +128.8 (c = 0.745, CHCl3);  
FTIR (thin film) 3257, 2974, 1603, 1587, 1470, 1448, 1373, 1323, 1163, 1067, 818, 
777, 756, 729 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 7.99 (dd, J = 8.6, 6.4 Hz, 1H, aromatic), 7.04 (s, 1H, 
NH), 6.93–6.73 (m, 2H, aromatic), 4.43–4.25 (m, 2H, OCH2CH2), 2.71–2.56 (m, 2H, 
NHCHCH2N, NHCHCHaHbN), 2.50 (dd, J = 12.8, 5.0 Hz, 1H, NCHaHbCH2O), 2.47 (s, 
3H, NCH3), 2.37–2.29 (m, 3H, NHCHCHaHbN, NCHaHbCH2O, CH3CHCH3), 0.99 (d, J = 









13C NMR (126 MHz, CDCl3) δ ppm 166.3 (d, 1JC–F = 254.7 Hz), 156.4 (d, 3JC–F = 10.6 
Hz), 133.7 (d, 3JC–F = 10.8 Hz), 126.2 (d, 4JC–F = 3.4 Hz), 109.7 (d, 2JC–F = 22.1 Hz), 105.1 
(d, 2JC–F = 25.0 Hz), 69.7, 55.7, 53.8, 53.1, 44.4, 28.9, 18.4, 15.6;  




diazecine 1,1-dioxide (3.9.2e) 
 
According to general procedure B, 3.9.2e (45.8 mg, 51%) was isolated as yellow oil.  
[𝜶]𝑫𝟐𝟎  = +89.0 (c = 0.125, CHCl3);  
FTIR (thin film) 3149, 2962, 1587, 1469, 1371, 1307, 1222, 1161, 1060, 835, 729 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.95 (d, J = 2.7 Hz, 1H, aromatic), 7.50 (dd, J = 8.8, 
2.7 Hz, 1H, aromatic), 7.14 (s, 1H, NH), 7.12 (d, J = 8.9 Hz, 1H, aromatic), 4.39–4.29 
(m, 2H, OCH2CH2), 2.75–2.69 (m, 1H, NHCHCH2N), 2.56 (ddd, J = 14.5, 10.5, 3.6 Hz, 
1H, NCHaHbCH2O), 2.48 (dd, J = 12.6, 5.1 Hz, 1H, NCHaHbCH2O), 2.45 (s, 3H, NCH3), 
2.38–2.25 (m, 3H, NHCHCHaHb, NHCHCHaHbN, CH3CHCH3), 0.98 (d, J = 6.9 Hz, 3H, 
CH3CHCH3), 0.81 (d, J = 7.2 Hz, 3H, CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 153.2, 134.1, 131.6, 131.3, 127.5, 118.7, 69.7, 55.4, 















thiadiazecine 1,1-dioxide (3.9.2f) 
 
According to general procedure B, 3.9.2f (42.1 mg, 45%) was isolated as a white solid.  
mp 138–142 ºC;  
[𝜶]𝑫𝟐𝟎  = -93.2 (c = 0.125, CHCl3);  
FTIR (thin film) 2962, 1588, 1467, 1371, 1159, 1060, 831, 819, 750 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.95 (d, J = 2.7 Hz, 1H, aromatic), 7.50 (dd, J = 8.8, 
2.7 Hz, 1H, aromatic), 7.11 (d, J = 8.8 Hz, 1H, aromatic), 7.05 (s, 1H, NH), 4.44–4.24 
(m, 2H, OCH2CH2), 2.83–2.72 (m, 1H, NHCHCH2N), 2.58 (ddd, J = 14.5, 10.6, 3.5 Hz, 
1H, NCHaHbCH2O), 2.50 (dd, J = 12.6, 5.1 Hz, 1H, NCHaHbCH2O), 2.44 (s, 3H, NCH3), 
2.35–2.25 (m, 2H, NHCHCHaHbN, NHCHCHaHb), 2.01–1.92 (m, 1H, 
CH3CHCHaHbCH3), 1.92–1.82 (m, 1H, CH3CHCHaHbCH3), 1.03–0.95 (m, 1H, 
CH3CHCHaHbCH3), 0.95–0.90 (m, 3H, CH3CHCH2CH3), 0.80 (d, J = 7.1 Hz, 3H, 
CH3CHCH2CH3);  
13C NMR (126 MHz, CDCl3) δ ppm 153.3, 134.1, 131.6, 131.3, 127.5, 118.6, 69.6, 55.7, 
















3,1'-cyclohexane] 1,1-dioxide (3.9.2g) 
 
According to general procedure B, 3.9.2g (42.6 mg, 46%) was isolated as brown oil.  
FTIR (thin film) 3245, 2956, 2931, 1591, 1488, 1458, 1319, 1153, 1062, 821, 705 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.47 (ddd, J = 8.2, 8.2, 5.9 Hz, 1H, aromatic), 7.13 
(ddd, J = 8.2, 1.1, 1.0 Hz, 1H, aromatic), 6.98 (ddd, J = 10.5, 8.4, 1.1 Hz, 1H, aromatic), 
6.55 (s, 1H, NH), 5.61–5.56 (m, 1H, OCHaHbCH2), 3.79 (dd, J = 5.1, 4.9 Hz, 1H, 
OCHaHbCH2), 3.38 (d, J = 5.8 Hz, 2H, NCH2CH2O), 3.25–3.09 (m, 2H, NHCCH2N), 
2.82 (s, 3H, NCH3), 1.99–1.87 (m, 4H, cyclohexyl), 1.70–1.44 (m, 6H, cyclohexyl);  
13C NMR (126 MHz, CDCl3) δ ppm 160.3(d, 1JC–F = 257.2 Hz), 154.5, 133.5 (d, 3JC–F = 
11.2 Hz), 123.8 (d, 3JC–F = 10.2 Hz), 119.5 (d, 4JC–F = 3.2 Hz), 113.4 (d, 2JC–F = 24.5 Hz), 
59.5, 58.9, 50.1, 42.7, 26.4 (2C), 25.0, 22.4, 22.1 (2C);  















[1,4,5,8]oxathiadiazecine 8,8-dioxide (3.9.2h) 
 
According to general procedure C, 3.9.2h (57.7 mg, 57%) was isolated as colorless oil.  
[𝜶]𝑫𝟐𝟎 = -48.1 (c = 1.805, CHCl3);  
FTIR (thin film) 3275, 2955, 1578, 1466, 1317, 1159, 1063, 852, 733, 702 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 7.93–7.71 (m, 1H, aromatic), 7.26–7.18 (m, 2H, 
aromatic), 5.69 (s, 1H, NH), 4.48 (dd, J = 11.5, 3.3 Hz, 1H, OCHaHbCHN), 3.90 (dd, J = 
11.4, 11.3 Hz, 1H, OCHaHbCHN), 3.40–3.26 (m, 1H, NHCHCH2N), 3.17 (ddt, J = 12.0, 
8.1, 3.8 Hz, 1H, NCHCH2O), 3.14–3.03 (m, 1H, NCHaHbCH2CH2), 2.50–2.38 (m, 3H, 
NHCHCH2N, NCHaHbCH2CH2), 2.01–1.90 (m, 1H, NCH2CH2CHaHb), 1.88–1.77 (m, 3H, 
NCH2CH2CH2, CH3CHCH3), 1.67 (ddd, J = 14.3, 8.4, 6.2 Hz, 1H, NHCHCHaHb), 1.40 
(td, J = 11.4, 4.6 Hz, 1H, NCH2CH2CHaHb), 1.10 (ddd, J = 14.0, 7.8, 6.2 Hz, 1H, 
NHCHCHaHb), 0.90 (dd, J = 6.9, 6.8 Hz, 6H, CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 156.0, 131.1, 130.8, 128.0, 124.5, 118.2, 74.0, 62.8, 
61.4, 56.7, 55.5, 40.9, 27.4, 24.7, 24.7, 22.7, 22.3;  













h][1,4,5,8]oxathia-diazecine 8,8-dioxide (3.9.2i) 
 
According to general procedure C, 3.9.2i (26.1 mg, 37%) was isolated as semi-white 
sticky oil.  
[𝜶]𝑫𝟐𝟎 = -6.6 (c = 1.33, CHCl3);  
FTIR (thin film) 3300, 2961, 1603, 1587, 1468, 1387, 1323, 1157, 1070, 839 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.99–7.76 (m, 1H, aromatic), 6.82–6.64 (m, 2H, 
aromatic), 4.84 (d, J = 6.9 Hz, 1H, NH), 4.45 (dd, J = 11.6, 3.1 Hz, 1H, OCHaHbCHN) 
3.99 (dd, J = 11.2, 11.1 Hz, 1H, OCHaHbCHN), 3.32 (ddd, J = 11.3, 5.9, 5.7 Hz, 1H, 
NHCHCH2N), 3.08 (dddd, J = 11.2, 8.7, 5.8, 3.1 Hz, 1H, NCHCH2O), 2.97 (ddd, J = 9.6, 
6.2, 4.5 Hz, 1H, NCHaHbCH2CH2), 2.71 (dd, J = 14.4, 5.6 Hz, 1H, NHCHCHaHbN), 2.56–
2.43 (m, 2H, NCHaHbCH2CH2, NHCHCHaHbN), 2.00–1.85 (m, 2H, CH3CHCH3, 
NCH2CH2CHaHb), 1.79–1.69 (m, 2H, NCH2CH2CH2), 1.45–1.31 (m, 1H, 
NCH2CH2CHaHb), 0.97 (dd, J = 6.9, 4.4 Hz, 6H, CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 166.0 (d, 1JC–F = 253.8 Hz), 157.5 (d, 3JC–F = 10.8 
Hz), 132.0 (d, 3JC–F = 10.9 Hz), 126.7 (d, 4JC–F = 3.2 Hz), 107.9 (d, 2JC–F = 22.2 Hz), 102.6 
(d, 2JC–F = 25.6 Hz), 74.0, 64.9, 62.8, 59.4, 57.5, 31.3, 27.2, 23.8, 18.7, 18.2;  












[1,2-h][1,4,5,8]oxathiadiazecine 8,8-dioxide (3.9.2j) 
 
According to general procedure B, 3.9.2j (54.4 mg, 54%) was isolated as yellow oil.  
[𝜶]𝑫𝟐𝟎  = -68.4 (c = 0.125, CHCl3);  
FTIR ((thin film) 2962, 2875, 1598, 1467, 1407, 1380, 1338, 1163, 1064, 786, 761 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.91 (d, J = 2.7 Hz, 1H, aromatic), 7.46 (dd, J = 8.8, 
2.7 Hz, 1H, aromatic), 7.06 (d, J = 8.8 Hz, 1H, aromatic), 6.85 (d, J = 5.7 Hz, 1H, NH), 
4.35 (dd, J = 11.8, 3.2 Hz, 1H, OCHaHbCHN), 3.90 (t, J = 11.6 Hz, 1H, OCHaHbCHN), 
3.20–2.95 (m, 2H, NHCHCH2N, NCHCH2O), 2.92–2.78 (m, 1H, NCHaHbCH2CH2), 
2.63–2.50 (m, 2H, NHCHCHaHbN, NCHaHbCH2CH2), 2.41 (dd, J = 13.5, 5.1 Hz, 1H, 
NHCHCHaHbN), 2.02–1.86 (m, 1H, NCH2CHaHbCH2), 1.86–1.75 (m, 2H, 
NCH2CHaHbCH2, NCH2CHaHbCHaHb), 1.76–1.62 (m, 2H, NCH2CHaHbCHaHb, 
CH3CHCHaHbCH3), 1.40–1.29 (m, 1H, CH3CHCHaHbCH3), 1.11–0.97 (m, 1H, 
CH3CHCHaHbCH3), 0.95 (d, J = 6.8 Hz, 3H, CH3CHCH2CH3), 0.90 (t, J = 7.3 Hz, 3H, 
CH3CHCH2CH3);  
13C NMR (126 MHz, CDCl3) δ ppm 153.1, 133.6, 131.6, 130.3, 126.7, 116.4, 73.5, 61.9, 
58.0, 57.2, 55.7, 37.0, 27.0, 25.4, 24.2, 15.8, 11.6;  














[1,2-h][1,4,5,8]oxathia-diazecine 8,8-dioxide (3.9.2k) 
 
According to general procedure B, 3.9.2k (54.9 mg, 57%) was isolated as a yellow/white 
solid.  
mp 152–156 ºC;  
[𝜶]𝑫𝟐𝟎  = -58.3 (c = 0.125, CHCl3);  
FTIR ((thin film) 2962, 2875, 1598, 1467, 1380, 1338, 1163, 1064, 786, 761 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.42 (ddd, J = 8.4, 5.8 Hz, 1H, aromatic), 7.07 (d, J 
= 6.2 Hz, 1H, NH), 6.89 (ddd, J = 8.5, 1.1, 1.1 Hz, 1H, aromatic), 6.82 (ddd, J = 9.6, 8.4, 
1.0 Hz, 1H, aromatic), 4.42 (dd, J = 11.8, 3.2 Hz, 1H, OCHaHbCHN), 3.92 (dd, J = 11.5, 
11.2 Hz, 1H, OCHaHbCHN), 3.19–3.04 (m, 2H, NHCHCH2N, NCHCH2O), 3.03–2.93 
(m, 1H, NCHaHbCH2CH2), 2.64 (dd, J = 13.8, 5.4 Hz, 1H, NHCHCHaHbN), 2.57 (ddd, J 
= 9.3, 9.2, 6.1 Hz, 1H, NCHaHbCH2CH2), 2.46 (dd, J = 13.8, 4.9 Hz, 1H, 
NHCHCHaHbN), 1.99–1.88 (m, 1H, NCH2CHaHbCH2), 1.88–1.61 (m, 4H, 
NCH2CHaHbCH2, NCH2CHaHbCH2, CH3CHCHaHbCH3), 1.38 (dddd, J = 13.1, 6.8, 3.6, 
3.5 Hz, 1H, CH3CHCHaHbCH3), 1.10–1.00 (m, 1H, CH3CHCHaHbCH3), 0.99 (d, J = 6.8 
Hz, 3H, CH3CHCH2CH3), 0.89 (t, J = 7.3 Hz, 3H, CH3CHCH2CH3);  
13C NMR (126 MHz, CDCl3) δ ppm 161.1 (d, 1JC–F = 259.8 Hz), 155.6, 133.5 (d, 3JC–F = 
11.0 Hz), 119.2 (d, 3JC–F = 13.1 Hz), 110.6 (d, 2JC–F = 24.2 Hz), 109.9 (d, 4JC–F = 3.6 Hz), 














h][1,4,5,8]oxathia-diazecine 8,8-dioxide (3.9.2l) 
 
According to general procedure B, 3.9.2l (25.7 mg, 42%) was isolated as colorless oil.  
[𝜶]𝑫𝟐𝟎 = +74.4 (c = 0.36, CHCl3);  
FTIR (thin film) 3286, 2962, 1603, 1587, 1475, 1383, 1329, 1163, 1070, 735, 698 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.94 (dd, J = 8.6, 6.5 Hz, 1H, aromatic), 6.92–6.76 
(m, 3H, aromatic, NH), 4.33 (dd, J = 11.9, 3.3 Hz, 1H, OCHaHbCHN), 3.92 (dd, J = 11.8, 
11.7 Hz, 1H, OCHaHbCHN), 3.16 (ddd, J = 10.2, 5.5, 4.8 Hz, 1H, NHCHCH2N), 3.06 
(ddt, J = 11.9, 8.6, 3.1 Hz, 1H, NCHCH2O), 2.71 (dt, J = 11.9, 5.9 Hz, 1H, 
NCHaHbCH2CH2), 2.64–2.50 (m, 2H, NCHaHbCH2CH2, NHCHCHaHbN), 2.37 (dd, J = 
13.5, 5.0 Hz, 1H, NHCHCHaHbN), 2.02–1.89 (m, 2H, CH3CHCH3, NCH2CH2CHaHb), 
1.87–1.78 (m, 2H, NCH2CH2CH2), 1.36 (ddt, J = 12.6, 6.6, 3.4 Hz, 1H, 
NCH2CH2CHaHb), 0.95 (dd, J = 17.2, 6.8 Hz, 6H, CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 166.0 (d, 1JC–F = 254.3 Hz), 156.2 (d, 3JC–F = 10.5 
Hz), 132.5 (d, 3JC–F = 10.8 Hz), 126.4 (d, 4JC–F = 3.3 Hz), 108.8 (d, 2JC–F = 22.2 Hz), 103.1 













oxathiadiazecine-6,1'-cyclohexane] 8,8-dioxide (3.9.2m) 
 
According to general procedure B, 3.9.2m (53.0 mg, 51%) was isolated as a white solid.  
mp 154–159 ºC;  
[𝜶]𝑫𝟐𝟎  = -24.0 (c = 0.125, CHCl3);  
FTIR (thin film) 2937, 1585, 1465, 1315, 1228, 1157, 1064, 819, 732 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.92 (d, J = 2.7 Hz, 1H, aromatic), 7.45 (dd, J = 8.8, 
2.7 Hz, 1H, aromatic), 7.05 (d, J = 8.8 Hz, 1H, aromatic), 6.30 (s, 1H, NH), 4.46 (dd, J = 
11.9, 3.2 Hz, 1H, OCHaHbCHN), 3.93 (dd, J = 11.8, 11.5 Hz, 1H, OCHaHbCHN), 3.24–
3.18 (m, 1H, NCHCH2O), 3.13 (dddd, J = 12.2, 9.3, 3.4, 3.3 Hz, 1H, NCHaHbCH2CH2), 
2.50–2.37 (m, 2H, NHCCHaHbN, NCHaHbCH2CH2), 2.17 (d, J = 14.1 Hz, 1H, 
NHCCHaHbN), 2.03–1.86 (m, 2H, NCH2CHaHbCHaHb, NCH2CH2CHaHb), 1.84–1.76 (m, 
2H, NCH2CHaHbCHaHb, NCH2CH2CHaHb), 1.75–1.63 (m, 2H, cyclohexyl), 1.58–1.50 
(m, 1H, cyclohexyl), 1.50–1.41 (m, 1H, cyclohexyl), 1.41–1.20 (m, 5H, cyclohexyl), 
1.14–1.04 (m, 1H, cyclohexyl);  
13C NMR (126 MHz, CDCl3) δ ppm 153.0, 133.6, 133.3, 129.6, 126.5, 116.3, 73.6, 63.7, 














h][1,4,5,8]oxathia-diazecine 5,5-dioxide (3.9.2n) 
 
According to general procedure C, 3.9.2n (44.7 mg, 36%) was isolated as sticky colorless 
oil.  
[𝜶]𝑫𝟐𝟎 = +30.1 (c = 0.59, CHCl3);  
FTIR (thin film) 3259, 2934, 1578, 1464, 1391, 1327, 1159, 1063, 812, 762, 733 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 7.80 (d, J = 8.3 Hz, 1H, aromatic), 7.29 (d, J = 1.8 
Hz, 1H, aromatic), 7.20 (d, J = 1.8 Hz, 1H, aromatic), 4.39 (dd, J = 10.7, 4.6 Hz, 1H, 
OCHaHbCHN), 3.75–3.60 (m, 1H, OCHaHbCHN), 3.42–3.25 (m, 1H, NCHCH2O), 2.79–
2.60 (m, 4H, NCH2CH2CH2CH2, NHCHCH2N, NHCHCHaHbN), 2.49–2.31 (m, 1H, 
NHCHCHaHbN), 1.99–1.86 (m, 1H, CH3CHCH3), 1.87–1.77 (m, 1H, 
NCH2CH2CHaHbCH2), 1.59–1.36 (m, 4H, NCH2CH2CHaHbCHaHb), 1.30–1.16 (m, 1H, 
NCH2CH2CH2CHaHb), 0.94 (d, J = 6.8 Hz, 3H, CH3CHCH3), 0.89 (d, J = 7.0 Hz, 3H, 
CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 156.5, 131.9, 127.7, 127.7, 125.7, 120.3, 73.7, 59.4, 














h][1,4,5,8]oxathiadiazacycloundecine 5,5-dioxide (3.9.2o) 
 
According to general procedure C, 3.9.2o (14.5 mg, 20%) was isolated as light yellow 
oil.  
[𝜶]𝑫𝟐𝟎 = +132.4 (c = 0.69, CHCl3);  
FTIR (thin film) 3202, 2935, 1580, 1470, 1389, 1325, 1163, 1065, 812, 733 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.82 (d, J = 8.3 Hz, 1H, aromatic), 7.21 (dd, J = 8.3, 
1.7 Hz, 1H, aromatic), 7.13 (d, J = 1.7 Hz, 1H, aromatic), 6.68 (s, 1H, NH), 4.56 (ddd, J 
= 11.9, 9.9, 4.4 Hz, 1H, OCHaHbCH2CHN), 4.43 (ddd, J = 11.9, 4.7, 4.6 Hz, 1H, 
OCHaHbCH2CHN), 3.20–2.99 (m, 2H, NHCHCHaHbN, NCHaHbCH2CH2CH2), 2.81 (ddd, 
J = 12.8, 8.9, 4.3 Hz, 1H, NHCHCH2N), 2.50 (dt, J = 14.1, 3.9 Hz, 1H, 
NCHaHbCH2CH2CH2), 2.35 (dt, J = 12.9, 4.4 Hz, 1H, NCHCH2CH2O), 2.15–2.05 (m, 2H, 
NHCHCHaHbN, NCHCHaHbCH2O), 2.01 (dt, J = 15.1, 5.0 Hz, 1H, NCHCHaHbCH2O), 
1.94 (ddd, J = 13.6, 9.2, 4.1 Hz, 1H, NCH2CH2CHaHbCH2), 1.77–1.68 (m, 1H, 
NCH2CH2CH2CHaHb), 1.68–1.50 (m, 4H, NCH2CH2CH2CH2, CH3CHCH3, 










1H, NCH2CH2CH2CHaHb), 0.87 (d, J = 6.6 Hz, 3H, CH3CHCH3), 0.79 (d, J = 6.6 Hz, 3H, 
CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 154.5, 132.3, 128.1, 126.3, 123.7, 116.2, 65.5, 55.5, 
50.5 (2C), 49.0, 43.6, 28.1, 24.7, 23.9, 23.5, 22.0, 21.3, 20.6;  




pyrido[1,2-h][1,4,5,8]oxa-thiadiazacycloundecine 5,5-dioxide (3.9.2p) 
 
According to general procedure C, 3.9.2p (23.3 mg, 22%) was isolated as a white solid.  
mp 152–157 ºC;  
[𝜶]𝑫𝟐𝟎 = +107.4 (c = 0.81, CHCl3);  
FTIR (thin film) 3205, 2934, 1580, 1470, 1387, 1327, 1163, 1065, 821, 733 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 7.81 (d, J = 8.3 Hz, 1H, aromatic), 7.20 (dd, J = 8.3, 
1.7 Hz, 1H, aromatic), 7.13 (d, J = 1.7 Hz, 1H, aromatic), 6.62 (s, 1H, NH), 4.54 (ddd, J 
= 11.6, 9.4, 4.4 Hz, 1H, OCHaHbCH2CHN), 4.40 (ddd, J = 11.6, 5.0, 4.9 Hz, 1H, 
OCHaHbCH2CHN), 3.17–3.03 (m, 1H, NCHaHbCH2CH2CH2), 2.96 (dd, J = 12.9, 4.6 Hz, 
1H, NHCHCHaHbN), 2.73 (ddd, J = 10.4, 4.6, 4.4 Hz, 1H, NHCHCH2N), 2.51 (d, J = 
14.3 Hz, 1H, NCHaHbCH2CH2CH2), 2.47–2.32 (m, 2H, CH3CHCH3, NCHCH2CH2O), 
2.29–2.08 (m, 2H, NHCHCHaHbN, NCHCHaHbCH2O), 1.95 (dddd, J = 14.6, 9.3, 5.1, 4.9 










NCH2CHaHbCH2CH2), 1.37–1.20 (m, 1H, NCH2CHaHbCH2CH2), 1.19–1.09 (m, 1H, 
NCH2CH2CH2CHaHb), 0.98 (d, J = 6.9 Hz, 3H, CH3CHCH3), 0.87 (d, J = 7.2 Hz, 3H, 
CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 154.8, 132.4, 128.1, 126.3, 123.7, 116.3, 66.0, 55.1, 
50.4, 50.2, 49.4, 29.1, 28.4, 23.6, 21.1, 20.5, 18.9, 15.6;  




[b][1,4,5,8]oxathia-diazecine 1,1-dioxide (3.10.2a) 
 
According to general procedure C, 3.10.2a (37.2 mg, 46%) was isolated as sticky 
colorless oil.  
[𝜶]𝑫𝟐𝟎 = +43.1 (c = 1.145, CHCl3);  
FTIR (thin film) 3267, 2962, 1603, 1585, 1475, 1454, 1371, 1323, 1163, 1068, 812, 
764, 737, 704 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 8.02 (dd, J = 8.8, 6.5 Hz, 1H, aromatic), 7.60–7.54 
(m, 2H, aromatic), 7.48 (s, 1H, NH), 7.45–7.35 (m, 3H, aromatic), 6.94 (dd, J = 10.3, 2.4 
Hz, 1H, aromatic), 6.87 (ddd, J = 8.7, 7.7, 2.3 Hz, 1H, aromatic), 5.25 (d, J = 2.5 Hz, 1H, 











NHCHCH2N), 2.55 (dd, J = 12.9, 5.2 Hz, 1H, NHCHCHaHbN), 2.32 (m, 1H, 
CH3CHCH3), 2.11 (dd, J = 12.1, 12.0 Hz, 1H, NHCHCHaHbN), 1.51 (s, 3H, NCH3), 1.09 
(d, J = 7.1 Hz, 3H, NCHCH3), 0.98 (d, J = 6.9 Hz, 3H, CH3CHCH3), 0.78 (d, J = 7.2 Hz, 
3H, CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 166.3 (d, 1JC–F = 254.6 Hz), 155.6 (d, 3JC–F = 10.7 
Hz), 135.0, 134.0 (d, 3JC–F = 10.8 Hz), 128.4, 128.3 (2C), 127.1 (2C), 125.1 (d, 4JC–F = 3.4 
Hz), 109.5 (d, 2JC–F = 22.0 Hz), 104.3 (d, 2JC–F = 25.2 Hz), 85.3, 56.7, 55.1, 52.9, 38.9, 
28.6, 18.3, 15.5, 10.6;  




[b][1,4,5,8]oxathia-diazecine 1,1-dioxide (3.10.2b) 
 
According to general procedure B, 3.10.2b (39.0 mg, 47%) was isolated as a white solid.  
mp 87–93 ºC;  
[𝜶]𝑫𝟐𝟎 = +12.8 (c = 0.69, CHCl3);  
FTIR (thin film) 3300, 2962, 1603, 1583, 1479, 1456, 1369, 1325, 1157, 1068, 843, 
770, 735, 700 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 7.97 (dd, J = 8.8, 6.6 Hz, 1H, aromatic), 7.56–7.45 











aromatic), 6.66 (dd, J = 10.6, 2.4 Hz, 1H, aromatic), 6.47 (s, 1H, NH), 4.78 (d, J = 9.9 
Hz, 1H, OCHPh), 3.10 (dq, J = 9.8, 6.5 Hz, 1H, NCHCH3), 2.82–2.59 (m, 2H, 
NHCHCH2N, NHCHCHaHbN), 2.40 (dd, J = 13.9, 7.2 Hz, 1H, NHCHCHaHbN), 2.15 (s, 
3H, NCH3), 1.98–1.79 (m, 1H, CH3CHCH3), 0.97 (d, J = 6.9 Hz, 6H, CH3CHCH3), 0.86 
(d, J = 6.6 Hz, 3H, NCHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 165.9 (d, 1JC–F = 253.7 Hz), 158.7 (d, 3JC–F = 10.8 
Hz), 138.5, 133.0 (d, 3JC–F = 10.7 Hz), 129.0 (2C), 128.8, 127.1 (2C), 124.2 (d, 4JC–F = 3.2 
Hz), 108.5 (d, 2JC–F = 22.0 Hz), 104.7 (d, 2JC–F = 25.3 Hz), 88.3, 67.8, 58.4, 52.5, 37.7, 
32.1, 19.0, 17.7, 10.6;  




[b][1,4,5,8]oxathia-diazecine 1,1-dioxide (3.10.2c) 
 
According to general procedure C, 3.10.2c (9.7 mg, 13%) was isolated as colorless oil.  
[𝜶]𝑫𝟐𝟎 = +73.2 (c = 0.335, CHCl3);  
FTIR (thin film) 3285, 2964, 1578, 1468, 1452, 1319, 1155, 1064, 804, 756, 702 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 7.78 (d, J = 8.4 Hz, 1H, aromatic), 7.52–7.47 (m, 
2H, aromatic), 7.46–7.40 (m, 2H, aromatic), 7.40–7.33 (m, 1H, aromatic), 7.07 (dd, J = 











OCHPh), 4.41 (s, 1H, NH), 4.01 (bs, 1H, NHCHCH2N), 3.19–3.08 (m, 1H, NCHCH3), 
2.78 (dd, J = 13.3, 2.9 Hz, 1H, NHCHCHaHbN), 2.23 (m, 4H, NHCHCHaHbN, NCH3), 
1.96–1.79 (m, 1H, CH3CHCH3), 1.09 (d, J = 6.8 Hz, 3H, CH3CHCH3), 1.00 (d, J = 6.9 
Hz, 3H, CH3CHCH3), 0.75 (d, J = 7.0 Hz, 3H, NCHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 157.8, 138.5, 131.0, 130.8, 128.9 (2C), 128.6, 
127.7, 126.7 (2C), 123.4, 118.8, 87.0, 60.4, 58.8, 58.0, 37.3, 32.3, 19.0, 18.0, 10.4;  




[b][1,4,5,8]oxathia-diazecine 1,1-dioxide (3.10.2d) 
 
According to general procedure C, 3.10.2d (33.2 mg, 30%) was isolated as a white solid.  
mp 165–169 ºC;  
[𝜶]𝑫𝟐𝟎 = +20.0 (c = 0.145, CHCl3);  
FTIR (thin film) 3265, 2960, 1602, 1586, 1473, 1451, 1373, 1323, 1163, 1066, 815, 
762, 734, 706 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 7.94 (dd, J = 8.8, 6.6 Hz, 1H, aromatic), 7.51–7.31 
(m, 5H, aromatic), 6.65 (ddd, J = 8.5, 8.3, 2.4 Hz, 1H, aromatic), 6.52 (dd, J = 10.4, 2.4 
Hz, 1H, aromatic), 4.68 (d, J = 9.3 Hz, 1H, OCHPh), 4.40 (d, J = 7.3 Hz, 1H, NH), 4.18 











Hz, 1H, NHCHCHaHbN), 2.26 (s, 3H, NCH3), 2.22–2.14 (m, 1H, NHCHCHaHbN), 1.94 
(dt, J = 13.3, 6.7 Hz, 1H, CH3CHCH3), 1.50 (dd, J = 14.0, 7.0 Hz, 1H, NHCHCHaHb), 
1.32 (ddd, J = 13.9, 7.7, 6.0 Hz, 1H, NHCHCHaHb), 1.04 (d, J = 6.6 Hz, 3H, 
CH3CHCH3), 1.02 (d, J = 6.8 Hz, 3H, CH3CHCH3), 0.77 (d, J = 7.0 Hz, 3H, NCHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 165.9 (d, 1JC–F = 253.3 Hz), 158.7 (d, 3JC–F = 11.0 
Hz), 138.6, 131.6 (d, 3JC–F = 10.9 Hz), 129.0 (2C), 128.6, 127.9 (d, 4JC–F = 3.5 Hz), 126.7 
(2C), 107.3 (d, 2JC–F = 22.3 Hz), 103.2 (d, 2JC–F = 25.5 Hz), 86.9, 60.9, 60.7, 52.5, 45.4, 
37.2, 24.7, 23.1, 22.8, 10.9;  






According to general procedure B, 3.10.2e (26.6 mg, 39%) was isolated as a white solid.  
mp 133–137 ºC;  
[𝜶]𝑫𝟐𝟎 = +106.8 (c = 0.825, CHCl3);  
FTIR (thin film) 2957, 1601, 1585, 1475, 1387, 1325, 1165, 1068, 849, 731 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 8.04–7.96 (m, 1H, aromatic), 7.22 (s, 1H, NH), 
6.89–6.83 (m, 2H, aromatic), 4.22–4.08 (m, 2H, OCH2CHN), 2.86 (dd, J = 13.0, 4.8 Hz, 










1H, NCHCH2), 2.35 (s, 3H, NCH3), 2.13 (dd, J = 13.0, 11.0 Hz, 1H, NHCHCHaHbN), 
1.87 (ddd, J = 13.7, 9.8, 3.7 Hz, 1H, NHCHCHaHb), 1.64–1.44 (m, 2H, NHCHCH2CH, 
NCHCH2CH), 1.39–1.20 (m, 2H, NHCHCHaHb, NCHCHaHb), 1.10 (ddd, J = 14.2, 8.7, 
5.8 Hz, 1H, NCHCHaHb), 0.91 (d, J = 6.6 Hz, 3H, CH3CHCH3), 0.85 (d, J = 6.6 Hz, 3H, 
CH3CHCH3), 0.77 (d, J = 6.6 Hz, 3H, CH3CHCH3), 0.71 (d, J = 6.5 Hz, 3H, CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 166.2 (d, 1JC–F = 254.8 Hz), 156.6 (d, 3JC–F = 10.5 
Hz), 133.6 (d, 3JC–F = 10.6 Hz), 126.1 (d, 4JC–F = 3.4 Hz), 109.6 (d, 2JC–F = 22.1 Hz), 104.6 
(d, 2JC–F = 25.0 Hz), 71.4, 57.7, 55.0, 49.4, 42.8, 36.1, 34.8, 25.3, 24.4, 23.7, 23.1, 22.0, 
21.5;  




oxathiadiazecine-6,1'-cyclohexane] 1,1-dioxide (3.10.2f) 
 
According to general procedure B, 3.10.2f (30.9 mg, 46%) was isolated as sticky 
colorless oil.  
[𝜶]𝑫𝟐𝟎 = +8.7 (c = 0.695, CHCl3);  
FTIR (thin film) 2953, 1605, 1589, 1468, 1425, 1391, 1317, 1159, 1070, 847, 733 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.97 (dd, J = 8.7, 6.5 Hz, 1H, aromatic), 6.84 (ddd, J 










10.2 Hz, 1H, OCHaHbC), 3.70 (d, J = 9.8 Hz, 1H, OCHaHbC), 2.99–2.84 (m, 2H, NHCH, 
NCHaHb), 2.43 (s, 3H, NCH3), 2.25–2.12 (m, 1H, NCHaHb), 1.94–1.66 (m, 8H, 
NHCHCH2CH, NHCHCHaHb, cyclohexyl), 1.64–1.47 (m, 1H, cyclohexyl), 1.43 (d, J = 
12.8 Hz, 1H, cyclohexyl), 1.36–1.11 (m, 3H, NHCHCHaHb, cyclohexyl), 0.84 (dd, J = 
6.6, 6.5 Hz, 6H, CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 165.9 (d, 1JC–F = 254.3 Hz), 157.7 (d, 3JC–F = 10.6 
Hz), 132.5 (d, 3JC–F = 10.7 Hz), 124.8, 109.3 (d, 2JC–F = 22.0 Hz), 104.2 (d, 2JC–F = 24.9 
Hz), 73.2, 59.8, 52.5, 49.3, 47.3, 36.8, 30.6, 28.1, 25.5, 24.3, 23.1, 22.8, 22.7, 22.4;  






According to general procedure B, 3.11.2a (33.1 mg, 44%) was isolated as yellow oil.  
[𝛼]!!"  = -140.3 (c = 0.125, CHCl3);  
FTIR (thin film) 3267, 2927, 1595, 1461, 1325, 1161, 790, 732 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.77 (d, J = 8.1 Hz, 1H, aromatic), 6.84 (s, 1H), 6.81 
(ddd, J = 8.0, 1.5, 0.7 Hz, 1H), 4.18 (d, J = 9.2 Hz, 1H, NHCHCH2N), 3.46 (dd, J = 14.8, 
2.5 Hz, 1H, NHCHCH2N), 3.41–3.24 (m, 2H, NHCHCHaHbN, NCHaHbCH2CH3), 3.18 








NHCHCHaHbN), 2.35 (s, 3H, PhCH3), 2.02–1.85 (m, 1H, CH3CHCH3), 1.66 (ddddd, J = 
7.3, 7.3, 7.3, 7.3, 7.3 Hz, 2H, NCH2CH2CH3), 1.04 (dd, J = 6.8, 5.0 Hz, 6H, CH3CHCH3), 
0.99 (t, J = 7.3 Hz, 3H, NCH2CH2CH3); 
13C NMR (126 MHz, CDCl3) δ ppm 148.6, 143.5, 131.1, 128.4, 121.7, 119.8, 61.4, 56.9, 
56.0, 30.3, 21.7, 21.5, 19.6, 19.0, 11.5;  





According to general procedure B, 3.11.2b (29.0 mg, 50%) was isolated as colorless oil.  
[𝛼]!!"  = -90.2 (c = 3.3, CHCl3);  
FTIR (thin film) 3258, 2957, 1578, 1468, 1369, 1319, 1151, 802, 733 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 7.68 (d, J = 8.5 Hz, 1H, aromatic), 7.12 (d, J = 1.8 
Hz, 1H, aromatic), 7.07 (dd, J = 8.5, 1.7 Hz, 1H, aromatic), 4.33 (d, J = 8.1 Hz, 1H, NH), 
3.68–3.55 (m, 1H, NHCHCH2N), 3.51 (dd, J = 15.2, 2.9 Hz, 1H, NHCHCHaHbN), 3.45–
3.34 (m, 1H, NCHaHbCH2CH2CH3), 3.28–3.17 (m, 1H, NCHaHbCH2CH2CH3), 3.05 (dd, J 
= 15.2, 8.3 Hz, 1H, NHCHCHaHbN), 1.86 (ddq, J = 12.9, 8.3, 6.5 Hz, 1H, CH3CHCH3), 
1.68–1.57 (m, 2H, NCH2CH2CH2CH3), 1.57–1.49 (m, 1H, NHCHCHaHbCH), 1.48–1.36 
(m, 2H, NCH2CH2CH2CH3), 1.29 (ddd, J = 13.9, 8.5, 5.5 Hz, 1H, NHCHCHaHbCH), 








13C NMR (126 MHz, CDCl3) δ ppm 149.3, 131.9, 129.7, 127.0, 123.1, 121.4, 58.5, 54.3, 
53.9, 40.8, 29.8, 24.6, 23.0, 21.9, 20.1, 13.9;  






According to general procedure C, 3.11.2c (41.1 mg, 50%) was isolated as a white solid.  
mp 140–144 ºC;  
[𝛼]!!" = -75.5 (c = 0.14, CHCl3);  
FTIR (thin film) 3275, 2957, 1578, 1458, 1325, 1155, 800, 783, 698 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 7.76 (d, J = 8.5 Hz, 1H, aromatic), 7.42–7.29 (m, 
5H, aromatic), 7.23 (d, J = 1.8 Hz, 1H, aromatic), 7.16 (dd, J = 8.4, 1.8 Hz, 1H, 
aromatic), 4.65 (d, J = 14.3 Hz, 1H, NCHaHbPh), 4.38 (d, J = 14.3 Hz, 1H, NCHaHbPh), 
4.30–4.17 (m, 1H, NH), 3.51–3.28 (m, 2H, NHCHCH2N, NHCHCHaHbN), 3.01–2.79 (m, 
1H, NHCHCHaHbN), 1.59–1.48 (m, 1H, CH3CHCH3), 1.35 (ddd, J = 14.2, 7.4, 7.0 Hz, 
1H, NHCHCHaHb), 1.09–0.96 (m, 1H, NHCHCHaHb), 0.79 (d, J = 6.5 Hz, 3H, 







13C NMR (126 MHz, CDCl3) δ ppm 149.8, 136.7, 129.7, 128.9 (2C), 128.3 (2C), 127.9, 
127.4, 127.35 124.2, 122.4, 58.3, 57.8, 53.7, 41.0, 24.5, 22.4, 22.0;  




diazepine 1,1-dioxide (3.11.2d) 
 
According to general procedure C, 3.11.2d (23.5 mg, 42%) was isolated as a light yellow 
solid.  
mp 155–161 ºC;  
[𝛼]!!" = -102.9 (c = 0.485, CHCl3);  
FTIR (thin film) 3258, 2959, 1578, 1468, 1375, 1325, 1155, 843, 798, 700 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.74 (dd, J = 8.4, 2.0 Hz, 1H, aromatic), 7.32 (d, J = 
7.9 Hz, 2H, aromatic), 7.26 (d, J = 5.0 Hz, 2H, aromatic), 7.27–7.21 (m, 1H, aromatic), 
7.19–7.11 (m, 1H, aromatic), 4.60 (d, J = 13.9 Hz, 1H, NCHaHbPh), 4.32 (d, J = 13.9 Hz, 
1H, NCHaHbPh), 4.23 (s, 1H, NH), 3.41 (dd, J = 14.9, 2.4 Hz, 1H, NHCHCH2N), 3.38–
3.30 (m, 1H, NHCHCHaHbN), 3.03–2.80 (m, 1H, NHCHCHaHbN), 1.60–1.46 (m, 1H, 







0.93 (m, 1H, NHCHCHaHb), 0.95–0.83 (m, 1H, NHCHCHaHb), 0.76 (d, J = 6.6 Hz, 3H, 
CH3CHCH3), 0.64 (d, J = 6.6 Hz, 3H, CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 150.0 (2C), 148.7, 134.0, 129.6, 128.5 (2C), 127.4, 
126.9 (2C), 124.0, 122.3, 57.9, 57.5, 53.8, 41.0, 33.9, 24.6, 24.0, 23.9, 22.3, 22.1;  




[1,2,5]thiadiazepine 1,1-dioxide (3.11.2e) 
 
According to general procedure B, 3.11.2e (59.6 mg, 53%) was isolated as brown oil.  
[𝛼]!!"  = -149.9 (c = 0.125, CHCl3);  
FTIR (thin film) 3267, 2968, 1604, 1573, 1477, 1433, 1325, 1161, 854, 742 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.93 (dd, J = 8.8, 6.4 Hz, 1H, aromatic), 7.65 (d, J = 
8.0 Hz, 2H, aromatic), 7.55 (d, J = 8.0 Hz, 2H, aromatic), 6.78–6.69 (m, 2H, aromatic), 
4.68 (d, J = 14.7 Hz, 1H, NCHaHbPh), 4.44 (d, J = 14.7 Hz, 1H, NCHaHbPh), 4.32 (d, J = 
9.1 Hz, 1H, NH), 3.43 (dd, J = 14.8, 2.2 Hz, 1H, NHCHCH2N), 3.29–3.14 (m, 1H, 
NHCHCHaHbN), 3.13–2.96 (m, 1H, NHCHCHaHbN), 1.85–1.66 (m, 1H, CH3CHCH3), 
0.86 (d, J = 6.8 Hz, 3H, CH3CHCH3), 0.79 (d, J = 6.7 Hz, 3H, CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 165.3 (d, 1JC–F = 253.5 Hz), 150.6 (d, 3JC–F = 10.1 







130.1, 128.5 (2C), 125.8 (q, 3JC–CF3 = 3.7 Hz, 2C), 124.0 (q, 1JC–CF3 = 273.1 Hz), 108.7 (d, 
2JC–F = 22.6 Hz), 106.5 (d, 2JC–F = 24.4 Hz), 60.7, 58.0, 56.4, 30.0, 19.0, 18.7;  




pine 1,1-dioxide (3.11.2f) 
 
According to general procedure B, 3.11.2f (46.1 mg, 55%) was isolated as a white solid.  
mp 145–148 ºC;  
[𝛼]!!"  = -27.0 (c = 0.125, CHCl3);  
FTIR (thin film) 3267, 2960, 1602, 1471, 1369, 1326, 1218, 1145, 1068, 815, 729 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.79 (d, J = 8.0 Hz, 1H, aromatic), 7.27–7.24 (m, 
1H, aromatic), 7.13 (bs, 1H, aromatic), 3.80 (ddd, J = 14.6, 7.7, 1.6 Hz, 1H, 
NCHCHaHbOCH2), 3.70–3.62 (m, 1H, NCHCH2OCHaHb), 3.59 (dd, J = 10.9, 9.2 Hz, 1H, 
NCHCHaHbOCH2), 3.54–3.42 (m, 1H, NCHCH2OCHaHb), 3.31 (dddd, J = 9.7, 9.7, 7.7, 
1.6 Hz, 1H, NHCHCH2N), 3.20–3.12 (m, 1H, NCHCH2OCH2), 2.94 (dd, J = 14.5, 9.6 
Hz, 1H, NHCHCHaHbN), 2.70 (dd, J = 14.5, 10.0 Hz, 1H, NHCHCHaHbN), 2.56 (s, 1H, 
NH), 2.40 (s, 3H, PhCH3), 1.92–1.80 (m, 1H CH3CHCH3), 1.09 (d, J = 6.5 Hz, 3H, 








13C NMR (126 MHz, CDCl3) δ ppm 144.5, 141.1, 140.1, 130.4, 129.1, 128.7, 61.9, 60.1, 
58.7, 47.6, 41.1, 29.3, 21.3, 20.6, 18.5;  
HRMS calculated for C15H22N2O3SH (M+H)+ 311.1429; found 311.1415 (TOF MS ES+). 
 
(S)-9-fluoro-3-isopropyl-5-(3-methoxypropyl)-2,3,4,5-tetrahydrobenzo[f][1,2,5]thia-
diazepine 1,1-dioxide (3.11.2g) 
 
According to general procedure B, 3.11.2g (50.0 mg, 56%) was isolated as yellow oil.  
[𝛼]!!"  = -140.7 (c = 0.125, CHCl3);  
FTIR (thin film) 3263, 2962, 1608, 1569, 1456, 1386, 1319, 1201, 1149, 1068, 723 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.85 (dd, J = 8.8, 6.5 Hz, 1H, aromatic), 6.74 (dd, J 
= 11.5, 2.4 Hz, 1H, aromatic), 6.66 (ddd, J = 8.8, 7.5, 2.4 Hz, 1H, aromatic), 4.54 (d, J = 
7.2 Hz, 1H, NH), 3.58–3.42 (m, 4H, NHCHCHaHbN, NHCHCH2N, NCH2CH2CH2OCH3), 
3.34 (s, 3H, NCH2CH2CH2OCH3), 3.33–3.30 (m, 1H, NCHaHbCH2CH2OCH3), 3.28–3.19 
(m, 2H, NHCHCHaHbN, NCHaHbCH2CH2OCH3), 2.01–1.93 (m, 1H, CH3CHCH3), 1.92–
1.83 (m, 2H, NCH2CH2CH2OCH3), 1.06 (d, J = 6.8 Hz, 3H, CH3CHCH3), 1.03 (d, J = 6.7 
Hz, 3H, CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 165.2 (d, 1JC–F = 252.1 Hz), 150.3 (d, 3JC–F = 10.5 
Hz), 130.8 (d, 3JC–F = 10.9 Hz), 129.2, 107.7 (d, 2JC–F = 22.7 Hz), 105.6 (d, 2JC–F = 24.7 











thiadiazepine 1,1-dioxide (3.11.2h) 
 
According to general procedure B, 3.11.2h (44.8 mg, 46%) was isolated as colorless oil.  
[𝛼]!!"  = +132.5 (c = 0.125, CHCl3);  
FTIR (thin film) 3267, 2931, 1506, 1488, 1458, 1386, 1326, 1220, 1157, 1058, 821 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.83 (d, J = 2.5 Hz, 1H, aromatic), 7.34 (dd, J = 8.8, 
2.6 Hz, 1H, aromatic), 7.05 (d, J = 8.8 Hz, 1H, aromatic), 4.49 (d, J = 9.4 Hz, 1H, NH), 
3.60–3.48 (m, 2H, NHCHCH2N, NCH2CH2CHaHbOCH3), 3.48–3.42 (m, 2H, 
NCH2CH2CHaHbOCH3, NCHaHbCH2CH2OCH3), 3.38 (dd, J = 14.8, 2.5 Hz, 1H, 
NHCHCHaHbN), 3.33 (s, 3H, NCH2CH2CH2OCH3), 3.29 (dd, J = 13.5, 6.8 Hz, 1H, 
NCHaHbCH2CH2OCH3), 3.04 (dd, J = 14.8, 9.6 Hz, 1H, NHCHCHaHbN), 1.90–1.78 (m, 
2H, NCH2CH2CH2OCH3), 1.74–1.64 (m, 1H, CH3CHCH2CH3), 1.59–1.49 (m, 1H, 
CH3CHCHaHbCH3), 1.36–1.25 (m, 1H, CH3CHCHaHbCH3), 1.01–0.93 (m, 6H, 
CH3CHCH2CH3);  
13C NMR (126 MHz, CDCl3) δ ppm 146.7, 134.8, 132.6, 128.1, 125.9, 120.7, 77.2, 69.8, 













3,1'-cyclohexane] 1,1-dioxide (3.11.2i) 
 
According to general procedure B, 3.11.2i (54.0 mg, 56%) was isolated as brown oil.  
FTIR (thin film) 3326, 2928, 1612, 1573, 1469, 1338, 1147, 1041, 773 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.27–7.22 (m, 1H, aromatic), 6.97 (s, 1H, NH), 6.48 
(d, J = 8.8, Hz, 1H, aromatic), 6.35 (ddd, J = 11.2, 8.1, 1.0 Hz, 1H, aromatic), 5.61–5.54 
(m, 1H, NCH2CH2CHaHbOCH3,), 4.95 (dd, J = 6.6, 6.5 Hz, 1H, NCH2CH2CHaHbOCH3), 
3.54–3.44 (m, 4H, NHCCH2N, NCH2CH2CH2OCH3), 3.36 (s, 3H, OCH3), 3.25 (ddd, J = 
6.7, 6.6, 5.0 Hz, 2H, NCH2CH2CH2OCH3), 2.00–1.84 (m, 5H, cyclohexyl), 1.65–1.55 (m, 
1H, cyclohexyl), 1.54–1.39 (m, 4H, cyclohexyl);  
13C NMR (126 MHz, CDCl3) δ ppm 161.1 (d, 1JC–F = 248.9 Hz), 148.6 (d, 4JC–F = 3.4 
Hz), 134.2 (d, 3JC–F = 12.7 Hz), 109.4 (d, 3JC–F = 14.0 Hz), 107.8, 101.1 (d, 2JC–F = 23.5 
Hz), 70.2, 58.8, 50.0, 40.8, 29.0, 26.2 (2C), 25.0, 22.3, 21.9 (2C);  











cyclohexane] 1,1-dioxide (3.11.2j) 
 
According to general procedure C, 3.11.2j (24.8 mg, 46%) was isolated as a white solid.  
mp 178–182 ºC;  
FTIR (thin film) 3454, 3263, 2934, 1580, 1487, 1369, 1312, 1150, 1057, 795, 733 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 7.68 (dd, J = 8.4, 1.7 Hz, 1H, aromatic), 7.25 (s, 1H, 
aromatic), 7.19 (dd, J = 8.4, 1.7 Hz, 1H, aromatic), 4.44 (s, 1H, NH), 3.81–3.66 (m, 2H, 
NCH2CH2OH), 3.57 (bs, 2H, NCH2CH2OH), 3.26 (bs, 2H, NCH2CNH), 2.85 (s, 1H, OH), 
1.75–1.53 (m, 6H, cyclohexyl), 1.50–1.27 (m, 4H, cyclohexyl);  
13C NMR (126 MHz, CDCl3) δ ppm 148.1, 129.5, 127.1, 125.8, 125.3, 122.6, 65.3, 59.5, 
59.1, 56.5, 25.6 (2C), 21.0 (3C);  




diazepine 1,1-dioxide (3.11.2k) 
 
According to general procedure C, 3.11.2k (50.4 mg, 46%) was isolated as colorless oil.  













FTIR (thin film) 3466, 3252, 2964, 1578, 1470, 1371, 1319, 1157, 1059, 795, 731 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 7.74 (dd, J = 8.6, 2.1 Hz, 1H, aromatic), 7.37 (d, J = 
2.0 Hz, 1H, aromatic), 7.29–7.22 (m, 1H, aromatic), 4.17 (d, J = 9.4 Hz, 1H, NH), 3.88–
3.76 (m, 1H, HOCHaHb), 3.68–3.57 (m, 2H, NCH2CH2), 3.51–3.36 (m, 3H, 
NCHaHBCHNH, NHCHCH2, OH), 3.33–3.22 (m, 1H, HOCHaHb), 2.85 (dd, J = 15.0, 10.4 
Hz, 1H, NCHaHBCHNH), 1.92–1.79 (m, 1H, CH3CHCH3), 1.06 (d, J = 6.8 Hz, 3H, 
CH3CHCH3), 1.02 (d, J = 6.9 Hz, 3H, CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 148.9, 135.6, 129.6, 127.7, 126.1, 125.5, 60.9, 60.0, 
58.9, 57.9, 30.0, 19.5, 18.3;  




diazepine 1,1-dioxide (3.11.2l) 
 
According to general procedure C, 3.11.2l (31.0 mg, 43%) was isolated as colorless oil.  
[𝛼]!!"  = -120.8 (c = 0.085, CHCl3);  
FTIR (thin film) 3454, 3250, 2957, 1576, 1470, 1367, 1319, 1155, 1061, 808, 789, 745, 
700 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.69 (d, J = 8.4 Hz, 1H, aromatic), 7.36 (d, J = 1.8 








3.82 (ddd, J = 13.6, 5.6, 3.9 Hz, 1H, HOCHaHb), 3.73–3.57 (m, 3H, NHCHCH2, 
NCH2CH2OH), 3.42 (s, 1H, OH), 3.36 (dd, J = 15.0, 2.1 Hz, 1H, NHCHCHaHbN), 3.32–
3.21 (m, 1H, HOCHaHb), 2.85–2.71 (m, 1H, NHCHCHaHbN), 1.93–1.79 (m, 1H, 
CH3CHCH3), 1.36 (ddd, J = 14.3, 9.1, 5.7 Hz, 1H, NHCHCHaHb), 1.30–1.18 (m, 1H, 
NHCHCHaHb), 0.98 (dd, J = 6.5, 6.4 Hz, 6H, CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 148.9, 135.6, 129.6, 127.7, 126.1, 125.5, 61.3, 60.1, 
58.0, 54.1, 40.7, 24.6, 23.0, 21.9;  




[1,2,5]thiadiazepine 1,1-dioxide (3.11.2m) 
 
According to general procedure C, 3.11.2m (28.5 mg, 12%) was isolated as a white solid.  
mp 150–154 ºC;  
[𝛼]!!"  = -143.5 (c = 0.365, CHCl3);  
FTIR (thin film) 3475, 3253, 2957, 1576, 1470, 1381, 1321, 1161, 1055, 808, 777, 727, 
694 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.76 (d, J = 8.4 Hz, 1H, aromatic), 7.35 (d, J = 1.8 
Hz, 1H, aromatic), 7.27–7.24 (m, 1H, aromatic), 3.98 (s, 1H, NH), 3.88–3.74 (m, 1H, 








HOCHaHb), 3.40 (dd, J = 11.0, 10.4 Hz, 1H, HOCHaHb), 2.47–2.26 (m, 1H, 
NHCHCHaHbN), 1.95–1.78 (m, 1H, CH3CHCH3), 1.40–1.19 (m, 5H, CH3CHN, 
NHCHCH2), 1.00 (dd, J = 6.3 Hz, 6H, CH3CHCH3); 
13C NMR (126 MHz, CDCl3) δ ppm 150.7, 134.6, 129.5, 127.8, 125.7, 125.5, 65.6, 60.9, 
54.0, 51.7, 41.1, 24.7, 23.0, 21.9, 13.9;  




[f][1,2,5]thiadiazepine 1,1-dioxide (3.11.2n) 
 
According to general procedure C, 3.11.2n (34.0 mg, 26%) was isolated as a white solid.  
mp 164–168 ºC;  
[𝛼]!!" = -187.1 (c = 1.29, CHCl3);  
FTIR (thin film) 3445, 3261, 2959, 1574, 1462, 1398, 1321, 1163, 1063, 808, 733 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 7.76 (d, J = 8.5 Hz, 1H, aromatic), 7.68 (d, J = 1.8 
Hz, 1H, aromatic), 7.35 (dd, J = 8.4, 1.8 Hz, 1H, aromatic), 4.06 (d, J = 9.2 Hz, 1H, NH), 
3.92–3.77 (m, 2H, NCHaHbCHNH, CHaHbOH), 3.68 (dd, J = 12.6, 4.8 Hz, 1H, 
CHaHbOH), 3.45 (ddd, J = 8.9, 8.8, 8.6 Hz, 1H, NHCHCH2N), 3.36–3.21 (m, 1H, OH), 
2.35 (dd, J = 15.6, 10.4 Hz, 1H, NCHaHbCHNH), 2.09 (d, J = 12.9 Hz, 1H, cyclohexyl), 








cyclohexyl), 1.48–1.34 (m, 2H, cyclohexyl), 1.31–1.17 (m, 1H, cyclohexyl), 1.06 (d, J = 
6.8 Hz, 3H, CH3CHCH3), 1.00 (d, J = 6.9 Hz, 3H, CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 147.9, 139.0, 131.8, 129.3, 127.6, 126.2, 63.6, 61.5, 
61.2, 50.3, 31.6, 31.2, 30.1, 25.5, 23.0, 22.8, 19.3, 18.2;  
HRMS calculated for C18H27BrN2O3SH (M+H)+ 431.1004; found 431.1019(TOF MS ES+). 
 
(S)-7-bromo-5-((S)-1-hydroxy-4-methylpentan-2-yl)-3-isobutyl-2,3,4,5 tetrahydro-
benzo[f][1,2,5]thiadiaze-pine 1,1-dioxide (3.11.2o) 
 
According to general procedure C, 3.11.2o (70.0 mg, 21%) was isolated as a white solid.  
mp 86–90 ºC;  
[𝛼]!!"  = +117.3 (c = 0.92, CHCl3);  
FTIR (thin film) 3470, 3250, 2955, 1578, 1470, 1402, 1323, 1163, 1068, 812 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 7.83 (d, J = 8.1 Hz, 1H, aromatic), 7.25–7.14 (m, 
2H, aromatic), 6.70 (d, J = 6.4 Hz, 1H, NH), 4.41 (dd, J = 11.7, 2.9 Hz, 1H, 
NCHCHaHbOH), 3.87 (dd, J = 11.8, 11.0 Hz, 1H, NCHCHaHbOH), 3.16–2.99 (m, 1H, 
NHCHCH2N), 2.77–2.57 (m, 2H, NCHCH2OH, NCHaHbCHNH), 2.40 (dd, J = 13.6, 4.8 
Hz, 1H, NCHaHbCHNH), 1.80–1.68 (m, 2H, CH3CHCH3, CH3CHCH3), 1.63 (ddd, J = 








J = 13.7, 7.0, 6.9 Hz, 1H, NHCHCHaHb), 0.98–0.88 (m, 9H, CH3CHCH3, CH3CHCH3), 
0.84 (d, J = 6.6 Hz, 3H, CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 155.2, 131.8, 129.7, 128.0, 124.9, 118.5, 75.2, 54.0, 
51.4, 51.3, 43.4, 42.0, 24.9, 24.3, 23.0, 22.7, 22.5, 22.4;  




[f][1,2,5]thiadiazepine 1,1-dioxide (3.11.2p) 
 
According to general procedure C, 3.11.2p (43.1 mg, 43%) was isolated as colorless oil.  
[𝛼]!!"  = -103.1 (c = 0.66, CHCl3);  
FTIR (thin film) 3512, 3252, 2957, 1578, 1543, 1470, 1371, 1315, 1150, 1040, 800, 
731, 700 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.67 (d, J = 8.5 Hz, 1H, aromatic), 7.20 (d, J = 1.8 
Hz, 1H, aromatic), 7.10 (dd, J = 8.5, 1.8 Hz, 1H, aromatic), 4.41 (d, J = 8.2 Hz, 1H, NH), 
3.68–3.56 (m, 2H, NHCHCH2N, NCHaHbCH2CHMe), 3.55–3.49 (m, 1H, 
HOCHaHbCHMe), 3.46 (dd, J = 15.1, 2.7 Hz, 1H, NHCHCHaHbN), 3.43–3.39 (m, 1H, 
HOCHaHbCHMe), 3.21 (ddd, J = 13.7, 8.3, 5.9 Hz, 1H, NCHaHbCH2CHMe), 2.95 (dd, J 









1.79–1.70 (m, 2H, NCH2CHaHbCHMe, OH), 1.53–1.43 (m, 2H, NHCHCHaHbCH, 
NCH2CHaHbCHMe), 1.27 (ddd, J = 14.0, 8.4, 5.6 Hz, 1H, NHCHCHaHbCH), 1.03–0.93 
(m, 9H, CH3CHCH3, HOCH2CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 149.3, 132.4, 129.7, 127.3, 123.8, 122.1, 67.7, 59.2, 
54.0, 52.3, 40.9, 33.4, 31.4, 24.6, 22.9, 21.9, 17.0;  






According to general procedure D, 3.12.1a (14.6 mg, 87%,) was isolated as colorless oil.  
[𝛼]!!"  = -29.1 (c = 0.945, CHCl3);  
FTIR (thin film) 2957, 1574, 1448, 1391, 1333, 1165, 839, 797, 694 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.74 (d, J = 8.4 Hz, 1H, aromatic), 7.56 (dd, J = 8.4, 
2.0 Hz, 1H, aromatic), 7.48 (d, J = 2.0 Hz, 1H, aromatic), 3.97–3.82 (m, 1H, NCHCH2N), 
3.72 (dddd, J = 14.7, 8.6, 2.4, 1.7 Hz, 1H, SNCHaHb), 3.42 (ddd, J = 14.1, 7.7, 2.5 Hz, 
1H, CNCHaHbCH2NS), 3.39–3.32 (m, 1H, CNCHaHbCH2NS), 3.26–3.21 (m, 1H, 
NCHaHbCHN), 3.21–3.16 (m, 1H, SNCHaHb), 2.73 (dd, J = 14.4, 9.1 Hz, 1H, 
NCHaHbCHN), 1.89–1.75 (m, 1H, CH3CHCH3), 1.68 (ddd, J = 14.3, 9.8, 4.7 Hz, 1H, 
NCHCHaHbCH), 1.14 (ddd, J = 13.8, 9.0, 4.6 Hz, 1H, NCHCHaHbCH), 0.95 (d, J = 6.8 







13C NMR (126 MHz, CDCl3) δ ppm 148.1, 143.2, 133.9, 131.3, 129.8, 126.8, 53.3, 51.1, 
51.07, 39.1, 38.3, 24.6, 23.2, 21.6;  




diazepine 1,1-dioxide (3.12.1b) 
 
According to general procedure D 3.12.1b (12.5 mg, 46%) was isolated as colorless oil.  
[𝛼]!!"  = -2.1 (c = 0.25, CHCl3);  
FTIR (thin film) 2957, 1574, 1456, 1381, 1331, 1161, 816, 789, 756, 698 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.72 (d, J = 8.4 Hz, 1H, aromatic), 7.59 (dd, J = 8.4, 
2.0 Hz, 1H, aromatic), 7.45 (d, J = 1.9 Hz, 1H, aromatic), 4.09–3.90 (m, 1H, NCHCH2N), 
3.51–3.29 (m, 4H, SNCH2CHCH3, NCHCHaHbN), 2.81 (dd, J = 14.3, 6.6 Hz, 1H, 
NCHCHaHbN), 1.84–1.77 (m, 1H, CH3CHCH3), 1.73 (ddd, J = 13.9, 10.2, 4.7 Hz, 1H, 
NCHCHaHbCH), 1.21 (ddd, J = 14.1, 9.0, 5.0 Hz, 1H, NCHCHaHbCH), 0.96 (dd, J = 6.5, 
3.8 Hz, 9H, NCHCH3, CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 144.3, 143.6, 136.0, 131.6, 129.1, 126.6, 56.2, 54.5, 
49.2, 44.8, 40.3, 25.1, 23.2, 21.5, 20.2;  













According to general procedure D, 3.12.1c (8.1 mg, 40%) was isolated as a white solid.  
mp 182–185 ºC;  
FTIR (thin film) 2935, 1574, 1452, 1393, 1327, 1167, 804, 694 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.67 (d, J = 8.4 Hz, 1H, aromatic), 7.53 (dd, J = 8.4, 
2.0 Hz, 1H, aromatic), 7.47 (d, J = 2.0 Hz, 1H, aromatic), 3.88 (ddd, J = 14.8, 6.9, 5.7 
Hz, 1H, SNCHaHb), 3.44 (ddd, J = 14.7, 8.5, 7.1 Hz, 1H, SNCHaHb), 3.38–3.30 (m, 2H, 
CNCH2CH2NS), 3.15 (ddd, J = 14.3, 1.3, 1.2 Hz, 1H, NCHaHbCNS), 2.94 (dd, J = 14.5, 
0.9 Hz, 1H, NCHaHbCNS), 2.20–2.09 (m, 1H, cyclohexyl), 1.89–1.77 (m, 3H, 
cyclohexyl), 1.75–1.65 (m, 1H, cyclohexyl), 1.49–1.35 (m, 3H, cyclohexyl), 1.34–1.21 
(m, 2H, cyclohexyl);  
13C NMR (126 MHz, CDCl3) δ ppm 148.9, 144.8, 133.7, 131.2, 128.7, 126.8, 60.5, 58.8, 
49.8, 41.3, 37.1, 36.9, 25.1, 22.8, 22.4;  


















According to general procedure C, 3.13.1a (2 mg, 5%) was isolated as colorless oil.  
[𝛼]!!"  = -377.9 (c = 0.08, CHCl3);  
FTIR (thin film) 2955, 1574, 1454, 1385, 1327, 1151, 789, 711 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 7.58 (d, J = 8.5 Hz, 1H, aromatic), 7.26 (d, J = 2.0 
Hz, 1H, aromatic), 7.20 (dd, J = 8.5, 1.9 Hz, 1H, aromatic), 4.03 (ddd, J = 15.6, 3.9, 2.6 
Hz, 1H, NCHaHbCH2CHMe), 3.88–3.68 (m, 2H, NCHaHbCHN), 3.37 (dd, J = 15.0, 3.7 
Hz, 1H, NCHaHbCHMe), 3.30–3.16 (m, 2H, NCHaHbCHN, NCHaHbCHMe), 3.03 (ddd, J 
= 15.6, 12.1, 1.6 Hz, 1H, NCHaHbCH2CHMe), 2.10 (ddd, J = 13.9, 9.4, 5.0 Hz, 2H, 
NCH2CHMe, NCHCHaHbCH), 1.94–1.80 (m, 1H, CH3CHCH3), 1.42 (dd, J = 15.5, 2.7 
Hz, 1H, NCH2CHaHbCHMe), 1.27–1.15 (m, 2H, NCHCHaHbCH, NCH2CHaHbCHMe), 
1.00 (d, J = 6.7 Hz, 3H, CH3CHCH3), 0.96 (d, J = 6.6 Hz, 3H CH3CHCH3), 0.90 (d, J = 
6.6 Hz, 3H, NCH2CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 147.7, 137.0, 129.5, 129.1, 126.5, 126.1, 57.3, 57.0, 
56.1, 54.3, 40.3, 34.7, 33.5, 25.4, 23.4, 22.3, 20.9;  




2,3,4,5,6,7hexahydrobenzo[b][1,4,5,8]oxathiadiazecine 1,1-dioxide (3.14.7) 
 












mp 50–55 ºC;  
[𝜶]𝑫𝟐𝟎 = +22.5 (c = 1.315, CHCl3);  
FTIR (thin film) 3514, 2953, 1601, 1587, 1477, 1454, 1389, 1321, 1155, 1070, 808, 
741, 700 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.98 (dd, J = 8.8, 6.5 Hz, 1H, aromatic), 7.41–7.25 
(m, 5H, aromatic), 6.79 (ddd, J = 8.7, 7.8, 2.4 Hz, 1H, aromatic), 6.72 (dd, J = 9.9, 2.4 
Hz, 1H, aromatic), 5.75 (s, 1H, NH), 4.46 (d, J = 11.8 Hz, 1H, OCHaHbC), 4.40 (d, J = 
11.9 Hz, 1H, OCHaHbC), 4.37 (dd, J = 12.3, 5.1 Hz, 1H, OCHCHaHbO), 3.90 (dd, J = 
11.9 Hz, 1H, OCHCHaHbO), 3.64 (bs, 1H, NHCHCH2N), 3.37–3.23 (m, 2H, OCHCH2O, 
NCHCH3), 3.14 (dd, J = 9.4, 4.1 Hz, 1H, HOCHaHbCH), 3.09–2.99 (m, 2H, 
NHCHCHaHbN, HOCHaHbCH), 2.53 (d, J = 12.7 Hz, 1H, NCHaHbCHO), 2.36–2.28 (m, 
2H, NCHaHbCHO, OH), 2.14 (dd, J = 15.1, 10.8 Hz, 1H, NHCHCHaHbN), 1.95–1.81 (m, 
1H, CH3CHCH3), 1.42 (ddd, J = 13.7, 7.7, 6.0 Hz, 1H, NHCHCHaHb), 1.14 (ddd, J = 
13.6, 7.9, 5.6 Hz, 1H, NHCHCHaHb), 0.98 (d, J = 6.5 Hz, 3H, NCHCH3), 0.93 (d, J = 6.5 
Hz, 3H, CH3CHCH3), 0.89 (d, J = 6.6 Hz, 3H, CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 165.7 (d, 1JC–F = 254.0 Hz), 157.2, 137.7, 132.2 (d, 
3JC–F = 10.8 Hz), 128.5 (2C), 127.9 (2C), 127.7 (2C), 108.6 (d, 2JC–F = 22.2 Hz), 104.1 (d, 
2JC–F = 24.5 Hz), 73.4, 72.2, 71.9, 69.4 (2C), 57.4, 56.3, 53.7, 46.1, 24.2, 23.0, 22.5, 9.5;  







2,3,4,5,6,7hexahydro-benzo[b][1,4,5,8]oxathiadiazecine 1,1-dioxide (3.14.8) 
 
According to general procedure B, 3.14.8 (30.5 mg, 42%) was isolated as colorless sticky 
oil.  
[𝜶]𝑫𝟐𝟎 = +45.9 (c = 0.535, CHCl3);  
FTIR (thin film) 3450, 3259, 2957, 1603, 1587, 1477, 1454, 1387, 1323, 1161, 1070, 
808, 733, 698 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.96 (ddd, J = 8.6, 6.4, 1.6 Hz, 1H, aromatic), 7.53–
7.44 (m, 2H, aromatic), 7.44–7.37 (m, 2H, aromatic), 7.38–7.29 (m, 1H, aromatic), 6.87–
6.79 (m, 1H, aromatic), 6.79 (ddd, J = 10.0, 1.8 Hz, 1H, aromatic), 6.42 (s, 1H, NH), 4.66 
(s, 2H, OCH2C), 4.56 (dd, J = 5.4, 3.1 Hz, 1H, OCHCH2O), 4.01 (dd, J = 10.5, 5.1 Hz, 
1H, OCHCHaHbO), 3.98–3.89 (m, 1H, OCHCHaHbO), 3.44–3.26 (m, 2H, HOCH2CH), 
3.06–2.96 (m, 1H, NHCHCH2N), 2.95–2.87 (m, 3H, NCH2CHO, OH), 2.77–2.64 (m, 1H, 
NCHCH3), 2.33 (dd, J = 14.8, 4.9 Hz, 1H, NHCHCHaHbN), 2.26 (dd, J = 14.9, 3.8 Hz, 
1H, NHCHCHaHbN), 1.65–1.53 (m, 1H, CH3CHCH3), 1.54–1.43 (m, 1H, NHCHCHaHb), 
0.96 (ddd, J = 13.5, 7.9, 5.6 Hz, 1H, NHCHCHaHb), 0.84 (dd, J = 6.5, 1.5 Hz, 3H, 
CH3CHCH3), 0.81 (dd, J = 6.7, 1.6 Hz, 3H, NCHCH3), 0.72 (dd, J = 6.6, 1.5 Hz, 3H, 
CH3CHCH3);  
13C NMR (126 MHz, CDCl3) δ ppm 165.9 (d, 1JC–F = 254.8 Hz), 155.5, 136.2, 132.3 (d, 












(d, 2JC–F = 25.2 Hz), 78.6, 75.0, 71.0, 64.8, 61.4, 55.8, 53.5, 51.6, 43.4, 24.1, 23.1, 21.8, 
10.0;  























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3 Experimental for Chapter 4 
General Procedure A: one-pot, sequential 3-component (sulfonylation, Michael and 
amide coupling).  To a pressure tube containing a solution of amine (1.44 mmol, 1.5 eq.) 
in dry CH2Cl2 (0.5 M), was added Et3N (1.91 mmol, 2.0 eq.).   The reaction mixture was 
stirred for 20 min and 2-chloroethane sulfonyl chloride (0.96 mmol, 1.0 eq.) was added in 
a drop-wise fashion.  The reaction was stirred overnight and CH2Cl2 was removed in 
vacuo upon completion of the reaction.  MeOH/water (0.5 M, 6:1), Et3N (1.91 mmol, 2.0 
eq.) and amino acid (1.15 mmol, 1.2 eq.) were added to the reaction mixture, which was 
stirred at 60 ºC for 12 h, after which solvents were evaporated to dryness.  DMF (0.08 M) 
(for cyclic amino acids), EDC (1.91 mmol, 2.0 eq.), HOBt (1.44 mmol, 1.5 eq.) and Et3N 
(1.91 mmol, 2.0 eq.) were added to the crude mixture.  The reaction was stirred at rt for 
12 h, followed by evaporation of DMF.  Water was added to the crude mixture, which 
was extracted with EtOAc (2x).   Layers were separated and solvent was removed under 
reduced pressure to afford the crude product.  The crude product was QC/purified by an 
automated preparative reverse phase HPLC (detected by mass spectroscopy).  For acyclic 
amino acids, CHCl3 was utilized as the solvent, followed by addition of EDC (1.91 mmol, 
2.0 eq.), HOBt (1.44 mmol, 1.5 eq.) and Et3N (1.91 mmol, 2.0 eq.).   The reaction was 
stirred at 50 ºC for 12 h after which time; water (equal volume of CHCl3 used) was added 
to the crude mixture and extraction of aqueous layer with EtOAc (2x).  Layers were 
separated and solvent was removed under reduced pressure to afford the crude product.  
The crude product was QC/purified by an automated preparative reverse phase HPLC 
(detected by mass spectroscopy). 
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General Procedure B: one-pot, sequential 3-component (sulfonylation, Michael and 
amide coupling).  To a pressure tube containing a solution of amine (1.0 mmol, 1.05 eq.) 
in dry CH2Cl2 (0.5 M), was added Et3N (1.91 mmol, 2.0 eq.).  The reaction mixture was 
stirred for 20 min and 2-chloroethane sulfonyl chloride (0.96 mmol, 1.0 eq.) was added in 
a drop-wise fashion.  The reaction was left to stir overnight and CH2Cl2 was removed in 
vacuo upon completion of the reaction.  MeOH/water (0.5 M, 5:1), Et3N (2.87 mmol, 3.0 
eq.) and amino acid (1.0 mmol, 1.05 eq.) were added to the reaction mixture, and stirred 
at 60 ºC for 12 h, after which solvents were evaporated to dryness.  DMF (0.08 M) (for 
cyclic amino acids), EDC (1.91 mmol, 2.0 eq.), HOBt (0.48 mmol, 0.5 eq.) and Et3N 
(1.91 mmol, 2.0 eq.) were added to the crude mixture.  The reaction was stirred at rt for 
12 h, followed by evaporation of DMF.  Water was added to the crude mixture, which 
was extracted with EtOAc (2x).   Layers were separated and solvent was removed under 
reduced pressure to afford the crude product.  The crude product was QC/purified by an 
automated preparative reverse phase HPLC (detected by mass spectroscopy).  For acyclic 
amino acids, CHCl3 was utilized as the solvent, followed by addition of EDC (1.91 mmol, 
2.0 eq.), HOBt (0.48 mmol, 0.5 eq.) and Et3N (1.91 mmol, 2.0 eq.).   The reaction was 
stirred at 50 ºC for 12 h after which time; water (equal volume of CHCl3 used) was added 
to the crude mixture and extraction of aqueous layer with EtOAc (2x).  Layers were 
separated and solvent was removed under reduced pressure to afford the crude product.  
The crude product was QC/purified by an automated preparative reverse phase HPLC 




pin-1(2H)-one 3,3-dioxide (4.1.4{5,6}) 
 
According to general procedure A, 4.1.4{5,6} (40.4 mg, 12%) was isolated as yellow oil. 
[𝜶]𝑫𝟐𝟎 = +79.1 (c = 0.239, CH2Cl2); 
FTIR (thin film) 3281, 2959, 1778, 1512, 1445, 1383, 1325, 1143, 1086, 1059, 820 cm-1; 
1H NMR (500 MHz, MeOD) δ ppm 7.28 (d, J = 7.6 Hz, 2H), 7.22 (d, J = 7.8 Hz, 2H), 
4.91 (s, 1H), 4.19 (s, 2H), 3.56 (s, 1H), 3.27–3.23 (m, 1H), 3.18–3.08 (m, 1H), 3.07–2.99 
(m, 1H), 2.96–2.82 (m, 2H), 2.71–2.65 (m, 1H), 2.11 (d, J = 10.9 Hz, 1H), 2.09–2.04 (m, 
1H), 1.90 (ddd, J = 10.8, 1.6, 1.6 Hz, 1H), 1.24–1.17 (m, 6H); 
13C NMR (126 MHz, MeOD) δ ppm 173.6, 149.7, 136.8, 129.2 (2C), 127.7 (2C), 81.5, 
63.8, 56.7, 52.6, 48.9, 47.5, 40.0, 35.1, 24.5 (2C); 
HRMS calculated for C17H24N2O4SH (M+H)+ 353.1535; found 353.1527 (TOF MS ES+). 
 
(8R,9aS)-2-(4-chlorobenzyl)-8-hydroxyhexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-
1(2H)-one 3,3-dioxide (4.1.4{4,7}) 
 
















[𝜶]𝑫𝟐𝟎  = +13.8 (c = 0.485, MeOH); 
FTIR (thin film) 3364, 3339, 2947, 1701, 1632, 1493, 1352, 1217, 1151, 1091, 835 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.37–7.32 (m, 2H), 7.31–7.28 (m, 2H), 5.07 (d, J = 
15.1 Hz, 1H), 4.87 (d, J = 15.1 Hz, 1H), 4.45–4.35 (m, 2H), 3.45 (ddd, J = 13.2, 11.9, 2.3 
Hz, 1H), 3.42–3.33 (m, 2H), 3.27–3.16 (m, 2H), 2.72 (m, 1H), 2.65 (ddd, J = 9.9, 5.2, 1.2 
Hz, 1H), 2.18 (s, 1H), 1.96 (dddd, J = 13.3, 8.7, 5.6, 1.2 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ ppm 171.4, 135.1, 133.6, 129.9 (2C), 128.7 (2C), 70.1, 
64.1, 56.5, 52.5, 47.9, 36.6, 30.9; 




[1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide (4.1.4{6,7}) 
 
According to general procedure A, 4.1.4{6,7} (143 mg, 38%) was isolated as light yellow 
oil. 
[𝜶]𝑫𝟐𝟎  = +8.4 (c = 0.45, MeOH); 
FTIR (thin film) 3350, 3337, 2947, 1703, 1510, 1435, 1352, 1221, 1151, 1109, 825 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.43 (d, J = 8.6 Hz, 2H), 7.17 (d, J = 8.2 Hz, 2H), 









3H), 3.28–3.16 (m, 2H), 2.72 (ddd, J = 13.3, 5.9, 5.8 Hz, 1H), 2.69–2.64 (m, 1H), 1.97 
(ddd, J = 13.7, 8.6, 5.5 Hz, 1H), 1.87 (s, 1H); 
13C NMR (126 MHz, CDCl3) δ ppm 171.7, 148.9, 135.5, 130.1 (2C), 121.2 (2C), 120.6 
(q, JC-F = 257.2 Hz), 70.4, 64.4, 56.8, 52.7, 48.0, 41.2, 36.8; 






According to general procedure A, 4.1.4{10,7} (145 mg, 39%) was isolated as a white 
solid. 
mp 113–116 ºC; 
[𝜶]𝑫𝟐𝟎  = +25.8 (c = 0.36, MeOH); 
FTIR (thin film) 3373, 3331, 2928, 1705, 1647, 1447, 1344, 1150, 1082, 989, 915 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 5.87 (dddd, J = 17.2, 10.3, 6.2, 5.3 Hz, 1H), 5.34 
(dd, J = 17.1, 1.4 Hz, 1H), 5.23 (dd, J = 10.3, 1.2 Hz, 1H), 4.51–4.36 (m, 4H), 3.52–3.33 
(m, 4H), 3.28 (dt, J = 12.7, 3.5 Hz, 1H), 2.75 (dddd, J = 12.8, 5.8, 5.8, 1.0 Hz, 1H), 2.67 
(ddd, J = 9.9, 5.3, 1.2 Hz, 1H), 1.96 (dddd, J = 14.2, 8.8, 5.7, 1.2 Hz, 1H), 1.58 (s, 1H);  














According to general procedure A, 4.1.4{1,4} (119 mg, 43%) was isolated as brown oil. 
[𝜶]𝑫𝟐𝟎  = +157.0 (c = 0.595, CH2Cl2); 
FTIR (thin film) 2930, 2872, 1690, 1443, 1369, 1344, 1148, 1020 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 4.27 (s, 1H), 3.90 (ddd, J = 8.2, 6.3, 3.5 Hz, 2H), 
3.85–8.76 (m, 1H), 3.54 (ddd, J = 14.4, 11.6, 3.0 Hz, 1H), 3.45 (ddd, J = 6.4, 5.9, 1.3 Hz, 
2H), 3.34 (s, 3H), 3.31 (ddd, J = 15.3, 3.7, 3.6 Hz, 1H), 3.23 (d, J = 13.8 Hz, 1H), 2.72–
2.64 (m, 1H), 2.62–2.56 (m, 1H), 2.13–2.05 (m, 1H), 2.03–1.87 (m, 2H), 1.81–1.68 (m, 
1H), 1.67–1.61 (m, 1H), 1.61–1.54 (m, 3H); 
13C NMR (126 MHz, CDCl3) δ ppm 172.8, 70.3, 60.9, 58.6, 52.7, 52.2, 47.9, 43.6, 29.8, 
27.4, 25.9, 19.9; 

















According to general procedure A, 4.1.4{7,4} (163.8 mg, 67%) was isolated as a brown 
solid. 
mp 125–129 ºC; 
[𝜶]𝑫𝟐𝟎  = +120.0 (c = 0.405, CH2Cl2); 
FTIR (thin film) 3285, 2926, 1699, 1346, 1148 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 4.79 (dd, J = 17.5, 2.4 Hz, 1H), 4.46 (dd, J = 17.6, 
2.4 Hz, 1H), 4.34 (s, 1H), 3.88 (ddd, J = 15.0, 12.0, 2.4 Hz, 1H), 3.65 (ddd, J = 15.0, 
11.9, 3.0 Hz, 1H), 3.39 (ddd, J = 15.3, 3.5, 3.5 Hz, 1H), 3.28 (s, 1H), 2.88–2.79 (m, 1H), 
2.63 (s, 1H), 2.29 (t, J = 2.5 Hz, 1H), 2.14–2.06 (m, 1H), 1.87–1.74 (m, 1H), 1.68 (s, 1H), 
1.63–1.57 (m, 3H); 
13C NMR (126 MHz, CDCl3) δ ppm 174.8, 78.5, 71.8, 60.6, 52.5, 52.2, 47.7, 34.0, 27.2, 
25.7, 19.6; 





According to general procedure A, 4.1.4{9,5} (109.3 mg, 42%) was isolated as dark 
brown oil. 
[𝜶]𝑫𝟐𝟎  = -159.0 (c = 0.595, CH2Cl2); 









1H NMR (500 MHz, CDCl3) δ ppm 5.03 (p, J = 7.3 Hz, 1H), 4.84 (dddd, J = 7.0, 7.0, 
1.0, 0.9 Hz, 1H), 4.80 (dddd, J = 7.1, 6.8, 1.1, 0.9 Hz, 1H), 4.76 (dd, J = 7.5, 7.4 Hz, 1H), 
4.50 (dd, J = 7.4, 7.3 Hz, 1H), 4.14 (dd, J = 4.0, 3.7 Hz, 1H), 3.82 (ddd, J = 15.1, 12.4, 
2.5 Hz, 1H), 3.68 (ddd, J = 14.1, 12.4, 3.4 Hz, 1H), 3.44 (ddd, J = 15.3, 3.1, 3.1 Hz, 1H), 
3.21 (ddd, J = 14.1, 2.7, 2.6 Hz, 1H), 3.06–2.97 (m, 1H), 2.75–2.69 (m, 1H), 2.24–2.16 
(m, 1H), 1.66–1.63 (m, 1H), 1.63–1.61 (m, 2H), 1.61–1.58 (m, 1H), 1.39–1.28 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ ppm 175.5, 76.5, 75.9, 62.5, 53.2, 52.2, 51.7, 47.2, 27.9, 
25.5, 20.2; 





According to general procedure A, 4.1.4{10,5} (140.6 mg, 57%) was isolated as brown 
oil. 
[𝜶]𝑫𝟐𝟎  = -161.0 (c = 0.395, CH2Cl2); 
FTIR (thin film) 2943, 1693, 1344, 1147, 1003, 928 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 5.90 (ddt, J = 16.5, 10.2, 6.1 Hz, 1H), 5.36 (dd, J = 
17.1, 1.3 Hz, 1H), 5.23 (dd, J = 10.3, 1.3 Hz, 1H), 4.46 (dddd, J = 15.3, 5.8, 1.4, 1.4 Hz, 
1H), 4.38 (dddd, J = 15.2, 6.5, 1.4, 1.3 Hz, 1H), 4.30 (dd, J = 3.5, 3.5 Hz, 1H), 3.83 (ddd, 








3.5, 3.4 Hz, 1H), 3.23 (ddd, J = 14.5, 3.0, 2.9 Hz, 1H), 2.75–2.64 (m, 1H), 2.62–2.56 (m, 
1H), 2.14–2.05 (m, 1H), 1.80–1.70 (m, 1H), 1.64 (ddd, J = 12.7, 4.4, 4.3 Hz, 1H), 1.62–
1.55 (m, 3H); 
13C NMR (126 MHz, CDCl3) δ ppm 172.6, 132.6, 119.0, 60.9, 52.9, 52.2, 47.9, 47.6, 
27.4, 25.9, 19.9; 
HRMS calculated for C11H18N2O3SH (M+H)+ 259.1116; found 259.1117 (TOF MS ES+). 
 
2-(4-(trifluoromethyl)benzyl)hexahydro-[1,4]oxazino[3,4-d][1,2,5]thiadiazepin-
1(2H)-one 3,3-dioxide (4.1.4{2,8}) 
 
According to general procedure A, 4.1.4{2,8} (111.1 mg, 31%) was isolated as a brown 
solid. 
mp 108–113 ºC; 
FTIR (thin film) 2916, 2856, 1693, 1615, 1429, 1325, 1150, 1067, 1053, 847 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.60 (s, 4H), 5.15 (d, J = 15.1 Hz, 1H), 4.99 (d, J = 
15.0 Hz, 1H), 4.34 (dd, J = 11.0, 2.0 Hz, 1H), 4.13 (dd, J = 3.1, 3.0 Hz, 1H), 3.90 (ddd, J 
= 14.7, 11.8, 2.5 Hz, 1H), 3.78 (ddd, J = 11.0, 3.2, 1.8 Hz, 1H), 3.68 (dd, J = 10.8, 3.0 
Hz, 1H), 3.63 (dd, J = 11.1, 2.9 Hz, 1H), 3.45 (ddd, J = 14.5, 12.0, 2.7 Hz, 1H), 3.36–











13C NMR (126 MHz, CDCl3) δ ppm 171.2, 140.8, 130.1 (q, 2JC-F = 32.4 Hz), 129.0 (2C), 
125.6 (q, 3JC-F = 3.8 Hz, 2C), 124.0 (q, 1JC-F = 272.2 Hz), 67.5, 66.9, 61.4, 52.6, 51.8, 
48.2, 47.3; 




1(2H)-one 3,3-dioxide (4.1.4{6,8}) 
 
According to general procedure A, 4.1.4{6,8} (177.9 mg, 47%) was isolated as a yellow 
solid. 
mp 102–107 ºC; 
FTIR (thin film) 3121, 2962, 2916, 1682, 1508, 1435, 1346, 1219, 1151, 1043, 851 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.54 (d, J = 8.6 Hz, 2H), 7.18 (d, J = 7.8 Hz, 2H), 
5.11 (d, J = 14.9 Hz, 1H), 4.94 (d, J = 14.9 Hz, 1H), 4.33 (d, J = 10.9 Hz, 1H), 4.10 (m, 
1H), 3.93–3.83 (m, 1H), 3.75 (ddd, J = 10.9, 3.3, 1.6 Hz, 1H), 3.69–3.60 (m, 2H), 3.47–
3.38 (m, 1H), 3.34–3.23 (m, 2H), 2.76 (dd, J = 11.2, 11.1 Hz, 1H), 2.37 (d, J = 11.9 Hz, 
1H); 
13C NMR (126 MHz, CDCl3) δ ppm 171.2, 148.9, 135.6, 130.6 (2C), 121.0 (2C), 120.4 















According to general procedure A, 4.1.4{2,1} (152 mg, 46%) was isolated as a yellow 
solid. 
mp 137–140 ºC; 
FTIR (thin film) 3016, 2974, 2934, 1711, 1620, 1452, 1325, 1234, 1163, 1150, 816 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.61 (d, J = 8.1 Hz, 2H), 7.53 (d, J = 8.0 Hz, 2H), 
5.12 (d, J = 15.5 Hz, 1H), 4.95 (d, J = 15.5 Hz, 1H), 4.65 (s, 1H), 3.4–3.16 (m, 5H), 
3.15–3.08 (m, 1H), 2.71–2.63 (m, 1H), 2.23–2.13 (m, 1H); 
13C NMR (126 MHz, Acetone-d6) δ ppm 173.2, 143.3, 129.9 (q, 2JC-F = 32.1 Hz), 129.1 
(2C), 126.2 (q, 3JC-F = 3.9 Hz, 2C), 125.4 (q, 1JC-F = 271.8 Hz), 66.7, 56.0, 52.4, 51.0, 
48.5, 21.1;  














According to general procedure A, 4.1.4{6,1} (112 mg, 32%) was isolated as a yellow 
solid. 
mp 104–108 ºC; 
FTIR (thin film) 3020, 2974, 1709, 1510, 1450, 1431, 1352, 1223, 1163, 1150, 843 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.45 (d, J = 8.7 Hz, 2H), 7.18 (d, J = 8.2 Hz, 2H), 
5.09 (d, J = 15.3 Hz, 1H), 4.88 (d, J = 15.3 Hz, 1H), 4.55 (dd, J = 8.3, 8.2 Hz, 1H), 3.40–
3.32 (m, 2H), 3.24–3.17 (m, 2H), 3.13 (ddd, J = 9.9, 7.7, 6.5 Hz, 1H), 3.09–3.01 (m, 1H), 
2.60 (dddd, J = 10.3, 10.1, 8.7, 8.5 Hz, 1H), 2.13 (dddd, J = 10.9, 7.7, 7.6, 1.8 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ ppm 172.0, 148.7, 135.3, 129.8 (2C), 121.0 (2C), 120.4 
(q, JC-F = 257.3 Hz), 65.9, 55.6, 51.4, 50.6, 47.5, 20.5; 





















mp 105–108 ºC; 
[𝜶]𝑫𝟐𝟎  = -14.5 (c = 0.38, MeOH); 
FTIR (thin film) 2970, 2945, 1703, 1493, 1352, 1151, 831 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.35 (d, J = 8.5 Hz, 2H), 7.30 (d, J = 8.5 Hz, 2H), 
5.06 (d, J = 15.1 Hz, 1H), 4.89 (d, J = 15.1 Hz, 1H), 4.17 (s, 1H), 3.44–3.07 (m, 5H), 
2.70–2.63 (m, 1H), 2.62–2.56 (m, 1H), 1.97–1.85 (m, 1H), 1.84–1.71 (m, 2H); 
13C NMR (126 MHz, MeOD) δ ppm 173.6, 137.5, 134.3, 130.8 (2C), 129.5 (2C), 65.6, 
58.7, 57.0, 51.9, 48.9, 27.9, 25.6; 






According to general procedure A, 4.1.4{5,2} (294 mg, 81%) was isolated as a yellow 
solid. 
mp 75–79 ºC; 
[𝜶]𝑫𝟐𝟎  = -43.0 (c = 0.27, CH2Cl2); 
FTIR (thin film) 3132, 2959, 1705, 1612, 1514, 1460, 1352, 1151, 831 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.33 (d, J = 8.1 Hz, 2H), 7.18 (d, J = 8.1 Hz, 2H), 








2.89 (hept, J = 6.9 Hz, 1H), 2.70–2.64 (m, 1H), 2.62–2.56 (m, 1H), 1.96–1.85 (m, 1H), 
1.79 (s, 2H), 1.24 (d, J = 6.9 Hz, 6H); 
13C NMR (126 MHz, MeOD) δ ppm 173.7, 149.5, 136.1, 129.4 (2C), 127.5 (2C), 65.7, 
58.8, 57.2, 52.1, 48.9, 35.3, 28.1, 25.7, 24.6 (2C); 





According to general procedure B, 4.1.4{8,2} (34.3 mg, 14%) was isolated as colorless 
oil. 
[𝜶]𝑫𝟐𝟎  = -14.9 (c = 1.495, MeOH); 
FTIR (thin film) 2959, 2872, 1703, 1454, 1383, 1352, 1148 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 4.10 (dd, J = 9.8, 2.5 Hz, 1H), 3.89–3.81 (m, 1H), 
3.80–3.73 (m, 1H), 3.45–3.35 (m, 2H), 3.32–3.19 (m, 2H), 3.16–3.10 (m, 1H), 2.67–2.61 
(m, 1H), 2.61–2.55 (m, 1H), 1.92–1.84 (m, 1H), 1.80–1.72 (m, 2H), 1.66–1.58 (m, 2H), 
1.40–1.29 (m, 2H), 0.94 (t, J = 7.4 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ ppm 171.7, 64.3, 57.9, 56.3, 50.8, 46.1, 31.5, 27.1, 24.7, 
20.0, 13.7; 











According to general procedure A, 4.1.4{1,3} (147.5 mg, 56%) was isolated as a light 
yellow sticky oil. 
[𝜶]𝑫𝟐𝟎  = +3.0 (c = 0.795, MeOH); 
FTIR (thin film) 2968, 2930, 1701, 1445, 1383, 1352, 1151, 1115 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 4.10 (dd, J = 9.8, 2.5 Hz, 1H), 3.95 (ddd, J = 14.2, 
7.1, 7.0 Hz, 1H), 3.87 (ddd, J = 14.2, 7.3, 7.1 Hz, 1H), 3.45–3.39 (m, 4H), 3.33 (s, 3H), 
3.29–3.23 (m, 2H), 3.15–3.11 (m, 1H), 2.67–2.61 (m, 1H), 2.60–2.55 (m, 1H), 1.95–1.85 
(m, 3H), 1.79–1.72 (m, 2H); 
13C NMR (126 MHz, CDCl3) δ ppm 171.8, 70.0, 64.3, 58.5, 57.8, 56.1, 50.8, 43.8, 29.4, 
27.1, 24.6; 




















mp 85–90 ºC; 
[𝜶]𝑫𝟐𝟎  = +197.0 (c = 0.22, CHCl3); 
FTIR (thin film) 2968, 2945, 1711, 1354, 1157 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 3.98 (dd, J = 10.3, 3.0 Hz, 1H), 3.40 (ddd, J = 13.9, 
3.1, 2.8 Hz, 1H), 3.35–3.25 (m, 2H), 3.25–3.17 (m, 1H), 3.16–3.10 (m, 1H), 2.73 (dddd, 
J = 7.0, 6.8, 3.8, 3.8 Hz, 1H), 2.61–2.53 (m, 2H), 1.97–1.86 (m, 1H), 1.80–1.67 (m, 2H), 
1.13–1.03 (m, 2H), 0.83–0.77 (m, 1H), 0.76–0.69 (m, 1H); 
13C NMR (126 MHz, MeOD) δ ppm 176.0, 67.1, 58.9, 57.4, 52.1, 28.7, 28.5, 25.4, 10.1, 
9.6; 
HRMS calculated for C10H16N2O3SH (M+H)+ 245.0960; found 245.0980 (TOF MS ES+). 
 
(S)-2-(4-(trifluoromethoxy)benzyl)hexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-
1(2H)-one 3,3-dioxide (4.1.4{6,3}) 
 
According to general procedure A, 4.1.4{6,3} (230.5 mg, 64%) was isolated as a light 
yellow solid. 
mp 107–111 ºC; 
[𝜶]𝑫𝟐𝟎  = +24.0 (c = 0.64, CH2Cl2); 
FTIR (thin film) 2991, 2939, 1693, 1506, 1429, 1352, 1221, 1159, 834 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.44 (d, J = 8.6 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H), 









3.35 (m, 1H), 3.31–3.21 (m, 3H), 3.18–3.12 (m, 1H), 2.68–2.64 (m, 1H), 2.61–2.57 (m, 
1H), 1.96–1.85 (m, 1H), 1.82–1.73 (m, 2H); 
13C NMR (126 MHz, CDCl3) δ ppm 171.8, 148.6, 135.5, 129.9 (2C), 120.9 (2C), 120.4 
(q, JC-F = 257.2 Hz), 64.3, 57.8, 56.3, 50.7, 47.9, 27.2, 24.7; 




thiadiazepine-9(2H)-carboxylate 3,3-dioxide (4.1.4{6,9}) 
 
According to general procedure B, 4.1.4{6,9} (195 mg, 41%) was isolated as a white 
solid. 
mp 155–158 ºC; 
FTIR (thin film) 2978, 2924, 1693, 1510, 1454, 1425, 1366, 1350, 1259, 1150, 827 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.47 (d, J = 7.6 Hz, 2H), 7.18 (d, J = 8.0 Hz, 2H), 
5.09 (d, J = 14.9 Hz, 1H), 4.97–4.84 (m, 1H), 4.46–4.33 (m, 1H), 4.28–4.17 (m, 1H), 
3.96–3.82 (m, 2H), 3.34–3.20 (m, 3H), 3.13–2.93 (m, 2H), 2.61–2.38 (m, 2H), 1.52 (s, 
9H); 
13C NMR (126 MHz, CDCl3) δ ppm 170.7, 148.9, 135.6, 130.5 (2C), 129.8, 121.0 (2C), 














carboxylate 3,3-dioxide (4.1.4{10,9}) 
 
According to general procedure B, 4.1.4{10,9} (75.4 mg, 22%) was isolated as light 
yellow oil. 
FTIR (thin film) 2976, 2918, 1693, 1425, 1366, 1348, 1165, 1148, 953, 926 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 5.91–5.81 (m, 1H), 5.33 (ddd, J = 16.9, 1.4, 1.4 Hz, 
1H), 5.21 (dd, J = 10.4, 2.7 Hz, 1H), 4.48–4.29 (m, 3H), 4.29–4.15 (m, 1H), 4.01–3.76 
(m, 2H), 3.51–3.42 (m, 1H), 3.39–3.32 (m, 1H), 3.28–3.20 (m, 1H), 3.11–2.92 (m, 2H), 
2.87–2.78 (m, 1H), 2.56 (d, J = 11.6 Hz, 1H), 1.48 (s, 9H); 
13C NMR (126 MHz, CDCl3) δ ppm 170.1, 154.9, 132.1, 119.3, 79.8, 60.6, 52.8, 51.9, 
47.6, 46.6, 44.8, 42.4, 28.4 (3C); 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(mg) Purity (%) 
4.1.4{1,6} 292.1093 293.1342 21.8 90.1 
4.1.4{2,6} 378.0861 379.0901 105.4 93.0 
4.1.4{4,6} 344.0598 345.0694 36.3 90.0 
4.1.4{5,6} 352.1457 353.1527 40.4 93.7 
4.1.4{6,6} 394.0810 395.0869 66.0 97.9 
4.1.4{7,6} 258.0674 - - - 
4.1.4{8,6} 276.1144 277.1385 43.5 90.1 
4.1.4{9,6} 276.0780 277.0840 33.9 100 
4.1.4{10,6} 260.0831 261.1055 10.2 52.0 
4.1.4{1,7} 292.1093 293.1190 11.1 90.0 
4.1.4{2,7} 378.0861 379.0935 19.5 100 
4.1.4{3,7} 260.0831 261.0893 38.9 90.6 
4.1.4{4,7} 344.0598 345.0662 70.3 98.7 
4.1.4{5,7} 352.1457 353.1518 42.2 96.1 
4.1.4{6,7} 394.0810 395.0885 142.7 94.7 
4.1.4{7,7} 258.0674 259.0735 118.6 92.2 
4.1.4{8,7} 276.1144 277.1204 28.6 93.2 
4.1.4{9,7} 276.0780 277.0837 129.2 100 
4.1.4{10,7} 260.0831 261.0894 112.4 94.5 
4.1.4{1,4} 290.1300 291.1388 119.0 96.0 
4.1.4{2,4} 376.1068 377.1151 107.8 100 
4.1.4{3,4} 258.1038 259.1096 19.6 100 
4.1.4{4,4} 342.0805 343.0888 121.0 97.1 
4.1.4{5,4} 350.1664 351.1736 28.1 94.9 
4.1.4{6,4} 392.1018 393.1090 129.8 98.4 
4.1.4{7,4} 256.0882 257.0960 163.8 93.0 
4.1.4{8,4} 274.1351 275.1406 56.4 86.7 
4.1.4{9,4} 274.0987 275.1081 59.8 98.8 
4.1.4{10,4} 258.1038 259.1118 83.3 98.8 
4.1.4{1,5} 290.1300 291.1398 39.5 100 
4.1.4{2,5} 376.1068 377.1159 54.1 100 
4.1.4{3,5} 258.1038 259.1097 35.0 97.6 
4.1.4{4,5} 342.0805 343.0895 88.7 95.3 
4.1.4{5,5} 350.1664 351.1737 142.1 91.4 
4.1.4{6,5} 392.1018 393.1095 17.7 100 
4.1.4{7,5} 256.0881 257.0954 178.9 100 
4.1.4{8,5} 274.1351 275.1428 89.6 100 
4.1.4{9,5} 274.0987 275.1075 109.3 98.8 
4.1.4{10,5} 258.1038 259.1117 140.6 97.9 
4.1.4{1,8} 292.1092 293.1186 50.4 100 
494 
 
4.1.4{2,8} 378.0861 379.0962 111.1 93.7 
4.1.4{3,8} 260.0831 261.0890 29.5 96.1 
4.1.4{4,8} 344.0598 345.0701 8.6 90.8 
4.1.4{5,8} 352.1457 353.1554 84.6 97.9 
4.1.4{6,8} 394.0810 395.0913 177.9 97.2 
4.1.4{7,8} 258.0674 259.0759 - - 
4.1.4{8,8} 276.1144 277.1225 35.3 90.0 
4.1.4{9,8} 276.0780 277.0822 68.1 100 
4.1.4{10,8} 260.0831 - - - 
4.1.4{1,1} 262.0987 263.1051 58.1 44.0 
4.1.4{2,1} 348.0755 349.0836 151.8 97.6 
4.1.4{3,1} 230.0725 231.0807 50.9 90.5 
4.1.4{4,1} 314.0492 315.0560 94.1 92.7 
4.1.4{5,1} 322.1351 323.1425 67.0 97.3 
4.1.4{6,1} 364.0705 365.0791 111.8 95.8 
4.1.4{7,1} 228.0569 229.0642 3.4 98.9 
4.1.4{8,1} 246.1038 247.1119 8.1 90.0 
4.1.4{9,1} 246.0674 - - - 
4.1.4{10,1} 230.0725 231.0798 22.2 100 
4.1.4{1,2} 276.1144 277.1212 254.2 91.7 
4.1.4{2,2} 362.0912 363.0969 212.5 93.7 
4.1.4{3,2} 244.0882 245.0984 115.0 98.9 
4.1.4{4,2} 328.0648 329.0753 134.6 100 
4.1.4{5,2} 336.1508 337.1581 182.0 100 
4.1.4{6,2} 378.0861 379.0934 294.0 96.2 
4.1.4{7,2} 242.0725 243.0789 18.7 81.4 
4.1.4{8,2} 260.1195 261.1294 34.3 90.2 
4.1.4{9,2} 260.0831 261.0898 6.3 87.0 
4.1.4{10,2} 244.0882 245.0962 1.9 70.1 
4.1.4{1,3} 276.1144 277.1233 147.5 95.3 
4.1.4{2,3} 362.0912 363.0984 169.8 96.1 
4.1.4{3,3} 244.0882 245.0980 67.8 94.0 
4.1.4{4,3} 328.0648 329.0736 157.4 100 
4.1.4{5,3} 336.1508 337.1537 133.2 92.5 
4.1.4{6,3} 378.0861 379.0945 230.5 97.1 
4.1.4{7,3} 242.0725 243.0823 73.0 90.3 
4.1.4{8,3} 260.1195 261.1297 18.0 95.6 
4.1.4{9,3} 260.0831 261.0927 38.7 92.0 
4.1.4{10,3} 244.0882 245.0957 126.0 92.1 
4.1.4{1,9} 391.1777 392.1824 94.0 100 
4.1.4{2,9} 477.1545 478.1597 9.3 83.7 
4.1.4{3,9} 359.1515 360.1583 46.8 92.2 
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4.1.4{4,9} 443.1282 444.1336 74.5 96.6 
4.1.4{5,9} 451.2141 452.2207 84.0 91.6 
4.1.4{6,9} 493.1494 494.1595 195.1 91.3 
4.1.4{7,9} 357.1358 358.1418 257.9 95.4 
4.1.4{8,9} 375.1828 376.188 99.2 93.1 
4.1.4{9,9} 375.1464 376.1509 171.9 100 
4.1.4{10,9} 359.1515 360.1563 75.4 98.8 
 
In-Silico Analysis 
Sketched electronic versions of the library compounds were imported into the Tripos 
Molecular Spreadsheet [2] wherein standard Lipinski Rule of 5 parameters (molecular 
weight, ClogP, number of H-acceptors, and number of H-donors [3]) plus the number of 
rotatable bonds and polar surface area were computed.  Lipinski violations were specified 
according to molecular weight > 500, ClogP > 5.0, number of acceptors > 10, number of 
donors > 5, and number of rotatable bonds > 5.  The structures were then exported into 
SDF format and coverted into three-dimensional protonated structures via Concord [5].  
Absorption, distribution, metabolism and excretion (ADME) profiles of these compounds 
was then generated via Volsurf [5].  Descriptors were generated using three probes 
(water, hydrophobic and carbonyl oxygen) with a grid space distribution of 1.0 Å.  
Predictions were then projected onto internal ADME models at the 5-component level.  
Finally diversity analysis was carried out using DiverseSolutions [6] using standard H-
aware 3D BCUT descriptors.  The library was then projected onto a chemical space 
defined by the following descriptors:  gastchrg_invdist2_000.550_K_L, 
gastchrg_invdist6_000.500_K_H, haccept_invdist2_001.000_K_H, tabpolar_invdist_-
000.250_K_H, tabpolar_invdist_000.500_K_L and populated (for comparison) by a 
recent version of the MLSMR screening set (ca. 7/2010; ~330,000 unique chemical 
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structures).  Diversity scores (div(A)) for our library were then generated for each of our 









where Nocc is the number of cells occupied by PubChem compounds in an evenly 
distributed 10×10×10×10×10 grid decomposition of the chemistry space, and pop(i) is the 
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[1] X-ray data related to compound 2.8.6 can be found in the publication: 
Samarakoon, T. B.; Loh, J. K.; Rolfe, A.; Le, L. S.; Yoon, S. Y.; Lushington, G. 
H.; Hanson, P. R. A Modular Reaction Pairing Approach to the Diversity-
Oriented Synthesis of Fused- and Bridged-Polycyclic Sultams. Org. Lett. 2011, 
13, 5148–5151. 
[2] X-ray data related to compound 2.11.3 would be published shortly. 
[3] All X-ray data related to Chapter Three molecules (3.1.2a, 3.9.2p, 3.10.2b, 














































































































































































Figure 1. 50% Probability Ellipsoid Drawing of 3.12.1c. 
